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Zusammenfassung 
Das Potenzial von humanen embryonalen Stammzellen (hESCs), in Hepatozyten-ähnliche 
Zellen (hepatocyte like cells, HLCs) zu differenzieren, ermöglicht Hepatozyten in 
unbegrenzter Anzahl für pharmakologische und toxikologische Untersuchungen sowie für 
Zelltherapien zur Behandlung von Leberversagen herzustellen. Obwohl zahlreiche 
wissenschaftliche Untersuchungen über die erfolgreiche Herstellung von HLCs aus hESCs 
berichten, existieren  immer noch kontroverse Angaben über die Ausprägung des 
Differenzierungsgrades zu homogenen Populationen von reifen Hepatozyten.  
Das primäre Ziel dieser Promotionsarbeit war es, ein umfassenderes Verständnis der 
Eigenschaften von stammzellabgeleiteten HLCs zu erreichen. Hierfür wurden durch die 
Verwendung eines bewährten Protokolls hESCs zu HLCs differenziert. Die Charakterisierung 
und Identität der stammzellabgeleiteten HLCs erfolgte durch die Ermittlung der 
Genexpressionsignatur  mittels GeneChip® Human Genome U133 Plus 2.0 Arrays. Die HLCs 
Genexpressionsignatur wurde anschließend mit der Genexpressionsignatur von hESCs und 
von frisch isolierten adulten Hepatozyten sowie von bis zu 14 Tage lang kultivierten adulten 
Hepatozyten verglichen. Durch die Anwendung eines breiten Spektrums von 
bioinformatischen Analyseprogrammen konnten die Gennetzwerke für erfolgreiche und 
erfolglose Hepatozytendifferenzierung sowie die involvierten regulativen 
Transkriptionsfaktoren identifiziert werden. 
Die Analyse der regulatorischen Gennetzwerke zeigte, dass HLCs einen hybriden Zelltyp 
darstellen, welcher Gensignaturen von Leber-, Darm-, Bindegewebs- und Stammzellen zeigt. 
Der unerwünschte “Colon”-Phänotyp stand hierbei im Zusammenhang mit 
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Transkriptionsfaktoren wie KLF5 und NKX2-3 sowie dem CDX2-Transkriptionsnetzwerk. 
Durch Clusteranalysen konnten stark korrelierende Gengruppen identifiziert werden, welche 
sowohl mit Funktionen der reifen Leber und einer Herunterregulierung der Zellproliferation 
zusammenhängen, als auch dem Expressionslevel der adulten Hepatozyten nahe kamen.  
Allerdings erreichten drei weiteren Gencluster nicht das Expressionslevel adulter 
Hepatozyten. Zwei dieser Cluster beinhalteten die Schlüsseltranskriptionsfaktoren SOX11, 
FOXQ1 und YBX3. Die dritte nicht erfolgreich exprimierte Clustergruppe, welche u.a. durch 
die Transkriptionsfaktoren HNF1A, CAR, FXR und PXR kontrolliert wird, zeigte signifikante 
Überschneidungen mit Genen, die in kultivierten Hepatozyten eher unterdrückt waren als in 
frisch isolierten Hepatozyten. Dies deutet darauf hin, dass in den gegenwärtig verwendeten in-
vitro Kulturbedingungen essentielle Stimuli für den Erhalt der Genexpression von 
Hepatozyten fehlen. Demzufolge könnten hierdurch auch die vergleichbaren Defizite von 
HLCs erklärt werden.  
Zusammenfassend kann festgestellt werden, dass durch den in dieser Arbeit verwendeten 
Ansatz zur Untersuchung von Genregulationsnetzwerken wichtige Transkriptionsfaktoren 
identifiziert werden konnten, welche sich als Interventionsziele zur Verbesserung der 
Differenzierung von hESCs zur reiferen HLCs anbieten. 
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Summary 
In the past decade, it has been recognized that human embryonic stem cells (hESCs) 
differentiation into hepatocyte like cells (HLCs) could offer an unlimited supply of 
hepatocytes for pharmacology, toxicology, and cell therapy for liver failure. Many research 
efforts claimed to have successfully engineered HLCs from hESCs. However, the degree of 
differentiation and identity of HLCs remains controversial.  
The primary goal of this thesis work was to obtain a comprehensive understanding of HLCs 
identity. Thus, HLCs were differentiated from hESCs using a well-established protocol. 
Genome-wide gene expression programs of hESCs and HLCs were analyzed using 
GeneChip® Human Genome U133 Plus 2.0 arrays. The resulting gene expression profiles of 
HLCs and hESCs were compared to freshly isolated adult hepatocytes and adult hepatocytes 
cultivated for up to 14 days.  Application of a broad range of bioinformatic tools and data 
mining approaches led to elucidation of gene networks and transcription factors (TFs) 
involved in the regulation of gene expression suggesting successful and failed hepatocyte 
differentiation. 
Gene regulatory network analysis revealed that HLCs represent a hybrid cell type with 
features of the liver, intestine, fibroblast, and stem cells.  The undesirable “colon” phenotype 
was associated with TFs such as KLF5, NKX2-3, as well as CDX2 transcriptional networks. 
Cluster analysis identified highly correlated groups of genes associated with mature liver 
functions and downregulated proliferation-associated genes, which approach levels of adult 
hepatocytes. However, three further clusters failed to reach the gene expression levels of adult 
hepatocytes.  Key TFs of two of these clusters include SOX11, FOXQ1, and YBX3. The third 
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cluster group, controlled by TFs such as HNF1A, CAR, FXR, and PXR, significantly overlaps 
with genes that are repressed in cultured adult hepatocytes relative to freshly isolated adult 
hepatocytes, suggesting that the current in vitro conditions lack stimuli essential for 
maintaining gene expression in hepatocytes, which consequently explains the corresponding 
functional deficiency of HLCs.  
In conclusion, the present gene regulatory network approach identified critical transcription 
factors for interventions to improve differentiation of hESCs to functional maturated 
hepatocytes.  
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Glossary 
Term Description 
% Percent 
° C Degree Celsius 
µg Microgram 
µl Microliter 
µm Micromolar 
Alexa Fluor® 488 Fluorescent synthetic green dye 
aRNA Amplified RNA 
BMPs Bone morphogenetic proteins 
BSA Bovine serum albumin 
cDNA Complementary deoxyribonucleic acid 
CO2 Carbon dioxide 
Cy®3 dye Bright, orange fluorescent dye 
DAPI 4',6-diamidino-2-phenylindole-a fluorescent stain 
DMEM Dulbecco's Modified Eagle Medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
FBS Fetal bovine serum 
FDR False discovery rate 
FGFs Fibroblast growth factors 
GlutaMAX™ Alternative to L-glutamine 
GO Gene Ontology  
H2O Water 
hESCs or ESC Human embryonic stem cells 
HGF Hepatocyte growth factor 
hHEPs or FH Freshly isolated adult human hepatocytes 
HLCs or HLC Hepatocyte like cells 
iPSCs or ihPSCs or iPS Human induced pluripotent stem cells  
L-15 basal medium  Leibovitz L-15 cell culture Medium 
ml Milliliter 
MTeSR™ Maintenance medium for hESCs and IPSCs from stem cell technologies 
ng Nanogram 
nM Nanomolar 
PBS Phosphate buffered saline 
RNA Ribonucleic acid 
RPM Revolutions per minute 
RPMI 1640 Roswell Park Memorial Institute medium 1640-cell culture   
RT-qPCR Real-time quantitative polymerase chain reaction 
SEM Standard error of the mean 
TFs or TF Transcription factors 
Wnt3a Wingless-type MMTV integration site family, member 3A    
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1 Introduction 
The liver is the largest gland, accounting for about 2 to 5% of total body weight, and a key 
metabolic organ [1]. It is responsible for over 500 functions in metabolism, detoxification, and 
synthetic processes [2]. Liver-related research was hampered by limited availability of the 
donor livers [2]. Over the last decade, in vitro generation of cell types from stem cells have 
been idealised as an alternative source to cell types in the liver [3, 4]. For this reason, it is 
paramount to understand the liver’s basic developmental stages, as well as differentiation 
mechanisms, maturation mechanisms, and their cell types [1]. Additionally, it is essential to 
determine how cells in the adult liver organise to create the three-dimensional structure that is 
so critical for liver function [1]. 
 
1.1 Embryonic liver development 
The liver development is a sequential process comprised of the various signalling processes 
that take place in spatial and temporal patterns [5]. Different vertebrate models are studied 
inclusively to understand various morphological transitions of liver development and 
differentiation [6, 7] . During embryonic gastrulation, the epiblast of the fertilised egg passes 
through the primitive streak and is incorporated into the endoderm and mesoderm (Fig. 1) [6]. 
After gastrulation, the endoderm transforms into a rudimentary gut tube along the dorsal-
ventral and anterior-posterior axes, which is then subdivided into three developmental 
domains foregut, midgut, and hindgut (Fig. 1) [6]. Liver development is initiated from the 
foregut endoderm (Fig. 1) and is controlled by a series of mutual interaction with the 
neighboring mesoderm [6]. During liver development, the tissue morphogenesis and cell 
identity is tightly controlled [6]. 
 2 
 
 
 
 
 
Figure 1: Schematic representation of liver specification 
During gastrulation, germ layer ectoderm and a transient precursor cell population, namely 
mesendoderm are formed. From mesendoderm, two germ layers, mesoderm and endoderm, 
are formed. After gastrulation, the endoderm transforms into the primitive gut tube, which is 
subdivided into foregut, midgut and hindgut regions. Embryonic liver originates from the 
foregut endoderm. (Adapted from [6]) 
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The mouse embryonic liver development originates from the ventral foregut endoderm on an 
embryonic day 8 (E8) [8]. The mouse liver development and maturation is accompanied by 
different cellular stages, cell to cell interactions (Fig. 2) and are characterized by various 
molecular markers (Fig. 2) [7]. The foregut endoderm cell population destined for hepatic fate 
begins to express transcription factors HHEX and HNF4A, hepatic genes alpha-fetoprotein 
(AFP) and albumin (ALB) [7]. The formation of the hepatic diverticulum, an outpocket of 
ventral foregut epithelium adjacent to the developing heart (Fig. 3) on E9 is the first 
morphological sign of liver development [5].  
 
 
Figure 2: Schematic Model of Regulatory Mechanisms and Cell Surface Markers for 
Hepatic Epithelial Cells during Mouse Liver Development 
The representative cell surface markers are shown. While EpCAM is transiently 
downregulated in hepatoblasts at the midgestational stage, its expression is restored in 
cholangiocytes, but not in hepatocytes, later on. DLK1 is also expressed in hepatoblasts but is 
not expressed in mature hepatocytes or cholangiocytes. (Adapted from [7]) 
 
While the anterior portion of the hepatic diverticulum develops into the liver and the 
intrahepatic biliary tree, the posterior part of the hepatic diverticulum develops into the 
gallbladder and extrahepatic bile ducts (EHBD) [5, 9]. At E9.5, the hepatoblast emerges as a 
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split from the epithelium and migrates into the adjacent septum transversum mesenchyme 
(STM) to materialise the liver bud [5]. The hepatoblast expresses gene markers including 
EPCAM, CD133, CDH1, DLK1, IGDCC4, CD13 and LIV2 (Fig. 2) and is capable of 
differentiating into both hepatocytes and cholangiocytes (Fig. 2) [7]. Delta-Like homolog 1 
(DLK1) is expressed early at E9.0 and decreases in the neonatal stage, disappearing entirely in 
adult hepatocytes [7, 10]. The loss of CDH1 (E-cadherin) from hepatoblast is vital for the 
migration and formation of liver bud [1, 11]. Fetal liver kinase FLK1 and growth factors 
HGF, midkine, and pleiotrophin are required for differentiation of hepatoblast into liver bud 
[12, 13].  Liver fibroblast and stellate cells are contributed by the STM [5].  
Between E10–15 continuous growth of the liver bud leads to the formation of the fetal liver 
and become a principal site of hematopoiesis [5]. The fetal liver is a core player in 
hematopoietic cell differentiation from its precursor cells. Oncostatin M, a cytokine produced 
by the blood cells, is responsible for the hepatocyte maturation (Fig. 2) [14]. It has been 
reported that notch signalling pathway is essential for the biliary system development (Fig. 2) 
[15].   
 
The liver fate specification and development is guided by three major pathways such as 
fibroblast growth factors (FGFs), bone morphogenetic proteins (BMPs) and wnt signalling 
(Fig. 3) [1]. Both FGFs and BMPs have an inductive role in liver development [16, 17]. FGFs 
molecules are secreted from the developing heart while BMPs are secreted from the septum 
transversum mesenchyme (STM) [1]. The FGFs mediated hepatic induction is concentration 
dependent and controlled by the position of the endoderm relative to the heart [18]. FGFs 
control the induction of hepatic genes through activation of the mitogen-activated protein 
kinase (MAPK) pathway and are independent of phosphoinositide 3-kinase (PI3K) signalling 
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[19]. Numerous FGFs such as FGF1, FGF2, FGF8 and FGF10 are expressed in the cardiac 
mesoderm during the onset of hepatogenesis [20]. A zinc finger transcription factor GATA4 
regulates the expression of BMP4 [17]; both GATA4 and BMP4 are essential for early liver 
development (Fig. 3) [1]. Purportedly there is flexibility on the relative timing of BMPs and 
FGFs to induce the differentiation of the distinct population of hepatic progenitors [21]. In the 
suggested model, transforming growth factor-beta (TGF-ß) acts as a developmental timer by 
preventing hepatic endoderm from differentiating inappropriately [21]. Moreover, it ensures 
that the endoderm retains competence for hepatic lineage [1, 21]. 
In contrast to FGFs and BMPs, the contribution of Wnt signalling in liver development is 
relatively complex [1]. At early stages, Wnt signalling represses liver development by 
inhibiting a crucial hepatic regulator HHEX, while in later stages wnt signalling promotes 
hepatogenesis (Fig. 3) [22]. The studies conducted on the zebrafish model suggested that Wnt 
protein Wnt2B is essential for the onset of hepatic differentiation of the progenitor cells. 
However, there is a mechanism to compensate for the loss of Wnt2B [23]. 
 
Apart from different signalling pathways, the liver specification and development is guided by 
a set of regulatory factors (Fig. 3) [24, 25]. Transcription factors FOXA1, FOXA2 and 
GATA4 [26], are expressed in the anterior endoderm [1] and termed as “pioneer factors” 
because they are essential in creating competence for liver development (Fig. 3) [27]. 
However, later stages of liver development happen independently of FOXA1 and FOXA2 
(Fig. 3) [28]. These three factors are capable of binding enhancers of albumin before the onset 
of its expression [29, 30]. Moreover, GATA6 and GATA4 contributes to hepatoblast 
development by enabling HHEX expression [31-33]. Hepatocyte nuclear factor HNF1B is 
also essential for hepatic specification, and studies conducted in mouse models suggest that 
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lack of HNF1B will severely compromise ALB, FOXA1, and FOXA2 expression in the liver 
bud (Fig. 3) [34]. 
 
 
Figure 3: Mechanism controlling early development of the hepatocytes 
Illustration showing the onset of differentiation of liver parenchymal cells indicating 
signalling molecules and transcription factors with proven regulatory roles. Initial functions 
of Wnt signalling promote posterior endodermal identity at the expense of anterior (e.g., 
prospective hepatic) identity, and must be inhibited anteriorly by local Wnt antagonist 
expression before liver development can proceed further. Later functions of Wnt signalling act 
in parallel with BMP and FGF signalling to drive hepatic specification, expansion, and 
differentiation. Foregut endoderm (End; pink), heart (He; red), liver bud (Lb; yellow), septum 
transversum mesenchyme/lateral plate mesoderm (STM; green), and vascular endothelial 
cells. (E; black). (Adapted from [1]) 
 
The hepatoblast migration is highly regulated by homeodomain factors ONECUT1 and 
ONECUT2 [35]. The prospero-related homeobox transcription factor PROX1 regulates the 
hepatoblast proliferation and migration from the primary liver bud [36]. T-Box factor TBX3 
(upstream of PROX1) promotes a hepatocyte specification of hepatoblast while repressing a 
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cholangiocyte fate [37]. There is an incredible synergy between different signalling pathways 
and transcription factors (Fig. 3) to coordinate the liver development.    
 
After a detailed study, it has been found that HNF1A, HNF1B, FOXA2, HNF4A, ONECUT1 
and NR5A2 are responsible for forming core regulatory circuitry of liver development [38]. 
Each of these TFs regulates each other, among them HNF1A, FOXA2, HNF4A, and 
ONECUT1 are auto-regulators [39]. Moreover, these TFs also regulates peripheral TFs by 
occupying their promoters [1]. Wilms Tumor factor 1 (WT1), expressed in mesothelial cells, 
is also essential for hepatic stellate cell and liver development [40]. 
 
1.2 Postnatal liver development 
The liver will continue to develop even after birth (postnatal period), which may extend up to 
5 years in humans [41]. During this phase of growth the liver acquires its adult gene 
expression program, which is essential for various physiological processes, including the drug 
metabolising enzymes [42, 43]. The postnatal developmental period is unique because 
hepatocytes proliferation and differentiation happen simultaneously [44]. During this time, the 
liver tends to achieve 2-5% weight [1] of the whole body [44]. The nuclear receptors NR1I2, 
NR1I3 and HNF4A, are key factors responsible for regulating the gene expression of the 
postnatal liver [44-46]. The significance of HNF4A in maintaining mature hepatocyte 
characteristics in the adult liver is supported by the fact that HNF4A alone bind 12% of 
human hepatocyte genes at the whole genome level [47].  
 
Experimental studies indicate that levels of ßeta-catenin is increased in the cytoplasm from 
postnatal day 5 to 20. Moreover, knockdown of ßeta-catenin results in a smaller liver size 
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highlighting its importance in the liver growth. Therefore, canonical wnt signalling is 
important for liver growth [48]. Besides wnt signalling, the postnatal liver size and maturation 
is regulated by yes-associated protein (YAP) [49], a downstream effector of the hippo 
signalling pathway [50]. YAP critically regulates gene expression by coordinating with 
HNF4A, HNF1B, PXR, and CAR [44]. The hippo and YAP may act as a switch between cell 
maturation and proliferation [44]. However, a central regulatory mechanism which guides 
postnatal liver development is still largely unknown [44].  
 
1.3  Adult liver and stem cells 
The liver parenchyma and non-parenchyma represent highly heterogeneous cell types 
consisting primarily of hepatocytes, cholangiocytes/bile duct, endothelial cells, sinusoidal 
endothelial cells, pit cells, kupffer cells, and the  stellate cells [1] (Table 1). Each cell type 
carries out specific functions (Table 1). Moreover, heterotypic cell-cell interactions are 
essential for proper liver function [51]. 
 
Cell Type Position in Liver Function 
Hepatocyte Parenchyma ∼70% of liver cell population 
Protein secretion 
Bile secretion 
Cholesterol metabolism 
Detoxification 
Urea metabolism 
Glucose/glycogen metabolism 
Acute phase response 
Blood clotting 
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Cholangiocyte/bile 
duct cell 
Duct epithelium ∼3% of liver cell population 
Form bile ducts to transport bile 
Control rate of bile flow 
Secrete water and bicarbonate 
Control pH of bile 
Endothelial cell Vasculature Form veins, arteries, venuoles, and 
arterioles 
Control blood flow 
Contribute toward parenchymal zonation 
Liver sinusoidal 
endothelial cell 
Sinusoids ∼2.5% of lobular parenchyma 
Form sinusoidal plexus to facilitate blood 
circulation 
Highly specialized 
Allow transfer of molecules and proteins 
between serum and hepatocytes 
Scavenger of macromolecular waste 
Cytokine secretion 
Antigen presentation 
Blood clotting 
Pit cell Liver natural 
killer cells 
Rare 
Cytotoxic activity 
Kupffer cell Sinusoids ∼2% of liver 
Scavengers of foreign material 
Secrete cytokines and proteases, etc. 
Hepatic stellate 
cell 
Perisinusoidal ∼1.4% of liver cells 
Maintenance of extracellular matrix, 
Vitamin A, and retinoid storage 
Controls microvascular tone 
Activated to become myofibroblast 
Contributes toward regenerative response 
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to injury 
Secretion of cytokines 
Table 1: Predominant cell types and their functions within the adult liver  
(Adapted from [1]) 
 
Despite the cellular heterogeneity (Table 1), the liver is a relatively homogenous organ [52]. 
The fundamental architectural unit of the liver is the liver lobule (Fig. 4) [1]. The hepatocytes 
are parenchyma of the liver and carry out most of the metabolic and synthetic functions (Table 
1). Hepatocytes are polarised epithelial cells, and their basolateral surfaces face sinusoidal 
endothelial cells (Fig. 4), which facilitates the exchange of molecules between the hepatocytes 
and blood vessels [1]. Tight junctions between neighboring hepatocytes form a canaliculus, 
which surrounds each hepatocyte [1]. Bile secreted from the hepatocytes is collected by the 
canaliculi and exported in a sequential manner to the gallbladder for storage [7]. 
 
 
Figure 4: Schematic Overview of Liver Lobule  
The portal triad consists of the portal vein, hepatic artery, and bile ducts. Blood from the 
portal vein and the hepatic artery flows toward the central vein between hepatocytes through 
the sinusoids surrounded by fenestrated hepatic sinusoidal endothelial cells (HSECs). Bile 
produced by hepatocytes is collected into bile ducts via the bile canaliculi. Kupffer cells, 
resident macrophages of the liver, are located at the luminal side of sinusoids, while hepatic 
stellate cells (HSCs) are positioned in close proximity to HSECs at the “space of Disse,” a 
location between hepatocytes and a sinusoid. The canal of Hering is the junctional region 
between hepatocytes and bile ducts. (Adapted from [7]) 
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Apart from different cell types (Table 1), the occurrence of stem cells in the adult human liver 
is well documented (Fig. 5) [7, 53]. However, the presence of stem cells in the normal liver 
remains controversial [54]. Adult liver stem cells are critical for tissue turnover and tissue 
repair when the liver is subjected to injury [7]. Unlike other organs (intestine and epidermis), 
hepatocytes turnover is slow [55] and in normal conditions hepatic tissue maintenance is 
achieved by the proliferation of mature hepatocytes, which happens throughout the liver 
parenchyma (Fig. 5) [7].  
Potential liver stem cells are identified based on cholangiocyte molecular markers such as 
EPCAM [56], CD133 [57] and MIC1-1C3 [58], which implicates the biliary system as a 
compartment that harbours “resident” liver stem cells (Fig. 5) [7]. Supporting this hypothesis 
is that fact that, EPCAM positive cells can be isolated from postnatal livers and fetal livers 
also contain human hepatic stem cells (hHpSCs) [59]. Moreover, experimental findings 
suggest that multipotent progenitor stem cells may be harbored in the peribiliary glands of the 
adult human liver, which can give rise to hepatocytes, cholangiocytes and pancreatic islets 
[60].  
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Figure 5: Stem/Progenitor Cells in Adult Liver under normal and injured Conditions 
Under normal physiological conditions, the homeostatic maintenance of hepatocytes is 
achieved predominantly by the proliferation of mature hepatocytes. Upon certain types of 
injury condition, unique epithelial cell populations with an immature phenotype, called adult 
liver progenitor cells (LPCs), emerge and expand, and are thought to contribute to the 
regeneration process due to their bilineage differentiation potential to both hepatocytes and 
cholangiocytes. Although the origin of LPCs is still not clear, the dominant theory is that they 
are derived from the canal of Hering, which may harbor putative “resident” stem cells as the 
exact cell of origin. Purification by cell sorting and subsequent culture experiments have 
demonstrated that the cholangiocyte marker-positive population from normal liver, as well as 
the cholangiocyte/LPC marker-positive subset from injured liver, contains a “potential” liver 
stem cell population defined in vitro by clonogenicity and bilineage differentiation potential. 
(Adapted from [7]) 
 
Liver progenitor cells (LPCs) are another class of stem cells known to appear only when the 
liver is injured (Fig. 5) [7]. It has been demonstrated in vitro that LPCs are bipotenial in nature 
(Fig. 5).  Multiple studies suggest that the site of origin of LPCs may be the canal of hering 
(Fig. 5); LPCs are identified using molecular markers such as CK19, EPCAM, and CD133.  
However, there is no direct proof for the origin of LPCs because there is a lack of genuine 
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molecular markers; these three previous markers are also used to isolate cholangiocytes from 
the normal liver, which is also capable of differentiating into both hepatocyte and 
cholangiocyte in vitro (Fig. 5). 
 
When the normal liver is treated with N, N′-Dicyclohexylcarbodiimide (DDC) a 
transmembrane molecule TACSTD2 (paralog of EPCAM) is expressed only in LPCs, but not 
in cholangiocytes [56].  Therefore, TACSTD2 would be a potential LPCs specific marker and 
may be used for further research. Forkhead Box L1 (FOXL1) and G Protein-Coupled 
Receptor 5 (LGR5) are being actively pursued to establish their use in LPCs related research 
[7]. Activation of LPCs is usually accompanied by inflammatory responses, inflammatory 
molecules such as tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL6) and 
interferon-gamma (INFG), which is coherent with the notion that LPCs are activated under 
chronic liver injury conditions [61-63].  Proliferation and differentiation of LPCs are regulated 
by hepatocyte growth factor (HGF) and epidermal growth factor (EGF) [64, 65].  
 
Although there have been advances in LPCs research, but the origin and possible role in the 
liver biology of LPCs remains elusive [54]. 
 
1.4 Liver diseases and therapeutic Possibilities 
Despite the unique capacity of the liver for regeneration, continuous insults lead to liver 
diseases associated with high morbidity and mortality rates, affecting over 600 million people 
around the globe [3]. Most liver processes are interconnected with functions of various 
organs; clinical and pathological studies have confirmed that liver diseases can manifest as 
systemic illness [2]. Liver diseases are predominantly divided into three categories [2].  
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Figure 6: Organ transplantation and cell-based therapies 
Currently, liver transplantation is the primary treatment for patients with liver failure and is 
the only therapy shown to improve survival. Because of the limited number of livers suitable 
for transplantation, advanced surgical procedures including split liver and partial donor 
transplants have been pursued clinically. Additionally, a diverse range of cell-based therapies 
are currently being explored to treat liver disease and liver failure. These include the 
transplantation of various adult and stem cell–derived cell populations, the development of 
extracorporeal BAL devices, and the implantation of engineered tissues. (Adapted from [2]) 
 
1.4.1 Chronic disease caused by metabolic dysfunction 
          These diseases are caused by defective secretion of key proteins, which are important 
for liver-based metabolism and functions. Urea cycle disorders, Crigler-Najjar syndrome, 
phenylketonuria and oxalosis are examples of metabolic liver diseases. Moreover, this type of 
liver diseases shows no signs of any structural or cellular damage in patients. Until now, these 
categories of patients are treated with organ transplantation. However, the clinical 
manifestation of these diseases may offer an ideal situation for cell-mediated therapy (Fig. 6). 
1.4.2 Acute liver failure caused by direct injury and loss of hepatocytes 
          Direct liver injury leads to necrosis of hepatocytes that signal the production of liver 
enzymes such as alanine transaminase and aspartate transaminase. These two enzymes are an 
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indicator of hepatocyte injury, but not a sign of liver failure. Organ transplantation is the 
successful treatment option available for acute hepatic failure. It is unclear yet, how 
hepatocyte transplantation is useful in treating these patients. However, extracorporeal devices 
like artificial liver may provide a clinical bridge to manage symptoms until the endogenous 
liver recovers (Fig. 6). 
1.4.3 Chronic liver failure caused by tissue damage and remodelling (or) cirrhosis   
          This class of liver diseases are a severe and chronic form of liver failure. Cirrhosis 
causes dysfunction of the liver, which eventually lead to secondary dysfunction of the kidney 
and lung. Hepatitis B or C infection, alcohol abuse, fat accumulation and autoimmune 
reactions are considered to be the major causes of cirrhosis. Also, antitrypsin deficiency, 
Wilson's disease, cystic diseases, and hemochromatosis include some of the inborn metabolic 
errors, which cause structural liver damage with cirrhosis, liver failure. Orthotopic liver 
transplantation is the definitive therapy for this category of patients (Fig. 6). 
 
The liver (partial or full organ) and the hepatocyte transplantation are the universal treatment 
options available for various liver diseases [2, 3]. In some metabolic disorders, normal 
hepatocyte transplantation in 2-5% of the liver parenchyma might be good enough to 
improve/regain liver function significantly [66]. For successful transplantation, different 
surgical options are considered based on the availability of donor organs such as split liver 
transplants and living-related partial donor [67]. However, liver and mature hepatocytes 
transplantation is limited by the insufficient availability of source material [3].  
 
For the generation of hepatocytes in large volumes, researchers are trying to induce and 
support the proliferation of adult hepatocytes in vitro conditions but these efforts are 
 16 
 
unsuccessful [68]. Moreover, attempts to prevent dedifferentiation of hepatocytes in vitro set-
up are also highly unsuccessful [69]. Therefore, continuous research efforts are placed to find 
an alternative source for generating sufficient hepatocytes for cell-mediated therapy as well as 
drug discovery and biomedical applications [3]. 
 
1.5  Generation of Hepatocyte Like Cells (HLCs) 
For the last few decades, an endeavour has been made to generate hepatocyte like cells from 
different cell sources (Fig. 7). These cell sources are weighed using parameters such as ethics, 
safety, supply, and scalability [3, 70, 71]. Among various cellular sources, Human Embryonic 
Stem Cells (hESCs) are one of the winners, although there are significant ethical issues 
associated with them [72]. Since discovery in 1998, hESCs have been considered as the “holy 
grail” of cell-mediated therapy and biomedical applications because of their self-renewal, 
proliferative nature and their ability to differentiate into any cell types in the presence of 
appropriate niches/cues [73, 74].  
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Figure 7: Sources of hepatocytes 
Obtaining appropriate sources of hepatocytes is a major limitation for developing cell-based 
therapies for treating liver disease. Many different approaches are under investigation 
including methods for improving the expansion of primary human hepatocytes in vitro, the 
directed differentiation of pluripotent stem cells (both ESCs and iPSCs), and the 
differentiation of either intrahepatic or extrahepatic adult progenitor cells, as well as new 
methods for the direct reprogramming of adult somatic cells to hepatic cells. (Adapted from 
[2]) 
 
Typical HLCs differentiation protocols are designed using existing knowledge of liver 
development and maturation that have been accumulated over the years from studies 
conducted in different vertebrate models [3]. These methods are a miniature of the hepatocyte 
developmental window, which contains appropriate molecular and cellular signals to induce 
hepatic lineage.  
Differentiation of hESCs into HLCs is performed using two different approaches, (i)  
“Directed differentiation” in which cytokines are applied systematically and (ii) “Direct 
conversion” in which hepatic transcription factors are overexpressed to achieve hepatic 
phenotype [75-77]. Sometimes both of these previous approaches are mixed to achieve a 
successful HLCs derivation. Freshly isolated adult hepatocytes are considered as “gold 
standard” to which gene expression profiles, as well as the functionality of derived HLCs, are 
compared [3]. 
In 2003, the first method to differentiate HLCs from hESCs was reported by Rambhtala and 
colleagues [78]. Since then, various groups across the world are in search of possible 
modifications to improve HLCs differentiation to obtain more homogeneous population. 
HLCs differentiation protocols vary significantly in terms of hESCs culturing that are either in 
a monolayer or aggregated in three-dimensional structures called “embryoid bodies” (EBs) 
[75]. The creation of embryoid bodies from hESCs is achieved either by suspension culture or 
using an extracellular matrix (ECM) coated culture plates [75]. 
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1.6 HLCs differentiation using embryoid bodies 
hESCs differentiation into three germ layers such as the ectoderm, mesoderm and endoderm is 
highly spontaneous [73]. These endodermal cells express nascent hepatic markers such as 
alpha-fetoprotein (AFP) and albumin (ALB) [79]. These methods do not use ‘Activin A’ to 
induce endoderm [75]. In 2004, Lavon and colleagues reported that hESCs can be 
differentiated into HLCs using an embryoid body approach, which can express ALB and is 
capable of growing in vitro for a few weeks [80]. Two years later, Bharvand and colleagues 
published an efficient EBs based protocol, which uses three-dimensional collagen type I 
scaffold with the sequential supplementation of different growth factors [81]. However, the 
EBs based HLCs differentiation is no longer preferred due to the lower differentiation 
efficiency and unpredictable outcomes [75].  
 
1.7  Methodical differentiation of hESCs into HLCs 
In monolayer culturing conditions, these protocols first differentiate the hESCs into definitive 
endodermal cells that are then further differentiated into hepatoblast and HLCs. Since 
hepatocytes are derivative of endoderm, the formation of endoderm is the first step in a 
multistep hESCs differentiation towards HLCs [82, 83]. Endoderm lineage is induced using a 
high concentration of Activin A, which mimics the nodal signalling pathway of embryonic 
gastrulation [83]. Activation of nodal signalling pathway leads to phosphorylation of TFs such 
as SMAD2 and SMAD3 [84]. Then these SMAD proteins are translocated to the nucleus and 
form a complex with transcription factor SMAD4 to initiate the activation of lineage-specific 
genes [75].  
Definitive endoderm was obtained by overexpression of transcription factor SOX17 in hESCs 
[85]. In a detailed study on the effect of the extracellular matrix and different growth factors, 
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it had been concluded that matrigel and 100 ng/ml of ‘Activin A’ enhance the efficiency of 
HLCs differentiation [86]. The combination of ‘Activin A’ and FGF2 enhanced the expression 
of endodermal genes such as SOX17, FOXA2 and CXCR4 [87]. Use of Wnt3a in 
combination with ‘Activin A’ for endoderm induction was proven to be effective by Hay and 
colleagues [88]. The repression of ectoderm and mesoderm lineages in endoderm 
differentiation was achieved by applying a combination of FGF, TGF-β, and wnt together 
with low BMP molecules [89].   
Hepatic induction of endodermal cell population is achieved by the use of BMPs, FGFs, 
chemical antagonist and synthetic epigenetic modifiers in low serum conditions [75]. The 
combination of FGF2 and BMP4 increased expression of albumin in endodermal population. 
Moreover, the combination of bFGF and BMP4 or FGF4 and BMP4 were also given to 
similar outcomes [90]. The inductance of endoderm cell population to hepatoblast was 
attained by using DMSO, which modifies histone acetylation [91]. The hepatic induction was 
enhanced by the addition of a low amount of FGF2, whereas the higher amount favours 
pancreatic lineage [92]. Combinatorial use of FGF1/2/4 and BMP2/4 increased the expression 
of Epithelial Cell Adhesion Molecule (EPCAM) in multiple cell clusters with adjacent cell 
clusters positive of cytokeratin such as CK7, and CK19 was well documented [87].  
Finally, hepatocyte polygonal multinuclear morphology and maturation is obtained by the 
application of hepatocyte growth factor/epidermal growth factor, oncostatin M, insulin and 
cortisone (hydrocortisone and dexamethasone) at different levels and concentration [75]. 
Besides using a different combination of cytokines, overexpression of transcription factors in 
combination with cytokines is used to push hESCs towards hepatic lineage. For example, the 
sequential transduction of TFs such as SOX17, HHEX and HNF4A was performed to 
differentiate hESCs into HLCs [93].   
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Overall, most of the hepatocyte differentiation methods follow a similar regime of cytokines. 
However, the difference lies in the composition of cytokines used in each successive cellular 
stage and number of days accompanying specific cellular stages (definitive endoderm, 
hepatoblast and HLCs) [3]. 
 
1.8 Gene regulatory layers 
In 1961, Jacob and Monod suggested a general model of gene regulation in a seminal paper. 
Since then, numerous efforts have been made to understand gene regulation mechanisms and 
involvement of other molecular components [94]. Stereotype embryonic development and 
maintenance of the adult gene expression program is governed by multilayered, complex, 
interconnected regulatory and functional elements [95, 96], [97-101]. Many factors are 
responsible for this molecular and cellular complexity that have gathered over the course of 
mammalian evolution, which includes pervasive transcription [102, 103], epigenetics [104, 
105], gene pleiotropy [106], post-transcriptional protein modifications [107], protein kinases 
[108], alternative splicing [109], trans-acting factors [110], cis-regulatory elements [111], and 
cell type-specific gene expression [112]. Understanding these different regulatory 
elements/factors will lead to comprehensive knowledge about the embryonic development and 
maintenance of differentiated cellular identity (adult cell/tissue types). Various research 
efforts such as “The Human Genome Project” (HGP) [113], “FANTOM Consortium” [114], 
“ENCODE Consortium” [115], “NIH Roadmap Epigenomics” [105], “GTEx”[116], “Human 
Kinome” [108] and “The Human Protein Atlas” [117] are conceptualized to understand the 
various gene regulatory and functional elements.  
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Since DNA is organised in chromatin fibres, genomic data access is controlled by an array of 
proteins including transcription factors (TFs), cofactors, chromatin remodelling proteins and 
histones [118]. In 1957, Waddington described the embryonic development using a term 
called “epigenetic landscape” where cellular differentiation and developmental (Fig. 8) 
competence is not part of the DNA sequence  [96, 105]. A variety of histone and DNA 
modifications, mainly are responsible for chromatin structure realignment [119], which attract 
TFs toward DNA either initiate or repress gene expression. 
 
 
Figure 8: Waddington developmental canal 
Waddington, following Morgan, characterized the process of development as essentially 
“epigenetic” and also introduced the metaphor of an “epigenetic landscape”, which he 
depicted with a ball rolling down a hill of bifurcating valleys symbolizing the specification of 
defined cell lineages and fates during the progress of differentiation. It is notable that 
Waddington’s usage of epigenetic to denote the origination and propagation of information 
about cellular states during differentiation differs considerably from its recent reformulation 
to mean “on the genome” and its association with chemical modifications. ESCs: embryonic 
stem cells. (Adapted from [96] and modified) 
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TFs are one of the trans-acting factors and a prime factor in transcriptional gene regulation 
[94]. In humans, estimates show that there are 2000 to 3000 DNA sequence binding TFs 
[118], which accounts approximately 10% of genes [120]. In the human body, each 
tissue/organ expresses the combination of cell type-specific and ubiquitous TFs for its 
development, maintenance and function [118, 121]. Cell type-specific TFs expressions are 
unique to their respective cell types and responsible for the reorganisation of global TFs 
binding profiles [121]. Cell type-specific combinatorial TFs binding and interactions are [122] 
necessary to establish TF-mediated gene regulatory networks (GRNs) [123, 124], which 
defines cellular identity. GRNs are hierarchical in nature [125]. Typical GRNs dictate cellular 
physiological capabilities and determine the cellular response to environmental fluctuations 
[125].  
 
1.9 Wherefore further research in HLCs 
Numerous publications suggest the satisfactory derivation of HLCs but their applications hit 
the roadblocks due to the immature nature of derived HLCs [3].  Since HLCs are obtained by 
mimicking molecular events of the liver development, their transcriptional program is 
overlooked and interpreted only in the context of hepatocytes with a handful of gene markers 
[126]. Such an overwhelming approach made our understanding more constrained [126]. 
Furthermore, little is known about the transcriptional regulatory networks controlling the 
HLCs differentiation program.  
Previously, there are serious concerns about the transcriptome similarity between in vitro 
engineered cell types and its in vivo counterpart [127-129]. Moreover, it is widely accepted 
that in vitro culturing environmental conditions foist specific changes in cellular gene 
expression [105, 130]. A potential application of this acquired knowledge will help to improve 
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HLCs derivation methods to yield mature and homogenous hepatocyte populations in the 
future.  
 
1.10 Objective of this work 
This Ph.D. thesis work was primarily done at the Institute of Neurophysiology at the 
University of Cologne (UKK). In this work, a gene expression program of HLCs was 
dissected in comparison with “gold standard” freshly isolated adult hepatocytes and cultivated 
hepatocytes (in both monolayer and sandwich conditions) using gene arrays. 
 
For this purpose, embryonic stem cells were differentiated into HLCs using a well-known 
method.  The authenticity of derived HLCs was checked by RT-qPCR and immunostaining 
assays.  Then global gene expression of HLCs and hESCs was analyzed by gene arrays.  The 
resulted gene expression profiles of HLCs and hESCs were compared with freshly isolated 
adult hepatocytes and cultivated adult hepatocytes by using a series of computational tools.   
 
The following were key intentions of this study: 
A. Differentiation of embryonic stem cells (hESCs) into hepatocyte like cells (HLCs) 
B. Profiling global gene expression of HLCs as well as hESCs and comparing with freshly 
isolated adult hepatocytes and cultivated adult hepatocytes 
C. Determining the state and identity of differentiation in HLCs and to estimate gene 
regulatory mechanism by transcription factors via “Network Influence Scores” (NIS) 
using CellNet platform 
D. Generation of gene clusters based on similar gene expression patterns and identification 
of transcription factors associated with each cluster 
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E. Analysing correlation between genes downregulated during cultivation of adult 
hepatocytes and minimally upregulated genes in HLCs 
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2 Materials and methods 
2.1 Materials 
Following materials and equipment were used in cell culture, molecular biology and 
microarray analysis. 
Table 2 List of materials utilised in this study 
 
 
List of molecular biology reagents, and instruments 
Item Company Catalogue no. 
4′,6-Diamidino-2-phenylindole 
dihydrochloride (DAPI) 
Invitrogen, USA D21490 
Automated cooling centrifuge -
5430R 
Eppendorf, Germany  - 
Bovine Serum Albumin SERVA Electrophoresis, 
Germany  
11946.01 
Chloroform,  Molecular biology 
grade  
SIGMA-ALDRICH, 
USA 
C2432  
Donkey anti-goat IgG (H+L) 
Alexa Fluor- 488 conjugated   
Dianova, Germany  705-486-147 
Donkey anti-rabbit IgG (H+L) Cy3 
conjugated  
Dianova, Germany  711-166-152 
Ethanol, Molecular biology grade - 
1 liter 
Merck, Germany 1009831000 
Experion RNA StdSen starter kit  Bio-Rad, USA 700-7111 
Experion™ Automated 
Electrophoresis System 
Bio-Rad, USA - 
FluorPreserve™ Reagent Merck, Germany 345787 
Goat anti-Human DPPIV/CD26  R&D Systems, USA AF1180 
Mini plate spinner-MPS1000 Labnet, USA - 
Nanodrop ND-1000 UV-Vis 
spectrophotometer 
Nanodrop, USA - 
Nuclease-Free Water (not DEPC-
Treated) 
Invitrogen, Ambion, 
USA 
AM9937 
Rabbit anti-Human serum albumin  Abcam, UK ab2406 
Real time PCR  - 7500FAST Applied Biosystems, 
USA 
- 
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RNase-Free DNase Set  Qiagen, Germany   79254 
RNeasy Mini Kit  Qiagen, Germany   74106 
SuperScript® VILO™ cDNA 
Synthesis Kit 
Invitrogen, USA 11754250 
Taqman gene expression master 
mix 
 Invitrogen, USA  4369016 
Thermomixer-1.5 ml 
microcentrifuge tube 
Eppendorf, Germany  - 
Triton™ X-100 SIGMA-ALDRICH, 
USA 
X100  
TRIzol® reagent  Invitrogen, USA  15596-018  
TWEEN® 20 SIGMA-ALDRICH, 
USA 
P9416  
VORTEX GENIE-2 Scientific Industries, 
USA 
- 
 
List of Cell culture, reagents and instruments 
Item Company Catalogue no. 
1X Dulbecco´s Phosphate buffered 
saline 
 Invitrogen, USA  14040174 
1X Dulbecco´s Phosphate buffered 
saline- No calcium, magnesium 
 Invitrogen, USA  14190169 
4-(2-Hydroxyethyl)piperazine-1-
ethanesulfonic acid, N-(2-
Hydroxyethyl)piperazine-N′-(2-
ethanesulfonic acid, HEPES) 
SIGMA-ALDRICH, 
USA 
H4034 
B-27® Supplement (50X), minus 
vitamin A 
 Invitrogen, USA  12587-010 
Beta-Mercaptoethanol (50 mM)   Invitrogen, USA  31350010 
Centrifuge- IEC CENTRA CL2 Thermo Scientific, USA - 
CO2 incubator -HERACELL 150i Thermo Scientific, USA - 
Confocal microscopy-FV1000 Olympus, Japan - 
D-MEM/F-12 (1:1) (1X), liquid - 
with GlutaMAX™ medium 
 Invitrogen, USA  31331-093 
DMSO, Cell culture grade SIGMA-ALDRICH, 
USA 
D2650  
Fetal bovine serum  Invitrogen, USA  944855K 
 GlutaMAX™  Invitrogen, USA  35050-038 
hESC-qualified Matrix, 5 ml 
*LDEV Free  
BD Biosciences, USA 354277 
Hydrocortisone hemisuccinate SIGMA-ALDRICH, 
USA 
H2270 
Insulin solution Human SIGMA-ALDRICH, 
USA 
I9278 
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KnockOut™ D-MEM  Invitrogen, USA  10829-018 
Knockout™ Serum Replacement    Invitrogen, USA  10828028 
L-15 Medium SIGMA-ALDRICH, 
USA 
L1518 
Laminar air flow bench- HB2448 Heraeus, Germany - 
Laminar air flow-EN12469 Thermo Scientific, USA - 
mFreSR™ Stem cell technologies, 
USA 
05854 
mTeSR™ Stem cell technologies, 
USA 
05850 
Non-essential amino acids  Invitrogen, USA  11140035 
Penicillin-Streptomycin (10,000 
U/ml) 
 Invitrogen, USA  15140122 
Phase contrast microscope-
Axiovert 25 
Zeiss, Germany - 
Recombinant Human /Murine/Rat 
Activin A (E.coli derived) 
Peprotech, USA 120-14E 
Recombinant Human FGF-
Basic (FGF2) 
Peprotech, USA AF-100-18C 
Recombinant Human HGF Peprotech, USA 100-39 
Recombinant Human 
Oncostatin M/OSM 
R&D Systems, USA 295-OM-010 
Recombinant Human Wnt-3a R&D Systems, USA 5036-WNP-
010 
RPMI-1640 medium  Invitrogen, USA  61870-044 
Sodium pyruvate solution SIGMA-ALDRICH, 
USA 
S8636  
StemPro® hESC SFM   Invitrogen, USA  A1000701 
Stereo microscope-LEICA MZ 125 Leica Microsystems, 
Germany 
- 
Tryptose Phosphate Broth solution SIGMA-ALDRICH, 
USA 
T8159 
Weighing balance-BP121S Sartorius, Germany - 
William’s E medium   Panbiotech, Germany P04-29050 
 
List of microarray, instruments, kits, and reagents 
Item Company Catalogue no. 
3 IVT Express Kit    Affymetrix, USA       901229 
Experion automated electrophoresis 
system  
 Bio-Rad, USA 701-7000 
Experion RNA StdSen starter kit   Bio-Rad, USA 700-7111 
GeneChip Fluidics Station 450  Affymetrix, USA        00-0079 
GeneChip Hybridization Oven 645   Affymetrix, USA       00-0331  
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GeneChip hybridization, wash and 
stain kit 
 Affymetrix, USA       900720  
GeneChip Scanner 3000 7G 
WholeGenome Association System 
 Affymetrix, USA      00-0362  
 Human Genome U133 Plus 2.0 
arrays 
 Affymetrix, USA       900467 
 
List of  plastic and glass consumables 
Item Company Catalogue no. 
1 ml pipettes SARSTEDT AG & CO, 
Germany 
86.1251.001 
1.5 ml Microcentrifuge  Tubes   Axygen, USA   MCT150-C 
10 cm petri dishes Corning Inc, USA 353003 
10 microliter filtered tips  Nerbe plus GmbH, 
Germany 
07-602-7300 
10 ml pipettes Labomedic, Germany 1110508 
100 microliter filtered tips  Nerbe plus GmbH, 
Germany 
07-642-7300 
1000 microliter filtered  tips  Nerbe plus GmbH, 
Germany 
07-692-7300 
15 ml tubes  Labomedic, Germany 1110502 
1ml sterile syringe BD plastipak, USA 300013 
2 ml pipettes SARSTEDT AG & CO, 
Germany 
86.1252.001 
20 microliter filtered tips  Nerbe plus GmbH, 
Germany 
07-622-7300 
200 microliter filtered tips  Nerbe plus GmbH, 
Germany 
07-662-7300 
25 ml pipettes Labomedic, Germany 1110611 
5 ml pipettes  Labomedic, Germany 1110507 
50 ml tubes  Labomedic, Germany 1110503 
6 cm petri dishes      Corning Inc, USA 353004 
 6-well cell culture plates    Corning Inc, USA 353046 
Glass cover slips VWR, Germany 16004-316 
Glass Pasteur pipette VWR, Germany 612-1701 
MicroAMP fast optical 96-well 
plate 
Applied Biosystems, 
USA 
4346906 
MircroAmp optical adhesive film Applied Biosystems, 
USA 
4311971 
Stainless steel sterile needle 20 
gauge 
BD microlance, USA 301300 
StemPro® EZPassage™ 
Disposable Stem Cell Passaging 
Tool 
Invitrogen, USA 23181-010 
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Sterile cell scraper Techno Plastic Products 
AG (TPP), Switzerland 
99002 
 
Table 3 List of TaqMan® gene expression Assays 
Following gene expression probes were obtained from Invitrogen, 
USA. 
 
Gene symbol Assay ID 
ALB Hs00910225_m1 
ALDH1A1 Hs00946916_m1 
CAR  Hs00901571_m1 
CEBPA  Hs00269972_s1 
CEBPB  Hs00270923_s1 
CEBPD  Hs00270931_s1 
E2F5 Hs00231092_m1 
FGB Hs00905942_m1 
FOXA1  Hs04187555_m1 
FOXA2 Hs00232764_m1 
FOXA3  Hs00270130_m1 
FOXQ1  Hs00536425_s1 
GAPDH (Endogenous control) 4333764F 
HNF1A Hs00167041_m1 
HNF4A Hs00230853_m1 
MYB  Hs00920558_m1 
SOX11  Hs00846583_s1 
TTR Hs00174914_m1 
YBX3  Hs04195573_u1 
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2.2 Methods 
2.2.1 hESCs culturing and maintenance at the Institute of Neurophysiology, University 
of Cologne (UKK) 
Human embryonic stem cell lines (WA09) was obtained from the Wicell Research Institute, 
USA. Permission to work with hESCs was given by the Robert Koch Institute, Berlin (AZ: 
1710-79-1-4-48). H9 cells were maintained in irradiated embryonic fibroblast feeder cell lines 
(CF1 mouse strain) using Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 
supplemented with 1% penicillin-streptomycin, 1% nonessential amino acids, 4 ng/ml of 
fibroblast growth factor-2 and 0.1 mM beta-mercaptoethanol. All cell cultures were performed 
at 37°C and 5% CO2. For every 5-7 days, cells were passaged using a STEMPRO® 
EZPassage™ tool under a stereomicroscope.  
For feeder-free conditions [131], H9 cells were grown in matrigel coated culture dishes using 
mTeSR™ or StemPro® hESC serum-free medium supplemented with 0.1 mM beta-
mercaptoethanol and 8 ng/ml of fibroblast growth factor-2. All experiments were carried out 
using hESCs of passage number between 35 and 70. 
2.2.2 Differentiation of hESCs into hepatocyte like cells (HLCs)  
H9 cells were differentiated into HLCs using a published procedure [88, 132]. Briefly, H9 
cells were grown in a feeder-free environment using matrigel coated dishes. It is a prerequisite 
that seeded cells reach 60-70% confluency. Once the cells reached required confluency, 
hESCs (DAY0) was harvested using TRIzol® for RNA isolation, before the start of HLCs 
differentiation.  
HLCs differentiation was initiated by washing cells twice with 1X PBS and refreshing with 
“Definitive endoderm medium” consisting of RPMI 1640-Glutamax basal media 
supplemented with 100 ng/ml of Activin A, 50 ng/ml of Wnt3a and 1XB27. 
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 After 72 hrs, the differentiation medium was changed to “Hepatoblast differentiation 
medium” consisting of Knockout-DMEM media supplemented with 20% KSOR, 1% DMSO, 
1% non-essential amino acid, 0.5% glutamax, and 0.1 mM beta-mercaptoethanol for 7 days.  
Finally, “Hepatic maturation medium” consisting of L-15 media supplemented with 10 
ng/ml HGF, 10% FBS, 20 ng/ml Oncostatin M, 8.3% tryptose phosphate broth, 10 µm 
hydrocortisone-21-Hemisuccinate and 1 µM insulin was used the for hepatic maturation, 
which lasted for 7 days. The medium was refreshed daily in each stage of differentiation. On 
completion of differentiation at day18, HLCs were harvested using TRIzol® for RNA 
isolation.  
HLCs-islands were collected from a heterogeneous population for RNA isolation as reported 
earlier [133]. Briefly, hepatocyte like islands were identified by phase contrast microscopical 
observation and mechanically dissected under a stereomicroscope. After dissection, hepatic 
islands were pooled and lysed using TRIzol® reagent. All TRIzol® cell lysates were stored at 
-80°C until further processing. RNA samples, including hESCs (DAY0), HLCs-total 
(DAY18), and HLCs-islands (DAY18) were analysed in triplicates using gene arrays.   
2.2.3 Freshly isolated adult human hepatocytes and culturing 
Freshly isolated adult human hepatocytes (hHEPs, DAY0) were obtained under patient 
informed consent from liver sections of patients undergoing surgical liver resection (following 
the 1975 declaration of Helsinki) as previously described [134]. Hepatocytes were obtained by 
two-step collagenase-I perfusion of liver sections. A detailed protocol for isolation was 
described in Godoy et al. 2013 [134].  Freshly isolated hepatocytes from three independent 
donors were lysed using TRIzol®, stored at -80°C until RNA was isolated and analysed for 
global gene expression.  
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hHEPs (DAY0) were cultured using Williams’ medium E supplemented with 10% fetal 
bovine serum, 1 mM insulin, 15 mM HEPES, 0.8 µg/ml hydrocortisone, 1% penicillin-
streptomycin, 1% glutamax, 1% non-essential amino acids and 1 mM sodium pyruvate in 
matrigel coated culture plates with a density of 150, 000 cells/cm2.  These cultivated adult 
hepatocytes were used as positive control for immunostaining. 
2.2.4 RNA isolation and cDNA synthesis 
Stored TRIzol® cell lysates were thawed and proceeded for RNA isolation. Total RNA was 
purified using the RNeasy mini kit as per manufacturer’s protocol. Concisely, cell lysates 
were homogenized using 20 gauge syringe needle. After successful homogenization, the 
samples were encouraged for phase separation by the addition of 0.2 milliliters of chloroform 
for each 1 milliliter of TRIzol®. Phase separation of the lysates was allowed to take place at 
room temperature for 2-5 minutes. After 5 minutes, lysates were centrifuged at a 14,000 RPM 
for 15 minutes at 4 °C. After completion of centrifugation, only an upper layer was removed 
and collected in a new 1.5-milliliter microcentrifuge tube. Precipitation of RNA was achieved 
by the addition of an equal volume of ice-cold ethanol and mixed gently. From now on, all 
centrifugation steps take place at room temperature. The resultant mixture was added to the 
RNeasy spin column and centrifuged at 11,500 RPM for 30 seconds. After discarding the 
flow-through, 350 microliters of RW1 buffer was added to the spin column and centrifuged at 
11,500 RPM for 30 seconds. Spin column was digested using RNase-free DNase to remove 
the genomic DNA. For each column, a mixture of DNase (10µl) + RDD buffer (70 µl) was 
added to the column and incubated for 15 minutes at room temperature. After 15 minutes, 
DNase digestion reaction was arrested by the addition of 350 microliters of RW1 buffer and 
spin column flow-through was discarded. Spin column was washed twice, in a back to back 
manner using RPE buffer by centrifuging at 11,500 RPM for 30 seconds. The empty spin 
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column was dried by centrifuging at 14,000 RPM for 2 minutes. Finally, RNA was eluted by 
the addition of 20-25 microliter water (RNase, DNase-free). Purified RNA was quantified 
using ND-1000 UV-Vis spectrophotometer. For microarray analysis, RNA Integrity Number 
(RIN) was evaluated using Experion RNA StdSen starter kit and Experion automated 
electrophoresis system. RNA samples with RIN more than 8.0 were used for microarray 
analysis. 
1 µg or 500 ng of total RNA was employed for cDNA synthesis using Vilo Superscript cDNA 
synthesis kit as per manufacturer’s protocol. The reaction mixture composition was indicated 
in Table 4. Initially, the reaction mixture was incubated for 10 minutes at 25°C. On 
completion of the initial incubation, cDNA synthesis was continued for 60 minutes at 42 °C. 
Then cDNA synthesis was terminated by incubating at 85 °C for 5 minutes. Resultant cDNA 
was stored in -20 °C until used for RT-qPCR assays. 
 
 
Table 4 cDNA synthesis reaction mixture 
 
2.2.5 RT-qPCR assays 
The RT-qPCR reaction was carried out using TaqMan gene expression assays in a 7500 fast 
real-time cycler as per manufacture’s protocol (Table 5). cDNA of 2 microliters was used in 
20 microliter PCR reaction (Table 6), which ran in three replicates for each gene (Table 3). 
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H2O was used as negative control. Relative gene expression (delta-delta Ct method [135]) 
was calculated using DataAssit software version 3.01 from Applied Biosystems, USA. For 
gene expression computation, either hESCs or hHEPs was used as calibrator and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the housekeeping gene. 
 
 
Table 5 RT-qPCR cycling conditions 
 
 
Table 6 RT-qPCR reaction mixture composition 
 
2.2.6 Immunostaining assay 
Immunostaining was preceded with fixation of hESCs and HLCs cells with ice-cold methanol 
at -20°C for 10 minutes. Adult hepatocytes cultured in matrigel were fixed with ice-cold 
methanol at -20°C for 10 minutes and used as positive control. After washing three times with 
1X PBS, fixed cells were permeabilized using Triton-X 100 (1:50) for 30 minutes at room 
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temperature.  After permeabilization, cells were again washed three times with 1X PBS. Then, 
cells were blocked with a blocking buffer made by dissolving 3% of BSA and 1% Tween-20.  
Overnight incubation of ALB (1:50) and DPPIV (1:100)  was performed at 4°C diluted in 1X 
PBS (contains 0.3% BSA and 1% Tween-20). Secondary antibodies donkey anti-goat IgG 
(H+L) Alexa Fluor-488 conjugated (1:100) and donkey anti-rabbit IgG (H+L) Cy3 conjugated 
(1:100) dissolved in 1X PBS (contains 0.3% BSA and 1% Tween-20) were used and 
incubated for 2 hours at room temperature. DAPI counterstaining (1:10000) in distilled water 
was performed for 90 minutes at room temperature. Finally, stained cells were washed with 
1X PBS and mounted with FluorPreserve™ reagent. The scanning of mounted glass slides 
was performed using a confocal microscope. 
2.2.7 Microarray analysis 
Transcriptome analysis of all samples was performed using Affymetrix Human Genome U133 
Plus 2.0 arrays as per manufacture’s protocol. Briefly, 100 ng of total RNA was amplified 
using Gene chip 3’ IVT Express Kit as per manufacture’s guidelines. The resulted aRNA was 
purified using magnetic beads and 15 micrograms of aRNA hybridized onto the human 
genome U133 plus 2.0 chips in a gene chip hybridization oven-645. Then chips were stained 
and washed using an Affymetrix HWS kit. The chips were scanned with Affymetrix gene chip 
Scanner-3000-7G. The quality control analysis was performed using the GCOS software of 
Affymetrix. 
2.2.8 Gene array data of HLCs and stem cells from our collaborators 
Gene array data (Human Genome U133 Plus 2.0 arrays) of HLCs and stem cells (hESCs and 
ihPSC) were obtained from two collaborating partners for comparative study. Between two 
collaborators, one is a Medical Research Council (MRC), United Kingdom and another is 
Cellectis stem cell company (CEL), Sweden.  MRC’s HLCs differentiated from human 
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embryonic stem cells (ESC), and detailed differentiation protocol can be found elsewhere 
[136].  On the other hand, CEL’s HLCs differentiated from both human embryonic stem cells 
(ESC) and induced pluripotent stem cells (ihPSC), independently [136]. 
2.2.9 Gene array data of cultured primary adult hepatocytes  
For comparative analysis with HLCs, gene array data of in vitro cultivated adult hepatocytes 
were obtained.  Gene array data (Human Genome U133 Plus 2.0 arrays) of cultured primary 
adult hepatocytes under two different conditions, the collagen monolayer and collagen 
sandwich conditions were generated at “Leibniz Research Centre for Working Environment 
and Human Factors”, Dortmund. In both conditions, primary adult hepatocytes were cultured 
for various time points like 01, 02, 03, 05, 07, 10, and 14 days using the previously published 
method (Godoy et al. 2013) [134]. Briefly, isolated human hepatocytes were removed from 
the debris by percol centrifugation method and plated (6-well plate) in both collagen-I coated 
(monolayer, at a density of 104,166) and between two layers of collagen-I gel (collagen 
sandwich, at a density of 88,542). The cells were cultured in serum-free William's E medium 
for the indicated time. The medium was refreshed daily.     
2.2.10 Microarray data analysis by our bioinformatic collaborator 
Our collaborator at the Leibniz Institute for Natural Product Research and Infection Biology, 
Hans-Knöll-Institute (HKI) in Jena (Germany) performed all microarray data analysis. This 
analysis includes gene array data of UKK, MRC, CEL, freshly isolated adult hepatocytes and 
cultivated adult hepatocytes. Affymetrix gene expression data were preprocessed using 
‘affyPLM’ packages [137] of the Bioconductor project [138]. Processing and visualisation 
(principal component analysis) of data were performed using MATLAB tools (Mathworks, 
USA).  
2.2.11 Computation of differentially expressed genes 
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To obtain the genes with the strongest evidence of differential expression, a linear model fit 
was applied for each genes using ‘limma’ (Linear Models for Microarray data) packages 
[139]. Gene array data from freshly isolated adult hepatocytes (hHEPs) was used as reference. 
The custom chip definition file from Brainarray [140] based on UniGene ID’s was used to 
annotate gene probesets. A false positive rate of a=0.05 with FDR correction [141] and a fold 
change greater 2 was taken as the levels of significance.  
2.2.12 Fuzzy clustering 
The time profiles of the differentially expressed genes in stem cells and HLCs were scaled 
between their corresponding absolute temporal extreme values to focus subsequent cluster 
analysis on the qualitative behavior of the expression profiles.  The time series clustered using 
fuzzy c-means [142] (fuzzy exponent=1.5; Maximum number of iterations=200; minimum 
cost function improvement=10-10). The optimum number (N) of the cluster was calculated by 
repeated calculations (number of iterations=100) of the fuzzy cluster index ‘separation index’. 
Fuzzy clustering identified twenty clusters and those with the strongest change in gene 
expression were selected, and similar gene expression patterns compiled into five cluster 
groups. The manually curated Gene Ontology database of BioBase Knowledge Library (BKL) 
of the ExPlainTM web service (BioBase GmbH, Germany) was used for gene ontology 
enrichment. 
2.2.13 Gene ontology (GO) analysis 
Genes that show a change of the ratios higher or lower than 2-fold change in the arrays at any 
of the time points have been considered as upregulated or downregulated and subjected to 
gene ontology enrichment. Each cluster group was functionally categorized using BioBase 
knowledge library (BKL) of the ExPlainTM web service (BioBase GmBH, Germany).  The 
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analysis performed on the list of genes corresponding to the combination of clusters into 
cluster groups.   
2.2.14 Transcription factor binding site (TFBS) enrichment analysis 
For identification of transcription factors whose binding sites are enriched in a given set of 
promoters, the PRIMA tool [143]  of the Expander software version 6.1 was used [144].  The 
analysis was performed on genes belonging to the each cluster group that are significantly (p-
value <0.05) changed more than 2-fold. All the human genes (From Ensembl release 42) were 
used as background gene set, the threshold of the p-value set to 0.01 and the region was 
scanned from -3000 to +200. 
2.2.15 Identification of deregulated transcription factors 
To identify deregulated transcription factors in HLCs cluster groups, the genes were mapped 
to specific transcription factor using the database TRANSFAC professional and categorised 
using the ExPLainTM web service. 
2.2.16 Euclidean distance (ED) measurement  
To evaluate the differentiation process, the Euclidean distance between the different cell types 
was calculated based on the expression of the level of differentially expressed genes. The 
pairwise Euclidean distances were computed using the statistic toolbox of Matlab 
(Mathworks, USA) for genes with a fold change > 2 and a fold discovery rate (FDR) corrected 
p-value less than 0.05.   
2.2.17 CellNet analysis 
CellNet tool was used to analyse tissue/cell identity based on global gene expression data of 
hESCs, ihPSC and HLCs from three independent labs UKK, MRC, and CEL and freshly 
isolated adult hepatocytes (hHEPs) as described in Cahan P et al. 2014 [126]. This algorithm 
also generates a metric for gene regulatory network associated with the genes belonging to 
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each tissue identity. The Network influence score (NIS) was computed for cell and tissues 
with a high value of the gene regulatory network to estimate the importance of transcription 
factors to normal and dysregulated gene regulatory network. Locally available R version of 
CellNet was used for all calculations (http://pcahan1.github.io/cellnetr/). 
 
2.2.18 Statistics 
Results were presented as mean ± SEM derived from three biological replicates. The 
graphical representations of data were performed using Graph Pad Prism version 4.0 (Graph 
Pad Software, USA). 
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3 Results 
3.1 Derivation of HLCs from human embryonic stem cells (hESCs)  
In Institute of Neurophysiology, University of Cologne (UKK) the primary objective was to 
differentiate hESCs (WA09) into hepatocyte like cells (HLCs). For this purpose, a previously 
published “Directed differentiation” method [88, 132] was employed. The authenticity of 
derived HLCs (DAY18) was checked by RT-qPCR and immunocytochemistry assays. 
Reproducibility of derivation was checked by performing three independent experiments. 
Freshly isolated primary adult human hepatocytes (hHEPs, DAY0) were used as a positive 
control. Primary hepatocytes were obtained from three independent donors.   
Hepatocyte markers such as the transcription factors HNF4A, HNF1A, and FOXA3 [1], 
albumin (ALB), transthyretin (TTR), fibrinogen beta chain (FGB), and the metabolizing 
enzyme aldehyde dehydrogenase (ALDH1A1) were analyzed using RT-qPCR to compare the 
expression levels of the three cell types hESCs, HLCs and hHEPs. The result shows that 
expression levels of all genes are below detection limits for hESCs (Fig. 9). A strong increase 
in expression levels was observed in HLCs compared to hESCs (Fig. 9). However, expression 
levels in HLCs still were clearly lower compared to freshly isolated adult hepatocytes 
(hHEPs).   
Next, immunostaining was applied to study whether HLCs adopt an epithelial morphology by 
analyzing expression of plasma protein albumin and the bile canaliculi marker DPP4, a well-
established marker of hepatocyte polarity [145].  
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Figure 9: Expression of hepatic gene markers in hESCs, HLCs, and hHEPs 
The Strong increase in the expression of gene markers ALB, ALDH1A1, FOXA3, FGB, TTR, 
HNF4A, and HNF1A confirm hepatocyte like cells (HLCs) derivation from hESCs. However, 
the expression did not increase to the level of hHEPs. For the relative gene expression 
calculation, hESCs was used as calibrator and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) as housekeeping gene.  The mean and standard error of the mean (SEM) of gene 
expression levels were representative of three independent experiments. Freshly isolated adult 
hepatocytes (hHEPs) were obtained from three independent donors. ALB: Albumin; 
ALDH1A1: Aldehyde dehydrogenase family 1 Member A1; FOXA3: forkhead box A3; FGB: 
fibrinogen beta chain; TTR: transthyretin; HNF1A: Hepatocyte nuclear factor 1-Alpha; 
HNF4A: Hepatocyte nuclear factor 4-Alpha;  hESCs (DAY0): human embryonic stem cells; 
HLCs (DAY18): hepatocyte like cells. 
 
The results of the immunostaining experiments show that hESCs express neither DPP4 nor 
albumin (Fig. 10A-C). After differentiation to HLCs staining for DPP4 became positive (Fig. 
10D). DPP4 staining showed a pattern similar to primary human hepatocytes that used as 
positive control (Fig. 10G). In both HLCs and primary hepatocytes, the DPP4 signal was seen 
at the membrane surrounding small canaliculi. Albumin showed a clear cytoplasmic staining 
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in HLCs (Fig. 10E). A similarly positive result for albumin was obtained for the cultivated 
primary human hepatocytes (Fig. 10H).   
 
Figure 10: Immunostaining for ALB and DPPIV (Bile canaliculi) gene markers 
Images A and B represents DPPIV, ALB for hESCs (DAY0) and image C represent a phase 
contrast microscopy image. Images D and E represents DPPIV, ALB for HLCs (DAY18) and 
image F represent a phase contrast microscopy image. Images G and H represents DPPIV, 
ALB for primary human hepatocytes and the image I represent phase contrast microscopy 
image of primary hepatocytes. Blue color represents DAPI cellular nuclei staining; Scale 
bar=100 micrometres; ALB: Albumin; DPPIV: Dipeptidyl peptidase-4; hESCs (DAY0): 
human embryonic stem cells; HLCs (DAY18): hepatocyte like cells. 
 
In conclusion, a robust method for derivation of HLCs from hESCs was established.  
Expression of genes typically expressed in human hepatocytes was verified using RT-qPCR.  
In addition, albumin and DPP4 immunostaining were positive. However, expression levels in 
HLCs were still lower compared to freshly isolated adult hepatocytes, suggesting that the 
differentiation process is still incomplete.  
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3.2 Global gene expression of HLCs, stem cells and primary hepatocytes 
An attempt to characterize the global gene expression of HLCs, hESCs, hiPSCs from three 
independent labs Institute of Neurophysiology of Uniklink, köln (UKK), Medical Research 
Council, United Kingdom (MRC), and Cellartis (CEL), Sweden (Fig. 11) was realized using 
Affymetrix Human Genome U133 Plus 2.0 arrays. These labs generated HLCs using three 
published differentiation methods [146-148] (Fig. 11), i.e. “Directed differentiation”. Each of 
these methods consists of successive intermediate cellular stages such as definitive endoderm 
and hepatoblast when stem cells differentiate into HLCs (Fig. 11). However, these three 
methods differ in terms of growth factors use and the number of days accompanying each 
cellular stage (refer Fig. 11 for more details). Gene array data of HLCs and hESCs (Fig. 11 
and Table 7) from UKK were generated in this Ph.D. thesis work. Conversely, the rest of gene 
array data (Fig. 11 and Table 7) were obtained from collaborating partners such as the MRC 
and CEL.  
RNA of HLCs, hESCs and iPSCs at indicated time points (Fig. 11) were collected in 
biological triplicates and analyzed (Table 7). The population of HLCs from UKK were 
heterogeneous in nature, so total heterogeneous population, hepatocyte like islands were 
collected independently and analyzed (Fig. 11 and Table 7).  For comparative global gene 
expression analysis, freshly isolated adult human hepatocytes (hHEPs, DAY0) from three 
independent donors were used. The samples above were fed into the bioinformatic pipeline. 
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Figure 11: Schematic representation of the HLCs differentiation protocol used by three 
labs 
Three independent labs such as the Institute of Neurophysiology at University of Cologne, 
köln (UKK), Medical Research Council (MRC), United Kingdom, and Cellartis (CEL), 
Sweden generated HLCs from stem cells using three published differentiation methods, i.e. 
“Directed differentiation.” Each method consists of successive intermediate cellular stages 
such as definitive endoderm and hepatoblast when stem cells differentiate into HLCs.  
However, these three methods differ in terms of growth factors use and the number of days 
accompanying each cellular stage.  RNA of HLCs, hESCs, and iPSCs at indicated time points 
were collected in biological triplicates and analyzed (refer Table 7). Differentiation of hESCs 
into HLCs from UKK was performed exclusively in this Ph.D. thesis work.   
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Table 7 Overview of different samples from three labs analyzed by gene array 
List of samples that were subjected to global gene expression analysis, which were obtained 
from three independent labs such as the Institute of Neurophysiology at University of Cologne 
(UKK), köln, Medical Research Council, United Kingdom (MRC), and Cellartis (CEL), 
Sweden.  Gene array data of HLCs and hESCs from UKK were generated in this Ph.D. thesis 
work.  The rest of gene array data were obtained from two collaborating partners such as the 
MRC and CEL. 
 
Computed differentially expressed genes among HLCs, hHEPs, hESCs [e.g. hHEPs vs. HLCs, 
hHEPs vs. hESCs and hHEPs vs. hiPSC] were filtered using a fold change 2 with a false 
discovery rate 5% that resulted in 10,420 genes and used for further analysis. 
Principal component analysis (PCA) was used to identify cluster structure [149] in gene 
expression data.  PCA of 1000 highest variant genes was used to understand the dynamics of 
gene expression (Fig. 12) and their manifestations as follows. 
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Figure 12: Principal component analysis (PCA) biplot of different samples 
PCA plotted with 1000 highest variant genes in stem cells and HLCs.  The cultivated adult 
hepatocytes in the collagen monolayer and sandwich conditions were also included in the 
biplot.  HLCs differentiated from stem cells move towards freshly isolated adult hepatocytes 
but do not reach there yet. Presented data was representative of three biological array 
replicates of each sample. Gene array data of freshly isolated adult human hepatocytes (FH 
or hHEPs) were generated using hepatocytes from three independent donors. Gene array data 
of cultivated hepatocytes for monolayer and sandwich conditions were generated at “Leibniz 
research center for working environment and human factors,” Dortmund.  PC1: Principal 
Component 1; PC2: Principal Component 2; Human heps: Includes cultivated adult human 
hepatocytes and freshly isolated adult human hepatocytes (FH); HLCs-total: the 
heterogeneous population of hepatocyte like cells(UKK); HLCs-island:hepatocyte like islands 
extracted from heterogeneous population (UKK); UKK: Institute of Neurophysiology at 
University of Cologne; MRC: Medical Research Council, United Kingdom; CEL: Cellartis, 
Sweden.  
 
A. HLCs differentiated from hESCs, iPSCs approach towards hHEPs but do not reach the 
position of hHEPs (labeled as ‘FH’ under Human heps in Fig. 12). It suggests a partial 
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gain of hepatic transcriptomic characteristics. Selective profiling of the HLCs-island 
had little effect on the global gene expression profile of HLCs (Fig. 12). These two 
observations were confirmed by Euclidean distance analysis (Table 8).  
Samples 
Euclidean distance to 
hHEPs (DAY0) 
(10,420 genes; 2-
fold) 
Euclidean distance to 
hHEPs (DAY0) (%) 
hESCs 
(DAY0) 
212.94 100 
HLCs-total 185.01 86.9 
HLCs-island 178.44 83.8 
 
Table 8 Euclidean distance measurement 
Euclidean distance between freshly isolated adult human hepatocytes (hHEPs) and hESCs, 
HLCs from UKK was calculated using a statistic toolbox of Matlab (Mathworks Inc., USA).  
Differentially expressed 10,420 genes at a fold change 2 with the false discovery rate 
adjusted p-value ≤ 0.05 was used for Euclidean distance measurement. The Euclidean 
measurement of HLCs was scaled to the values of hESCs that were set to 100%.  HLCs-total: 
the heterogeneous population of hepatocyte like cells (UKK); HLCs-island: hepatocyte like 
islands extracted from the heterogeneous population (UKK); hESCs: human embryonic stem 
cells. 
 
B. Even though HLCs from three labs positioned as a distinct cluster, their distance to 
pluripotent cells and adult hepatocytes was relatively same, suggesting that HLCs from 
three different labs have a similar gene expression pattern (Fig. 12).  
C. Dedifferentiation of adult human hepatocytes in vitro and associated changes in gene 
expression pattern was well known [134]. Therefore, comparison of gene expression 
profiles of both monolayer and sandwich cultivated primary adult hepatocytes (up to 14 
days) with HLCs suggests that prolonged cultivation brings primary adult hepatocytes 
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towards HLCs (labelled as under Human heps in Fig. 12). This observation was supported 
by the Euclidean distance (ED) measurement between primary hepatocytes (hHEPs or 
hepatocytes cultivated in monolayer or sandwich culture environments) and HLCs and 
hESCs (Fig. 13). 
 
Figure 13: Euclidean distance measurement among adult hepatocytes, hESCs, hiPSC 
and HLCs 
The Euclidean distance(ED) measurement between primary hepatocytes (hHEPs or cultivated 
in monolayer or sandwich culture environments) and HLC from UKK (HLCs-island), MRC 
(HLC-MRC-D21), and CEL (HLC-CEL-hESC and HLC-CEL-hiPSC). Euclidean distances 
were computed using all differentially expressed genes with a cut-off of 2-fold and a FDR 
adjusted p-value ≤ 0.05. The ED of cultivated adult hepatocytes scaled to the values of hHEPs 
that were defined as 100%. HLCs-island: hepatocyte like islands extracted from the 
heterogeneous population (UKK); UKK: Institute of Neurophysiology at University of 
Cologne, köln; MRC: Medical Research Council, United Kingdom; CEL: Cellartis, Sweden; 
hESCs: human embryonic stem cells; hiPSC: human induced pluripotent stem cells; CS: 
collagen sandwich; CM: collagen monolayer; FH or hHEPs: freshly isolated adult 
hepatocytes. 
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D. Pluripotent stem cells hESCs, iPSCs from different labs clustered closely. Likewise, 
freshly isolated primary hepatocytes from three independent donors were positioned in 
close proximity (Fig. 12). 
Finally, the partial hepatic differentiation of HLCs was also confirmed by hierarchical 
clustering of 10,420 genes (Fig. 14). 
 
Figure 14: Hierarchical clustering of HLCs, hESCs, iPSCs and hHEPs 
Hierarchical clustering was used as an illustration of differentially expressed genes among 
different samples. Hierarchical clustering was performed for a set of 10, 420 genes with a fold 
change 2; p-value <0.05. Dendrogram suggests all HLCs samples clustered towards freshly 
isolated adult hepatocytes (hHEPs).  Gene probesets signal intensity (in log2 scale) was used 
as a scale for heatmap and suggest partial differentiation of HLCs. Presented data was 
representative of three biological array replicates of each sample.  Gene array data of freshly 
isolated adult human hepatocytes (hHEPs) were generated using hepatocytes from three 
independent donors. HLCs-total: the heterogeneous population of hepatocyte like cells 
(UKK); HLCs-island: hepatocyte like islands extracted from the heterogeneous population 
(UKK); UKK: Institute of Neurophysiology at University of Cologne; MRC: Medical 
Research Council, United Kingdom; CEL: Cellartis, Sweden; hESCs: human embryonic stem 
cells. 
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Collectively, the global gene expression analysis indicates that HLCs differentiated towards 
freshly isolated adult hepatocytes, but also inherited underdeveloped hepatic transcriptomic 
features.   
 
3.3 Gene regulatory network analysis demonstrates multi-organ differentiation in 
HLCs 
Further characterization of HLCs from three independent labs such as the Institute of 
Neurophysiology, University of Cologne (UKK), Medical Research Council (MRC), United 
Kingdom, and Cellartis (CEL), Sweden was performed using the CellNet bioinformatic 
algorithm [126]. CellNet analyzes cellular identity using global gene expression profiles and 
gene regulatory networks of different human tissues and cell types.  For this purpose, gene 
array data of HLCs, hESCs, and iPSCs from the aforementioned labs and freshly isolated 
adult hepatocytes (hHEPs) were analyzed in triplicates by CellNet. 
 
The CellNet analysis indicated that hHEPs and embryonic stem cells (hESCs) scored a single 
tissue classification of “liver,” “esc” (Fig. 15), respectively. On the other hand, HLCs 
classified as mixed tissue types such as “liver,” “esc,”  “colon” and “fibroblast” (Fig. 15).  
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Figure 15: Cell and tissue type classification probability 
 Freshly isolated adult hepatocytes (hHEPs), stem cells (hESCs, hiPSC) and hepatocyte like 
cells (HLCs) from three independent labs UKK, CEL, and MRC were analyzed by the CellNet 
algorithm. Global gene expression profiles of the aforementioned samples were analyzed and 
compared to the training expression profiles defining each of 16 human tissues or cells, as 
described in Cahan et al. 2014 [126]. The maximal classification scores were observed for 
hHEPs and hESCs from UKK corresponds to “liver” and “esc,” respectively.  HLCs (total, 
island) from UKK were classified into different tissues such as “esc,” “liver,”“colon,” and 
“fibroblast.”  Presented data was representative of three biological array replicates of each 
sample.  Gene array data of freshly isolated adult hepatocytes (hHEPs) were generated using 
hepatocytes from three independent donors. HLCs-total: the heterogeneous population of 
hepatocyte like cells (UKK); HLCs-island: hepatocyte like islands extracted from the 
heterogeneous population(UKK); UKK: Institute of Neurophysiology at University of 
Cologne; MRC: Medical Research Council, United Kingdom; CEL: Cellartis, Sweden; 
hESCs: human embryonic stem cells; hiPSC: human induced pluripotent stem cells.  
 
Moreover, the CellNet algorithm estimates a metric of the gene regulatory network (GRN) 
associated with the tissue classifications. The metric integrates TFs influence over gene 
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expression, based on studies such as Chromatin Immunoprecipitation Sequencing (Chip-Seq) 
and gene expression profiles after TFs overexpression or knockdown [126].  
In this regard, hESCs and hHEPs scored with a maximal GRN status, i.e. 1 for “stem cells” 
and “liver,” respectively (Fig. 16A). HLCs showed a strong but still incomplete decrease in 
the “hESCs” GRN status (Fig. 16A) suggesting stem cell characteristics linger in HLCs.  
Conversely, a strong increase in “liver” GRN status was detected in HLCs (Fig. 16A) than 
hESCs. Interestingly, the liver GRN status was reaching scores equal or higher than 0.5 in 
HLCs (Fig. 16A). Moreover, GRN status revealed an increase in “colon” and “fibroblast” 
status for HLCs (Fig. 16A), in agreement with the tissue classification (Fig. 15) analysis.  
Finally, CellNet also generates a “Network Influence Score” (NIS), whereby the potential 
influence of each transcription factor on each gene regulatory network is estimated (Fig. 16B) 
[126]. The hESCs network contains TFs with well-known roles in stem cell biology such as 
NANOG and POU5F1B. The NIS of these TFs was high in hESCs and strongly reduced in 
HLCs (Fig. 16B). Nevertheless, TFs such as SALL2 and LIN28A remained with a high NIS 
in HLCs (Fig. 16B).   
The NIS for the “liver” GRN identified several liver-enriched TFs such as NR1H4 (FXR), 
CAR (NR1I3), PXR (NR1I2) and HNF4A, whose low influence in hESCs was partially 
increased in HLCs (Fig. 16B).   
In the same way, NIS analysis identified several colon-enriched TFs such as KLF5, CDX2, 
and NKX2-3, whose influence increased in HLCs than hESCs (Fig. 16B).  The expression 
levels of  KLF5 and CDX2 was increased in HLCs than in hHEPs (Fig. 17), supporting the 
estimation of their activity in HLCs.  Furthermore, colon-enriched genes such as MEP1A and 
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CDH17 were also strongly induced in HLCs (Fig. 17).  The tissue specificity of KLF5, CDX2, 
MEP1A, and CDH17 was validated using the human protein atlas portal [150] (Fig. 17). The 
protein atlas contains RNA and protein data of numerous tissues and cell types.   
The NIS of fibroblast-enriched genes contains TFs such as TWIST1 and SNAI2, known to 
promote epithelial to mesenchymal transition (EMT), thereby representing an unwanted 
feature (Fig. 16B). 
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Figure 16: CellNet enables identification of multi-tissue gene regulatory networks in 
HLCs from three labs (UKK, MRC, and CEL)  
A) Gene regulatory network (GRN) status in hHEPs, hESCs, hiPSC, and HLCs Bars 
represent the strength of tissue-specific gene regulatory network.  GRN for hESCs, liver, 
colon, and fibroblast was established by training in CellNet, representing the maximum 
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value of 1.0.  HLCs showed a strong, but still an incomplete decrease in the “hESCs” 
gene regulatory network status suggesting stem cell characteristics lingers in HLCs.  A 
strong increase in “liver” gene regulatory network status was detected in HLCs than in 
hESCs.  Interestingly, liver gene regulatory network status was reaching scores equal or 
higher than 0.5 in HLCs.  Moreover, GRN status revealed an increase in “colon” and 
“fibroblast” status for HLCs. B) Identification of transcription factors with the highest 
influence on the hESCs, liver, colon and fibroblast gene regulatory network CellNet 
establishes a metric for the influence of TFs over the genes contained in each tissue GRN, 
i.e. Network Influence Score (NIS).  The heat maps indicate the top ten TFs with the 
highest influence on each GRN.  The hESCs network contains TFs with well-known roles 
in stem cell biology such as NANOG and POU5F1B.  The NIS of these TFs was high in 
hESCs and strongly reduced in HLCs.  Nevertheless, TFs such as SALL2 and LIN28A 
remained with a high NIS in HLCs.		The NIS for the “liver” GRN identified several liver-
enriched TFs such as NR1H4 (FXR), CAR (NR1I3), PXR (NR1I2) and HNF4A, whose low 
influence in hESCs was partially increased in HLCs.  The NIS analysis identified various 
colon-enriched TFs such as KLF5, CDX2, and NKX2-3, whose influence increased in 
HLCs than hESCs.		The NIS of fibroblast-enriched genes contains TFs such as TWIS1 and 
SNAI2, known to promote epithelial to mesenchymal transition (EMT), thereby 
representing an unwanted feature. Presented data was representative of three biological 
array replicates of each sample. Gene array data of freshly isolated adult hepatocytes 
(hHEPs) were generated using hepatocytes from three independent donors. HLCs-total: 
the heterogeneous population of hepatocyte like cells (UKK); HLCs-island: hepatocytes 
like island extracted from the heterogeneous population (UKK); UKK: Institute of 
Neurophysiology at University of Cologne; MRC: Medical Research Council, United 
Kingdom; CEL: Cellartis, Sweden; hESCs: human embryonic stem cells; hiPSC: human 
induced pluripotent stem cells;TFs or TF: transcription factors. 
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Figure 17: Identification of colon-associated genes in HLCs from three labs (UKK, 
MRC, and CEL) 
The left side of the figure panel indicates the expression levels of the transcription factors 
KLF5, CDX2, and colon genes MEP1A and CDH17 in hESCs and HLCs, which was extracted 
from gene array data.  Expression levels of these colon-enriched genes increased in HLCs 
compared to hESCs. The tissue specificity for these genes was validated by querying the 
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tissue-based map of the human proteome [150]. Here, representative pictures of 
immunostainings for the aforementioned genes are shown, indicating the nuclear expression 
of KLF5 and CDX2 in the colon crypts, and the membranous expression of  MEP1A and 
CDH17. On the right side of the figure panel, the colon-enriched expression of these genes is 
also shown, which was extracted from RNA sequencing (RNA-seq) data.  Presented data was 
representative of three biological array replicates of each sample.  CDX2: CDX2 caudal type 
homeobox 2; KLF5: Kruppel-like factor 5; MEP1A: Meprin A, Alpha; CDH17: Cadherin 17, 
LI Cadherin;  HLCs-total: the heterogeneous population of hepatocyte like cells(UKK); 
HLCs-island: hepatocytes like island extracted from the heterogeneous population (UKK); 
UKK: Institute of Neurophysiology at University of Cologne; MRC: Medical Research 
Council, United Kingdom; CEL: Cellartis, Sweden; ESCs: human embryonic stem cells; 
hiPSC: human induced pluripotent stem cells. 
 
In conclusion, CellNet unveiled details of the differentiation stage of HLCs, namely the 
acquisition of mixed phenotype with the partial loss of stem cell characteristics and gain of the 
hepatocyte, colon, and fibroblast lineages. 
3.4 Cluster groups identify TFs between successful and insufficient differentiation 
processes 
Fuzzy c-means clustering is a pattern recognition algorithm [142] that could help to identify 
differentially expressed gene clusters in HLCs in comparison with freshly isolated adult 
hepatocytes (hHEPs). For this purpose, differentially expressed 10,420 genes (from earlier 
section 3.2) in hESCs and HLCs (total and island) from UKK were subjected to the Fuzzy c-
means clustering.   
Fuzzy clustering sorted differentially expressed genes into distinct clusters, and this precise 
clustering will allow to identify different biological process motifs in HLCs. Consequently, 
each cluster was analyzed for probable gene ontologies with the help of manually curated 
Gene Ontology database of BioBase Knowledge Library (BKL). Resulting gene ontologies 
with a p-value less than 0.05 were considered as statistically significant.   
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To further evaluate transcriptional regulation in HLCs, differentially expressed TFs and 
overrepresentation of transcription factor binding sites (TFBS) in the correlated gene groups 
were determined. For this purpose, gene clusters were subjected to transcription factors 
binding site analysis using Promoter Integration in Microarray Analysis Algorithm (PRIMA) 
of the EXPression ANalyzer and DisplayER (EXPANDER) version 6.1 [143, 144]. Twenty 
clusters were formed that were assigned to five cluster groups (Fig. 18) as below.  
1. Cluster group II & I represents “Mature liver functions.” 
2.  Cluster group III & IV represents “Proliferation process” 
3. Cluster group V represents “Extracellular matrix (ECM) and Migration” 
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Figure 18: Cluster groups represent complete and partial hepatic differentiation of 
HLCs 
Fuzzy clustering of 10,420 differentially expressed genes in hESCs and HLCs generated 20 
distinct clusters that represent well-defined gene expression patterns.  These 20 clusters 
consist of 10,212 genes while 208 genes do not fit into any cluster regime and were classified 
as outliers. Five cluster groups such as Mature liver functions (Cluster group I and II), 
Proliferation process (Cluster group III and IV) and Extracellular matrix (ECM), migration 
(Cluster group V) were formed by selecting clusters containing genes with average fold 
changes over 5-fold. The cluster groups contain 3,217 genes, allowing for a more robust and 
precise bioinformatic analysis. The most relevant biological motifs and their representative 
genes were shown. Furthermore, the potential transcriptional mechanisms such as 
deregulated transcription factors and overrepresented transcription factor binding sites in 
each cluster group were also shown.  TFBS: Transcription factor binding sites; TF or TFs: 
transcription factors; hESCs: human embryonic stem cells; HLCs: Hepatocytes like cells.  
 
3.4.1 Cluster group I: Mature liver functions 
Cluster group I consist of 1,057 genes (Appendix Table 9) with low expression in hESCs that 
increased after HLCs differentiation to levels comparable to those in hHEPs.  Cluster group I 
are enriched in gene ontologies (GO) associated with mature liver functions, including 
“metabolic process” (GO:0008152), “catalytic activity” (GO:00038) and “immune system 
process” (GO:0002376). Hence, cluster group I represents successful HLCs differentiation.  
Cluster group I contains various TFs with known roles in hepatocyte differentiation, including 
transcriptionally upregulated HNF1A, HNF4A, FOXA1, FOXA2, CEBPA, CEBPB, and 
CEBPD (Fig. 18). The upregulation of aforementioned TFs was validated using RT-qPCR by 
comparing expression levels in hESCs, HLCs, and hHEPs (Fig. 19). Expression levels were 
normalized to those in hHEPs. Expression levels of FOXA1, FOXA2, CEBPA, CEBPB, and 
CEBPD was upregulated in HLCs than in hESCs (Fig. 19).  Validation results of HNF1A and 
HNF4A were presented in earlier section 3.1 (Fig. 9).  
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Figure 19: RT-qPCR validation of transcription factors belong to the cluster group I  
Expression levels of transcription factors FOXA1, FOXA2, CEBPA, CEBPB, and CEBPD 
were analyzed in hESCs, HLCs, and hHEPs. All these genes were upregulated in HLCs than 
in hESCs. For the relative gene expression calculation, hHEPs was used as calibrator and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as housekeeping gene. The mean and 
SEM were computed from the expression levels of three biological replicates (hESCs and 
HLCs).  Freshly isolated adult human hepatocytes (hHEPs) from three independent donors 
were used.  FOXA1: Forkhead Box Protein A1; FOXA2: Forkhead Box Protein A2; CEBPA: 
CCAAT/enhancer-binding protein, alpha; CEBPB: CCAAT/enhancer-binding protein, beta; 
CEBPD: CCAAT/enhancer-binding protein, delta; hESCs (DAY0): human embryonic stem 
cells; HLCs (DAY18): hepatocyte like cells; SEM: standard error of the mean. 
 
Moreover, HNF1A binding sites were significantly enriched in cluster group I (Fig. 18). The 
increased expression of these TFs is consistent with successful hepatocyte differentiation of 
HLCs, since their role as inducers of liver-specific is well-established [151].  
3.4.2 Cluster group II: Mature liver functions 
Cluster group II consists of 447 genes (Appendix Table 10) with low expression in hESCs that 
were minimally induced after differentiation into HLCs. The enriched gene ontology terms 
were similar to the cluster group I such as “metabolic process” (GO:0008152), “catalytic 
activity” (GO:00038) and “immune system process” (GO:0002376). However, cluster group 
II genes did not reach the levels of hHEPs. This cluster group contains TFs controlling liver 
metabolic functions, such as CAR, FXR, SHP, and PXR (Fig. 18). These TFs were minimally 
induced in HLCs than in hHEPs. Expression of CAR was validated using RT-qPCR by 
comparing the expression levels in hESCs, HLCs, and hHEPs (Fig. 20). Expression levels 
were normalized to those in hHEPs. CAR is minimally induced in HLCs than in hHEPs (Fig. 
20). 
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Figure 20: RT-qPCR validation of transcription factor belongs to the cluster group II  
Expression levels of transcription factor CAR was analyzed in hESCs, HLCs, and hHEPs.  
NR1I3 is minimally induced in HLCs than in hHEPs. For the relative gene expression 
calculation, hHEPs was used as calibrator and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) as housekeeping gene. The mean and SEM were computed from the expression 
levels of three biological replicates (hESCs and HLCs). Freshly isolated adult human 
hepatocytes (hHEPs) from three independent donors were used. hESCs (DAY0): human 
embryonic stem cells; HLCs (DAY18): hepatocyte like cells; SEM: standard error of the 
mean;  NR1I3: Nuclear Receptor Subfamily 1, Group I, Member 3. 
 
The low expression of these TFs in HLCs is consistent with the NIS results for the “liver” 
gene regulatory network (refer earlier section 3.3). The binding site for HNF1A was also 
overrepresented in cluster group II. The complexity of the gene regulatory networks is 
illustrated by the fact that overrepresented binding sites of HNF1A appear in both, cluster I 
and II. The difference between cluster group I and II may be due to HNF1A interaction 
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partners. Indeed, FXR and PXR functionally interact with HNF1A show low expression in 
HLCs. 
3.4.3 Cluster group III: Proliferation process 
Cluster group III consists of 1,562 genes (Appendix Table 11) whose expression was high in 
hESCs and strongly decreased during differentiation into HLCs.  Cluster group III enriched in 
GO terms such as “cell cycle” (GO:0007049), and “regulation of mitosis” (GO:0007088).  
Genes in these categories include cyclins as well as cyclin-dependent kinases, and the 
involved transcriptionally upregulated TFs as well as overrepresented TFBS are well 
established as control factors of proliferation such as E2F5 and MYB (Fig. 18). 
Downregulation of cell cycle associated genes suggests repression of the self-renewal 
potential, a hallmark of pluripotent stem cell differentiation. This microarray finding was 
validated using RT-qPCR by analyzing the expression of MYB in hHEPs, HLCs, and hESCs 
(Fig. 21). Expression levels were normalized to those in hHEPs. MYB is highly expressed in 
hESCs and strongly reduced during HLCs differentiation (Fig. 21). 
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Figure 21: RT-qPCR validation of transcription factor belongs to the cluster group III   
The expression level of MYB was analyzed in hESCs, HLCs, and hHEPs. MYB is highly 
expressed in hESCs and decreased strongly during HLCs differentiation. The relative gene 
expression was calculated using hHEPs as calibrator and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) as housekeeping gene. The mean and SEM were computed from the 
expression levels of three biological replicates (hESCs and HLCs). Freshly isolated adult 
human hepatocytes (hHEPs) from three independent donors were used. MYB: V-Myb Avian 
Myeloblastosis Viral Oncogene Homolog; human embryonic stem cells; HLCs (DAY18): 
hepatocyte like cells; hESCs: human embryonic stem cells; SEM: standard error of the mean. 
 
3.4.4 Cluster group IV: Proliferation process  
Cluster group IV contains 101 genes (Appendix Table 12) with high expression in hESCs that 
did not decrease to the expression levels of hHEPs during HLCs differentiation. Cluster group 
IV associated to gene ontologies such as “regulation of nuclear division” and “regulation of 
mitosis”. Cluster group IV is part of the cell cycle process machinery. It includes genes such 
as CCBN1, CDK1, ECT2, TOP2A, and TTK. Although the expression of these genes was 
downregulated in HLCs compared to hESCs, their levels remained above those of hHEPs. It 
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contains only one TFs, i.e. SOX11 (Fig. 18). This finding was validated using RT-qPCR by 
comparing expression in hESCs, HLCs, and hHEPs (Fig. 22). Expression levels were 
normalized to those in hHEPs. While cell cycle associated transcription factor MYB 
expression strongly reduced in HLCs (Fig. 21), the expression levels of E2F5 remained 
elevated in HLCs (Fig. 22), suggesting that E2F5 may be responsible for the sustained 
expression of cell-cycle associated genes in cluster group IV. 
 
 
Figure 22: RT-qPCR validation of transcription factors belong to the cluster group IV  
Expression levels of SOX11 and  E2F5 were analyzed in hESCs, HLCs, and hHEPs.  E2F5 
was highly expressed in hESCs and remained elevated in HLCs than in hHEPs. On the other 
hand, SOX11 is highly expressed in hESCs and downregulated during HLCs differentiation.  
The relative gene expression was calculated using hHEPs as calibrator and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) as housekeeping gene. The mean and SEM were 
representative of three biological replicates for each cell type (hESCs and HLCs). Freshly 
isolated adult human hepatocytes (hHEPs) from three independent donors were used.  hESCs 
(DAY0): human embryonic stem cells; HLCs (DAY18): hepatocyte like cells; SEM: standard 
error of the mean; E2F5: E2F Transcription Factor 5; SOX11: SRY (Sex Determining Region 
Y)-Box 11. 
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3.4.5 Cluster group V: Extracellular matrix and Migration 
Cluster group V contains 505 genes (Appendix Table 13).  These genes were expressed 4-fold 
higher in hESCs compared to hHEPs and which further increase during HLCs differentiation.  
GO terms such as “extracellular region” (GO:0005576) and “cell migration” (GO:0016477) 
were overrepresented in cluster group V. Genes in these categories include extracellular 
matrix genes such as  collagens (e.g. COL1A1, COL12A1), other matrix genes (FBN1, 
LAMB3 and LAMA5), integrins (e.g. ITGA3, IGA6, and ITGAV) and cytokines (EGF, 
WNT5A). The deregulated TFs identified in this cluster group, including FOXQ1, YBX3, 
TWIST1, and SOX4, may be responsible for the immature nature of differentiated HLCs. For 
example, FOXQ1 is an oncogene found to be overexpressed in colorectal [152] and breast 
cancer [153], where it induces proliferation, dedifferentiation, and epithelial to mesenchymal 
transition.  Moreover, FOXQ1 is also overexpressed in hepatocellular carcinoma and induces 
metastasis [154]. Likewise, YBX3 induces proliferation and dedifferentiation [155, 156].  The 
upregulation of TFs FOXQ1 and YBX3 was validated using RT-qPCR by analyzing the 
expression in hESCs, HLCs, and hHEPs (Fig. 23). Expression levels were normalized to those 
in hHEPs.  Expression of YBX3 was increased in HLCs than in hESCs (Fig. 23). Therefore, 
cluster group V was considered to be the undesirable resultant of HLCs differentiation.   
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Figure 23: RT-qPCR validation of transcription factors belong to the cluster group V 
Expression levels of YBX3 and FOXQ1 were analyzed in hESCs, HLCs, and hHEPs. The 
expression level of YBX3 was increased in HLCs than in hESCs. For the relative gene 
expression calculation, hHEPs was used as calibrator and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) as housekeeping gene. The mean and SEM were representative of 
three biological replicates (hESCs and HLCs). Freshly isolated adult human hepatocytes 
(hHEPs) from three independent donors were used. hESCs (DAY0): human embryonic stem 
cells; HLCs (DAY18): hepatocyte like cells; SEM: standard error of the mean; YBX3; Y Box 
Binding Protein 3; FOXQ1: Forkhead Box Q1. 
 
In conclusion, cluster group analysis reveals gene groups representing successful and failed 
outcomes in HLCs differentiation. Moreover, identification of critical TFs responsible for 
aberrant gene clusters in HLCs, thereby giving a basis for overexpression or knockdown 
approaches to improve HLCs differentiation. 
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3.5 Cultivation-dependent repression of liver metabolism genes 
It is well known that primary hepatocytes dedifferentiate in culture, whereby expression of 
many metabolic genes decreases. Intriguingly, in vitro dedifferentiated adult hepatocytes 
resemble stem cell derived HLCs, which can be seen from the PCA (refer earlier section 3.2, 
Fig. 12) and can also be objectified by the analysis of Euclidean distances (refer previous 
section 3.2, Fig. 13). Therefore, one might hypothesise that if the same genes which decrease 
during cultivation in adult hepatocytes also remain low after differentiation of stem cells into 
HLCs, this mutual deficiency may be due to failure of culture conditions to deliver critical 
factors of differentiation present in vivo, i.e. real liver tissue environment. To test this 
proposed theory, the correlation between downregulated genes after 14 days of monolayer 
culture of adult hepatocytes and the gene expression in HLCs minus expression in freshly 
isolated adult hepatocytes was studied.   
Interestingly, a highly significant correlation (Fig. 24A) was obtained (P<0.001; R=0.54). 
Further analysis of the 10, 20 and 40% genes with the highest correlation coefficients as 
indicated by red, purple and green colors (Fig. 24A), respectively was performed.  
Intriguingly, these genes (Fig. 24B) belong predominantly to the cluster group II (refer earlier 
section 3.4). This correlation remained high even when including the top 20 or 40 % genes 
(Fig. 24B). As described above, metabolism related GO terms are enriched in Cluster group II 
(refer earlier section 3.4). Likewise, metabolism GO terms were enriched in the top 10% to 40 
% correlated genes. Notably, all of these genes are expressed at much lower levels in HLCs 
than in adult hepatocytes. The same genes were also downregulated during a 14 days 
cultivation period, when the hepatocytes were kept in two-dimensional monolayer cultures.  
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To see if decreased expression of metabolic genes is explained by a change in culture 
conditions. For this purpose, three-dimensional cultivation of hepatocytes was used. In three-
dimensional (3D) culture system, hepatocytes were cultured between two layers of soft gel 
collagen. Three-dimensional system abolished the decrease in the expression of some genes 
including ADH1C, CYP4F2, CYP7A1, and HSD11B1, but the condition remained similar for 
the majority of genes. 
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Figure 24: Comparable repression of metabolism associated genes during cultivation of 
adult hepatocytes and differentiated HLCs  
A) Correlation between genes repressed in adult hepatocytes after 14 days of cultivation in 
two-dimensional (collagen monolayer) environments and genes deregulated in HLCs-islands 
compared to hHEPs. The red dots represent the top 10%, while the purple and green dots 
correspond to the additional 20 and 40% genes with the highest correlation. B) Venn diagram 
analysis indicates the high overlap between top 10, 20, and 40% correlated genes with genes 
in Cluster group II (from earlier section 3.4). The light blue circles represent genes in each 
Cluster group as described in Fig. 18 (from earlier section 3.4). Red circles represent genes 
in the top 10 to 40% with the highest correlation, as described in Fig. A.	Gene array data of 
HLCs and cultivated adult hepatocytes (in monolayer and sandwich conditions) at different 
time points were generated in triplicates. Gene array data of freshly isolated adult 
hepatocytes (hHEPs) were generated using hepatocytes from three independent donors.  
HLCs-island:	 hepatocyte like islands extracted from the heterogeneous population (UKK); 
UKK: Institute of Neurophysiology at University of Cologne; CM: collagen monolayer. 
 
Taken together, mechanism inherent to in vitro culturing antagonizes the differentiation 
towards mature hepatocytes, affecting both the stability of adult hepatocytes and the potential 
for a gain of mature hepatocyte functions in HLCs. 
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4 Discussion 
The differentiation of hESCs to hepatocyte like cells (HLCs) opens exciting new possibilities 
to generate an unlimited supply of human hepatocytes for numerous applications [157, 158]. 
Generation of HLCs similar to freshly isolated adult hepatocytes in terms of transcriptome and 
function is a desirable outcome of stem cell engineering [126, 159, 160]. Indeed, recent 
studies reported that hESCs derived HLCs exhibited liver functions [161, 162]. However, 
different critical viewpoints on the differentiation status of HLCs have been published [163].  
Transcriptome analysis of embryos E20 to E32 had identified crucial TFs and putative 
molecular network responsible for early human organogenesis [164]. Therefore, transcriptome 
analysis of HLCs along with freshly isolated adult hepatocytes was performed to understand 
key TFs and gene networks that drive HLCs differentiation form hESCs.  In this regard, HLCs 
generated from hESCs using a well-established protocol. Validation of differentiated HLCs 
was performed using RT-qPCR (Fig. 9) and immunostaining techniques (Fig. 10).  Among the 
panel of markers used for HLCs validation, transcription factors such as HNF1A, HNF4A, 
and FOXA3 are critical for liver development [1, 5]. Moreover, these three transcription 
factors are also critical for proper functioning of the liver and maintaining the liver 
architecture. In adult hepatocytes, genome-wide chromatin immunoprecipitation assay 
suggests that HNF4A is capable of binding 12% of human hepatic genes [47]. However, 
comparative global gene expression analysis (Fig. 12 and 14) suggested that HLCs obtained 
partial hepatic transcriptomic features. The presence of DPPIV on the apical side of HLCs 
along with the cytoplasmic presence of albumin confirmed the epithelial polarity of derived 
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HLCs (Fig. 10). Hepatic epithelial morphology is important for proper functioning of the adult 
liver [7].  
4.1 Decoding cellular identity of HLCs 
The present genome-wide study demonstrates that the interpretation of HLCs almost fully 
differentiated hepatocytes might be further away from the truth than previously suggested.  In 
reality, the hybrid phenotype of the liver, colon, stem cells and fibroblast is obtained (Fig. 15 
and 16). This seems to be in agreement with established principles of human embryonic 
development.  After gastrulation, the naive endoderm transforms into a primitive gut tube that 
becomes regionalized into foregut, midgut, and hindgut domains. As the development 
proceeds, the foregut develops into the liver while hindgut forms the large intestine. In line 
with this, a recent proteomics approach demonstrated that HLCs resemble embryonic than 
mature liver [165]. 
Results of the present GRN analysis show that HLCs represent a progenitor cell type, which 
has neither been classified as liver nor as colon, with high expression of the colon-associated 
TFs such as KLF5, CDX2, and NKX2-3 (Fig. 16 and 17). Nonetheless, the in vivo counterpart 
of HLCs is unclear. To further differentiate HLCs to pure populations of mature hepatocytes it 
will be useful to suppress TFs responsible for colon development in HLCs. 
 
4.2 Gene expression alternations during HLCs differentiation 
The fuzzy clustering analysis demonstrated that gene expression alternations during the HLCs 
differentiation process fall into five distinct groups (Fig. 18). Cluster group I supports the 
‘favorable’ interpretation obtained in several previous studies. It contains hepatic metabolic 
genes that strongly upregulated during the differentiation process. However, it should be 
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considered that also cluster group II contains genes representative of normal liver functions, 
such as metabolism, and synthesis of coagulation and complement factors. In contrast to 
cluster group I they remain orders of magnitudes lower than those in adult hepatocytes.  
Interestingly, cluster group II genes overlap significantly with genes whose expression 
decreases during in vitro culturing of adult hepatocytes (Fig. 24A-B). This striking overlap 
could mean that the critical mechanisms responsible for maintenance of the liver’s metabolic 
genes are generally absent in vitro.  In this study, TFs responsible for maintenance of cluster 
group II in adult hepatocytes are identified, which may helpful to improve stem cell 
differentiation into maturated HLCs (Fig. 18). The binding site of HNF1A, a TFs involved in 
the expression of genes characteristic of differentiated hepatocytes [151] is overrepresented in 
cluster group II genes. Moreover, ‘liver transcription factors’ such as CAR, FXR, and PXR 
are upregulated in HLCs but only to levels of much lower than those observed in adult 
hepatocytes.   
The second ‘favorable’ Cluster group III contains proliferation-associated genes that are 
suppressed during the differentiation process, thereby reaching the low expression levels of 
adult hepatocytes. In contrast, cluster group IV is also associated contains proliferation-
associated genes, but expression levels stay higher compared to adult hepatocytes. These 
genes are regulated by transcription factor SOX11 (Fig. 18). Cluster group V contains genes 
whose expression is upregulated in HLCs than in adult hepatocytes. These genes include 
extracellular matrix proteins and integrins as well as transcription factor TWIST1, which 
previously have been reported to be upregulated when adult hepatocytes dedifferentiate in 
culture [166-168].  
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These ‘unfavourable’ clusters (II, IV and V) contain totally 1,053 genes (28.7%) compared to 
the much higher number of 2,619 (71.3%) genes of the favourable clusters (I and III). 
Therefore, the majority of genes induced during differentiation approach similar to those of 
primary hepatocytes (Appendix Table 9 and 11). However, a major hurdle on the path to stem 
cell derived HLCs are control mechanisms of cluster groups II, IV, and V (Appendix Table 
10, 12 and 13). Since the TFs controlling their expression have been identified in this study, 
research in future should aim at adjusting their activity to levels of adult hepatocytes. 
 
4.3 Usage of HLCs in Biomedical Research 
Apart from a potential application of the HLCs for treatment of degenerative liver diseases, 
HLCs become very  attractive in pharmacological and toxicological research [3].  Several 
studies have demonstrated the applicability of HLCs to study the development of liver disease 
and to elucidate liver toxicity mechanisms [169, 170].  Their applications are however, limited 
as they are classified as immature and hybrid cell types [2, 3, 126, 160, 171, 172].  A major 
drawback could be the fact that HLCs do not exhibit important phase I-II metabolizing 
enzyme activities [147, 158, 163].  Even after reaching an optimal matured state, a 
challenging issue remains to keep a functional and phenotypical stability of HLCs under long-
term cell culture conditions [3, 172].  Moreover, transplantation studies conducted in mouse 
models suggest that HLCs exhibited minimal or even no functional improvement in the host 
environment [3].   
The present dissertation contributes to the identification of key target transcription factors for 
improving maturation of HLCs (Fig. 18).  Therefore, it opens new horizons for improving 
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maturation and functionality of HLCs for their application in regenerative medicine and drug 
discovery. 
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5 Conclusion 
The present comprehensive genome-wide study of hepatocyte like cells has potential 
applications in stem cell engineering of hepatocytes. This study is successful in revealing the 
strengths and limitations of current protocols aiming at the generation of hepatocyte like cells 
from human embryonic stem cells. The observation of colon fate specification and definition 
of five cluster groups, two are in agreement with hepatocyte like cells differentiation and three 
problematic clusters, and their assignment to key transcription factors give a basis for 
improvements of  stem cell differentiation methods in future. 
Overall, the presented findings will be helpful in designing novel differentiation protocols, 
which may yield mature hepatocyte populations.  
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6 Appendix     
 
The values in the tables are fold changes. 
Table 9  Cluster group I: Mature liver functions 
Total number of genes: 1,057 
The list of 1057 genes represents a cluster group I that is responsible for mature liver 
functions as described in chapter 3.4.1, Fig. 18. Column 1(from left to right) represents the 
gene symbol and column 2 represents the corresponding gene description. Column 3 and 4 
contain the fold change values of hHEPs vs. hESCs. Column 5 and 6 contain fold change 
values of hHEPs vs. HLCs. HLCs-total: the heterogeneous population of hepatocyte like cells; 
HLCs-island: hepatocyte like islands extracted from the heterogeneous population; hESCs: 
human embryonic stem cells; hHEPs:  freshly isolated adult hepatocytes; vs.: versus. 
Symbol Description hESC1 hESC2 HLCs-
total 
HLCs-
islands 
EMC3 ER membrane protein complex subunit 3 -2.32 -2.38 -1.6 -1.52 
MED8 mediator complex subunit 8 -2.52 -2.63 -1.22 -1.13 
C6orf89 chromosome 6 open reading frame 89 -2.54 -2.61 -1.08 -1.17 
TM9SF1 transmembrane 9 superfamily member 1 -2.33 -2.36 -1.66 -1.72 
SLC12A7 solute carrier family 12 (potassium/chloride 
transporter), member 7 
-2.86 -2.95 -1.29 -1.5 
TMED4 transmembrane emp24 protein transport domain 
containing 4 
-2.97 -3.13 -1.12 -1.1 
SNX14 sorting nexin 14 -3.02 -2.98 -1.16 -1.14 
QPRT quinolinate phosphoribosyltransferase -2.46 -2.81 -1.17 -1.15 
ZNF654 zinc finger protein 654 -2.65 -2.83 -1.51 -1.61 
TMEM9B TMEM9 domain family, member B -2.28 -2.38 -1.5 -1.5 
GUK1 guanylate kinase 1 -2.38 -2.62 -1.14 -1.15 
RIOK3 RIO kinase 3 -1.99 -2.04 -1.42 -1.44 
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MPPE1 metallophosphoesterase 1 -2.86 -2.88 -1.38 -1.21 
RRBP1 ribosome binding protein 1 -2.12 -2.65 -1.36 -1.31 
DNALI1 dynein, axonemal, light intermediate chain 1 -3.06 -2.82 -1.23 1.01 
DNAJC1 DnaJ (Hsp40) homolog, subfamily C, member 1 -2.33 -2.84 -1.28 -1.24 
KLHL8 kelch-like family member 8 -3.29 -3.17 -1.56 -1.66 
SPRYD7 SPRY domain containing 7 -2.75 -2.71 -1.14 -1.3 
FBXL17 F-box and leucine-rich repeat protein 17 -2.03 -2.26 -1.36 -1.6 
TPST1 tyrosylprotein sulfotransferase 1 -2.9 -3.12 -1.31 -1.36 
LYSMD3 LysM, putative peptidoglycan-binding, domain 
containing 3 
-2.39 -2.52 -1.14 -1.02 
FOXP1 forkhead box P1 -2.64 -2.38 -1.42 -1.38 
HLA-C major histocompatibility complex, class I, C -2.71 -3 -1.27 -1.27 
---   -2.59 -2.49 -1.41 -1.34 
GOLGA5 golgin A5 -2.6 -2.67 -1.19 -1.01 
FAM134A family with sequence similarity 134, member A -2.53 -2.66 -1.75 -1.98 
PNPLA8 patatin-like phospholipase domain containing 8 -3.55 -3.81 -1.77 -1.42 
ITFG1 integrin alpha FG-GAP repeat containing 1 -3.44 -3.74 -1.38 -1.4 
TNFAIP1 tumor necrosis factor, alpha-induced protein 1 
(endothelial) 
-2.54 -2.62 -1.07 -1.26 
TAB3 TGF-beta activated kinase 1/MAP3K7 binding 
protein 3 
-2.48 -2.54 -1.82 -1.73 
KIAA1715 KIAA1715 -3.61 -3.49 -1.19 -1.1 
DNAJC3 DnaJ (Hsp40) homolog, subfamily C, member 3 -2.45 -2.5 -1.87 -1.7 
PSAP prosaposin -2.71 -2.99 -1.3 -1.25 
TMCC1 transmembrane and coiled-coil domain family 1 -2.7 -2.71 -1.42 -1.65 
SDF4 stromal cell derived factor 4 -2.83 -3.09 -1.73 -1.93 
REEP5 receptor accessory protein 5 -2.68 -2.65 -1.77 -1.62 
CMPK1 cytidine monophosphate (UMP-CMP) kinase 1, 
cytosolic 
-2.51 -2.77 1.01 1.06 
RAB2A RAB2A, member RAS oncogene family -2.32 -2.55 -1.14 -1.19 
TPRG1L tumor protein p63 regulated 1-like -2.46 -2.53 -1.68 -1.72 
CHIC2 cysteine-rich hydrophobic domain 2 -2.13 -2.23 1 -1.28 
CRELD1 cysteine-rich with EGF-like domains 1 -2.52 -2.46 -1.13 1.04 
ASXL1 additional sex combs like 1 (Drosophila) -2.11 -2.22 -1.4 -1.47 
BLZF1 basic leucine zipper nuclear factor 1 -2.55 -2.54 -1.73 -1.36 
PPCS phosphopantothenoylcysteine synthetase -3.41 -3.62 -1.86 -1.89 
NDEL1 nudE neurodevelopment protein 1-like 1 -2.01 -2.17 -1.13 -1.22 
GATC glutamyl-tRNA(Gln) amidotransferase, subunit C -3.47 -3.52 -1.84 -1.81 
ZFHX3 zinc finger homeobox 3 -1.92 -1.88 -1.17 -1.18 
KLF3 Kruppel-like factor 3 (basic) -2.87 -2.71 -1.78 -1.78 
HSD17B14 hydroxysteroid (17-beta) dehydrogenase 14 -2.15 -2.27 -1.36 -1.12 
KIF13B kinesin family member 13B -3.8 -3.79 -1.61 -1.69 
NHLRC3 NHL repeat containing 3 -3.65 -3.64 -1.89 -1.71 
SCYL1 SCY1-like 1 (S. cerevisiae) -3 -3.21 -1.26 -1.22 
EGLN1 egl-9 family hypoxia-inducible factor 1 -3.19 -3.55 -1.11 -1.34 
PLEKHA1 pleckstrin homology domain containing, family A 
(phosphoinositide binding specific) member 1 
-2.49 -2.59 -1.18 -1.23 
EVI5 ecotropic viral integration site 5 -3.47 -3.82 -1.13 -1.16 
EDEM3 ER degradation enhancer, mannosidase alpha-like 3 -2.82 -3.31 -1.52 -1.61 
ZMYM6NB ZMYM6 neighbor -1.76 -1.8 -1.45 -1.49 
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ZNF148 zinc finger protein 148 -2.55 -2.63 -1.81 -1.57 
USP38 ubiquitin specific peptidase 38 -2.58 -2.72 -1.81 -2.31 
C11orf24 chromosome 11 open reading frame 24 -2.11 -2.08 -1.47 -1.47 
DUSP3 dual specificity phosphatase 3 -2.1 -2.27 -1.54 -1.42 
ALCAM activated leukocyte cell adhesion molecule -3.27 -3.36 -1.53 -1.47 
DENND1B DENN/MADD domain containing 1B -2.84 -2.83 -1.65 -1.54 
EXT1 exostosin glycosyltransferase 1 -1.9 -1.92 -1.07 -1.2 
TMEM256 transmembrane protein 256 -2.57 -2.32 -1.39 -1.29 
GPR39 G protein-coupled receptor 39 -1.75 -1.88 -1.45 -1.37 
DNAJB2 DnaJ (Hsp40) homolog, subfamily B, member 2 -2.4 -2.56 -1.76 -1.81 
RAB14 RAB14, member RAS oncogene family -2.44 -2.64 -1.61 -1.91 
DOPEY2 dopey family member 2 -3.45 -3.1 -1.61 -1.85 
SCO2 SCO2 cytochrome c oxidase assembly protein -2.52 -3.01 -1.28 -1.27 
TMUB2 transmembrane and ubiquitin-like domain 
containing 2 
-2.12 -2.05 -1.28 -1.16 
DCAF10 DDB1 and CUL4 associated factor 10 -2.59 -2.76 1.02 -1.04 
REEP3 receptor accessory protein 3 -2.31 -2.22 -1.28 -1.39 
BAD BCL2-associated agonist of cell death -2.44 -2.5 -1.26 -1.12 
RNF103 ring finger protein 103 -2.62 -2.66 -1.19 -1.12 
ERMAP erythroblast membrane-associated protein (Scianna 
blood group) 
-2.38 -2.66 -1.89 -1.83 
IFNAR2 interferon (alpha, beta and omega) receptor 2 -3.07 -2.96 -2.17 -1.96 
ATP7A ATPase, Cu++ transporting, alpha polypeptide -2.17 -2.02 1.02 -1.04 
HGSNAT heparan-alpha-glucosaminide N-acetyltransferase -2.08 -2.13 -1.23 -1.3 
FOXO3 forkhead box O3 -2.38 -2.05 -1.55 -1.74 
APPBP2 amyloid beta precursor protein (cytoplasmic tail) 
binding protein 2 
-3.22 -3.22 1.15 -1.07 
CYB5R1 cytochrome b5 reductase 1 -3.11 -3.46 -1.83 -1.66 
DST dystonin -2.29 -2.53 -1.52 -1.12 
CAPN7 calpain 7 -2.34 -2.59 1.04 1.09 
PLA2G15 phospholipase A2, group XV -2.17 -2.3 -1.88 -1.88 
LEPROT leptin receptor overlapping transcript -3.38 -3.57 -1.2 -1.21 
GOLGB1 golgin B1 -3.1 -3.03 -2 -1.33 
TBC1D2 TBC1 domain family, member 2 -2.48 -2.79 -2.18 -1.98 
SCAPER S-phase cyclin A-associated protein in the ER -4.66 -3.86 -1.63 -1.25 
SNX4 sorting nexin 4 -2.64 -3.06 -2.01 -1.65 
TPRA1 transmembrane protein, adipocyte asscociated 1 -2.39 -2.39 -1.46 -1.37 
DIP2C DIP2 disco-interacting protein 2 homolog C 
(Drosophila) 
-2.54 -2.54 -1.45 -1.58 
TPK1 thiamin pyrophosphokinase 1 -3.14 -3.19 -1.41 -1.45 
MOV10 Mov10, Moloney leukemia virus 10, homolog 
(mouse) 
-2.02 -2.05 -1.38 -1.39 
CEPT1 choline/ethanolamine phosphotransferase 1 -2.89 -3.14 -1.85 -2.16 
SORCS2 sortilin-related VPS10 domain containing receptor 2 -2.31 -2.31 -1.75 -1.93 
CASC4 cancer susceptibility candidate 4 -2.96 -3.12 -1.15 -1.18 
SGPP1 sphingosine-1-phosphate phosphatase 1 -3.03 -2.95 1.27 1.28 
WBP1L WW domain binding protein 1-like -2.1 -2.2 -1.11 -1.34 
NCOA4 nuclear receptor coactivator 4 -2.02 -2.22 -1.55 -1.67 
RAB21 RAB21, member RAS oncogene family -2.49 -2.29 -1.66 -2.04 
GINM1 glycoprotein integral membrane 1 -3.19 -3.17 -1.39 -1.35 
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LY6E lymphocyte antigen 6 complex, locus E -3.39 -3.36 -1.42 -1.41 
TMEM219 transmembrane protein 219 -2.41 -2.65 -1.17 -1.04 
CDK19 cyclin-dependent kinase 19 -1.8 -1.75 -1.1 -1.31 
ABCG1 ATP-binding cassette, sub-family G (WHITE), 
member 1 
-2.2 -2.1 -1.13 1.28 
CLCN5 chloride channel, voltage-sensitive 5 -4.12 -4.07 -1.37 -1.52 
ERAP1 endoplasmic reticulum aminopeptidase 1 -3.69 -3.6 -1.37 -1.53 
DENND5B DENN/MADD domain containing 5B -2.85 -2.87 -1.51 -1.64 
KLHDC10 kelch domain containing 10 -2.62 -2.53 -1.3 -1.4 
ETHE1 ethylmalonic encephalopathy 1 -3.22 -3.09 -1.1 -1.07 
RNPEPL1 arginyl aminopeptidase (aminopeptidase B)-like 1 -1.62 -1.7 -1.15 -1.16 
TMEM187 transmembrane protein 187 -3.62 -3.66 -1.7 -1.77 
SLC35B3 solute carrier family 35 (adenosine 3'-phospho 5'-
phosphosulfate transporter), member B3 
-2.81 -2.92 1.15 1.1 
ITPRIPL2 inositol 1,4,5-trisphosphate receptor interacting 
protein-like 2 
-1.99 -2.29 1.13 -1.27 
IL22RA1 interleukin 22 receptor, alpha 1 -2.23 -2.39 -2.12 -1.91 
FAM134C family with sequence similarity 134, member C -2.81 -2.86 -1.54 -1.81 
MAFF v-maf avian musculoaponeurotic fibrosarcoma 
oncogene homolog F 
-2.42 -2.26 -1.05 -1.54 
ATF6 activating transcription factor 6 -3.56 -3.35 -1.45 -1.43 
FLJ20021 uncharacterized LOC90024 -2.02 -2.23 -1.41 -1.46 
VAMP7 vesicle-associated membrane protein 7 -2.02 -2.1 -1.17 -1.18 
LINC00674 long intergenic non-protein coding RNA 674 -2.7 -2.71 -1.39 -1.54 
ATG4A autophagy related 4A, cysteine peptidase -2.6 -2.61 -1.66 -1.52 
HEXA hexosaminidase A (alpha polypeptide) -2.32 -2.53 -1.12 -1 
FAM73A family with sequence similarity 73, member A -3.81 -3.78 1.07 1.04 
TMEM50B transmembrane protein 50B -3.53 -3.81 -1.4 -1.29 
PLEKHA7 pleckstrin homology domain containing, family A 
member 7 
-4.12 -3.59 -1.4 -1.85 
FBXL3 F-box and leucine-rich repeat protein 3 -2.88 -3.01 -1.29 -1.37 
PSME1 proteasome (prosome, macropain) activator subunit 
1 (PA28 alpha) 
-3.87 -3.69 -1.23 -1.21 
ZBTB38 zinc finger and BTB domain containing 38 -1.59 -1.66 -1.6 -1.65 
DNAH5 dynein, axonemal, heavy chain 5 -2.08 -2.04 -2.17 -2.22 
IER5L immediate early response 5-like -2.2 -2.3 1.07 -1.03 
PRKAB2 protein kinase, AMP-activated, beta 2 non-catalytic 
subunit 
-2.18 -2.11 1.05 1.03 
IFI35 interferon-induced protein 35 -2.98 -2.78 -2.1 -1.84 
TAPBP TAP binding protein (tapasin) -1.75 -1.75 -1.16 -1.14 
SLC1A4 solute carrier family 1 (glutamate/neutral amino 
acid transporter), member 4 
-2.48 -2.63 -1.7 -1.75 
CBX4 chromobox homolog 4 -2.17 -2.05 1.12 -1.02 
FAM174A family with sequence similarity 174, member A -4.28 -4.41 -1.04 -1.13 
POLK polymerase (DNA directed) kappa -3.37 -3.81 -1.54 -1.24 
TRIQK triple QxxK/R motif containing -3.44 -3.55 1.18 1.25 
JAK1 Janus kinase 1 -4.12 -4.5 -1.25 -1.36 
PCMTD1 protein-L-isoaspartate (D-aspartate) O-
methyltransferase domain containing 1 
-4.16 -4.4 -1.36 -1.29 
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SOCS3 suppressor of cytokine signaling 3 -1.74 -1.94 1.22 -1.04 
TET2 tet methylcytosine dioxygenase 2 -1.82 -1.84 -1.01 -1.15 
GALE UDP-galactose-4-epimerase -2.84 -3.07 -1.86 -1.55 
MAGI3 membrane associated guanylate kinase, WW and 
PDZ domain containing 3 
-1.51 -1.72 -1.33 -1.41 
EBF4 early B-cell factor 4 -2.11 -2.07 -1.5 -1.58 
TESK1 testis-specific kinase 1 -1.96 -2 -1.33 -1.28 
ACO2 aconitase 2, mitochondrial -2.1 -2.41 -1.51 -1.38 
ABHD5 abhydrolase domain containing 5 -1.89 -2.05 -1.74 -1.57 
ZDHHC9 zinc finger, DHHC-type containing 9 -2.51 -2.54 -1.91 -1.95 
LOC728431 uncharacterized LOC728431 -2.21 -2.15 -1.77 -1.47 
MAN1A2 mannosidase, alpha, class 1A, member 2 -1.51 -1.67 -1.38 -1.35 
HEBP1 heme binding protein 1 -5.83 -5.06 -1.27 -1.36 
HNF1B HNF1 homeobox B -1.94 -2.09 -1.4 -1.25 
RER1 retention in endoplasmic reticulum sorting receptor 
1 
-2.33 -2.37 -1.81 -1.78 
LIG4 ligase IV, DNA, ATP-dependent -3.39 -4.1 -2.3 -2.03 
PPP3CC protein phosphatase 3, catalytic subunit, gamma 
isozyme 
-2.71 -3.05 1.4 1.51 
CLDN3 claudin 3 -2.44 -2.33 -1.89 -1.69 
FAM177A1 family with sequence similarity 177, member A1 -2.12 -2.01 -1.1 -1.06 
TMEM59 transmembrane protein 59 -4.25 -4.18 -1.06 -1.03 
KIAA0247 KIAA0247 -3.2 -3.5 -1.32 -1.6 
ANKRA2 ankyrin repeat, family A (RFXANK-like), 2 -3.57 -3.83 1.14 1.05 
RAB32 RAB32, member RAS oncogene family -1.77 -2 -1.28 -1.3 
LMO7 LIM domain 7 -2.19 -2.03 -1.76 -1.81 
OSTF1 osteoclast stimulating factor 1 -2.41 -2.85 -1.43 -1.61 
PDXDC1 pyridoxal-dependent decarboxylase domain 
containing 1 
-2.1 -2.12 -1.11 -1.14 
USP47 ubiquitin specific peptidase 47 -2.47 -2.69 -1.54 -1.36 
SGMS1 sphingomyelin synthase 1 -2.53 -2.56 1.02 -1.19 
LMNA lamin A/C -1.93 -2.12 -1.42 -1.38 
CEP104 centrosomal protein 104kDa -2.24 -2.22 -1.42 -2.02 
ERBB2IP erbb2 interacting protein -3.02 -2.79 -1.87 -1.79 
C19orf10 chromosome 19 open reading frame 10 -2.79 -3.19 -1.9 -2.04 
SLC35A1 solute carrier family 35 (CMP-sialic acid 
transporter), member A1 
-2.98 -3.44 -1.63 -1.74 
ANAPC16 anaphase promoting complex subunit 16 -2.6 -2.55 -1.41 -1.54 
CACNA1D calcium channel, voltage-dependent, L type, alpha 
1D subunit 
-2.03 -1.98 -1.92 -1.72 
TMEM106A transmembrane protein 106A -2.49 -2.49 -1.66 -1.63 
KRBOX4 KRAB box domain containing 4 -3.51 -3.02 -1.62 -1.67 
YPEL3 yippee-like 3 (Drosophila) -2.7 -2.7 -1.41 -1.39 
LAMB2 laminin, beta 2 (laminin S) -4.6 -4.16 -1.7 -1.44 
STAM2 signal transducing adaptor molecule (SH3 domain 
and ITAM motif) 2 
-1.85 -2.07 -1.61 -1.56 
NUCB2 nucleobindin 2 -4.04 -5.54 -1.35 1.23 
NADSYN1 NAD synthetase 1 -2.44 -2.52 -2.05 -2 
RND3 Rho family GTPase 3 -1.74 -1.78 1.2 -1 
EPS8L2 EPS8-like 2 -2.99 -2.86 -1.29 -1.2 
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LCOR ligand dependent nuclear receptor corepressor -3.69 -3.69 -1.49 -1.45 
OS9 osteosarcoma amplified 9, endoplasmic reticulum 
lectin 
-2.22 -2.39 -1.37 -1.52 
FNDC3A fibronectin type III domain containing 3A -1.98 -2.07 -1.5 -1.54 
DCTN3 dynactin 3 (p22) -1.96 -1.97 1.12 1.16 
DUSP28 dual specificity phosphatase 28 -1.67 -1.61 1.01 -1.01 
LOC100507557 uncharacterized LOC100507557 -3.25 -3.06 1.05 -1.1 
FCHO2 FCH domain only 2 -2.66 -2.86 -2.02 -1.81 
CTSL cathepsin L -4.22 -4.46 -1.24 -1.18 
ELF1 E74-like factor 1 (ets domain transcription factor) -3.12 -3.67 1.12 1.1 
SIDT2 SID1 transmembrane family, member 2 -2.11 -2.04 1.25 1.19 
FBXL4 F-box and leucine-rich repeat protein 4 -3.12 -3.39 -1.49 -1.64 
STX17 syntaxin 17 -2.4 -2.38 -1.75 -1.74 
LETMD1 LETM1 domain containing 1 -3.15 -2.99 -1.16 -1.04 
FAM213A family with sequence similarity 213, member A -1.59 -1.72 -1.61 -1.61 
RNH1 ribonuclease/angiogenin inhibitor 1 -2.49 -2.54 -1.33 -1.43 
TMPRSS2 transmembrane protease, serine 2 -2.96 -2.87 -2.05 -1.91 
AMICA1 adhesion molecule, interacts with CXADR antigen 
1 
-2.41 -2.49 -2.09 -2.04 
ZNF800 zinc finger protein 800 -2.22 -2.44 -1.55 -1.62 
MIEN1 migration and invasion enhancer 1 -2.4 -2.47 -1.45 -1.47 
STS steroid sulfatase (microsomal), isozyme S -1.62 -1.67 -1.5 -1.59 
AOAH acyloxyacyl hydrolase (neutrophil) -1.72 -1.67 -1.56 -1.61 
IRF2BP2 interferon regulatory factor 2 binding protein 2 -2.94 -2.66 -1.53 -1.78 
IL32 interleukin 32 -3.35 -3.84 -1.6 -1.29 
MBTPS2 membrane-bound transcription factor peptidase, site 
2 
-2.69 -2.5 -1.43 -1.5 
CD164 CD164 molecule, sialomucin -2.23 -2.48 1.52 1.45 
CADM1 cell adhesion molecule 1 -2.21 -2.49 1.11 -1.32 
TRIM38 tripartite motif containing 38 -2.86 -2.78 1.05 1.07 
HIPK3 homeodomain interacting protein kinase 3 -1.49 -1.44 -1.09 -1.06 
ZNF823 zinc finger protein 823 -1.6 -2.18 1.11 -1.12 
DHRS7 dehydrogenase/reductase (SDR family) member 7 -4.03 -3.49 -1.93 -1.75 
GABARAP GABA(A) receptor-associated protein -2.04 -2.28 1.2 1.14 
MLLT6 "myeloid/lymphoid or mixed-lineage leukemia 
(trithorax homolog, Drosophila); translocated to, 6" 
-1.67 -1.83 -1.43 -1.36 
GLRX glutaredoxin (thioltransferase) -2.94 -3.51 -1.07 1.04 
BNIP3 BCL2/adenovirus E1B 19kDa interacting protein 3 -4.04 -5.01 -1.22 -1.6 
FAM107B family with sequence similarity 107, member B -3.26 -3.37 -1.42 -1.36 
CLN5 ceroid-lipofuscinosis, neuronal 5 -4.25 -4.7 -2.11 -2.03 
SLC46A1 solute carrier family 46 (folate transporter), member 
1 
-1.99 -1.99 -1.52 -1.52 
TAP1 transporter 1, ATP-binding cassette, sub-family B 
(MDR/TAP) 
-2.16 -1.97 -1.48 -1.58 
TRADD TNFRSF1A-associated via death domain -2.4 -2.43 -1.37 -1.48 
MKNK1 MAP kinase interacting serine/threonine kinase 1 -2.37 -2.56 -1.39 -1.51 
RHBG Rh family, B glycoprotein (gene/pseudogene) -1.93 -1.84 -1.32 -1.16 
PERP PERP, TP53 apoptosis effector -1.34 -1.73 1.14 1.08 
---   -4.71 -5.74 -1.55 -1.89 
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IAH1 isoamyl acetate-hydrolyzing esterase 1 homolog (S. 
cerevisiae) 
-4.21 -4.05 -1.13 -1.03 
CITED2 Cbp/p300-interacting transactivator, with Glu/Asp-
rich carboxy-terminal domain, 2 
-3.07 -3.16 1.61 1.29 
CAMTA2 calmodulin binding transcription activator 2 -1.76 -1.71 -1.03 -1.04 
AFTPH aftiphilin -2.26 -2.34 -1.89 -2 
C1orf85 chromosome 1 open reading frame 85 -2.18 -2.27 -2.17 -2.17 
NDUFC2 NADH dehydrogenase (ubiquinone) 1, subcomplex 
unknown, 2, 14.5kDa 
-1.65 -1.74 -1.49 -1.52 
PEX11B peroxisomal biogenesis factor 11 beta -4.79 -4.93 -1.56 -1.7 
KIFAP3 kinesin-associated protein 3 -3.74 -3.84 1.45 1.46 
NEDD4 neural precursor cell expressed, developmentally 
down-regulated 4, E3 ubiquitin protein ligase 
-4.8 -5.61 -1.14 -1.05 
AKTIP AKT interacting protein -1.89 -2.01 -1.01 -1.07 
SLC35D2 solute carrier family 35 (UDP-GlcNAc/UDP-
glucose transporter), member D2 
-4.37 -4.79 -1.09 1.03 
DDIT3 DNA-damage-inducible transcript 3 -3.08 -3.43 -1.28 1.11 
KDELR2 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum 
protein retention receptor 2 
-2.39 -2.43 1.64 1.67 
IFT20 intraflagellar transport 20 homolog 
(Chlamydomonas) 
-3.3 -3.34 1.55 1.64 
NEK7 NIMA-related kinase 7 -2.5 -3.08 1.76 1.55 
ERBB3 v-erb-b2 avian erythroblastic leukemia viral 
oncogene homolog 3 
-4.04 -3.39 -2.26 -2.09 
CHURC1 churchill domain containing 1 -2.31 -2.25 -1.77 -1.67 
RNF149 ring finger protein 149 -6.51 -6.84 -1.64 -1.84 
NUCB1 nucleobindin 1 -2.43 -2.42 -1.64 -1.53 
MERTK c-mer proto-oncogene tyrosine kinase -2.32 -3.14 1.3 1.62 
RAPGEF5 Rap guanine nucleotide exchange factor (GEF) 5 -2.55 -2.75 -2.57 -1.93 
TERF2IP telomeric repeat binding factor 2, interacting protein -2.99 -2.78 1.06 -1.09 
NMT2 N-myristoyltransferase 2 -3.45 -3.16 -1.97 -2.06 
PLOD1 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 -3.06 -3.04 1.88 1.79 
HECA headcase homolog (Drosophila) -5.79 -5.24 -1.47 -1.62 
RASSF4 Ras association (RalGDS/AF-6) domain family 
member 4 
-2.26 -2.16 1.22 1.27 
REV3L REV3-like, polymerase (DNA directed), zeta, 
catalytic subunit 
-3.95 -4.39 -2.25 -2.25 
ZFYVE16 zinc finger, FYVE domain containing 16 -2.87 -3.18 -1.55 -1.26 
ZBTB42 zinc finger and BTB domain containing 42 -1.96 -2.08 -1.5 -1.57 
BRI3 brain protein I3 -3.07 -3.38 -1.85 -1.93 
DERA deoxyribose-phosphate aldolase (putative) -4.1 -4.16 -1.62 -1.45 
FAM91A1 family with sequence similarity 91, member A1 -2.1 -2.11 -1.49 -1.5 
BTG1 B-cell translocation gene 1, anti-proliferative -4.68 -4.24 -2.03 -1.98 
UFL1 UFM1-specific ligase 1 -2.24 -2.35 1.14 1.34 
TNRC18 trinucleotide repeat containing 18 -2.08 -2.53 1.02 -1.17 
CD47 CD47 molecule -3.16 -2.91 -1.11 -1.05 
HINT3 histidine triad nucleotide binding protein 3 -3.36 -3.62 -2.4 -2.64 
SPATA18 spermatogenesis associated 18 -2.08 -2 1.26 1.08 
C6orf120 chromosome 6 open reading frame 120 -2.54 -2.58 -2.07 -2.16 
MTM1 myotubularin 1 -2.28 -2.32 -2.2 -2.23 
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P4HB prolyl 4-hydroxylase, beta polypeptide -3.56 -4.13 -1.08 -1.13 
SPAG1 sperm associated antigen 1 -2.42 -2.88 -2.14 -1.87 
FBXL15 F-box and leucine-rich repeat protein 15 -2.31 -2.5 -1.52 -1.15 
CLN3 ceroid-lipofuscinosis, neuronal 3 -1.67 -1.83 -1.26 -1.21 
SERPINB1 serpin peptidase inhibitor, clade B (ovalbumin), 
member 1 
-2.25 -2.74 -1.03 -1.09 
SERTAD2 SERTA domain containing 2 -4.28 -4.84 -1.47 -1.71 
TTC14 tetratricopeptide repeat domain 14 -2.49 -2.71 -2.26 -1.8 
NINJ1 ninjurin 1 -2.2 -1.99 -1.62 -1.46 
RPS27L ribosomal protein S27-like -1.99 -2.06 -1.89 -1.92 
ZBTB41 zinc finger and BTB domain containing 41 -3.08 -3.03 -1.48 -1.01 
CRTC3 CREB regulated transcription coactivator 3 -2.68 -2.54 1.16 1.11 
DGAT1 diacylglycerol O-acyltransferase 1 -6.09 -6.03 -1.26 1.12 
RAB7L1 RAB7, member RAS oncogene family-like 1 -5.26 -5.17 -2.01 -1.73 
ADCY6 adenylate cyclase 6 -1.61 -1.58 1.31 1.27 
NPHP3 nephronophthisis 3 (adolescent) -2.79 -3.04 -1.58 -1.53 
RFK riboflavin kinase -1.95 -2.16 -1.16 -1.23 
NRIP1 nuclear receptor interacting protein 1 -2.43 -3.1 -2.2 -2.41 
ACOT13 acyl-CoA thioesterase 13 -5.15 -4.73 -2.37 -1.77 
TMEM139 transmembrane protein 139 -2.1 -2.04 -2.07 -2 
NBR2 neighbor of BRCA1 gene 2 (non-protein coding) -2.14 -2.14 -2.05 -1.94 
DENND4C DENN/MADD domain containing 4C -2.92 -2.88 -1.26 -1.49 
RAB4A RAB4A, member RAS oncogene family -2.03 -2.12 -1.94 -1.99 
AP1M1 adaptor-related protein complex 1, mu 1 subunit -2.16 -2.18 -1.46 -1.52 
DAP death-associated protein -1.69 -1.69 1.34 1.39 
CAMK2D calcium/calmodulin-dependent protein kinase II 
delta 
-2.67 -3.07 1.57 1.54 
TMEM106B transmembrane protein 106B -2.36 -2.27 -1.15 1.03 
STIM1 stromal interaction molecule 1 -2.31 -2.25 -1.84 -1.67 
CAMSAP3 calmodulin regulated spectrin-associated protein 
family, member 3 
-2.38 -2.29 -2.17 -2.09 
CD151 CD151 molecule (Raph blood group) -1.72 -1.87 1.03 -1 
CAST calpastatin -4.38 -4.54 1.52 1.51 
FAM162A family with sequence similarity 162, member A -2.83 -2.54 -1.21 1.09 
SCARB2 scavenger receptor class B, member 2 -6.65 -6.6 -1.79 -1.86 
IPP intracisternal A particle-promoted polypeptide -2.04 -1.98 -1.03 -1.2 
LSMD1 LSM domain containing 1 -1.95 -2.27 -1.18 -1.12 
NUMB numb homolog (Drosophila) -2.06 -2.18 -1.51 -1.66 
TIPARP TCDD-inducible poly(ADP-ribose) polymerase -3.35 -4.3 -1.37 -1.46 
TLCD2 TLC domain containing 2 -3.9 -4.14 -1.47 -1.43 
CPPED1 calcineurin-like phosphoesterase domain containing 
1 
-3.33 -3.55 -2.84 -3.01 
RAB22A RAB22A, member RAS oncogene family -2.03 -2.07 -1.32 -1.41 
TCF25 transcription factor 25 (basic helix-loop-helix) -2.3 -2.49 -1.45 -1.43 
TMBIM1 transmembrane BAX inhibitor motif containing 1 -5.51 -5.08 -1.09 1.04 
OSBPL2 oxysterol binding protein-like 2 -2.13 -2.24 -1.1 -1.16 
IGF2R insulin-like growth factor 2 receptor -2.19 -2.37 -2.43 -2.68 
LMAN2 lectin, mannose-binding 2 -2.45 -2.56 -2.16 -2.06 
MGAT4B mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-
acetylglucosaminyltransferase, isozyme B 
-3.75 -3.76 -1.96 -2.24 
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LOC728730 uncharacterized LOC728730 -3.97 -3.7 1.29 1.77 
PIGH phosphatidylinositol glycan anchor biosynthesis, 
class H 
-3.35 -3.78 1.74 1.68 
SIAE sialic acid acetylesterase -3.27 -3.54 -1.2 -1.14 
CASP8 caspase 8, apoptosis-related cysteine peptidase -1.67 -1.68 -1.52 -1.57 
TNS3 tensin 3 -5.24 -4.38 -1.77 -2.8 
DISP1 dispatched homolog 1 (Drosophila) -2.42 -2.25 -1.41 -1.65 
HMOX1 heme oxygenase (decycling) 1 -2.17 -1.9 -1.56 -1.87 
DLC1 deleted in liver cancer 1 -1.87 -2.4 -1.13 -1.36 
FEM1C fem-1 homolog c (C. elegans) -2.42 -2.13 -2.25 -2.55 
SLC35F5 solute carrier family 35, member F5 -3.38 -3.9 1.37 1.2 
ZNF846 zinc finger protein 846 -1.7 -1.69 1.32 1.34 
HIGD1A HIG1 hypoxia inducible domain family, member 
1A 
-1.48 -1.61 -2.06 -2.22 
GOLGA2 golgin A2 -2.08 -2.31 1.09 -1.13 
ERGIC1 endoplasmic reticulum-golgi intermediate 
compartment (ERGIC) 1 
-2.73 -2.67 -1.74 -1.83 
HIST1H2BI histone cluster 1, H2bi -1.65 -1.91 -2.09 -1.92 
TSPAN31 tetraspanin 31 -3.14 -2.76 -1.35 -1.5 
CTSA cathepsin A -3.64 -3.78 -2.48 -2.33 
ZC3H12C zinc finger CCCH-type containing 12C -3.46 -3.25 1.04 -1.03 
KBTBD3 kelch repeat and BTB (POZ) domain containing 3 -2.55 -2.48 -1.68 -1.41 
MYO5B myosin VB -4.36 -4.24 -1.02 -1.03 
MARCH2 membrane-associated ring finger (C3HC4) 2, E3 
ubiquitin protein ligase 
-2.45 -2.29 -1.68 -1.69 
TNFRSF10D tumor necrosis factor receptor superfamily, member 
10d, decoy with truncated death domain 
-1.53 -1.44 -1.36 -1.56 
SPOP speckle-type POZ protein -2.26 -2.48 -1.66 -1.83 
LTB lymphotoxin beta (TNF superfamily, member 3) -2.39 -2.51 -1.83 -1.5 
FPGT fucose-1-phosphate guanylyltransferase -2.5 -2.55 -1.91 -1.92 
ENPP4 ectonucleotide pyrophosphatase/phosphodiesterase 
4 (putative) 
-3.05 -3.13 -2.9 -2.24 
EMP2 epithelial membrane protein 2 -3.32 -3.13 1.66 1.51 
LMBRD2 LMBR1 domain containing 2 -2.66 -2.62 -2.24 -2.27 
YPEL5 yippee-like 5 (Drosophila) -1.81 -2.29 1.58 1.5 
PECAM1 platelet/endothelial cell adhesion molecule 1 -1.67 -1.67 -1.16 1.07 
ZNF395 zinc finger protein 395 -3.93 -4.04 2.07 1.97 
PPP1R11 protein phosphatase 1, regulatory (inhibitor) subunit 
11 
-1.47 -1.6 -1.42 -1.6 
NCOA1 nuclear receptor coactivator 1 -1.91 -2.11 1.16 1.22 
PLEKHM3 pleckstrin homology domain containing, family M, 
member 3 
-2.09 -2.19 -1.39 -2.01 
OPTN optineurin -3.42 -4.18 1.7 1.64 
SMYD2 SET and MYND domain containing 2 -1.37 -1.55 -1.23 -1.28 
PITRM1 pitrilysin metallopeptidase 1 -1.88 -2.04 -1.51 -1.44 
ALG9 ALG9, alpha-1,2-mannosyltransferase -2.14 -2.14 -1.35 -1.48 
HIPK2 homeodomain interacting protein kinase 2 -1.94 -1.92 -1.53 -1.81 
MPZL2 myelin protein zero-like 2 -3.13 -3 -1.19 -1.14 
BTBD6 BTB (POZ) domain containing 6 -1.52 -1.52 -1.5 -1.5 
PMM1 phosphomannomutase 1 -4.15 -4.28 -1.29 -1.09 
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CD59 CD59 molecule, complement regulatory protein -3.72 -3.76 1.19 1.18 
ZNF224 zinc finger protein 224 -3.2 -3.14 -2.16 -1.83 
ECE1 endothelin converting enzyme 1 -2.21 -2.23 -1.47 -1.54 
RPS6KA3 ribosomal protein S6 kinase, 90kDa, polypeptide 3 -5.19 -5.54 -1.27 -1.02 
MICALL2 MICAL-like 2 -1.88 -1.83 -1.39 -1.18 
FGFR3 fibroblast growth factor receptor 3 -1.9 -2.24 -1.34 -1.38 
SGMS2 sphingomyelin synthase 2 -3.09 -2.91 -1.12 -1.17 
RNASE1 ribonuclease, RNase A family, 1 (pancreatic) -1.58 -1.54 -1.1 1.07 
SNX1 sorting nexin 1 -2.01 -2.19 -1.58 -1.57 
CHID1 chitinase domain containing 1 -3.52 -3.85 -1.85 -1.82 
BPNT1 3'(2'), 5'-bisphosphate nucleotidase 1 -2.93 -2.59 -1.87 -1.92 
LOC286437 uncharacterized LOC286437 -2.96 -3.05 -2.73 -2.76 
IRF6 interferon regulatory factor 6 -1.64 -1.64 -1.13 -1.16 
PIEZO2 piezo-type mechanosensitive ion channel 
component 2 
-1.43 -1.71 -1.59 -1.48 
DOCK8 dedicator of cytokinesis 8 -2.22 -2.31 -1.25 -1.58 
SHANK2 SH3 and multiple ankyrin repeat domains 2 -2.7 -2.29 -1.19 -1.41 
FBXO17 F-box protein 17 -4.46 -4.46 -1.51 -1.28 
NUDT19 nudix (nucleoside diphosphate linked moiety X)-
type motif 19 
-3.79 -3.93 -1.77 -2.3 
ISG20 interferon stimulated exonuclease gene 20kDa -2.62 -2.63 -1.03 1.29 
KRT222 keratin 222 -2.06 -2.02 -1.87 -1.65 
MBNL1 muscleblind-like splicing regulator 1 -5.42 -4.85 -2.36 -2.44 
H1F0 H1 histone family, member 0 -4.64 -4.23 -2.07 -2.13 
SPSB1 splA/ryanodine receptor domain and SOCS box 
containing 1 
-1.95 -1.89 1.45 1.26 
BCDIN3D BCDIN3 domain containing -1.54 -1.57 -1.47 -1.45 
LAMTOR5 late endosomal/lysosomal adaptor, MAPK and 
MTOR activator 5 
-2.18 -2.14 -1.43 -1.33 
LRCH1 leucine-rich repeats and calponin homology (CH) 
domain containing 1 
-2.45 -2.38 -1.51 -1.42 
PIGB phosphatidylinositol glycan anchor biosynthesis, 
class B 
-3.11 -2.75 -1.56 -1.41 
MAF v-maf avian musculoaponeurotic fibrosarcoma 
oncogene homolog 
-4.83 -4.75 -1.37 -1.39 
APOBEC3F apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like 3F 
-1.46 -1.55 -1.55 -1.49 
MAB21L3 mab-21-like 3 (C. elegans) -1.67 -1.7 -1.62 -1.57 
C12orf23 chromosome 12 open reading frame 23 -4.27 -4.66 2.38 1.96 
PTER phosphotriesterase related -3.87 -3.78 -3.28 -2.93 
MAP3K2 mitogen-activated protein kinase kinase kinase 2 -3.31 -3.67 -2.3 -2.07 
ATP9A ATPase, class II, type 9A -4.76 -3.74 -1.42 -1.31 
TCAIM T cell activation inhibitor, mitochondrial -5.2 -5.32 -2.19 -1.83 
SOAT1 sterol O-acyltransferase 1 -2.89 -3.09 -1.89 -2.14 
PLEKHF2 pleckstrin homology domain containing, family F 
(with FYVE domain) member 2 
-2.36 -2.2 -1.2 -1.67 
ADCY9 adenylate cyclase 9 -3.18 -3.22 -1.55 -1.72 
TRIM56 tripartite motif containing 56 -2.57 -2.6 -1.39 -1.77 
PCYOX1 prenylcysteine oxidase 1 -5.93 -5.98 -1.89 -2.26 
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CGN cingulin -4.3 -4.13 -3.28 -3.06 
HBP1 HMG-box transcription factor 1 -3.48 -3.43 -1.38 -1.42 
CLIP1 CAP-GLY domain containing linker protein 1 -1.71 -2.17 1.03 1.09 
SLC22A5 solute carrier family 22 (organic cation/carnitine 
transporter), member 5 
-3.71 -3.64 1.73 1.51 
CHMP2A charged multivesicular body protein 2A -4.32 -4.31 -1.62 -1.46 
GOLGA4 golgin A4 -2.77 -3.22 -1.8 -1.1 
MICAL2 microtubule associated monooxygenase, calponin 
and LIM domain containing 2 
-1.78 -1.77 1.83 1.61 
KBTBD11 kelch repeat and BTB (POZ) domain containing 11 -4 -3.65 -3.45 -3.02 
IRF1 interferon regulatory factor 1 -2.57 -2.52 -1.74 -1.99 
TRPV6 transient receptor potential cation channel, 
subfamily V, member 6 
-2.2 -2.29 -1.9 -1.91 
TMBIM6 transmembrane BAX inhibitor motif containing 6 -1.8 -1.92 -1.65 -1.58 
RRAD Ras-related associated with diabetes -2.09 -2.04 -1.49 -1.51 
CALCOCO2 calcium binding and coiled-coil domain 2 -5.47 -5.66 -1.28 -1.33 
LIMCH1 LIM and calponin homology domains 1 -1.9 -2.04 1.18 1.28 
CARD6 caspase recruitment domain family, member 6 -1.88 -1.68 -1.41 -1.32 
NUDT16 nudix (nucleoside diphosphate linked moiety X)-
type motif 16 
-2.18 -2.11 -1.62 -1.58 
KLF10 Kruppel-like factor 10 -2.48 -2.26 1.61 1.06 
FZD4 frizzled family receptor 4 -1.34 -1.41 1.1 1.08 
C8orf47 chromosome 8 open reading frame 47 -2.61 -2.48 -1.94 -2.61 
PPA2 pyrophosphatase (inorganic) 2 -2 -2.09 -1.75 -1.76 
SSR4 signal sequence receptor, delta -1.77 -2.13 1.29 1.26 
PHC2 polyhomeotic homolog 2 (Drosophila) -2.03 -1.97 1.51 1.4 
VPS54 vacuolar protein sorting 54 homolog (S. cerevisiae) -2.24 -2.28 -1.01 -1.05 
MVP major vault protein -4.23 -4 -1.07 -1.15 
LINC00894 long intergenic non-protein coding RNA 894 -2.51 -2.36 -2.16 -1.6 
FAM13C family with sequence similarity 13, member C -1.92 -1.8 -2.53 -2.39 
HBEGF heparin-binding EGF-like growth factor -1.36 -1.4 -1.16 -1.36 
MANSC1 MANSC domain containing 1 -4 -3.57 -2.7 -3.63 
MRPS36 mitochondrial ribosomal protein S36 -1.88 -2.01 -1.92 -1.64 
PLOD2 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 -7.09 -8.15 -1.51 -1.93 
RNF43 ring finger protein 43 -3.13 -2.98 -2.04 -2.12 
PJA2 praja ring finger 2, E3 ubiquitin protein ligase -2.53 -2.42 1.43 1.48 
PDIA5 protein disulfide isomerase family A, member 5 -6.56 -6.93 -1.53 -1.25 
C4orf3 chromosome 4 open reading frame 3 -3.89 -3.69 -1.96 -2.4 
MXD1 MAX dimerization protein 1 -3.37 -3.25 -2.13 -1.97 
NCF2 neutrophil cytosolic factor 2 -1.68 -1.66 -1.59 -1.58 
RNF19A ring finger protein 19A, RBR E3 ubiquitin protein 
ligase 
-1.76 -2.22 -1.66 -1.66 
IFNGR1 interferon gamma receptor 1 -2.44 -2.9 1.02 1.21 
KIF16B kinesin family member 16B -2.41 -2.41 -1.91 -1.86 
MBD6 methyl-CpG binding domain protein 6 -2.35 -2.39 -2.03 -2.2 
KLHL28 kelch-like family member 28 -1.83 -2.07 -1.28 -1.18 
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) -3.49 -2.88 1.78 1.53 
IDS iduronate 2-sulfatase -1.76 -1.69 -1.06 -1.34 
LRMP lymphoid-restricted membrane protein -1.22 -1.2 -1.15 -1.02 
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SERINC1 serine incorporator 1 -4.9 -5.51 -1.69 -2.01 
PCED1A PC-esterase domain containing 1A -3.71 -3.89 -2.13 -1.82 
C1orf63 chromosome 1 open reading frame 63 -3.61 -3.59 -1 1.78 
NDFIP1 Nedd4 family interacting protein 1 -2.79 -2.8 -1.4 -1.5 
ARHGDIB Rho GDP dissociation inhibitor (GDI) beta -1.98 -1.89 1.6 1.63 
TMEM123 transmembrane protein 123 -1.38 -1.69 1.24 1.23 
GALNT2 UDP-N-acetyl-alpha-D-galactosamine:polypeptide 
N-acetylgalactosaminyltransferase 2 (GalNAc-T2) 
-1.67 -1.94 -2.18 -2.51 
ASAH1 N-acylsphingosine amidohydrolase (acid 
ceramidase) 1 
-2.43 -2.66 1.1 -1.04 
TGM2 transglutaminase 2 -2.97 -2.81 1.02 -1.1 
STAT4 signal transducer and activator of transcription 4 -1.37 -1.42 1.22 1.51 
ADK adenosine kinase -2.97 -3.19 -1.83 -1.68 
AES amino-terminal enhancer of split -2.14 -2.37 -1.93 -1.9 
SMIM1 small integral membrane protein 1 -3.55 -3.87 1.72 2.03 
TRIM63 tripartite motif containing 63, E3 ubiquitin protein 
ligase 
-1.91 -1.94 -1.4 1.22 
LACTB lactamase, beta -2.85 -3.2 -1.75 -1.69 
SERINC2 serine incorporator 2 -2.88 -2.95 -2.45 -2.56 
ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide -2.33 -2.76 2.35 1.91 
ACVR1B activin A receptor, type IB -1.67 -1.65 -1.29 -1.38 
LRRC31 leucine rich repeat containing 31 -1.94 -1.92 -1.62 -1.65 
SUMF1 sulfatase modifying factor 1 -3.39 -3.01 -2.33 -2.93 
RAP1A RAP1A, member of RAS oncogene family -3.22 -3.11 -1.38 -1.31 
VPS13C vacuolar protein sorting 13 homolog C (S. 
cerevisiae) 
-3.1 -3.52 -2.11 -2.07 
VRK3 vaccinia related kinase 3 -2.36 -2.34 -2.19 -2.25 
NCKAP5 NCK-associated protein 5 -3.92 -3.79 -3.23 -3.38 
COG1 component of oligomeric golgi complex 1 -2.16 -2.43 -1.67 -1.43 
UBXN4 UBX domain protein 4 -1.87 -2.11 -1.26 -1.12 
AAMDC adipogenesis associated, Mth938 domain containing -3.62 -3.7 -1.96 -1.85 
PARP16 poly (ADP-ribose) polymerase family, member 16 -2.28 -2.27 -1.09 -1.11 
GNS glucosamine (N-acetyl)-6-sulfatase -2.84 -3.02 1.07 1.14 
SPAG5-AS1 SPAG5 antisense RNA 1 -1.32 -1.29 1.12 1.32 
XPNPEP2 X-prolyl aminopeptidase (aminopeptidase P) 2, 
membrane-bound 
-1.97 -1.95 -1.38 -1.18 
TP53I13 tumor protein p53 inducible protein 13 -3.3 -3.37 -2.34 -2 
WNT11 wingless-type MMTV integration site family, 
member 11 
-2.44 -2.41 1.01 -1.08 
RSL1D1 ribosomal L1 domain containing 1 -1.9 -1.97 -1.75 -1.78 
OSMR oncostatin M receptor -2.78 -2.78 -1.17 -1.29 
APLP2 amyloid beta (A4) precursor-like protein 2 -1.55 -1.81 1.2 1.21 
ENPP7 ectonucleotide pyrophosphatase/phosphodiesterase 
7 
-1.43 -1.42 -1.28 -1.35 
GSTM4 glutathione S-transferase mu 4 -2.01 -2.01 -1.73 -1.49 
YIPF4 Yip1 domain family, member 4 -3.92 -3.67 1.18 -1.06 
SLC25A44 solute carrier family 25, member 44 -1.86 -1.87 -2.6 -2.11 
LPGAT1 lysophosphatidylglycerol acyltransferase 1 -5.32 -6.3 -1.9 -1.56 
IRS1 insulin receptor substrate 1 -4.1 -3.6 -2.25 -3.31 
LOC100506713 uncharacterized LOC100506713 -2.05 -2.08 -1.77 -1.8 
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PEX12 peroxisomal biogenesis factor 12 -2.1 -2.42 -1.15 -1.2 
TMEM117 transmembrane protein 117 -2.9 -2.48 -1.15 -1.17 
TOR1B torsin family 1, member B (torsin B) -2.05 -1.98 -1.42 -1.48 
ABHD16A abhydrolase domain containing 16A -1.94 -2.15 -2.3 -2.31 
SULF2 sulfatase 2 -1.31 -1.99 1.11 -1 
RNASEL ribonuclease L (2',5'-oligoisoadenylate synthetase-
dependent) 
-1.75 -1.84 1.18 -1.03 
PRLR prolactin receptor -1.99 -2.01 -1.09 -1.19 
CASP7 caspase 7, apoptosis-related cysteine peptidase -7.45 -7.82 -2.51 -3 
EPDR1 ependymin related 1 -1.59 -1.47 -1.94 -1.95 
HIST2H2BE histone cluster 2, H2be -2.03 -2.25 -2.1 -2.12 
PURA purine-rich element binding protein A -5.26 -6.1 -2.1 -2.35 
TP53INP2 tumor protein p53 inducible nuclear protein 2 -2.68 -3.38 -1.63 -1.92 
SMIM6 small integral membrane protein 6 -2.52 -2.18 -2.05 -1.96 
SLC35A3 solute carrier family 35 (UDP-N-acetylglucosamine 
(UDP-GlcNAc) transporter), member A3 
-2.93 -3.08 -3.41 -2.85 
FLVCR2 feline leukemia virus subgroup C cellular receptor 
family, member 2 
-2.43 -2.41 -2.17 -2.01 
DCBLD1 discoidin, CUB and LCCL domain containing 1 -1.36 -1.61 -2.14 -2.23 
ATP10D ATPase, class V, type 10D -4.09 -3.58 3.01 1.95 
PSTPIP2 proline-serine-threonine phosphatase interacting 
protein 2 
-3.48 -3.45 1.63 1.71 
SCARB1 scavenger receptor class B, member 1 -3.8 -3.76 -2.25 -1.98 
GLRX2 glutaredoxin 2 -1.4 -1.66 -2.61 -2.49 
SSFA2 sperm specific antigen 2 -5.05 -5.45 1.4 1.12 
KLF4 Kruppel-like factor 4 (gut) -2.71 -3.09 -2.29 -2.66 
PDE4DIP phosphodiesterase 4D interacting protein -2.46 -2.51 -1.77 -1.68 
NOSTRIN nitric oxide synthase trafficking -1.75 -1.66 -1.05 1.26 
HERPUD2 HERPUD family member 2 -2.32 -2.12 1.28 1.08 
SOAT2 sterol O-acyltransferase 2 -1.98 -1.8 1.35 1.51 
HECTD4 HECT domain containing E3 ubiquitin protein 
ligase 4 
-2.5 -2.49 -1.75 -1.86 
GRHL1 grainyhead-like 1 (Drosophila) -4.27 -4.02 -1.26 -1.44 
AMPD2 adenosine monophosphate deaminase 2 -2.18 -2.01 1.03 -1 
IRAK4 interleukin-1 receptor-associated kinase 4 -1.93 -1.98 -1.65 -1.62 
MICALCL MICAL C-terminal like -1.52 -1.38 -1.31 -1.23 
ISG15 ISG15 ubiquitin-like modifier -2.75 -2.81 -2.94 -2.51 
DPP7 dipeptidyl-peptidase 7 -4.59 -4.55 -1.51 -1.32 
PLA2G12A phospholipase A2, group XIIA -3.77 -3.76 -2.13 -2.05 
GOLIM4 golgi integral membrane protein 4 -1.91 -2.19 -2.27 -2.71 
XPA xeroderma pigmentosum, complementation group A -2.3 -2.66 -2.51 -2.22 
UBE2B ubiquitin-conjugating enzyme E2B -2.78 -2.8 -2.37 -2.63 
NRTN neurturin -3.15 -2.68 -1.03 -1 
BTG2 BTG family, member 2 -1.2 -1.35 1.37 1.44 
HLA-J major histocompatibility complex, class I, J 
(pseudogene) 
-2.21 -2.41 -1.63 -1.42 
PON2 paraoxonase 2 -5.61 -6.12 -1.21 -1.13 
LCP1 lymphocyte cytosolic protein 1 (L-plastin) -2.57 -2.49 -1.05 1.14 
KIAA1598 KIAA1598 -4.57 -4.35 -1.87 -1.79 
ETFA electron-transfer-flavoprotein, alpha polypeptide -2.97 -2.78 -1.59 -1.51 
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ANKS4B ankyrin repeat and sterile alpha motif domain 
containing 4B 
-2.36 -2.23 -2.08 -1.83 
NDFIP2 Nedd4 family interacting protein 2 -2.5 -2.66 1.17 1.27 
MIA2 melanoma inhibitory activity 2 -2.55 -2.5 -2 -1.57 
GLT8D1 glycosyltransferase 8 domain containing 1 -3.27 -3.44 -1.03 -1.09 
ZNF277 zinc finger protein 277 -2.85 -2.91 -1.83 -1.38 
SOX6 SRY (sex determining region Y)-box 6 -2.18 -2.08 1.26 1.14 
MIR22HG MIR22 host gene (non-protein coding) -2.97 -3.96 1.64 1.24 
TRMT10A tRNA methyltransferase 10 homolog A (S. 
cerevisiae) 
-1.68 -1.66 -1.99 -2.11 
TRAM2 translocation associated membrane protein 2 -1.01 -1.1 -1.13 -1.26 
NAGPA N-acetylglucosamine-1-phosphodiester alpha-N-
acetylglucosaminidase 
-1.63 -1.64 -1.75 -1.5 
CCDC92 coiled-coil domain containing 92 -2.86 -3.51 -1.17 -1.25 
ADCK2 aarF domain containing kinase 2 -1.98 -1.94 1.07 1.04 
ARFGAP3 ADP-ribosylation factor GTPase activating protein 
3 
-4.2 -4.18 1.74 1.79 
PCP4L1 Purkinje cell protein 4 like 1 -1.6 -1.69 -1.28 -1.04 
LOC100507291 uncharacterized LOC100507291 -1.67 -1.7 1.02 1.14 
RAMP1 receptor (G protein-coupled) activity modifying 
protein 1 
-5.4 -4.6 -1.07 1.18 
CYB561A3 cytochrome b561 family, member A3 -1.17 -1.16 -1.23 -1.23 
DYNLT3 dynein, light chain, Tctex-type 3 -6.29 -6.26 -2.08 -1.49 
EDEM2 ER degradation enhancer, mannosidase alpha-like 2 -2.25 -2.26 -1.74 -1.59 
TIFA TRAF-interacting protein with forkhead-associated 
domain 
-5.22 -5.61 -1.6 -1.46 
RASGRP3 RAS guanyl releasing protein 3 (calcium and DAG-
regulated) 
-1.3 -1.33 -1.27 -1.14 
FNIP1 folliculin interacting protein 1 -2.37 -2.47 -1.67 -1.61 
SRPR signal recognition particle receptor (docking 
protein) 
-2.46 -2.55 -1.7 -1.78 
AGO4 argonaute RISC catalytic component 4 -2.21 -2.12 -1.53 -1.56 
TIMP3 TIMP metallopeptidase inhibitor 3 -3.32 -3.32 2.11 1.59 
TPP1 tripeptidyl peptidase I -4.49 -4.62 -2.47 -2.38 
TCEAL1 transcription elongation factor A (SII)-like 1 -4.99 -5.03 2.02 2.41 
KIFC3 kinesin family member C3 -2.42 -2.63 -2.21 -2.29 
AHNAK AHNAK nucleoprotein -3.98 -4.44 -1.21 -1.21 
VAMP8 vesicle-associated membrane protein 8 -1.02 -1.65 -2.03 -2.03 
MARVELD2 MARVEL domain containing 2 -2.02 -2.29 -3.07 -3.07 
CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma 
growth stimulating activity, alpha) 
-2.97 -2.88 -3.11 -2.87 
PHF11 PHD finger protein 11 -3.76 -4.01 -2.53 -2.55 
DNAJB4 DnaJ (Hsp40) homolog, subfamily B, member 4 -3.1 -2.98 -1.95 -1.91 
CHD9 chromodomain helicase DNA binding protein 9 -2.88 -2.58 -1.05 1.13 
PLEKHA6 pleckstrin homology domain containing, family A 
member 6 
-3.15 -3.32 -1.47 -1.58 
WDR13 WD repeat domain 13 -4.32 -4.28 -1.52 -1.48 
C5orf24 chromosome 5 open reading frame 24 -2.11 -2.35 1.28 -1.02 
P4HTM prolyl 4-hydroxylase, transmembrane (endoplasmic 
reticulum) 
-1.44 -1.33 1.22 1.41 
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LINC01003 long intergenic non-protein coding RNA 1003 -4.19 -5.02 -1.9 -1.75 
BBIP1 BBSome interacting protein 1 -2.84 -3.08 -1.92 -1.82 
MEF2C myocyte enhancer factor 2C -1.45 -1.39 1.26 1.16 
SPPL2A signal peptide peptidase like 2A -2.22 -2.77 -2.77 -2.46 
TBRG1 transforming growth factor beta regulator 1 -1.82 -1.98 -1.75 -1.32 
CAPN12 calpain 12 -3.93 -3.88 -1.8 1.05 
TDRD7 tudor domain containing 7 -1.59 -2.37 1.05 1.15 
MAGT1 magnesium transporter 1 -1.59 -1.59 -1.85 -2.1 
RHBDD2 rhomboid domain containing 2 -1.28 -1.16 1.12 1.25 
OTUD1 OTU domain containing 1 -2.28 -2.38 1.01 -1.19 
---   -1.91 -2.09 -1.43 -1.55 
ARRDC4 arrestin domain containing 4 -7.17 -6.25 2.76 1.99 
CYSTM1 cysteine-rich transmembrane module containing 1 -2.19 -2.18 -1.06 1.26 
RFTN1 raftlin, lipid raft linker 1 -2.92 -2.81 -1.12 -1.5 
LNX1 ligand of numb-protein X 1, E3 ubiquitin protein 
ligase 
-7.77 -5.22 -2.02 -2 
C4orf33 chromosome 4 open reading frame 33 -2.17 -2.19 -1.6 -1.37 
SLC19A3 solute carrier family 19 (thiamine transporter), 
member 3 
-5.25 -4.69 -1.58 -1.82 
TRIM14 tripartite motif containing 14 -2.04 -1.82 -2.23 -2.29 
---   -2.14 -2.06 -2.92 -2.75 
PAPSS2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 -4.93 -4.64 -2.69 -2.25 
SYNPO synaptopodin -2.33 -2.31 -1.42 -1.74 
PLK2 polo-like kinase 2 -1.11 -1.32 1.15 -1.38 
PDLIM5 PDZ and LIM domain 5 -1.9 -1.98 -2.07 -2.2 
NEK6 NIMA-related kinase 6 -4.23 -4.62 -1.52 -1.6 
INHBA inhibin, beta A -2.83 -2.98 1.08 1.11 
KHNYN KH and NYN domain containing -1.48 -1.64 1.44 1.29 
ACSS3 acyl-CoA synthetase short-chain family member 3 -1.03 -1.51 -2.32 -2.21 
CXCL16 chemokine (C-X-C motif) ligand 16 -2.84 -2.71 1.07 1.44 
AGA aspartylglucosaminidase -4.11 -4.48 -4.92 -4.68 
LGALS3BP lectin, galactoside-binding, soluble, 3 binding 
protein 
-3.26 -2.99 1.24 1.22 
NOL3 nucleolar protein 3 (apoptosis repressor with CARD 
domain) 
-2.32 -2.4 -1.45 -1.47 
SECISBP2L SECIS binding protein 2-like -1.76 -2.09 -1.07 -1.27 
CAPN5 calpain 5 -1.99 -1.95 -1.9 -1.77 
CLDN23 claudin 23 -2.5 -2.96 -3.38 -4.07 
TOM1 target of myb1 (chicken) -2.35 -2.52 -2.13 -1.85 
FAM114A1 family with sequence similarity 114, member A1 -8.08 -7.36 1.68 1.52 
CALML4 calmodulin-like 4 -3.73 -3.6 1.01 1.22 
LOC100505812 uncharacterized LOC100505812 -1.37 -1.33 -1.38 -1.37 
RNASET2 ribonuclease T2 -4.12 -3.9 1.51 1.53 
NEDD9 neural precursor cell expressed, developmentally 
down-regulated 9 
-1.53 -1.59 2 1.76 
PDGFC platelet derived growth factor C -4.72 -5.16 -1.58 -2.21 
PLLP plasmolipin -2.42 -2.33 1.2 1.42 
FN1 fibronectin 1 -3.76 -4.08 1.8 1.6 
TRAK2 trafficking protein, kinesin binding 2 -2.06 -2.14 -1.87 -1.67 
DAZAP2 DAZ associated protein 2 -6.98 -6.77 -1.51 -1.52 
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ZFAND2A zinc finger, AN1-type domain 2A -6.58 -6.47 -2.34 -1.88 
USP3 ubiquitin specific peptidase 3 -1.24 -1.39 -1.1 1.01 
NPTXR neuronal pentraxin receptor -2.69 -2.19 -2.38 -2.56 
FRK fyn-related kinase -4.39 -4.49 -3.38 -2.79 
ERO1L ERO1-like (S. cerevisiae) -2.49 -2.4 -1.19 -1.25 
NUDT14 nudix (nucleoside diphosphate linked moiety X)-
type motif 14 
-1.53 -1.62 -1.88 -2.06 
ZAK sterile alpha motif and leucine zipper containing 
kinase AZK 
-3.11 -3.26 -2.53 -3.09 
AGPAT3 1-acylglycerol-3-phosphate O-acyltransferase 3 -4.07 -4.76 -1.84 -2.03 
LOC100507311 uncharacterized LOC100507311 -1.53 -1.5 -1.14 -1.04 
KDM6B lysine (K)-specific demethylase 6B -1.11 -1.24 1.33 1.13 
PLA2G1B phospholipase A2, group IB (pancreas) -1.25 -1.25 -1.19 -1.12 
TTC3 tetratricopeptide repeat domain 3 -2.8 -3.43 2.22 2.31 
PHYHIPL phytanoyl-CoA 2-hydroxylase interacting protein-
like 
-1.06 -1.04 -1.05 1 
HIST1H2AE histone cluster 1, H2ae -1.28 -1.65 -2.52 -2.36 
SPATA2L spermatogenesis associated 2-like -2.29 -2.46 -2.24 -2.69 
NHSL1 NHS-like 1 -1.79 -1.92 -1.93 -2.2 
NRP1 neuropilin 1 -4.12 -5.08 -1.08 -1.45 
SLC33A1 solute carrier family 33 (acetyl-CoA transporter), 
member 1 
-2.8 -3.05 -3.56 -3.12 
LMBRD1 LMBR1 domain containing 1 -4.25 -4.86 -1.8 -1.88 
ILVBL ilvB (bacterial acetolactate synthase)-like -2.8 -2.96 -2.3 -2.16 
NCOA7 nuclear receptor coactivator 7 -10.56 -10.32 -2.06 -3.02 
SLC5A9 solute carrier family 5 (sodium/sugar cotransporter), 
member 9 
-3.16 -3.43 -2.85 -2.09 
EMP1 epithelial membrane protein 1 -2.75 -2.52 -1.08 -1.32 
SAT1 spermidine/spermine N1-acetyltransferase 1 -5.58 -5.46 1.57 1.78 
LOC730101 uncharacterized LOC730101 -2.36 -2.57 -1.65 -1.76 
CCL5 chemokine (C-C motif) ligand 5 -1.2 -1.23 -1.1 -1.05 
AKAP13 A kinase (PRKA) anchor protein 13 -1.79 -2.06 -1.9 -2.19 
ABHD3 abhydrolase domain containing 3 -8.12 -9.54 -2.94 -2.57 
PPAPDC2 phosphatidic acid phosphatase type 2 domain 
containing 2 
-2.32 -2.42 -2.49 -2.63 
SLC9A3R1 solute carrier family 9, subfamily A (NHE3, cation 
proton antiporter 3), member 3 regulator 1 
-1.41 -1.52 2.14 1.83 
GSTO1 glutathione S-transferase omega 1 -1.47 -1.62 -2.33 -2.1 
COLEC11 collectin sub-family member 11 -2.76 -2.77 1.59 1.16 
PROSER2 proline and serine-rich protein 2 -6.05 -6.87 -1.84 -2.53 
TM4SF20 transmembrane 4 L six family member 20 -1.45 -1.47 -1.41 -1.33 
CFLAR CASP8 and FADD-like apoptosis regulator -3.57 -3.75 -2.25 -2.19 
KLHL5 kelch-like family member 5 -4.07 -4.16 -4.93 -4.51 
CMPK2 cytidine monophosphate (UMP-CMP) kinase 2, 
mitochondrial 
-5.3 -5.42 -4.4 -4.28 
MORC4 MORC family CW-type zinc finger 4 -8.45 -7.34 1.3 1.2 
SH3BP5 SH3-domain binding protein 5 (BTK-associated) -3.3 -3.47 2.17 1.83 
SPTLC3 serine palmitoyltransferase, long chain base subunit 
3 
-5.06 -4.46 1.14 -1.04 
IFI16 interferon, gamma-inducible protein 16 -3.5 -4.23 1.87 2.13 
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LSR lipolysis stimulated lipoprotein receptor -1.67 -1.75 -2.88 -2.73 
CHMP4C charged multivesicular body protein 4C -1.2 -1.42 -1.62 -1.89 
LOC728613 programmed cell death 6 pseudogene -1.3 -1.33 -1.28 -1.37 
ITM2B integral membrane protein 2B -1.4 -1.37 1.19 1.16 
TMEM37 transmembrane protein 37 -3.32 -3.24 -2.17 -2.14 
TBX3 T-box 3 -4.06 -5.55 -1.48 -1.66 
FAM228B family with sequence similarity 228, member B -2.99 -2.86 2 2.6 
P2RX4 purinergic receptor P2X, ligand-gated ion channel, 
4 
-1.87 -1.82 1.08 1.32 
MGAT4A mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-
acetylglucosaminyltransferase, isozyme A 
-3.35 -3.26 -1.06 1.1 
SCML4 sex comb on midleg-like 4 (Drosophila) -1.59 -1.61 1.81 1.91 
HIST1H2BK histone cluster 1, H2bk -1.09 -2.11 -1.94 -1.86 
BACE1 beta-site APP-cleaving enzyme 1 -2.8 -3 1.81 1.92 
LOC100506358 uncharacterized LOC100506358 -5.97 -5.97 -3.17 -1.95 
MBNL2 muscleblind-like splicing regulator 2 -4.87 -4.78 -1.16 -1.26 
SOCS6 suppressor of cytokine signaling 6 -1.54 -1.67 -2.01 -2.51 
TXNIP thioredoxin interacting protein -10.7 -10.48 1.39 1.62 
MPP1 membrane protein, palmitoylated 1, 55kDa -1.21 -1.26 -1.3 -1.2 
APOLD1 apolipoprotein L domain containing 1 -2.04 -2.12 -1.76 -2.21 
S100A16 S100 calcium binding protein A16 -2.59 -2.36 1.85 2.05 
LOC145474 uncharacterized LOC145474 -2.66 -2.96 -2.33 -2.06 
RAB24 RAB24, member RAS oncogene family -2.26 -2.19 1.37 1.47 
ABCG2 ATP-binding cassette, sub-family G (WHITE), 
member 2 
-2.54 -3.18 -1.01 -1.13 
PLEKHG1 pleckstrin homology domain containing, family G 
(with RhoGef domain) member 1 
-2.7 -2.42 -1.68 -1.72 
TNFAIP3 tumor necrosis factor, alpha-induced protein 3 -7.94 -7.38 2.82 2.34 
SORBS1 sorbin and SH3 domain containing 1 -2.11 -2.05 -2.5 -2.43 
SOWAHA sosondowah ankyrin repeat domain family member 
A 
-3.28 -3.07 2.41 2.39 
MME membrane metallo-endopeptidase -3.24 -2.94 2.48 2.39 
MGAM maltase-glucoamylase (alpha-glucosidase) -1.52 -1.53 -1.52 -1.42 
NR2F2 nuclear receptor subfamily 2, group F, member 2 -6.76 -6.75 1.63 1.21 
HIST1H2BF histone cluster 1, H2bf 1.28 -1.05 -1.38 -1.37 
ABHD12 abhydrolase domain containing 12 -1.38 -1.42 -1.47 -1.51 
MORN1 MORN repeat containing 1 -2.56 -2.72 -2.43 -2.17 
P4HA1 prolyl 4-hydroxylase, alpha polypeptide I -2.73 -2.85 3.88 3.47 
FAM89A family with sequence similarity 89, member A -1.19 -2.26 3.39 2.5 
CD99 CD99 molecule -2.72 -3.15 3.05 2.89 
LIPA lipase A, lysosomal acid, cholesterol esterase -1.94 -2.1 -3.5 -3.06 
FAM151A family with sequence similarity 151, member A -2.24 -2.1 1.45 1.34 
SYTL5 synaptotagmin-like 5 -1.34 -1.25 1.68 1.6 
ANXA4 annexin A4 -12.94 -14.13 -1.7 -1.8 
OR7E14P olfactory receptor, family 7, subfamily E, member 
14 pseudogene 
-1.39 -1.1 -1.85 -1.92 
ATP7B ATPase, Cu++ transporting, beta polypeptide -4.66 -4.96 4.87 3.68 
RHOU ras homolog family member U -6.92 -7.39 2.73 2.7 
GATA6-AS1 GATA6 antisense RNA 1 (head to head) -1.8 -3.61 2.46 2.86 
RHOBTB3 Rho-related BTB domain containing 3 -1.84 -3.93 2.83 2.23 
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MIR100HG mir-100-let-7a-2 cluster host gene (non-protein 
coding) 
-2.35 -2.49 -1.26 -1.67 
COX7A1 cytochrome c oxidase subunit VIIa polypeptide 1 
(muscle) 
-2.46 -2.67 -2.83 -2.73 
TMEM45B transmembrane protein 45B -3.65 -3.59 -2.28 -1.85 
WNK4 WNK lysine deficient protein kinase 4 -1.16 -1.11 -1.11 1.03 
TSPAN1 tetraspanin 1 -1.19 -1.15 -1.01 1.19 
PPFIBP2 PTPRF interacting protein, binding protein 2 (liprin 
beta 2) 
-9.3 -12.44 -4.44 -4.18 
INPP1 inositol polyphosphate-1-phosphatase -8.38 -8.48 -3.51 -3.41 
KLF6 Kruppel-like factor 6 -7.28 -8.84 -2.37 -3.36 
SLCO2B1 solute carrier organic anion transporter family, 
member 2B1 
-7.03 -6.62 -3.22 -2.98 
MPC2 mitochondrial pyruvate carrier 2 -15.67 -15.33 -4.85 -3.78 
FUCA1 fucosidase, alpha-L- 1, tissue -13.02 -14.11 -4.28 -3.98 
ABHD15 abhydrolase domain containing 15 -7.95 -7.55 -3.32 -3.94 
GSTK1 glutathione S-transferase kappa 1 -13.79 -15.08 -3.94 -3.58 
ACYP2 acylphosphatase 2, muscle type -7.48 -8.99 -4.58 -4.2 
HDHD3 haloacid dehalogenase-like hydrolase domain 
containing 3 
-9.05 -9.21 -4.73 -4.2 
PCGF5 polycomb group ring finger 5 -9.79 -9.58 -4.09 -3.27 
DTX3L deltex 3-like (Drosophila) -15.1 -13.16 -4.06 -4.92 
APOE apolipoprotein E -12.21 -13.76 -3.88 -2.99 
C10orf32 chromosome 10 open reading frame 32 -8.05 -8.11 -3.71 -4.4 
PTGR1 prostaglandin reductase 1 -10.83 -15.02 -2.88 -2.8 
CTBS chitobiase, di-N-acetyl- -14.75 -17.46 -2.39 -1.98 
C4orf32 chromosome 4 open reading frame 32 -13.03 -11.64 -5.89 -5.97 
SETD7 SET domain containing (lysine methyltransferase) 7 -8.03 -10.73 -3.07 -3.72 
SLC22A18 solute carrier family 22, member 18 -10.74 -11.12 -2.66 -2.29 
MEGF9 multiple EGF-like-domains 9 -10.2 -10.52 -6.69 -6.31 
SLC23A1 solute carrier family 23 (ascorbic acid transporter), 
member 1 
-10.45 -9.56 -3.47 -2.74 
YPEL2 yippee-like 2 (Drosophila) -10.52 -10.79 -2.79 -2.8 
C2orf72 chromosome 2 open reading frame 72 -10.19 -10.53 -2.61 -2.45 
RAB27A RAB27A, member RAS oncogene family -6.19 -7.63 -3.44 -2.92 
REEP6 receptor accessory protein 6 -17.5 -17.3 -2.81 -2.4 
COMMD3 COMM domain containing 3 -14.98 -15.78 -2.56 -2.8 
IL6R interleukin 6 receptor -16.27 -15.62 -3.58 -3.88 
CPQ carboxypeptidase Q -16.03 -15.47 -6.06 -5.38 
AQP11 aquaporin 11 -6.31 -6 -3.59 -3.33 
MST1 macrophage stimulating 1 (hepatocyte growth 
factor-like) 
-12.47 -11.67 -5.48 -3.63 
TSHZ1 teashirt zinc finger homeobox 1 -17.47 -17.62 -2.63 -3.43 
PXDC1 PX domain containing 1 -16.95 -18.11 -3.24 -3.43 
LURAP1L leucine rich adaptor protein 1-like -9.74 -8.94 -3.54 -4.42 
TMEM120A transmembrane protein 120A -11.48 -12.28 -2.34 -1.89 
ACAA1 acetyl-CoA acyltransferase 1 -15.24 -15.27 -7.89 -6.35 
FAM8A1 family with sequence similarity 8, member A1 -9.99 -10.47 -2.67 -2.45 
MGST2 microsomal glutathione S-transferase 2 -6.79 -9.23 -4.2 -4.63 
C1orf115 chromosome 1 open reading frame 115 -18.46 -16.22 -3.51 -3.34 
 97 
 
IFIT3 interferon-induced protein with tetratricopeptide 
repeats 3 
-7.64 -8.06 -4.76 -4.39 
CPEB4 cytoplasmic polyadenylation element binding 
protein 4 
-11.15 -9.6 -2.97 -2.95 
IL10RB interleukin 10 receptor, beta -9.74 -10.97 -2.55 -2.91 
LAMP2 lysosomal-associated membrane protein 2 -8.16 -8.46 -2.68 -2.38 
ZHX1 zinc fingers and homeoboxes 1 -24.57 -24.27 -3.04 -2.69 
PID1 phosphotyrosine interaction domain containing 1 -6.69 -6.49 -5.05 -4.74 
HMGCL 3-hydroxymethyl-3-methylglutaryl-CoA lyase -12.66 -12.83 -4.08 -3.77 
APOL6 apolipoprotein L, 6 -6.23 -6.1 -4.92 -5.17 
HSDL2 hydroxysteroid dehydrogenase like 2 -14.85 -15.05 -2.97 -3.31 
RCAN1 regulator of calcineurin 1 -15.13 -15.38 -3.85 -4 
TMEM140 transmembrane protein 140 -7.42 -6.74 -3.55 -2.83 
NFIL3 nuclear factor, interleukin 3 regulated -9.63 -10.55 -3.14 -3.35 
MXI1 MAX interactor 1, dimerization protein -11.05 -12.6 -2.17 -2.45 
SLC9B2 solute carrier family 9, subfamily B (NHA2, cation 
proton antiporter 2), member 2 
-4.93 -4.77 -3.16 -2.76 
CAMK2N1 calcium/calmodulin-dependent protein kinase II 
inhibitor 1 
-19.83 -18.88 -2.62 -2.84 
CTSZ cathepsin Z -8.31 -9.89 -4.66 -4.88 
SAT2 spermidine/spermine N1-acetyltransferase family 
member 2 
-10.29 -10.82 -4.23 -3.36 
ABCC3 ATP-binding cassette, sub-family C (CFTR/MRP), 
member 3 
-7.63 -7.36 -6.7 -6.01 
PRRG4 proline rich Gla (G-carboxyglutamic acid) 4 
(transmembrane) 
-21.3 -20.32 -2.11 -2.48 
C4orf19 chromosome 4 open reading frame 19 -12.07 -11.72 -7.09 -7.21 
FAXDC2 fatty acid hydroxylase domain containing 2 -6.64 -6.45 -2.42 -2.5 
STOM stomatin -17.36 -17.76 -3.03 -2.94 
NFKBIA nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, alpha 
-4.64 -6.64 -3.15 -2.93 
SERPINE1 serpin peptidase inhibitor, clade E (nexin, 
plasminogen activator inhibitor type 1), member 1 
-6.71 -6.65 -2.41 -3.62 
FAM134B family with sequence similarity 134, member B -19.94 -17.66 -7.16 -5.47 
DEPDC7 DEP domain containing 7 -33.59 -37.49 -3.35 -2.67 
SLC35D1 solute carrier family 35 (UDP-GlcA/UDP-GalNAc 
transporter), member D1 
-15.85 -15.49 -5.54 -6.36 
MAN1A1 mannosidase, alpha, class 1A, member 1 -15.76 -23.27 -1.85 -2.4 
DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9 -7.51 -8.11 -1.64 -1.42 
C1RL complement component 1, r subcomponent-like -11.42 -10.82 -5.54 -5.01 
HSD17B11 hydroxysteroid (17-beta) dehydrogenase 11 -29.22 -29.03 -4.43 -3.41 
PPARA peroxisome proliferator-activated receptor alpha -13.84 -13.46 -5.06 -5.32 
C11orf54 chromosome 11 open reading frame 54 -35.21 -35.99 -4.52 -3.4 
INSIG2 insulin induced gene 2 -15.16 -14.69 -3.04 -3.21 
ATP8B1 ATPase, aminophospholipid transporter, class I, 
type 8B, member 1 
-11.09 -13.82 -2.21 -2.45 
ETFB electron-transfer-flavoprotein, beta polypeptide -8.17 -10.14 -4.02 -4.55 
AIG1 androgen-induced 1 -13.5 -10.22 -7.74 -7.17 
EPS8 epidermal growth factor receptor pathway substrate 
8 
-10.73 -12.51 -1.68 -1.96 
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SLC31A2 solute carrier family 31 (copper transporter), 
member 2 
-6.52 -6.73 -2.77 -2.49 
AGPAT9 1-acylglycerol-3-phosphate O-acyltransferase 9 -12 -10.98 -7 -6.8 
PNRC1 proline-rich nuclear receptor coactivator 1 -7.14 -8.09 -1.51 -1.63 
C1orf53 chromosome 1 open reading frame 53 -5.36 -5.6 -4.4 -4.75 
MAN2B2 mannosidase, alpha, class 2B, member 2 -7.78 -9 -2.59 -2.88 
TBC1D8B TBC1 domain family, member 8B (with GRAM 
domain) 
-14.58 -14.58 -3.4 -3.13 
B2M beta-2-microglobulin -12.09 -12.09 -1.78 -1.66 
CTSH cathepsin H -11.74 -10.19 -1.38 1.11 
CREG1 cellular repressor of E1A-stimulated genes 1 -8.08 -8.14 -1.73 -1.83 
DGAT2 diacylglycerol O-acyltransferase 2 -11.43 -11.67 -5.93 -4.16 
PPP1R16A protein phosphatase 1, regulatory subunit 16A -7.88 -8.69 -5.77 -4.59 
PLA2G12B phospholipase A2, group XIIB -13.86 -14 -3.19 -2.09 
ST3GAL1 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 -7.79 -7.43 -1.94 -2.48 
IRF9 interferon regulatory factor 9 -5.27 -4.91 -2.53 -2.68 
ARSD arylsulfatase D -6.12 -6.29 -3.17 -3.52 
SCML1 sex comb on midleg-like 1 (Drosophila) -17.79 -17.31 -6.43 -4.15 
AQP3 aquaporin 3 (Gill blood group) -6.75 -6.76 -1.73 -1.8 
EFHD1 EF-hand domain family, member D1 -7.89 -7.11 -1.64 -1.73 
ARAP2 ArfGAP with RhoGAP domain, ankyrin repeat and 
PH domain 2 
-6.82 -6.51 -1.67 -1.21 
MAST4 microtubule associated serine/threonine kinase 
family member 4 
-5.5 -5.35 -2.75 -2.63 
NFKBIZ nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, zeta 
-16.31 -14.61 -7.37 -7.88 
CASP4 caspase 4, apoptosis-related cysteine peptidase -16.84 -16.5 -11.69 -10.96 
---   -8.17 -8.22 -4.24 -4.67 
PLIN2 perilipin 2 -14.74 -12.1 -1.76 -2.33 
RNFT1 ring finger protein, transmembrane 1 -7.23 -7.56 -4.74 -4.78 
SLC39A5 solute carrier family 39 (zinc transporter), member 
5 
-6.3 -6.27 -3.94 -3.3 
DHRS3 dehydrogenase/reductase (SDR family) member 3 -13.63 -11.98 -3.58 -4.15 
CRAT carnitine O-acetyltransferase -7.18 -7.78 -3.73 -3.48 
IL1R2 interleukin 1 receptor, type II -8.81 -8.94 -3.08 -1.7 
ZFP36 ZFP36 ring finger protein -10.82 -10.95 -3.89 -4.01 
BCL6 B-cell CLL/lymphoma 6 -15.76 -15.48 -4.72 -4.37 
GIPC2 GIPC PDZ domain containing family, member 2 -31.79 -30.29 -7.12 -7.9 
JUNB jun B proto-oncogene -9.41 -9.23 -3.57 -5.22 
RBKS ribokinase -12.46 -11.91 -7.68 -6.97 
SLC2A10 solute carrier family 2 (facilitated glucose 
transporter), member 10 
-13.01 -12.16 -1.84 -2.09 
GDF15 growth differentiation factor 15 -25.28 -24.31 -3.66 -3.53 
LTBP3 latent transforming growth factor beta binding 
protein 3 
-8.46 -8.39 -3.59 -3.65 
SLC25A20 solute carrier family 25 (carnitine/acylcarnitine 
translocase), member 20 
-10.12 -10.38 -5.64 -4.95 
FRMD4B FERM domain containing 4B -26.33 -23.43 -1.99 -2.16 
RND1 Rho family GTPase 1 -9.48 -8.53 -5.5 -5.16 
IFNAR1 interferon (alpha, beta and omega) receptor 1 -7.61 -7.29 -4.41 -5.09 
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KCNJ8 potassium inwardly-rectifying channel, subfamily J, 
member 8 
-17.35 -16.99 -6.32 -3.9 
TMEM27 transmembrane protein 27 -15.09 -29.44 -2.97 -2.13 
HLA-E major histocompatibility complex, class I, E -7.08 -7.28 -1.66 -1.58 
NRBP2 nuclear receptor binding protein 2 -22.03 -20.22 -7.94 -4.84 
SUN2 Sad1 and UNC84 domain containing 2 -8.04 -7.58 -3.93 -4.28 
SNTB1 syntrophin, beta 1 (dystrophin-associated protein 
A1, 59kDa, basic component 1) 
-5.85 -5.65 -6.71 -6.09 
ZBTB16 zinc finger and BTB domain containing 16 -9.33 -9.77 -2.26 -2.35 
CTSB cathepsin B -37.29 -39.3 -2.02 -2.25 
RETSAT retinol saturase (all-trans-retinol 13,14-reductase) -11.52 -11.4 -7.23 -7.17 
CPM carboxypeptidase M -6.46 -6.38 -3.35 -3.36 
MBNL3 muscleblind-like splicing regulator 3 -11.53 -12.01 -3.23 -3.07 
IFIH1 interferon induced with helicase C domain 1 -28.67 -27.84 -9.41 -10.11 
PARP9 poly (ADP-ribose) polymerase family, member 9 -5.4 -5.15 -3.33 -2.98 
SCP2 sterol carrier protein 2 -8.78 -8.57 -4.48 -4.27 
GPX3 glutathione peroxidase 3 (plasma) -5.63 -6.58 -5.85 -4.63 
SHC2 SHC (Src homology 2 domain containing) 
transforming protein 2 
-6 -5.91 -2.41 -2.09 
STARD10 StAR-related lipid transfer (START) domain 
containing 10 
-21.63 -23.16 -5.84 -5.32 
SLC7A9 solute carrier family 7 (amino acid transporter light 
chain, bo,+ system), member 9 
-8.34 -7.7 -6.06 -5.13 
LGSN lengsin, lens protein with glutamine synthetase 
domain 
-12.07 -11.4 -8.37 -7.8 
FAS Fas cell surface death receptor -9.74 -9.29 -6.8 -8.41 
BHLHE40 basic helix-loop-helix family, member e40 -5.67 -6.91 -3.41 -4.58 
SMPDL3A sphingomyelin phosphodiesterase, acid-like 3A -33.85 -40.13 -5.1 -4.39 
IFI6 interferon, alpha-inducible protein 6 -14.27 -14.39 -2.25 -2.14 
AKAP9 A kinase (PRKA) anchor protein 9 -10.49 -13.34 -6.94 -4.16 
ID2 inhibitor of DNA binding 2, dominant negative 
helix-loop-helix protein 
-3.43 -5.4 -2.24 -2.66 
ACADVL acyl-CoA dehydrogenase, very long chain -16.22 -16.32 -4.85 -4.18 
ABHD2 abhydrolase domain containing 2 -8.36 -8.49 -5.56 -5.99 
IL8 interleukin 8 -5.42 -5.23 -5.64 -5.58 
ERRFI1 ERBB receptor feedback inhibitor 1 -9.29 -10.14 -1.21 -1.5 
DENND4A DENN/MADD domain containing 4A -10.29 -10.55 -6.32 -5.88 
SMLR1 small leucine-rich protein 1 -17.74 -17.4 -7.09 -5.47 
TP53TG1 TP53 target 1 (non-protein coding) -9.03 -8.82 -2.36 -2.4 
CEACAM1 carcinoembryonic antigen-related cell adhesion 
molecule 1 (biliary glycoprotein) 
-5.21 -5.01 -3.98 -3.42 
ACOT4 acyl-CoA thioesterase 4 -9.8 -9.1 -10.46 -9.82 
TOB1 transducer of ERBB2, 1 -10.39 -10.28 -3.58 -4.54 
FAM69A family with sequence similarity 69, member A -11.85 -11.61 -6.5 -4.93 
FNIP2 folliculin interacting protein 2 -8.38 -8.39 -6.27 -6.12 
EDEM1 ER degradation enhancer, mannosidase alpha-like 1 -6.31 -6.96 -2.89 -2.59 
LGALS8 lectin, galactoside-binding, soluble, 8 -7.32 -7.3 -3.74 -3.43 
TFPI tissue factor pathway inhibitor (lipoprotein-
associated coagulation inhibitor) 
-32.9 -24.15 -1.68 -1.39 
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HERPUD1 homocysteine-inducible, endoplasmic reticulum 
stress-inducible, ubiquitin-like domain member 1 
-6.95 -7.88 -2.02 -2.6 
RGCC regulator of cell cycle -7.55 -8.26 -2.14 -2.24 
LINC00849 long intergenic non-protein coding RNA 849 -20.28 -18.35 -8.38 -8.22 
SMIM14 small integral membrane protein 14 -12.65 -11.12 -5.54 -6.37 
MT2A metallothionein 2A -18.04 -20.19 -3.45 -2.89 
GDA guanine deaminase -49.16 -46.56 -4.68 -3.71 
HSBP1L1 heat shock factor binding protein 1-like 1 -35.53 -39.24 -1.29 1.07 
TST thiosulfate sulfurtransferase (rhodanese) -12.58 -14.08 -7.74 -6.14 
GPR126 G protein-coupled receptor 126 -44.58 -35.01 -3.55 -4.24 
KLB klotho beta -26.05 -25.47 -2.74 -2.05 
AGMAT agmatine ureohydrolase (agmatinase) -13.73 -11.6 -11.82 -9.7 
CNKSR3 CNKSR family member 3 -6.5 -7.42 -4.24 -4.33 
ABCA1 ATP-binding cassette, sub-family A (ABC1), 
member 1 
-21.35 -19.4 -1.58 -1.18 
PTPN3 protein tyrosine phosphatase, non-receptor type 3 -8.96 -9.03 -6.48 -6.26 
PIK3R1 phosphoinositide-3-kinase, regulatory subunit 1 
(alpha) 
-3.62 -4.35 -2.28 -2.44 
CREB3L3 cAMP responsive element binding protein 3-like 3 -5.6 -5.67 -4.61 -4.95 
MGLL monoglyceride lipase -15.29 -14.17 -5.59 -6.3 
SLC15A1 solute carrier family 15 (oligopeptide transporter), 
member 1 
-9.94 -8.66 -4.64 -3.28 
COBLL1 cordon-bleu WH2 repeat protein-like 1 -10.13 -10.98 -1.46 -1.37 
THRB thyroid hormone receptor, beta -9.96 -9.87 -1.46 -1.59 
IRF8 interferon regulatory factor 8 -6.58 -6.22 -3.24 -3.56 
GPR128 G protein-coupled receptor 128 -24.2 -22.64 -7.65 -6.76 
TMEM14A transmembrane protein 14A -7.11 -7.73 -2.01 -1.95 
ELF3 E74-like factor 3 (ets domain transcription factor, 
epithelial-specific ) 
-5.93 -5.77 -3.62 -4.23 
PPARG peroxisome proliferator-activated receptor gamma -4.68 -4.59 -1.7 -1.4 
MTUS1 microtubule associated tumor suppressor 1 -8.49 -10.08 -2.39 -1.92 
BIRC3 baculoviral IAP repeat containing 3 -4.99 -4.71 -3.23 -2.65 
FBXO8 F-box protein 8 -7.9 -8.67 -2.6 -2.98 
IL13RA1 interleukin 13 receptor, alpha 1 -6.27 -8 -3.44 -4 
TNFSF13B tumor necrosis factor (ligand) superfamily, member 
13b 
-4.56 -4.57 -3.45 -2.73 
G0S2 G0/G1switch 2 -36.59 -38.03 -2.6 1.11 
CEBPA CCAAT/enhancer binding protein (C/EBP), alpha -17.94 -14.78 -5.98 -6.14 
DCAF6 DDB1 and CUL4 associated factor 6 -6.37 -7.02 -2.08 -1.83 
NR1H3 nuclear receptor subfamily 1, group H, member 3 -7.52 -7.23 -5.25 -3.93 
MTCH2 mitochondrial carrier 2 -8.34 -7.61 -4.45 -4.38 
POLD4 polymerase (DNA-directed), delta 4, accessory 
subunit 
-5.72 -5.92 -3.61 -3.05 
IL1R1 interleukin 1 receptor, type I -7.99 -7.74 1.18 1.02 
RDH10 retinol dehydrogenase 10 (all-trans) -4.46 -5.01 -2.9 -3.07 
HPGD hydroxyprostaglandin dehydrogenase 15-(NAD) -35.63 -38.49 -9 -5.43 
GCHFR GTP cyclohydrolase I feedback regulator -7.3 -7.5 -5.68 -5.17 
GADD45A growth arrest and DNA-damage-inducible, alpha -5.11 -5.34 -2.09 -2.57 
NNT nicotinamide nucleotide transhydrogenase -11.91 -13.22 -2.48 -2.8 
 101 
 
POLR3GL polymerase (RNA) III (DNA directed) polypeptide 
G (32kD)-like 
-8.04 -8.74 -2.63 -3.03 
DNAJC22 DnaJ (Hsp40) homolog, subfamily C, member 22 -13.23 -12.86 -10.17 -9.25 
ZG16 zymogen granule protein 16 -17.53 -15.45 -3.29 -1.58 
GBP2 guanylate binding protein 2, interferon-inducible -15.88 -16.11 1.23 1.54 
DHRS1 dehydrogenase/reductase (SDR family) member 1 -12.91 -11.71 -7.57 -6.42 
PARP14 poly (ADP-ribose) polymerase family, member 14 -7.28 -7.71 -3.67 -3.41 
TPD52L1 tumor protein D52-like 1 -12.14 -11.32 -2.01 -1.79 
DDX60L DEAD (Asp-Glu-Ala-Asp) box polypeptide 60-like -10.27 -10.02 -8.6 -7.89 
DMD dystrophin -4.86 -5.72 -5.43 -4.88 
PLD1 phospholipase D1, phosphatidylcholine-specific -4.71 -4.49 -1.95 -1.95 
IDNK idnK, gluconokinase homolog (E. coli) -9.37 -8.97 -5.77 -5.93 
DDC dopa decarboxylase (aromatic L-amino acid 
decarboxylase) 
-5.87 -6.11 -1.79 -1.31 
FAM46A family with sequence similarity 46, member A -15.56 -16 1.33 1.34 
CTAGE5 CTAGE family, member 5 -4.91 -5.07 -3.81 -3.09 
OXSM 3-oxoacyl-ACP synthase, mitochondrial -6.31 -6.97 -3.44 -3.16 
NAAA N-acylethanolamine acid amidase -8.11 -7.57 -6.55 -6.11 
FLJ22763 uncharacterized LOC401081 -24.89 -24.88 -2.16 -1.9 
RASD1 RAS, dexamethasone-induced 1 -7.64 -7.64 -1.74 -1.16 
IL6ST interleukin 6 signal transducer (gp130, oncostatin M 
receptor) 
-14.75 -17.2 1.42 1.32 
KYNU kynureninase -14.01 -13.81 -9.79 -7.92 
TMEM45A transmembrane protein 45A -9.31 -8.49 -1.43 -1.75 
F10 coagulation factor X -32.5 -32.62 -7.05 -5.19 
DUSP1 dual specificity phosphatase 1 -13.63 -13.41 -4.6 -5.08 
EPAS1 endothelial PAS domain protein 1 -10.84 -9.55 1.94 1.75 
CST3 cystatin C -6.43 -7.92 1.28 1.4 
SQRDL sulfide quinone reductase-like (yeast) -25.14 -21.06 -6.43 -5.69 
CMTM8 CKLF-like MARVEL transmembrane domain 
containing 8 
-7.63 -7.93 -4.87 -4.83 
SH3BGRL2 SH3 domain binding glutamic acid-rich protein like 
2 
-6.06 -5.69 -2.64 -2.5 
ANKRD37 ankyrin repeat domain 37 -13.52 -11.67 -6.16 -9.12 
CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) -17.11 -17.57 -4.41 -5.74 
ZADH2 zinc binding alcohol dehydrogenase domain 
containing 2 
-6.88 -7.18 -2.81 -3.4 
TRIM4 tripartite motif containing 4 -16.69 -15.61 -13.13 -12.34 
TBC1D9 TBC1 domain family, member 9 (with GRAM 
domain) 
-3.07 -3.72 -1.54 -1.97 
NBEAL1 neurobeachin-like 1 -7.56 -7.81 -5.18 -4.95 
IFIT5 interferon-induced protein with tetratricopeptide 
repeats 5 
-6.43 -6.2 -2.95 -3.35 
NDRG1 N-myc downstream regulated 1 -10.73 -12.44 1.37 1.15 
MST1L macrophage stimulating 1-like -6.42 -6.51 -5.95 -4.66 
GALM galactose mutarotase (aldose 1-epimerase) -5.83 -5.93 -3.48 -3.45 
SLC2A9 solute carrier family 2 (facilitated glucose 
transporter), member 9 
-3.56 -3.11 -3.15 -2.46 
PLA2G2A phospholipase A2, group IIA (platelets, synovial 
fluid) 
-9.43 -9.54 1.07 1.43 
 102 
 
KIAA0895 KIAA0895 -8.21 -9.51 1.09 1.02 
GBP3 guanylate binding protein 3 -40.45 -39.73 -5.56 -4.63 
FOXA2 forkhead box A2 -1.89 -2.56 -4.1 -3.65 
UNC5CL unc-5 homolog C (C. elegans)-like -5.84 -5.3 -2.35 -2.15 
CRYL1 crystallin, lambda 1 -23.19 -22.83 -6.79 -5.19 
SIL1 SIL1 nucleotide exchange factor -5.29 -5.27 -2.72 -2.54 
CNGA1 cyclic nucleotide gated channel alpha 1 -9.45 -8.96 -7.24 -7.26 
LIPG lipase, endothelial -4.34 -6.18 -5.09 -6.74 
MPC1 mitochondrial pyruvate carrier 1 -13.47 -12.69 -5.64 -4.55 
NR3C1 nuclear receptor subfamily 3, group C, member 1 
(glucocorticoid receptor) 
-4 -4.96 -1.53 -1.73 
LYRM1 LYR motif containing 1 -7.73 -7.09 -4.87 -4.55 
ARRDC3 arrestin domain containing 3 -18.76 -17.24 -1.02 -1.43 
SGK1 serum/glucocorticoid regulated kinase 1 -14.59 -11.54 -2.38 -2.74 
FBXO6 F-box protein 6 -6.52 -6.3 -1.32 -1.04 
CHST13 carbohydrate (chondroitin 4) sulfotransferase 13 -10.98 -9.91 -10.5 -8.95 
ST3GAL6 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 -16.44 -17.14 -4.18 -4.01 
CIDEB cell death-inducing DFFA-like effector b -9.43 -8.59 -5.83 -4.7 
CREBRF CREB3 regulatory factor -7.08 -7.22 -2.96 -2.55 
CD68 CD68 molecule -4.96 -5.03 -3.04 -2.77 
SLC51A solute carrier family 51, alpha subunit -25.29 -22.52 -6.75 -4.56 
CCDC68 coiled-coil domain containing 68 -10.99 -11.36 -5.13 -5.13 
DEPTOR DEP domain containing MTOR-interacting protein -11.98 -12.74 -2.05 -2.68 
LPIN2 lipin 2 -10.45 -11.76 -6.13 -7.11 
HIST1H2BD histone cluster 1, H2bd -3.13 -3.71 -3.15 -3.69 
EFNA1 ephrin-A1 -27.9 -26.83 -3.53 -2.92 
FOXA1 forkhead box A1 -20.11 -25.51 -5.24 -4.81 
CIB1 calcium and integrin binding 1 (calmyrin) -5.5 -5.79 -2.32 -1.97 
VCAM1 vascular cell adhesion molecule 1 -16.43 -16.84 -7.65 -4.51 
ACP2 acid phosphatase 2, lysosomal -4.32 -4.26 -4.46 -4.35 
S100A9 S100 calcium binding protein A9 -6.07 -5.56 -2.59 -2.71 
ATXN1 ataxin 1 -8.25 -8.81 -1.23 -1.46 
SEPP1 selenoprotein P, plasma, 1 -55.4 -59.08 -1.16 -1.02 
GPR137B G protein-coupled receptor 137B -11.66 -8.5 -3.7 -4.2 
CEBPD CCAAT/enhancer binding protein (C/EBP), delta -68.4 -61.31 -1.07 -1.21 
CYP4X1 cytochrome P450, family 4, subfamily X, 
polypeptide 1 
-11.78 -11.89 -5.51 -6.43 
GLCE glucuronic acid epimerase -6.64 -7.03 -5.56 -6.15 
HLA-B major histocompatibility complex, class I, B -6.44 -6.78 -2.19 -2.03 
SLC1A1 solute carrier family 1 (neuronal/epithelial high 
affinity glutamate transporter, system Xag), 
member 1 
-3.91 -5.08 -1.75 -1.62 
CYP1A1 cytochrome P450, family 1, subfamily A, 
polypeptide 1 
-19.78 -20.07 -1.31 -2.3 
TSPAN8 tetraspanin 8 -35.78 -36.39 -15.04 -11.31 
GPRC5C G protein-coupled receptor, family C, group 5, 
member C 
-5.65 -5.26 -1.17 -1.11 
LINC00341 long intergenic non-protein coding RNA 341 -8.3 -9.36 -1.53 -2.16 
CCL20 chemokine (C-C motif) ligand 20 -6.14 -6.08 -4.38 -4.66 
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SLC3A1 solute carrier family 3 (amino acid transporter 
heavy chain), member 1 
-29.75 -26.24 1.07 1.66 
ALPK2 alpha-kinase 2 -7.16 -8.92 1.43 1.58 
DIO1 deiodinase, iodothyronine, type I -156.4 -152.7 -10.17 -6.41 
RNASE4 ribonuclease, RNase A family, 4 -252.1 -247.3 -9.75 -7.29 
SERPINA3 serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 3 
-133.5 -139.1 -12.96 -9.44 
NNMT nicotinamide N-methyltransferase -207.2 -197.8 -11.65 -15.31 
HGD homogentisate 1,2-dioxygenase -126.4 -110.5 -14.62 -8.84 
GHR growth hormone receptor -125.4 -169.3 -10.42 -8.42 
AGT angiotensinogen (serpin peptidase inhibitor, clade 
A, member 8) 
-100.8 -95.13 -13.82 -7.65 
HSD17B2 hydroxysteroid (17-beta) dehydrogenase 2 -105.2 -100.9 -21.84 -20.93 
AHSG alpha-2-HS-glycoprotein -258 -234 -9.15 -3.6 
VTN vitronectin -126.6 -126.5 -7.57 -4.73 
C5 complement component 5 -280.2 -248 -33.66 -15.25 
TNFSF10 tumor necrosis factor (ligand) superfamily, member 
10 
-115.6 -113.6 -6.79 -5.22 
CFI complement factor I -260.7 -248.4 -57.9 -23.94 
ALDH1A1 aldehyde dehydrogenase 1 family, member A1 -391.7 -374.9 -3.85 -2.62 
A1CF APOBEC1 complementation factor -110.2 -103.7 -43.98 -27.9 
SERPINA1 serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 1 
-305.6 -291.7 -13.35 -7.22 
CFB complement factor B -374.8 -369.2 -34.86 -19.57 
FABP1 fatty acid binding protein 1, liver -585.4 -565.4 -9.08 -8.88 
MTTP microsomal triglyceride transfer protein -235.9 -221.1 -4.64 -3.21 
A2M alpha-2-macroglobulin -284.9 -353 -7.35 -3.02 
ASGR2 asialoglycoprotein receptor 2 -77.99 -79.75 -19.94 -14.2 
ACMSD aminocarboxymuconate semialdehyde 
decarboxylase 
-87.32 -87.31 -38.72 -23.78 
AKR1D1 aldo-keto reductase family 1, member D1 -417.1 -417.6 -22.99 -22.51 
PLG plasminogen -337.5 -340.8 -51.4 -26.98 
TM4SF4 transmembrane 4 L six family member 4 -104.1 -92.88 -13.68 -7.65 
LEAP2 liver expressed antimicrobial peptide 2 -116.4 -104 -11.38 -9.41 
RBP4 retinol binding protein 4, plasma -415.3 -438.9 -2.49 -1.71 
HPX hemopexin -77.35 -74.01 -30.25 -17.88 
F2 coagulation factor II (thrombin) -76.8 -63.58 -30.71 -23.29 
CXCL2 chemokine (C-X-C motif) ligand 2 -406.5 -376.2 -77.89 -48.89 
GSTA1 glutathione S-transferase alpha 1 -371.9 -368.8 -2.82 -2.25 
SULT2A1 sulfotransferase family, cytosolic, 2A, 
dehydroepiandrosterone (DHEA)-preferring, 
member 1 
-203 -196.6 -37.86 -25.94 
FGL1 fibrinogen-like 1 -130 -125.7 -45.52 -13.97 
SLC40A1 solute carrier family 40 (iron-regulated transporter), 
member 1 
-144.6 -267.3 -1.31 -1.57 
MBL2 mannose-binding lectin (protein C) 2, soluble -308.4 -285.3 -39.52 -38.76 
AMBP alpha-1-microglobulin/bikunin precursor -315.2 -302.8 -55.25 -22.52 
TF transferrin -532.6 -523.2 -94.37 -14.16 
APOA1 apolipoprotein A-I -283.1 -338.2 -1.92 -1.42 
APOC3 apolipoprotein C-III -501.8 -464.8 -3.05 -1.8 
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SLC10A1 solute carrier family 10 (sodium/bile acid 
cotransporter), member 1 
-42.46 -41.19 -17.36 -10.04 
RNF128 ring finger protein 128, E3 ubiquitin protein ligase -223.4 -205 -6.75 -4.46 
GBA3 glucosidase, beta, acid 3 -101.7 -94.98 -14.87 -9.02 
FGA fibrinogen alpha chain -693.7 -656 -2.07 -1.51 
APOA2 apolipoprotein A-II -313.3 -794.5 -1.93 -1.76 
C3 complement component 3 -131.7 -143.5 -42.21 -27.2 
RGN regucalcin -76.61 -71.01 -10.43 -8.07 
CPS1 carbamoyl-phosphate synthase 1, mitochondrial -155.1 -116.4 -10.28 -10.72 
GBP1 guanylate binding protein 1, interferon-inducible -110.6 -108.8 -31.16 -44.59 
C8orf4 chromosome 8 open reading frame 4 -170 -161.5 -1.28 -1.92 
SERPIND1 serpin peptidase inhibitor, clade D (heparin 
cofactor), member 1 
-242.2 -246.7 -57.47 -36.95 
FGG fibrinogen gamma chain -747.8 -786.6 -1.21 -1 
ASGR1 asialoglycoprotein receptor 1 -97.49 -90.45 -14.74 -9.04 
TTR transthyretin -160.9 -152.5 -1.09 1.06 
FGB fibrinogen beta chain -886.4 -866.6 -1.2 -1.03 
PROS1 protein S (alpha) -107.2 -120.7 -4.75 -4 
SERPINA5 serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 5 
-62.73 -62.83 -25.33 -19.02 
CLRN3 clarin 3 -63.31 -56.18 -10.39 -7.44 
AKR1C3 aldo-keto reductase family 1, member C3 -62.37 -63.58 -10.2 -5.54 
LIPC lipase, hepatic -97.13 -94.46 -23.72 -15.04 
ANG angiogenin, ribonuclease, RNase A family, 5 -188.1 -171.8 -33.1 -21.22 
APOB apolipoprotein B -49.47 -48.9 -4.9 -3.21 
AKR1C1 aldo-keto reductase family 1, member C1 -192.7 -163.1 -23.84 -9.07 
ALDOB aldolase B, fructose-bisphosphate -398.8 -411.6 -49.12 -21.89 
GJB2 gap junction protein, beta 2, 26kDa -52.34 -49.24 -9.59 -9.76 
ANPEP alanyl (membrane) aminopeptidase -78.05 -64.1 -4.93 -3.64 
H19 H19, imprinted maternally expressed transcript 
(non-protein coding) 
-48.9 -47.23 -32.44 -28.54 
FMO5 flavin containing monooxygenase 5 -47.97 -45.37 -13.99 -8.87 
SLC46A3 solute carrier family 46, member 3 -35.48 -53.26 -16.55 -16.01 
TMEM56 transmembrane protein 56 -76.94 -74.2 -17.63 -14.89 
ACSL5 acyl-CoA synthetase long-chain family member 5 -34.63 -33.82 -11.56 -12.44 
C8B complement component 8, beta polypeptide -178.4 -161.3 -16.76 -10.52 
LBP lipopolysaccharide binding protein -29.95 -26.69 -17.98 -7.69 
TMEM176B transmembrane protein 176B -48.02 -49.09 -32.06 -27.06 
 
Table 10  Cluster group II: Mature liver functions 
Total number of genes: 447 
The list of 447 genes represents a cluster group II that is responsible for mature liver 
functions as described in chapter 3.4.2, Fig. 18. Column 1(from left to right) represents the 
gene symbol and column 2 represents the corresponding gene description. Column 3 and 4 
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contain the fold change values of hHEPs vs. hESCs. Column 5 and 6 contain fold change 
values of hHEPs vs. HLCs. HLCs-total: the heterogeneous population of hepatocyte like cells; 
HLCs-island: hepatocyte like islands extracted from the heterogeneous population; hESCs: 
human embryonic stem cells; hHEPs: freshly isolated adult hepatocytes; vs.: versus. 
 
Symbol Description hESC1 hESC2 HLCs-
total 
HLCs-
islands 
LOC100505985 uncharacterized LOC100505985 -10.64 -10.08 -10.64 -9.89 
APOL1 apolipoprotein L, 1 -12.62 -12.58 -12.75 -12.84 
FCN2 ficolin (collagen/fibrinogen domain containing 
lectin) 2 
-11 -11.04 -10.22 -9.7 
IYD iodotyrosine deiodinase -16.32 -16.56 -13.23 -13.04 
GIMAP2 GTPase, IMAP family member 2 -11.93 -11.49 -10.97 -10.74 
BDH1 3-hydroxybutyrate dehydrogenase, type 1 -12.83 -12.34 -11.41 -9.84 
C14orf105 chromosome 14 open reading frame 105 -15.22 -14.62 -14.62 -14.54 
MLXIPL MLX interacting protein-like -13.37 -13.64 -13.27 -10.94 
PALMD palmdelphin -12.06 -11.31 -8.35 -8.01 
NDRG2 NDRG family member 2 -11.09 -10.92 -7.63 -7.94 
ABCA9 ATP-binding cassette, sub-family A (ABC1), 
member 9 
-12.14 -11.22 -12.46 -12.45 
LYZ lysozyme -10.82 -10.62 -10.36 -9.58 
GNE glucosamine (UDP-N-acetyl)-2-epimerase/N-
acetylmannosamine kinase 
-13.18 -11.63 -8.8 -9.96 
IFI27 interferon, alpha-inducible protein 27 -10.17 -10.39 -9.55 -9.25 
PRODH2 proline dehydrogenase (oxidase) 2 -11.34 -10.61 -10.08 -9.91 
CD163 CD163 molecule -13.14 -12.49 -12.57 -12.73 
GREM2 gremlin 2, DAN family BMP antagonist -10.34 -11.34 -10.94 -11.2 
DCXR dicarbonyl/L-xylulose reductase -14.59 -14.01 -8.41 -7.2 
S100A8 S100 calcium binding protein A8 -9.12 -8.93 -8.35 -8.21 
KHK ketohexokinase (fructokinase) -13.62 -13.27 -15.07 -14.27 
LOC283587 uncharacterized LOC283587 -11.06 -10.67 -10.58 -10.16 
TBX15 T-box 15 -9.14 -9.89 -8.82 -8.35 
ADHFE1 alcohol dehydrogenase, iron containing, 1 -10.59 -9.93 -8.35 -7.19 
CTSS cathepsin S -12.36 -11.96 -12.18 -11.51 
SELENBP1 selenium binding protein 1 -21.01 -19.67 -7.4 -6.61 
N4BP2L1 NEDD4 binding protein 2-like 1 -13.62 -12.65 -8.3 -7.77 
NFIA nuclear factor I/A -14.43 -13.87 -15.96 -15.4 
DNAJC12 DnaJ (Hsp40) homolog, subfamily C, member 12 -13.38 -12.7 -13.38 -12.33 
DNASE1L3 deoxyribonuclease I-like 3 -11.7 -12.18 -9.16 -8.73 
LOC145837 uncharacterized LOC145837 -8.52 -8.73 -8.57 -8.1 
C1QB complement component 1, q subcomponent, B 
chain 
-8.26 -7.93 -8.34 -8.13 
LDHD lactate dehydrogenase D -12.75 -12.15 -9.9 -9.89 
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PIK3C2G phosphatidylinositol-4-phosphate 3-kinase, catalytic 
subunit type 2 gamma 
-12.49 -12.04 -10.52 -10.73 
ETFDH electron-transferring-flavoprotein dehydrogenase -20.53 -22.43 -17.22 -16.95 
SGK2 serum/glucocorticoid regulated kinase 2 -12.43 -12.54 -10.21 -9.8 
HLA-DRA major histocompatibility complex, class II, DR 
alpha 
-12.27 -11.64 -9.57 -9.43 
ABCC6 ATP-binding cassette, sub-family C (CFTR/MRP), 
member 6 
-15.14 -15.08 -13.03 -11.52 
PXMP2 peroxisomal membrane protein 2, 22kDa -16.74 -17.02 -21.86 -20.96 
C11orf96 chromosome 11 open reading frame 96 -15.81 -16.16 -6.84 -9.37 
LOC730102 quinone oxidoreductase-like protein 2 pseudogene -18.99 -18.17 -20.3 -19.15 
IFI44 interferon-induced protein 44 -8.17 -8.33 -7.47 -7.5 
SELE selectin E -13.6 -13.04 -13.5 -13.03 
DUSP10 dual specificity phosphatase 10 -7.73 -10.53 -11.22 -13.1 
TRPM8 transient receptor potential cation channel, 
subfamily M, member 8 
-10.72 -9.77 -10.63 -10.51 
MYOM1 myomesin 1 -8.38 -8.09 -8.05 -8.97 
CA5A carbonic anhydrase VA, mitochondrial -18.45 -18.41 -19.01 -17.16 
SLC22A7 solute carrier family 22 (organic anion transporter), 
member 7 
-12.91 -12.81 -7.97 -5.62 
CSAD cysteine sulfinic acid decarboxylase -28.54 -30.69 -14.67 -12.12 
XAF1 XIAP associated factor 1 -13.39 -13.03 -13.03 -12.53 
ADRB2 adrenoceptor beta 2, surface -7.65 -7.46 -9.92 -10.05 
FMO4 flavin containing monooxygenase 4 -11.51 -10.94 -6.31 -6.39 
CYP7B1 cytochrome P450, family 7, subfamily B, 
polypeptide 1 
-9.07 -8.63 -9.33 -8.57 
MARC2 mitochondrial amidoxime reducing component 2 -20.62 -20.25 -18.81 -16.39 
PROZ protein Z, vitamin K-dependent plasma 
glycoprotein 
-17.67 -18.69 -14.97 -10.79 
SYTL4 synaptotagmin-like 4 -20.27 -20.03 -18.66 -17.42 
FAH fumarylacetoacetate hydrolase 
(fumarylacetoacetase) 
-30.52 -31.15 -9.12 -9.14 
EPHX1 epoxide hydrolase 1, microsomal (xenobiotic) -6.93 -7.59 -8.92 -8.67 
GADD45B growth arrest and DNA-damage-inducible, beta -14.54 -17.68 -6.23 -8.55 
CPEB3 cytoplasmic polyadenylation element binding 
protein 3 
-28.03 -26.79 -14.53 -16.19 
GPLD1 glycosylphosphatidylinositol specific phospholipase 
D1 
-9.9 -8.95 -9.62 -9.57 
SLC41A2 solute carrier family 41 (magnesium transporter), 
member 2 
-16.03 -15.53 -13.58 -13.96 
ENTPD5 ectonucleoside triphosphate diphosphohydrolase 5 -10.91 -11.08 -11.04 -8.51 
ALAS1 aminolevulinate, delta-, synthase 1 -16.76 -17.26 -10.04 -9.86 
RORC RAR-related orphan receptor C -13.48 -12.68 -12.15 -11.1 
NADK2 NAD kinase 2, mitochondrial -28.61 -27.65 -14.36 -14.51 
ASB9 ankyrin repeat and SOCS box containing 9 -11.5 -10.2 -13.41 -12.45 
SLC17A1 solute carrier family 17 (organic anion transporter), 
member 1 
-8.28 -7.98 -7.86 -7.89 
CYP4A11 cytochrome P450, family 4, subfamily A, 
polypeptide 11 
-9.69 -10.74 -10.82 -10.68 
RTP3 receptor (chemosensory) transporter protein 3 -8.31 -8.05 -8.46 -8.18 
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SLC6A12 solute carrier family 6 (neurotransmitter 
transporter), member 12 
-7.27 -6.95 -6.75 -6.06 
CYP2A7 cytochrome P450, family 2, subfamily A, 
polypeptide 7 
-7.47 -6.41 -9.21 -7.13 
CD1D CD1d molecule -5.19 -7.89 -10.38 -11.6 
CYP27A1 cytochrome P450, family 27, subfamily A, 
polypeptide 1 
-12.56 -12.51 -8.35 -8.23 
ACTR3C ARP3 actin-related protein 3 homolog C (yeast) -12.23 -11.67 -11.93 -11.54 
NR1I2 nuclear receptor subfamily 1, group I, member 2 -12.47 -12.57 -13.64 -13.24 
F8 coagulation factor VIII, procoagulant component -7.11 -6.95 -7.73 -7.78 
ANO1 anoctamin 1, calcium activated chloride channel -9.67 -9.58 -9.08 -9.14 
CES2 carboxylesterase 2 -17.77 -17.96 -15.41 -16.25 
PHYH phytanoyl-CoA 2-hydroxylase -22.22 -22.15 -11.08 -9.73 
SHBG sex hormone-binding globulin -6.58 -6.25 -6.66 -6.17 
XDH xanthine dehydrogenase -10.41 -9.59 -9.81 -9.02 
METTL7A methyltransferase like 7A -21.88 -14.93 -7.49 -9.01 
HBB hemoglobin, beta -8.47 -8.07 -6.77 -6 
LOC150381 uncharacterized LOC150381 -13.57 -12.16 -15.77 -14.93 
INHBB inhibin, beta B -18.21 -15.93 -5.52 -6.61 
TPRG1 tumor protein p63 regulated 1 -7.95 -7.68 -7.45 -7.42 
CLDN14 claudin 14 -8.83 -9.23 -10.01 -10.4 
HRSP12 heat-responsive protein 12 -11.78 -11.34 -23.05 -19.72 
LOC100507577 uncharacterized LOC100507577 -26.99 -26.95 -11.37 -10.17 
PFKFB1 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 1 
-7.37 -7.33 -7.02 -6.23 
DAO D-amino-acid oxidase -7.56 -7.4 -10.08 -10.35 
MUT methylmalonyl CoA mutase -15.4 -14.53 -9.8 -8.86 
CYP2A6 cytochrome P450, family 2, subfamily A, 
polypeptide 6 
-11.39 -11.78 -12.37 -11.49 
PNPO pyridoxamine 5'-phosphate oxidase -8.69 -9.39 -8.09 -9.47 
GCKR glucokinase (hexokinase 4) regulator -19.55 -18.31 -19.1 -13.86 
ART4 ADP-ribosyltransferase 4 (Dombrock blood group) -8.69 -8.34 -4.41 -4.92 
C19orf80 chromosome 19 open reading frame 80 -15.57 -15.87 -11.93 -11.68 
ATF5 activating transcription factor 5 -19.56 -21.11 -28.77 -27.05 
FUOM fucose mutarotase -8.89 -10.51 -12.34 -10.23 
C1QC complement component 1, q subcomponent, C 
chain 
-7.63 -7.12 -6.92 -6.4 
TSLP thymic stromal lymphopoietin -16.11 -16.17 -15.81 -19.11 
ADIRF adipogenesis regulatory factor -16.53 -17.02 -18.51 -16.48 
ACADL acyl-CoA dehydrogenase, long chain -20.65 -20.12 -19.71 -18.87 
HNMT histamine N-methyltransferase -11.3 -10.42 -10.29 -8.58 
TTPA tocopherol (alpha) transfer protein -14.96 -14.91 -15.93 -14.71 
CXCL13 chemokine (C-X-C motif) ligand 13 -10.94 -10.91 -8.19 -8.25 
SDS serine dehydratase -14.72 -14.44 -13.87 -13.1 
PC pyruvate carboxylase -13.89 -14.38 -9.1 -10.41 
F7 coagulation factor VII (serum prothrombin 
conversion accelerator) 
-13.77 -12.89 -5.05 -5.27 
SORBS2 sorbin and SH3 domain containing 2 -27.49 -25.39 -10.25 -14.45 
SLC22A3 solute carrier family 22 (organic cation transporter), 
member 3 
-5.92 -9.97 -7.37 -5.24 
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MLIP muscular LMNA-interacting protein -16.06 -15.1 -13.86 -12.02 
TMEM220 transmembrane protein 220 -13.43 -11.42 -21.28 -15.85 
RARRES3 retinoic acid receptor responder (tazarotene 
induced) 3 
-15.48 -13.32 -7.13 -7.48 
CPED1 cadherin-like and PC-esterase domain containing 1 -10.3 -10.2 -3.32 -3.45 
RBP5 retinol binding protein 5, cellular -16.53 -16.2 -17.49 -16.43 
ABCG8 ATP-binding cassette, sub-family G (WHITE), 
member 8 
-5.97 -5.24 -6.69 -6.64 
KAT2B K(lysine) acetyltransferase 2B -31.74 -31.49 -4.69 -5.5 
NR0B2 nuclear receptor subfamily 0, group B, member 2 -14.56 -12.58 -14.53 -14.22 
PECR peroxisomal trans-2-enoyl-CoA reductase -22.54 -18.35 -15.64 -11.24 
FXYD1 FXYD domain containing ion transport regulator 1 -14.8 -13.58 -15.36 -16.25 
OGDHL oxoglutarate dehydrogenase-like -11.95 -11.61 -15.79 -16.15 
CTSO cathepsin O -11.73 -11.84 -6.88 -7.97 
ZNF385B zinc finger protein 385B -17.54 -16.88 -17.22 -16.9 
STEAP3 STEAP family member 3, metalloreductase -7.44 -7.95 -12.95 -14.76 
ALDH6A1 aldehyde dehydrogenase 6 family, member A1 -25.59 -25.96 -6.69 -5.97 
CYP4F12 cytochrome P450, family 4, subfamily F, 
polypeptide 12 
-14.94 -14.19 -13.05 -11.95 
NFIC nuclear factor I/C (CCAAT-binding transcription 
factor) 
-7.7 -7.69 -6.47 -7.13 
ABCC2 ATP-binding cassette, sub-family C (CFTR/MRP), 
member 2 
-24.71 -25.69 -8.92 -5.47 
C1orf168 chromosome 1 open reading frame 168 -30.02 -29.21 -5.93 -4.29 
CYP4F11 cytochrome P450, family 4, subfamily F, 
polypeptide 11 
-8.29 -7.97 -7.84 -7.7 
MASP2 mannan-binding lectin serine peptidase 2 -14.94 -14.19 -13.54 -13.36 
CPS1-IT1 CPS1 intronic transcript 1 (non-protein coding) -8.68 -8.5 -8.28 -7.48 
IGFALS insulin-like growth factor binding protein, acid 
labile subunit 
-7.57 -7.36 -7.32 -6.94 
ASL argininosuccinate lyase -18.34 -20.28 -29.58 -21.36 
S1PR1 sphingosine-1-phosphate receptor 1 -14.71 -14.12 -3.62 -4.37 
SLC47A1 solute carrier family 47 (multidrug and toxin 
extrusion), member 1 
-19.18 -19.68 -9.6 -11.1 
TYROBP TYRO protein tyrosine kinase binding protein -10.39 -9.78 -6.83 -6.74 
CAPN3 calpain 3, (p94) -10.39 -10.39 -8.25 -7.58 
ZBTB20 zinc finger and BTB domain containing 20 -22.83 -21.48 -10.93 -8.89 
SKAP1 src kinase associated phosphoprotein 1 -16 -15.86 -13.43 -11.01 
MFSD2A major facilitator superfamily domain containing 2A -6.5 -6.42 -9.99 -10.46 
PDK4 pyruvate dehydrogenase kinase, isozyme 4 -31.23 -28.19 -10.87 -14.91 
METTL7B methyltransferase like 7B -17.95 -17.95 -9.44 -7.63 
UGT2B17 UDP glucuronosyltransferase 2 family, polypeptide 
B17 
-7.3 -7.28 -6.09 -6.77 
MAFB v-maf avian musculoaponeurotic fibrosarcoma 
oncogene homolog B 
-10.91 -12.64 -7.05 -9.78 
CPN1 carboxypeptidase N, polypeptide 1 -19.51 -19.61 -10.85 -8.4 
FCN3 ficolin (collagen/fibrinogen domain containing) 3 -6.64 -6.9 -3.71 -3.15 
ALDH4A1 aldehyde dehydrogenase 4 family, member A1 -7.21 -6.75 -9.45 -9.71 
ARL5B-AS1 ARL5B antisense RNA 1 -31.54 -31.4 -10.43 -8.54 
ECHDC2 enoyl CoA hydratase domain containing 2 -46.29 -43.82 -11.71 -9.61 
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SERPINF2 serpin peptidase inhibitor, clade F (alpha-2 
antiplasmin, pigment epithelium derived factor), 
member 2 
-41.11 -42.46 -15.05 -12.13 
ASS1 argininosuccinate synthase 1 -32.46 -33.67 -39.34 -29.9 
NFIB nuclear factor I/B -9.03 -9.7 -19.34 -17.57 
GADD45G growth arrest and DNA-damage-inducible, gamma -38.28 -40.04 -15.44 -12.48 
GSAP gamma-secretase activating protein -38.85 -36.85 -27.63 -24.73 
CNTN3 contactin 3 (plasmacytoma associated) -32.69 -31.65 -11.38 -9.1 
IFIT1 interferon-induced protein with tetratricopeptide 
repeats 1 
-28.75 -25.56 -4.36 -3.96 
SEC16B SEC16 homolog B (S. cerevisiae) -6.52 -6.51 -6.76 -6.77 
PLCG2 phospholipase C, gamma 2 (phosphatidylinositol-
specific) 
-6.53 -6.17 -7.47 -7.45 
AR androgen receptor -9.48 -8.76 -16.01 -15.58 
RCL1 RNA terminal phosphate cyclase-like 1 -6.57 -6.39 -15.84 -15.2 
DEFB1 defensin, beta 1 -25.08 -25.81 -10.57 -7.3 
EGR1 early growth response 1 -26.17 -13.45 -6.4 -23.5 
FOSB FBJ murine osteosarcoma viral oncogene homolog 
B 
-6.19 -5.8 -5.72 -6.13 
ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), 
member 1 
-15.19 -14.22 -14.09 -14.17 
ASPA aspartoacylase -23.33 -22.63 -18.58 -17.16 
SRD5A2 steroid-5-alpha-reductase, alpha polypeptide 2 (3-
oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2) 
-18.38 -16.67 -17.82 -16.47 
TTC38 tetratricopeptide repeat domain 38 -10.72 -11.09 -8.19 -7.18 
ACSM3 acyl-CoA synthetase medium-chain family member 
3 
-27.98 -27.31 -16.98 -15.24 
SMOC1 SPARC related modular calcium binding 1 -6.25 -5.96 -4.93 -5.06 
DHODH dihydroorotate dehydrogenase (quinone) -8.7 -8.84 -12.16 -11.33 
EGR2 early growth response 2 -16.57 -11.48 -6.11 -13.89 
ACOX1 acyl-CoA oxidase 1, palmitoyl -13.56 -13.96 -10.14 -11.13 
AHR aryl hydrocarbon receptor -17.95 -16.93 -13.27 -16.13 
HLA-DPA1 major histocompatibility complex, class II, DP 
alpha 1 
-9.36 -8.92 -8.08 -6.96 
MAOA monoamine oxidase A -28.67 -30.46 -6.04 -4.67 
ONECUT2 one cut homeobox 2 -7.25 -7.67 -10.92 -9.79 
APOC1 apolipoprotein C-I -17.1 -21.55 -4.88 -3.64 
LYSMD2 LysM, putative peptidoglycan-binding, domain 
containing 2 
-6.51 -6.23 -12.72 -13.22 
EPHX2 epoxide hydrolase 2, cytoplasmic -47.58 -46.79 -16.71 -13.35 
MT1G metallothionein 1G -22.5 -22.43 -24.8 -20.42 
PAQR9 progestin and adipoQ receptor family member IX -8.53 -7.82 -18.28 -17.55 
TRIM55 tripartite motif containing 55 -11.02 -10.84 -1.52 -1.7 
GATM glycine amidinotransferase (L-arginine:glycine 
amidinotransferase) 
-24.45 -27.27 -11.11 -8.62 
ALDH5A1 aldehyde dehydrogenase 5 family, member A1 -17.61 -16.52 -6.17 -6.81 
CLU clusterin -31.58 -28.84 -17.16 -16.87 
ABLIM3 actin binding LIM protein family, member 3 -8 -7.59 -6.1 -5.59 
ST6GAL1 ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 -7.77 -7.81 -13.1 -12.86 
ANGPTL4 angiopoietin-like 4 -12.43 -13.04 -7.62 -9.56 
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ARSE arylsulfatase E -6.03 -8.67 -8.89 -7.57 
ACOX2 acyl-CoA oxidase 2, branched chain -27.21 -32.09 -23.58 -21.19 
CLDN1 claudin 1 -30.85 -29.62 -19.2 -14.7 
SHMT1 serine hydroxymethyltransferase 1 (soluble) -6.68 -7.4 -15.64 -12.58 
IL1RAP interleukin 1 receptor accessory protein -39.21 -38.71 -17.3 -15.66 
TNFSF14 tumor necrosis factor (ligand) superfamily, member 
14 
-7.44 -6.93 -7.72 -7.84 
ALDH2 aldehyde dehydrogenase 2 family (mitochondrial) -17.16 -18.71 -7.31 -7.42 
GLS2 glutaminase 2 (liver, mitochondrial) -20.73 -18.09 -29.23 -27.49 
ACADSB acyl-CoA dehydrogenase, short/branched chain -18.44 -23.26 -34.16 -26.39 
JUN jun proto-oncogene -15.13 -15.68 -3.46 -4.17 
NUPR1 nuclear protein, transcriptional regulator, 1 -29.44 -30.46 -17.77 -12.39 
PLA1A phospholipase A1 member A -24.22 -22.57 -17.22 -16.17 
PRAP1 proline-rich acidic protein 1 -30.05 -29.52 -17.4 -13.56 
NSUN6 NOP2/Sun domain family, member 6 -10.54 -11.21 -12.86 -9.01 
SLC17A3 solute carrier family 17 (organic anion transporter), 
member 3 
-8.21 -7.26 -6.82 -6.81 
BCO2 beta-carotene oxygenase 2 -27.26 -25.1 -2.33 -2.34 
GOLT1A golgi transport 1A -21.61 -21.41 -16.56 -11.17 
TMEM176A transmembrane protein 176A -23.74 -22.76 -10.25 -8.75 
HYAL1 hyaluronoglucosaminidase 1 -25.17 -23.81 -23.3 -19.13 
LGALS4 lectin, galactoside-binding, soluble, 4 -25.86 -24.28 -5.78 -4.96 
ZMAT1 zinc finger, matrin-type 1 -9.64 -10.24 -11.35 -10.98 
TM4SF5 transmembrane 4 L six family member 5 -30.39 -31.6 -8.14 -4.63 
CUX2 cut-like homeobox 2 -11.68 -12.33 -45.71 -41.21 
ABCA5 ATP-binding cassette, sub-family A (ABC1), 
member 5 
-43.74 -34.48 -17.08 -12.85 
ENPEP glutamyl aminopeptidase (aminopeptidase A) -39.39 -42.81 -5.82 -8.71 
GPX2 glutathione peroxidase 2 (gastrointestinal) -13.17 -14.96 -5.55 -5.2 
OAS1 2'-5'-oligoadenylate synthetase 1, 40/46kDa -8.2 -7.95 -7.71 -7.13 
ABAT 4-aminobutyrate aminotransferase -76.75 -72.14 -9.88 -9.47 
SYBU syntabulin (syntaxin-interacting) -38.78 -36.76 -20.72 -22.5 
KLF9 Kruppel-like factor 9 -22.5 -22.61 -3.37 -3.72 
NR4A2 nuclear receptor subfamily 4, group A, member 2 -4.61 -5.83 -10.54 -10.23 
CDO1 cysteine dioxygenase type 1 -27.54 -23.9 -29.56 -29.84 
MT1F metallothionein 1F -9.7 -10.13 -12.11 -8.72 
NMRK1 nicotinamide riboside kinase 1 -12.35 -14.95 -6.68 -6.28 
UGT2A3 UDP glucuronosyltransferase 2 family, polypeptide 
A3 
-28.01 -25.61 -24.06 -22.62 
SULT1E1 sulfotransferase family 1E, estrogen-preferring, 
member 1 
-29.4 -28.25 -12.04 -8.95 
ABHD6 abhydrolase domain containing 6 -10.94 -14.99 -7.75 -8.08 
GSDMB gasdermin B -16.3 -16.82 -8.13 -4.67 
NEAT1 nuclear paraspeckle assembly transcript 1 (non-
protein coding) 
-26.59 -25.62 -11.82 -9.62 
AGXT2 alanine--glyoxylate aminotransferase 2 -28.61 -27.27 -13.02 -9.74 
HPN hepsin -29.59 -31.25 -12.39 -9.63 
GRB14 growth factor receptor-bound protein 14 -8.95 -6.91 -86.97 -76.1 
SLC27A2 solute carrier family 27 (fatty acid transporter), 
member 2 
-65.05 -54.17 -17.61 -17.37 
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DECR1 2,4-dienoyl CoA reductase 1, mitochondrial -11.76 -11.53 -6.65 -5.96 
PBLD phenazine biosynthesis-like protein domain 
containing 
-45.2 -41.07 -20.61 -14.55 
INHBE inhibin, beta E -5.48 -6.41 -45.62 -52.55 
ECM2 extracellular matrix protein 2, female organ and 
adipocyte specific 
-29.69 -30.23 -17.15 -10.37 
SULT1A1 sulfotransferase family, cytosolic, 1A, phenol-
preferring, member 1 
-56.5 -51.54 -4.4 -3.73 
SERPINF1 serpin peptidase inhibitor, clade F (alpha-2 
antiplasmin, pigment epithelium derived factor), 
member 1 
-56.78 -62.94 -1.51 -1.4 
MAOB monoamine oxidase B -32.42 -31.09 -13.83 -12.96 
UPB1 ureidopropionase, beta -44.65 -45.9 -42.03 -35.24 
ALDH1L1 aldehyde dehydrogenase 1 family, member L1 -42.39 -38.38 -37.03 -35.41 
CYP2J2 cytochrome P450, family 2, subfamily J, 
polypeptide 2 
-49.08 -46.64 -38.33 -34.11 
PRG4 proteoglycan 4 -32.02 -31.66 -33.6 -32.06 
CYP7A1 cytochrome P450, family 7, subfamily A, 
polypeptide 1 
-34.61 -34.41 -35.66 -36.68 
F11 coagulation factor XI -34.68 -36.16 -36.41 -34.44 
ITIH4 inter-alpha-trypsin inhibitor heavy chain family, 
member 4 
-46.25 -43.49 -40.3 -32.75 
CYP3A43 cytochrome P450, family 3, subfamily A, 
polypeptide 43 
-29.05 -26.77 -29.48 -28.6 
ACOT12 acyl-CoA thioesterase 12 -41.43 -37.4 -38.5 -35.3 
CPN2 carboxypeptidase N, polypeptide 2 -39.94 -41.38 -37.92 -34.37 
GRAMD1C GRAM domain containing 1C -55.14 -53.7 -29.74 -31.11 
IDO2 indoleamine 2,3-dioxygenase 2 -30.84 -30.14 -29.02 -29.01 
SERPINA4 serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 4 
-38.04 -36.52 -32.08 -29.55 
APOA5 apolipoprotein A-V -27.65 -27.17 -21.23 -19.67 
TTC36 tetratricopeptide repeat domain 36 -40.7 -38.97 -38.42 -34.77 
SRGN serglycin -43.4 -39.59 -28.68 -42.7 
TFR2 transferrin receptor 2 -47.93 -45.73 -50.45 -45.28 
AKR7A3 aldo-keto reductase family 7, member A3 (aflatoxin 
aldehyde reductase) 
-32.8 -33.57 -22.49 -22.64 
GLYATL1 glycine-N-acyltransferase-like 1 -38.98 -37.86 -42.43 -36.09 
CCL16 chemokine (C-C motif) ligand 16 -25.37 -24.71 -25.31 -23.29 
GLYAT glycine-N-acyltransferase -30.97 -30.23 -30.28 -27.38 
NR1I3 nuclear receptor subfamily 1, group I, member 3 -36.63 -36.06 -34.2 -28.88 
CSTA cystatin A (stefin A) -51.15 -46.11 -48.71 -52.51 
SLC25A47 solute carrier family 25, member 47 -30.79 -31.45 -34.26 -32.74 
LEPR leptin receptor -40.24 -40.22 -18.96 -18.25 
HAO2 hydroxyacid oxidase 2 (long chain) -24.25 -22.93 -26.49 -25.19 
C5orf27 chromosome 5 open reading frame 27 -30.01 -28.17 -28.22 -26.3 
F12 coagulation factor XII (Hageman factor) -74.08 -65.96 -57.3 -49.35 
BLNK B-cell linker -55.56 -56.32 -27.65 -35.68 
C8G complement component 8, gamma polypeptide -24.23 -23.44 -26.37 -28.37 
G6PC glucose-6-phosphatase, catalytic subunit -43.9 -41.62 -34.97 -28.98 
DMGDH dimethylglycine dehydrogenase -43.11 -46.65 -58.71 -58.29 
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CYP2B6 cytochrome P450, family 2, subfamily B, 
polypeptide 6 
-24 -23 -25.77 -27.83 
SLC17A2 solute carrier family 17, member 2 -60.09 -59.84 -58.11 -53.38 
THRSP thyroid hormone responsive -38.7 -36.27 -38.45 -36.14 
LOC100507389 uncharacterized LOC100507389 -21.52 -21.16 -20.78 -20.59 
LRG1 leucine-rich alpha-2-glycoprotein 1 -70.56 -62.68 -51.37 -39.13 
CYP1A2 cytochrome P450, family 1, subfamily A, 
polypeptide 2 
-32.45 -31.79 -30.58 -29.74 
HAL histidine ammonia-lyase -34.06 -31.1 -32.63 -30.39 
CYP2C18 cytochrome P450, family 2, subfamily C, 
polypeptide 18 
-65.91 -62.28 -60.54 -58.21 
CYP4V2 cytochrome P450, family 4, subfamily V, 
polypeptide 2 
-71.2 -69.39 -67.54 -70.36 
LINC01018 long intergenic non-protein coding RNA 1018 -36 -34.19 -39.26 -36.29 
HLF hepatic leukemia factor -42.57 -41.53 -38.56 -36.97 
RUNDC3B RUN domain containing 3B -35.55 -32.72 -41.3 -40.41 
NAT8 N-acetyltransferase 8 (GCN5-related, putative) -29.16 -29.22 -26.02 -24.49 
CNDP1 carnosine dipeptidase 1 (metallopeptidase M20 
family) 
-23.68 -20.26 -25.12 -22.46 
RAPGEF4 Rap guanine nucleotide exchange factor (GEF) 4 -30.84 -31.25 -32.87 -33.76 
AOX1 aldehyde oxidase 1 -67.79 -71.74 -55.84 -55.86 
IGF1 insulin-like growth factor 1 (somatomedin C) -21.12 -20.24 -16.4 -17.14 
TCEA3 transcription elongation factor A (SII), 3 -54.19 -53.92 -43.9 -40.32 
C1S complement component 1, s subcomponent -111.6 -101.7 -47.32 -41.83 
RDH16 retinol dehydrogenase 16 (all-trans) -43.99 -40.09 -41.6 -41.04 
SERPINA6 serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 6 
-65.52 -62.57 -56.42 -40.21 
FETUB fetuin B -62.95 -61.4 -62.91 -51.4 
PGLYRP2 peptidoglycan recognition protein 2 -50.77 -53.06 -54.34 -52.74 
ABCB4 ATP-binding cassette, sub-family B (MDR/TAP), 
member 4 
-48.63 -44.07 -46.73 -48.59 
HMGCS2 3-hydroxy-3-methylglutaryl-CoA synthase 2 
(mitochondrial) 
-78.79 -84.64 -36.11 -46.7 
ETNPPL ethanolamine-phosphate phospho-lyase -26.61 -34.18 -79.52 -76.35 
LPA lipoprotein, Lp(a) -78.35 -76.86 -68.75 -54.42 
SLC25A18 solute carrier family 25 (glutamate carrier), member 
18 
-25.65 -25.43 -19.57 -14.5 
HHEX hematopoietically expressed homeobox -11.86 -21.73 -52.19 -48.18 
CAT catalase -78.84 -71.61 -75.08 -73.19 
ADH6 alcohol dehydrogenase 6 (class V) -58.36 -55.83 -54.27 -51.25 
GPR88 G protein-coupled receptor 88 -20.41 -19.53 -22.6 -21.55 
PPARGC1A peroxisome proliferator-activated receptor gamma, 
coactivator 1 alpha 
-34.42 -36.81 -42.25 -41.83 
CYP2B7P1 cytochrome P450, family 2, subfamily B, 
polypeptide 7 pseudogene 1 
-14.85 -14.1 -16.61 -14.82 
GAS2 growth arrest-specific 2 -60.76 -57.41 -48.04 -47.08 
HGFAC HGF activator -19.91 -18.9 -20.46 -19.39 
KNG1 kininogen 1 -92.68 -93.46 -59.06 -33.49 
HFE2 hemochromatosis type 2 (juvenile) -75.3 -71.39 -86.12 -80.26 
PROC protein C (inactivator of coagulation factors Va and 
VIIIa) 
-61.44 -58.48 -45.16 -34.7 
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CYP39A1 cytochrome P450, family 39, subfamily A, 
polypeptide 1 
-33.3 -33.71 -32.17 -30.26 
NAT2 N-acetyltransferase 2 (arylamine N-
acetyltransferase) 
-35.87 -31.58 -31.73 -31.44 
MYRIP myosin VIIA and Rab interacting protein -18.06 -17.54 -30.61 -30.46 
CYP4F2 cytochrome P450, family 4, subfamily F, 
polypeptide 2 
-46.85 -50.44 -47.5 -46.39 
FBP1 fructose-1,6-bisphosphatase 1 -71.81 -67.22 -53.45 -45.49 
SLC27A5 solute carrier family 27 (fatty acid transporter), 
member 5 
-22.43 -21.34 -35.48 -36.52 
KMO kynurenine 3-monooxygenase (kynurenine 3-
hydroxylase) 
-56.92 -54.99 -50.91 -51.25 
C1R complement component 1, r subcomponent -161.9 -156.9 -56.33 -52.88 
SERPINA10 serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 10 
-128.9 -129.7 -98.24 -58.88 
MAT1A methionine adenosyltransferase I, alpha -66.33 -61.5 -23.5 -17.37 
FTCD formimidoyltransferase cyclodeaminase -21.1 -20.66 -17.63 -14.41 
NT5E 5'-nucleotidase, ecto (CD73) -28.37 -26.09 -16.17 -23.18 
CYP3A7 cytochrome P450, family 3, subfamily A, 
polypeptide 7 
-65.22 -59.46 -21.87 -22.06 
AGXT alanine-glyoxylate aminotransferase -60.04 -58.24 -64.87 -62.8 
PLSCR4 phospholipid scramblase 4 -38.37 -56.4 -9.3 -10.52 
HOGA1 4-hydroxy-2-oxoglutarate aldolase 1 -18.16 -17.67 -14.38 -13.65 
EVA1A eva-1 homolog A (C. elegans) -36.71 -34.94 -12.54 -14.18 
PPP1R3C protein phosphatase 1, regulatory subunit 3C -52.48 -49.48 -39.57 -40.23 
PZP pregnancy-zone protein -16.39 -14.37 -14.61 -11 
EHHADH enoyl-CoA, hydratase/3-hydroxyacyl CoA 
dehydrogenase 
-79.92 -82.83 -50.62 -45.68 
C2 complement component 2 -21.36 -21.73 -22.49 -20.72 
AKR1C2 aldo-keto reductase family 1, member C2 -30.54 -30.34 -19.12 -16.64 
HABP2 hyaluronan binding protein 2 -24.45 -24.14 -21.28 -21.1 
PROX1 prospero homeobox 1 -41.68 -40 -33.62 -33.18 
BBOX1 butyrobetaine (gamma), 2-oxoglutarate dioxygenase 
(gamma-butyrobetaine hydroxylase) 1 
-77.63 -78.25 -67.99 -68.24 
SLC38A4 solute carrier family 38, member 4 -123.5 -113.7 -121.7 -
122.64 
SLC30A10 solute carrier family 30, member 10 -39 -37.35 -26.63 -21.94 
CYP2C19 cytochrome P450, family 2, subfamily C, 
polypeptide 19 
-48.24 -39.84 -49.26 -49.31 
LOC100130232 LP2209 -76.69 -71.61 -71.02 -72.51 
IGJ immunoglobulin J polypeptide, linker protein for 
immunoglobulin alpha and mu polypeptides 
-20.26 -20.33 -20.32 -20.59 
KLKB1 kallikrein B, plasma (Fletcher factor) 1 -17.91 -17.24 -103.9 -87.92 
CYP3A5 cytochrome P450, family 3, subfamily A, 
polypeptide 5 
-121.2 -117.6 -58.51 -40.2 
A1BG alpha-1-B glycoprotein -122.1 -119.7 -34.12 -29.16 
ECHDC3 enoyl CoA hydratase domain containing 3 -32.37 -31.36 -39.22 -36.69 
RARRES2 retinoic acid receptor responder (tazarotene 
induced) 2 
-47.82 -37.67 -27.22 -29.93 
PIPOX pipecolic acid oxidase -19.21 -16.28 -107 -
103.65 
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APOM apolipoprotein M -45.9 -40.42 -11.97 -9.31 
FOLH1 folate hydrolase (prostate-specific membrane 
antigen) 1 
-94.86 -91.66 -88.26 -87 
NR1H4 nuclear receptor subfamily 1, group H, member 4 -41.79 -37.98 -36.35 -31.27 
LOC201651 arylacetamide deacetylase (esterase) pseudogene -19.58 -17.98 -19.2 -19.13 
LCAT lecithin-cholesterol acyltransferase -27.88 -27.47 -22.81 -19.76 
ACSL1 acyl-CoA synthetase long-chain family member 1 -54.65 -43.88 -12.03 -12.13 
ZGPAT zinc finger, CCCH-type with G patch domain -25.64 -28.68 -37.2 -35.22 
AGTR1 angiotensin II receptor, type 1 -30.7 -30.37 -15.06 -14.7 
SERPINA7 serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 7 
-129.4 -136.9 -86.13 -38.43 
SERPING1 serpin peptidase inhibitor, clade G (C1 inhibitor), 
member 1 
-86.56 -77.48 -13.62 -11.71 
FOS FBJ murine osteosarcoma viral oncogene homolog -33.18 -28.5 -9.66 -19.23 
LINC00261 long intergenic non-protein coding RNA 261 -11.06 -20.92 -16.98 -11.56 
SLC13A5 solute carrier family 13 (sodium-dependent citrate 
transporter), member 5 
-63.96 -62.08 -14.1 -10.06 
AKR1C4 aldo-keto reductase family 1, member C4 -276.2 -290.3 -256.2 -243.1 
APCS amyloid P component, serum -212.6 -216 -192.7 -
189.68 
GYS2 glycogen synthase 2 (liver) -230.7 -213 -220.5 -
211.45 
HRG histidine-rich glycoprotein -259.9 -255.4 -192.4 -
118.31 
CYP2C9 cytochrome P450, family 2, subfamily C, 
polypeptide 9 
-167 -155.5 -164.4 -
152.22 
CRP C-reactive protein, pentraxin-related -177.8 -172.1 -183.5 -
172.22 
CFHR2 complement factor H-related 2 -226.6 -226.2 -186.1 -
189.57 
CD14 CD14 molecule -169.4 -166.8 -152.9 -
145.14 
HAO1 hydroxyacid oxidase (glycolate oxidase) 1 -172.1 -162 -173.3 -
164.23 
ALDH8A1 aldehyde dehydrogenase 8 family, member A1 -390.7 -374.1 -235.9 -132.7 
CFHR5 complement factor H-related 5 -201.8 -193.5 -199 -
195.11 
APOF apolipoprotein F -269.8 -268.3 -266 -
255.78 
ACSM5 acyl-CoA synthetase medium-chain family member 
5 
-130.7 -125.9 -115.7 -
118.74 
CYP3A4 cytochrome P450, family 3, subfamily A, 
polypeptide 4 
-127.5 -119.3 -101.7 -94.97 
LINC00844 long intergenic non-protein coding RNA 844 -254.9 -255.4 -259 -
256.09 
SLCO1B3 solute carrier organic anion transporter family, 
member 1B3 
-131.8 -132.1 -125.4 -
120.19 
C4BPA complement component 4 binding protein, alpha -119.8 -108 -111.6 -
106.78 
VNN1 vanin 1 -149.4 -150.6 -157.3 -
152.04 
DPYS dihydropyrimidinase -248 -251 -265.5 -
252.43 
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SLC22A1 solute carrier family 22 (organic cation transporter), 
member 1 
-111.5 -122.1 -137.1 -
126.81 
LECT2 leukocyte cell-derived chemotaxin 2 -97.66 -95.61 -104 -97.3 
CFH complement factor H -385.7 -392.5 -403.6 -
374.21 
AZGP1 alpha-2-glycoprotein 1, zinc-binding -337.4 -319.6 -341 -
338.02 
PON1 paraoxonase 1 -208.9 -210.8 -73.58 -50.57 
AFM afamin -111.2 -109.3 -100.7 -89.27 
HSD11B1 hydroxysteroid (11-beta) dehydrogenase 1 -198.8 -193.6 -213.6 -
216.53 
ABCA8 ATP-binding cassette, sub-family A (ABC1), 
member 8 
-151.6 -149.8 -75.09 -
105.66 
ADH1C alcohol dehydrogenase 1C (class I), gamma 
polypeptide 
-285.3 -269.3 -260.4 -
279.43 
FMO3 flavin containing monooxygenase 3 -332.2 -320.9 -290.2 -
168.51 
ANXA10 annexin A10 -119.9 -117.1 -114.3 -
107.96 
CYP2C8 cytochrome P450, family 2, subfamily C, 
polypeptide 8 
-591.8 -644.4 -656 -
548.95 
ADH4 alcohol dehydrogenase 4 (class II), pi polypeptide -607.6 -590 -250.5 -
233.35 
C3P1 complement component 3 precursor pseudogene -91.91 -88.56 -102.8 -
101.61 
CPB2 carboxypeptidase B2 (plasma) -350.1 -337 -292.9 -
239.68 
ITIH2 inter-alpha-trypsin inhibitor heavy chain 2 -191 -171 -102.9 -47.61 
AMDHD1 amidohydrolase domain containing 1 -190.9 -196.9 -155.9 -
133.54 
LINC01093 long intergenic non-protein coding RNA 1093 -90.55 -85.96 -91.73 -89.93 
BAAT bile acid CoA: amino acid N-acyltransferase 
(glycine N-choloyltransferase) 
-121.9 -129.2 -103.7 -92.98 
F9 coagulation factor IX -520.4 -498.2 -521.2 -
484.31 
C6 complement component 6 -144.8 -134.2 -104.2 -78.35 
AADAC arylacetamide deacetylase -183.2 -167.3 -152.7 -
128.94 
HSD17B6 hydroxysteroid (17-beta) dehydrogenase 6 -106.7 -109.7 -289.4 -
214.49 
SLC6A1 solute carrier family 6 (neurotransmitter 
transporter), member 1 
-94.42 -98.89 -111.2 -
102.22 
ITIH3 inter-alpha-trypsin inhibitor heavy chain 3 -328.6 -365.8 -203.5 -
123.95 
C9 complement component 9 -548.8 -539.7 -595.4 -
570.15 
ADH1B alcohol dehydrogenase 1B (class I), beta 
polypeptide 
-448.3 -439.3 -472.3 -
461.66 
BHMT2 betaine--homocysteine S-methyltransferase 2 -118.6 -120.3 -120.9 -122.4 
CYP2E1 cytochrome P450, family 2, subfamily E, 
polypeptide 1 
-426.2 -413.8 -376.3 -
353.94 
UGT2B15 UDP glucuronosyltransferase 2 family, polypeptide 
B15 
-184.4 -188.2 -181.7 -
175.87 
ADH1A alcohol dehydrogenase 1A (class I), alpha -510.3 -508.2 -524 -
 116 
 
polypeptide 501.91 
PON3 paraoxonase 3 -153.7 -151.7 -144.2 -
143.04 
TDO2 tryptophan 2,3-dioxygenase -519.7 -470.7 -114.5 -80.77 
HAMP hepcidin antimicrobial peptide -282.5 -286 -246 -
228.01 
ARG1 arginase 1 -395 -375.2 -323.2 -
182.63 
TAT tyrosine aminotransferase -96.27 -90.67 -98.94 -88.98 
SLCO1B1 solute carrier organic anion transporter family, 
member 1B1 
-109.1 -102.8 -109.7 -99.16 
UGT2B4 UDP glucuronosyltransferase 2 family, polypeptide 
B4 
-726.6 -678.5 -670.7 -
506.34 
AQP9 aquaporin 9 -59.76 -55.11 -54.02 -50.21 
CYP8B1 cytochrome P450, family 8, subfamily B, 
polypeptide 1 
-134.2 -129.4 -125.1 -
109.76 
BCHE butyrylcholinesterase -187 -189.7 -211.1 -
236.46 
ORM2 orosomucoid 2 -447.7 -435 -256.6 -98.94 
HPR haptoglobin-related protein -195.5 -190.6 -141.7 -
101.01 
C8A complement component 8, alpha polypeptide -123.6 -113.1 -67.35 -52.88 
GC group-specific component (vitamin D binding 
protein) 
-1396 -1332 -1425 -
1374.7 
SLC2A2 solute carrier family 2 (facilitated glucose 
transporter), member 2 
-286.7 -280.6 -189.8 -
116.47 
APOH apolipoprotein H (beta-2-glycoprotein I) -737.7 -726.7 -532.6 -
235.61 
PAH phenylalanine hydroxylase -533.3 -487.2 -390 -
300.18 
F5 coagulation factor V (proaccelerin, labile factor) -102.3 -101.2 -89.22 -71.43 
ANGPTL3 angiopoietin-like 3 -302.2 -283.9 -247.3 -81.1 
GNMT glycine N-methyltransferase -81.81 -73.2 -76.19 -68.07 
C4BPB complement component 4 binding protein, beta -126.7 -126.6 -110.9 -67.87 
SERPINC1 serpin peptidase inhibitor, clade C (antithrombin), 
member 1 
-438.8 -424 -131.7 -67.33 
OTC ornithine carbamoyltransferase -70.31 -66 -56.79 -49.85 
MT1M metallothionein 1M -215.9 -222.7 -197.1 -
155.47 
HPD 4-hydroxyphenylpyruvate dioxygenase -102.8 -95.26 -75.42 -79.18 
ITIH1 inter-alpha-trypsin inhibitor heavy chain 1 -129.1 -123.3 -76.63 -49.16 
IGFBP1 insulin-like growth factor binding protein 1 -305.5 -305.4 -295.1 -
280.47 
ABCA6 ATP-binding cassette, sub-family A (ABC1), 
member 6 
-77.47 -73.43 -77.81 -70.96 
ABCG5 ATP-binding cassette, sub-family G (WHITE), 
member 5 
-66.08 -75.53 -72.64 -73.93 
SPP2 secreted phosphoprotein 2, 24kDa -71.22 -61.37 -57.74 -64.26 
F13B coagulation factor XIII, B polypeptide -135.4 -132 -122.7 -76.5 
CP ceruloplasmin (ferroxidase) -150.9 -146.5 -147.7 -
111.99 
BHMT betaine--homocysteine S-methyltransferase -107.7 -104 -75.49 -74.06 
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ALB albumin -1744 -1738 -190.6 -38.11 
PCK1 phosphoenolpyruvate carboxykinase 1 (soluble) -999.4 -990 -22.61 -47.15 
HP haptoglobin -613.4 -684.1 -150.3 -62.24 
ORM1 orosomucoid 1 -1060 -978.4 -65.28 -14.19 
 
 
Table 11 Cluster group III: Proliferation process 
Total number of genes: 1,562 
The list of 1,562 genes represents a cluster group III that is responsible for proliferation 
process as described in chapter 3.4.3, Fig. 18. Column 1(from left to right) represents the 
gene symbol and column 2 represents the corresponding gene description. Column 3 and 4 
contain the fold change values of hHEPs vs. hESCs. Column 5 and 6 contain fold change 
values of hHEPs vs. HLCs. HLCs-total: the heterogeneous population of hepatocyte like cells; 
HLCs-island: hepatocyte like islands extracted from the heterogeneous population; hESCs: 
human embryonic stem cells; hHEPs: freshly isolated adult hepatocytes; vs.: versus. 
 
Symbol Description hESC1 hESC2 HLCs-
total 
HLCs-
islands 
TDP1 tyrosyl-DNA phosphodiesterase 1 3.21 3.36 1.45 1.36 
ZMYND8 zinc finger, MYND-type containing 8 3.13 3.22 1.34 1.38 
DROSHA drosha, ribonuclease type III 2.8 3 1.41 1.15 
XPO5 exportin 5 3.08 3 1.21 1.22 
NCL nucleolin 3.29 3.39 1.2 1.19 
IPO11 importin 11 2.97 3.06 1.16 1.11 
CCNF cyclin F 3.81 3.63 1.5 1.29 
TTF1 transcription termination factor, RNA polymerase I 2.85 2.92 1.35 1.52 
SSRP1 structure specific recognition protein 1 3.89 3.6 1.46 1.35 
WDR75 WD repeat domain 75 3.52 3.12 1.02 1.05 
SLIRP SRA stem-loop interacting RNA binding protein 3.86 3.83 1.06 1.21 
DIMT1 DIM1 dimethyladenosine transferase 1 homolog (S. 
cerevisiae) 
3.33 3.2 1.35 1.3 
MAK16 MAK16 homolog (S. cerevisiae) 3.84 3.8 1.2 1.26 
KIF1A kinesin family member 1A 3.96 3.52 1.13 1.13 
ATIC 5-aminoimidazole-4-carboxamide ribonucleotide 
formyltransferase/IMP cyclohydrolase 
3.41 3.59 1.11 1.21 
CPSF3 cleavage and polyadenylation specific factor 3, 
73kDa 
3.67 3.83 1.15 1.19 
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POLD3 polymerase (DNA-directed), delta 3, accessory 
subunit 
2.97 3.27 1.26 1.2 
HNRNPC heterogeneous nuclear ribonucleoprotein C (C1/C2) 3.35 3.75 -1.01 1.07 
DSN1 DSN1, MIS12 kinetochore complex component 2.77 2.75 1.31 1.1 
HENMT1 HEN1 methyltransferase homolog 1 (Arabidopsis) 2.52 3.02 1.24 1.25 
CRLF3 cytokine receptor-like factor 3 3.83 3.75 1.35 1.14 
NUP155 nucleoporin 155kDa 3.35 3.38 1.34 1.35 
WDR12 WD repeat domain 12 3.93 4.07 1.14 1.15 
TK1 thymidine kinase 1, soluble 4.18 3.99 1.49 1.51 
FAM155A family with sequence similarity 155, member A 3.63 4.06 1.32 1.26 
LSM2 LSM2 homolog, U6 small nuclear RNA associated 
(S. cerevisiae) 
2.9 2.59 1.34 1.29 
MGME1 mitochondrial genome maintenance exonuclease 1 3.8 4.03 1.17 1.08 
PSMC3IP PSMC3 interacting protein 4.18 4.03 1.07 1.05 
IPO5 importin 5 4.03 4.25 1.32 1.34 
PAK1 p21 protein (Cdc42/Rac)-activated kinase 1 3.26 3.81 1.41 1.48 
HEATR1 HEAT repeat containing 1 4.33 4.48 1.36 1.3 
CENPN centromere protein N 4.05 4.08 1.11 1.05 
SNRNP40 small nuclear ribonucleoprotein 40kDa (U5) 3.89 3.73 1.45 1.44 
MRPL47 mitochondrial ribosomal protein L47 3.02 2.96 1.11 1.26 
C14orf169 chromosome 14 open reading frame 169 4.23 4.25 1.52 1.33 
UBE3D ubiquitin protein ligase E3D 3.24 2.96 1.05 1.16 
NUDT21 nudix (nucleoside diphosphate linked moiety X)-
type motif 21 
3.46 3.34 1.53 1.58 
TCF19 transcription factor 19 4.19 4.01 1.69 1.78 
C17orf75 chromosome 17 open reading frame 75 2.98 3.18 -1.03 1.08 
CAD carbamoyl-phosphate synthetase 2, aspartate 
transcarbamylase, and dihydroorotase 
2.88 2.88 1.16 1.21 
GNL3 guanine nucleotide binding protein-like 3 
(nucleolar) 
3.22 2.97 1.56 1.8 
XPO1 exportin 1 (CRM1 homolog, yeast) 4.34 4.46 1.5 1.25 
NUP54 nucleoporin 54kDa 3.38 3.4 -1 1.05 
RNPS1 RNA binding protein S1, serine-rich domain 3.63 3.79 1.55 1.51 
GTF3C2 general transcription factor IIIC, polypeptide 2, beta 
110kDa 
3.35 3.4 1.56 1.53 
USP10 ubiquitin specific peptidase 10 4.11 3.63 1.77 1.6 
METTL21A methyltransferase like 21A 3.08 3.43 -1.08 1.01 
SRSF3 serine/arginine-rich splicing factor 3 3.19 3.35 1.11 -1.13 
GGCT gamma-glutamylcyclotransferase 2.63 2.93 1.26 1.31 
SMARCAD1 SWI/SNF-related, matrix-associated actin-
dependent regulator of chromatin, subfamily a, 
containing DEAD/H box 1 
4.13 3.68 1.19 1.41 
RAD51 RAD51 recombinase 3.46 3.53 1.85 1.77 
TMEM178B transmembrane protein 178B 3.48 4.03 1.49 1.48 
LOC100289092 uncharacterized LOC100289092 2.75 3.02 1.07 1.11 
ILF3 interleukin enhancer binding factor 3, 90kDa 3.64 3.54 1.37 1.22 
EXOSC9 exosome component 9 4.9 5.12 1.22 1.37 
CHCHD3 coiled-coil-helix-coiled-coil-helix domain 
containing 3 
4.07 4.32 -1.01 -1.02 
SNRPF small nuclear ribonucleoprotein polypeptide F 4.39 4.39 1.12 1.04 
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DEK DEK oncogene 4.21 4.23 -1.12 1.05 
UBLCP1 ubiquitin-like domain containing CTD phosphatase 
1 
3.5 3.4 1.09 1.17 
AEN apoptosis enhancing nuclease 3.42 3.73 1.18 1.07 
APEX1 APEX nuclease (multifunctional DNA repair 
enzyme) 1 
3.82 3.82 1.45 1.54 
GNL2 guanine nucleotide binding protein-like 2 
(nucleolar) 
3.9 4.01 1.58 1.9 
NOLC1 nucleolar and coiled-body phosphoprotein 1 3.27 2.99 1.03 1.09 
PPT1 palmitoyl-protein thioesterase 1 4.15 4.24 1.35 1.17 
MTMR9 myotubularin related protein 9 2.66 2.86 1.44 1.26 
RBBP4 retinoblastoma binding protein 4 2.65 2.7 1.11 1.14 
UBR5 ubiquitin protein ligase E3 component n-recognin 5 2.23 2.4 1.19 1.13 
BYSL bystin-like 3.73 3.61 1.26 1.26 
SIX4 SIX homeobox 4 2.84 3.08 1.75 1.61 
DDX21 DEAD (Asp-Glu-Ala-Asp) box helicase 21 4.55 4.51 1 1.16 
TCF3 transcription factor 3 3.94 4.09 1.82 1.66 
ZNF551 zinc finger protein 551 2.93 3.28 1.17 1.09 
CDC123 cell division cycle 123 4.5 4.36 1.28 1.33 
YTHDF2 YTH domain family, member 2 3.69 3.71 1.29 1.07 
QSER1 glutamine and serine rich 1 2.7 2.74 -1.02 -1.08 
DDX20 DEAD (Asp-Glu-Ala-Asp) box polypeptide 20 4.06 4.16 1.11 -1.07 
DTYMK deoxythymidylate kinase (thymidylate kinase) 4.69 4.58 1.41 1.25 
TGIF1 TGFB-induced factor homeobox 1 4.27 3.99 1.46 1.12 
XPOT exportin, tRNA 3.48 3.38 1.51 1.36 
NUP107 nucleoporin 107kDa 4.33 4.4 -1.12 1.03 
PSMD11 proteasome (prosome, macropain) 26S subunit, 
non-ATPase, 11 
2.83 2.89 1.14 1.25 
YARS2 tyrosyl-tRNA synthetase 2, mitochondrial 2.98 3.03 1.01 -1.07 
TCF7L1 transcription factor 7-like 1 (T-cell specific, HMG-
box) 
4.34 4.04 1.81 1.73 
URB2 URB2 ribosome biogenesis 2 homolog (S. 
cerevisiae) 
3.5 3.77 1.36 1.22 
FAXC failed axon connections homolog (Drosophila) 2.87 3.14 1.22 1.23 
PNO1 partner of NOB1 homolog (S. cerevisiae) 3.37 3.4 -1.01 -1.15 
R3HDM1 R3H domain containing 1 3.28 3.35 1.03 1.01 
NME1 NME/NM23 nucleoside diphosphate kinase 1 4.15 4.13 -1.17 -1.21 
KIAA0020 KIAA0020 3.44 3.05 -1.18 1.08 
TCERG1 transcription elongation regulator 1 3.81 3.78 1.56 1.79 
ZNF184 zinc finger protein 184 3 2.88 1.51 1.37 
POLA2 polymerase (DNA directed), alpha 2, accessory 
subunit 
3.8 3.7 1.47 1.41 
MRPL3 mitochondrial ribosomal protein L3 3.3 3.4 1.23 1.3 
ZNF567 zinc finger protein 567 2.6 2.59 1.52 1.79 
RPA1 replication protein A1, 70kDa 2.81 2.77 1.65 1.49 
NOP16 NOP16 nucleolar protein 4.73 4.68 1.17 1.19 
ESCO2 establishment of sister chromatid cohesion N-
acetyltransferase 2 
4.52 4.37 1.3 1.31 
ZNF286A zinc finger protein 286A 3.02 3.15 1.55 1.5 
MAD2L2 MAD2 mitotic arrest deficient-like 2 (yeast) 3.23 2.98 1.38 1.39 
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SAAL1 serum amyloid A-like 1 4.91 4.98 1.42 1.42 
PARP1 poly (ADP-ribose) polymerase 1 3.96 4.29 1.03 -1.15 
DNMT3A DNA (cytosine-5-)-methyltransferase 3 alpha 4.32 4.66 1.47 1.4 
UPF3B UPF3 regulator of nonsense transcripts homolog B 
(yeast) 
2.84 2.78 -1.21 -1.09 
HSPH1 heat shock 105kDa/110kDa protein 1 4.29 3.58 1.06 1.09 
ANP32A acidic (leucine-rich) nuclear phosphoprotein 32 
family, member A 
3.54 3.51 1.47 1.28 
HTATSF1 HIV-1 Tat specific factor 1 2.82 2.63 1.41 1.3 
CCT7 chaperonin containing TCP1, subunit 7 (eta) 4.34 4.29 1.72 1.64 
C1orf109 chromosome 1 open reading frame 109 3.7 4.06 2.13 1.93 
LRR1 leucine rich repeat protein 1 4.74 4.84 -1.13 -1.12 
CCDC88C coiled-coil domain containing 88C 3.08 3.25 1.14 1.13 
CPVL carboxypeptidase, vitellogenic-like 3.08 2.98 1.26 1.31 
NAA15 N(alpha)-acetyltransferase 15, NatA auxiliary 
subunit 
4.3 4.19 -1.21 -1.08 
SNN stannin 3.4 3.57 1.85 1.64 
TRIM28 tripartite motif containing 28 4.66 4.18 1.88 1.86 
STRBP spermatid perinuclear RNA binding protein 3.02 3.42 1.18 1.11 
NARS asparaginyl-tRNA synthetase 3.19 2.91 1.34 1.35 
ACVR2B activin A receptor, type IIB 3.14 3.24 2.16 1.93 
SRM spermidine synthase 4.46 4.13 1.09 1.17 
SNRPB2 small nuclear ribonucleoprotein polypeptide B 3.49 3.53 1.59 1.64 
GTF3C4 general transcription factor IIIC, polypeptide 4, 
90kDa 
3.96 4.44 1.98 1.87 
HNRNPD heterogeneous nuclear ribonucleoprotein D (AU-
rich element RNA binding protein 1, 37kDa) 
4.35 4.5 -1.16 -1.26 
ABI2 abl-interactor 2 2.77 2.98 2.02 1.94 
HNRNPM heterogeneous nuclear ribonucleoprotein M 4.08 3.92 -1.29 -1.41 
MATR3 matrin 3 3.26 3.16 1.49 1.41 
PDSS1 prenyl (decaprenyl) diphosphate synthase, subunit 1 4.56 4.29 -1.05 1.18 
C10orf137 chromosome 10 open reading frame 137 3.68 3.81 1.45 1.53 
PWWP2A PWWP domain containing 2A 2.22 2.27 1.27 1.21 
CCT3 chaperonin containing TCP1, subunit 3 (gamma) 4.07 4.12 1.24 1.27 
GRPEL2 GrpE-like 2, mitochondrial (E. coli) 3.26 3.32 1.76 1.69 
SMNDC1 survival motor neuron domain containing 1 3.49 3.36 1.41 1.27 
PRMT5 protein arginine methyltransferase 5 5.38 5.28 1.55 1.63 
FAM213B family with sequence similarity 213, member B 2.36 2.62 1.09 1.06 
PHIP pleckstrin homology domain interacting protein 3.1 2.98 1.35 1.78 
WRN Werner syndrome, RecQ helicase-like 2.4 2.49 -1.15 -1.08 
KNSTRN kinetochore-localized astrin/SPAG5 binding protein 3.94 3.6 1.48 1.38 
NVL nuclear VCP-like 3.14 3.23 1.34 1.5 
PHF5A PHD finger protein 5A 4.39 4.45 1.54 1.48 
CPSF2 cleavage and polyadenylation specific factor 2, 
100kDa 
3.89 3.9 1.04 -1.11 
GAR1 GAR1 ribonucleoprotein 4.34 4.33 1.15 1.13 
LSM7 LSM7 homolog, U6 small nuclear RNA associated 
(S. cerevisiae) 
2.69 2.45 1.29 1.46 
NIF3L1 NIF3 NGG1 interacting factor 3-like 1 (S. 
cerevisiae) 
2.65 2.62 -1.05 -1.08 
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TMEM35 transmembrane protein 35 3.23 3.48 1.6 1.53 
PPAP2C phosphatidic acid phosphatase type 2C 4.46 4.41 1.03 1.2 
NOP56 NOP56 ribonucleoprotein 5.89 5.47 1.16 1.18 
SAC3D1 SAC3 domain containing 1 2.39 2.69 1.62 1.39 
RNASEH1-
AS1 
RNASEH1 antisense RNA 1 4.11 4.34 -1.11 -1.07 
GINS4 GINS complex subunit 4 (Sld5 homolog) 3.81 4.13 1.38 1.39 
CCDC137 coiled-coil domain containing 137 3.54 3.5 1.21 1.24 
SLC6A15 solute carrier family 6 (neutral amino acid 
transporter), member 15 
4.32 4.81 1.69 1.68 
PFDN4 prefoldin subunit 4 3.97 4 1.91 1.86 
NDC1 NDC1 transmembrane nucleoporin 4.68 4.87 -1.24 -1.26 
RLN2 relaxin 2 2.71 3.27 1.41 1.48 
HNRNPDL heterogeneous nuclear ribonucleoprotein D-like 2.53 2.55 -1.06 -1.02 
ZNF146 zinc finger protein 146 3 2.72 1.24 1.25 
NIFK nucleolar protein interacting with the FHA domain 
of MKI67 
3.94 3.82 1.05 1.14 
TAF5 TAF5 RNA polymerase II, TATA box binding 
protein (TBP)-associated factor, 100kDa 
3.23 3.18 1.11 1.05 
CDC45 cell division cycle 45 4.42 4.8 1.33 1.49 
DCAF12L1 DDB1 and CUL4 associated factor 12-like 1 3.77 4.17 1.44 1.68 
RRAS2 related RAS viral (r-ras) oncogene homolog 2 3.07 2.78 1.09 1.04 
LOC100996481 DNA primase large subunit-like 2.27 2.09 1.3 1.33 
TARS threonyl-tRNA synthetase 4.07 4.03 1.2 -1.01 
AGPAT5 1-acylglycerol-3-phosphate O-acyltransferase 5 3.87 3.81 -1.35 -1.54 
PRR11 proline rich 11 4.93 4.76 1.77 1.37 
FANCG Fanconi anemia, complementation group G 3.32 3.44 1.2 1.17 
STX6 syntaxin 6 3.2 3.42 1.96 1.64 
HNRNPR heterogeneous nuclear ribonucleoprotein R 2.95 2.93 1.46 1.33 
NIP7 NIP7, nucleolar pre-rRNA processing protein 3.4 3.86 1.07 -1.27 
PAICS phosphoribosylaminoimidazole carboxylase, 
phosphoribosylaminoimidazole 
succinocarboxamide synthetase 
4.2 4.32 1.05 -1.12 
ZNF678 zinc finger protein 678 3.1 3.02 1.22 1.37 
RBBP8 retinoblastoma binding protein 8 3.67 3.37 -1.4 -1.26 
NOL7 nucleolar protein 7, 27kDa 3.38 3.33 1.35 1.3 
HAUS6 HAUS augmin-like complex, subunit 6 3.28 3.15 -1.24 -1.19 
KCMF1 potassium channel modulatory factor 1 2.6 2.74 1.44 1.36 
SART3 squamous cell carcinoma antigen recognized by T 
cells 3 
2.5 2.44 1.05 -1.1 
ZNF721 zinc finger protein 721 3.44 3.67 -1.34 -1.01 
C4orf21 chromosome 4 open reading frame 21 2.91 2.67 -1.05 1.02 
PRKD3 protein kinase D3 3.94 3.48 1.51 1.46 
BRIP1 BRCA1 interacting protein C-terminal helicase 1 3.69 4.1 -1.05 1.01 
CHAF1A chromatin assembly factor 1, subunit A (p150) 5.6 5.18 1.01 -1.07 
ACOT7 acyl-CoA thioesterase 7 2.43 2.36 -1.16 -1.23 
HSPA4 heat shock 70kDa protein 4 3.8 3.53 1.15 1.2 
JADE1 jade family PHD finger 1 3.17 3.5 1.14 -1.07 
INA internexin neuronal intermediate filament protein, 
alpha 
3.85 4.06 1.73 1.48 
 122 
 
G3BP1 GTPase activating protein (SH3 domain) binding 
protein 1 
4.07 3.75 -1.12 -1.44 
ZNF398 zinc finger protein 398 2.75 3.07 1.49 1.38 
TSR1 TSR1, 20S rRNA accumulation, homolog (S. 
cerevisiae) 
5.46 5.21 -1.26 -1.35 
SUCLA2 succinate-CoA ligase, ADP-forming, beta subunit 3.77 3.42 1.29 1.36 
CSNK1E casein kinase 1, epsilon 2.41 2.5 1.64 1.46 
ADNP2 ADNP homeobox 2 2.5 2.78 -1.04 -1.29 
LSM4 LSM4 homolog, U6 small nuclear RNA associated 
(S. cerevisiae) 
2.37 2.16 1.07 -1.05 
USP1 ubiquitin specific peptidase 1 5.37 5.15 1.36 1.23 
GABBR1 gamma-aminobutyric acid (GABA) B receptor, 1 3.53 3.21 1.87 2.15 
TOP2B topoisomerase (DNA) II beta 180kDa 3.29 3.25 1.22 1.36 
RQCD1 RCD1 required for cell differentiation1 homolog (S. 
pombe) 
3.21 3.21 1.56 1.45 
BUB3 BUB3 mitotic checkpoint protein 2.87 2.84 1.46 1.33 
MCM8 minichromosome maintenance complex component 
8 
2.61 2.54 -1.14 -1.11 
DTD1 D-tyrosyl-tRNA deacylase 1 5.63 5.85 -1.2 -1.28 
HNRNPAB heterogeneous nuclear ribonucleoprotein A/B 6.17 6.11 1.14 1.01 
RNF138 ring finger protein 138, E3 ubiquitin protein ligase 5.05 5.68 1.04 -1.08 
ASUN asunder spermatogenesis regulator 2.87 2.77 -1.21 -1.27 
CASC5 cancer susceptibility candidate 5 2.96 2.63 1.38 1.31 
NUDT1 nudix (nucleoside diphosphate linked moiety X)-
type motif 1 
5.18 4.98 -1.04 -1.18 
ZNF589 zinc finger protein 589 2.92 3.05 1.54 1.66 
DUT deoxyuridine triphosphatase 4.67 4.84 1.18 -1.02 
---   3.12 3.24 1.3 1.44 
DCTPP1 dCTP pyrophosphatase 1 2.68 2.9 1.02 1.07 
MYBL2 v-myb avian myeloblastosis viral oncogene 
homolog-like 2 
3.64 3.58 -1.06 -1.09 
LOC645321 uncharacterized LOC645321 2.96 2.82 1.15 1.24 
BRCA1 breast cancer 1, early onset 2.43 2.52 -1.14 -1.16 
ATAD5 ATPase family, AAA domain containing 5 2.83 2.38 1.49 1.74 
PRPF38A pre-mRNA processing factor 38A 2.61 2.64 -1.05 -1.19 
TBC1D31 TBC1 domain family, member 31 3.17 2.94 -1.19 -1.26 
APITD1 apoptosis-inducing, TAF9-like domain 1 4.36 4.43 -1.24 -1.31 
CARM1 coactivator-associated arginine methyltransferase 1 2.79 2.99 1.37 1.32 
DFFA DNA fragmentation factor, 45kDa, alpha 
polypeptide 
2.6 2.64 1.7 1.57 
KIF21B kinesin family member 21B 3.31 3.84 2.36 2.16 
PTBP1 polypyrimidine tract binding protein 1 3.46 3.31 1.23 1.12 
QTRTD1 queuine tRNA-ribosyltransferase domain containing 
1 
3.94 4.44 -1.42 -1.68 
TOX thymocyte selection-associated high mobility group 
box 
2.14 2.73 1.15 -1.02 
CCAR1 cell division cycle and apoptosis regulator 1 3.1 2.99 -1.29 -1.08 
DDX39A DEAD (Asp-Glu-Ala-Asp) box polypeptide 39A 6.01 5.81 -1.41 -1.22 
WDR76 WD repeat domain 76 1.91 2.16 -1.04 -1.04 
MRPS23 mitochondrial ribosomal protein S23 2.83 2.65 1.16 1.27 
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FBL fibrillarin 4.81 4.88 1.71 1.59 
KIAA1586 KIAA1586 3.83 3.89 1.54 2.09 
HMGA1 high mobility group AT-hook 1 3.06 3.05 1.32 1.32 
NAA25 N(alpha)-acetyltransferase 25, NatB auxiliary 
subunit 
2.41 2.45 1.3 1.36 
CHRNA5 cholinergic receptor, nicotinic, alpha 5 (neuronal) 4.05 4.73 1.25 1.2 
LARS leucyl-tRNA synthetase 3.85 3.59 1.46 1.19 
RFC2 replication factor C (activator 1) 2, 40kDa 2.7 2.66 -1.26 -1.4 
PDCD2L programmed cell death 2-like 5.01 5.15 1.21 1.3 
SPRY1 sprouty homolog 1, antagonist of FGF signaling 
(Drosophila) 
4.7 4.6 1.39 -1.07 
POLD1 polymerase (DNA directed), delta 1, catalytic 
subunit 
3.06 3.09 1.98 1.94 
RBM15 RNA binding motif protein 15 2.87 2.95 1.08 -1.12 
HMGXB4 HMG box domain containing 4 2.79 2.79 1.44 1.35 
DENR density-regulated protein 3.65 3.54 1.56 1.51 
ARHGAP11A Rho GTPase activating protein 11A 2.87 2.82 -1.08 -1.17 
CDK4 cyclin-dependent kinase 4 4.13 3.89 1.84 1.89 
CCDC77 coiled-coil domain containing 77 2.73 2.96 -1.2 -1.27 
DRAXIN dorsal inhibitory axon guidance protein 3.22 3.43 -1.11 -1.14 
CELSR3 cadherin, EGF LAG seven-pass G-type receptor 3 2.3 2.61 1.84 1.91 
RPRD1A regulation of nuclear pre-mRNA domain containing 
1A 
2.44 2.09 1.08 1.09 
TGS1 trimethylguanosine synthase 1 2.79 2.96 -1.03 -1.06 
CEP68 centrosomal protein 68kDa 2.33 2.53 1.05 -1.1 
HMGB3 high mobility group box 3 4.26 4.01 -1.19 -1.41 
LRRTM4 leucine rich repeat transmembrane neuronal 4 1.93 2.19 1.39 1.36 
SYT6 synaptotagmin VI 3.6 4.18 1.48 1.41 
TRIM65 tripartite motif containing 65 2.75 2.47 1.57 1.4 
C1QBP complement component 1, q subcomponent binding 
protein 
4.14 4 -1.3 -1.34 
RRM1 ribonucleotide reductase M1 4 3.96 1.54 1.37 
SFPQ splicing factor proline/glutamine-rich 5.15 4.98 -1.08 -1.43 
NUP43 nucleoporin 43kDa 2.17 2.13 1.28 1.16 
TROAP trophinin associated protein 2.94 2.69 1.6 1.65 
YLPM1 YLP motif containing 1 2.5 2.69 1.17 -1.03 
GSG2 germ cell associated 2 (haspin) 3.36 3.34 1.37 1.51 
PPRC1 peroxisome proliferator-activated receptor gamma, 
coactivator-related 1 
3.45 3.76 -1.09 -1.25 
ALMS1 Alstrom syndrome 1 4.12 4.31 -1.48 -1.65 
CTDSPL2 CTD (carboxy-terminal domain, RNA polymerase 
II, polypeptide A) small phosphatase like 2 
3.18 3.16 1.64 1.56 
PSMA4 proteasome (prosome, macropain) subunit, alpha 
type, 4 
3.21 3.59 1.42 1.74 
RUVBL1 RuvB-like AAA ATPase 1 5.25 5.38 -1.05 -1.07 
NXPE3 neurexophilin and PC-esterase domain family, 
member 3 
2.73 2.87 1.77 1.52 
CEP152 centrosomal protein 152kDa 2.46 2.34 1.04 1.01 
HSPA14 heat shock 70kDa protein 14 3.11 3.12 -1.4 -1.34 
VBP1 von Hippel-Lindau binding protein 1 3.28 2.97 1.32 1.27 
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ACACA acetyl-CoA carboxylase alpha 3.59 3.79 1.01 -1.07 
UNG uracil-DNA glycosylase 5.27 5.86 -1.3 -1.47 
ZNF260 zinc finger protein 260 2.87 2.65 1.38 1.37 
NRARP NOTCH-regulated ankyrin repeat protein 2 2.49 1.6 1.47 
MED22 mediator complex subunit 22 2.71 2.87 1.09 1.06 
LPL lipoprotein lipase 2.54 2.9 2.13 2.17 
TNNI3 troponin I type 3 (cardiac) 2.58 2.63 1.72 1.9 
USP28 ubiquitin specific peptidase 28 3.76 4.03 1.34 1.2 
CMSS1 cms1 ribosomal small subunit homolog (yeast) 3.6 3.74 -1.56 -1.41 
AQR aquarius intron-binding spliceosomal factor 2.55 2.48 1.1 1.21 
KIAA0947 KIAA0947 2.72 2.69 1.23 1.14 
PSMD14 proteasome (prosome, macropain) 26S subunit, 
non-ATPase, 14 
3.27 3.07 -1.04 1.05 
RFX7 regulatory factor X, 7 4.46 4.16 1.73 1.27 
LRRC8B leucine rich repeat containing 8 family, member B 3.05 3.06 -1.45 -1.47 
C11orf48 chromosome 11 open reading frame 48 3.04 2.84 -1.43 -1.11 
MTF2 metal response element binding transcription factor 
2 
4.43 4.59 1.62 1.43 
BRIX1 BRX1, biogenesis of ribosomes, homolog (S. 
cerevisiae) 
7.17 7.21 1.58 1.75 
PELI1 pellino E3 ubiquitin protein ligase 1 2.65 2.38 1.27 1.42 
RNF44 ring finger protein 44 4.78 4.95 1.72 1.38 
COPS3 COP9 signalosome subunit 3 2.92 3.02 1.08 1.09 
DKC1 dyskeratosis congenita 1, dyskerin 6.62 6.38 1.43 1.5 
DHX15 DEAH (Asp-Glu-Ala-His) box helicase 15 4.25 4.24 1.84 1.87 
MAGOHB mago-nashi homolog B (Drosophila) 2.97 3.6 1.43 1.29 
SEMG1 semenogelin I 4.32 4.39 1.15 1.29 
PSME3 "proteasome (prosome, macropain) activator 
subunit 3 (PA28 gamma; Ki)" 
3.43 3.48 -1.06 -1.1 
PTGES3 prostaglandin E synthase 3 (cytosolic) 2.84 2.91 1.21 1.12 
COA1 cytochrome c oxidase assembly factor 1 homolog 
(S. cerevisiae) 
2.2 2.06 1.22 1.3 
RPF2 ribosome production factor 2 homolog (S. 
cerevisiae) 
3.01 2.87 -1.28 1.02 
CIRH1A cirrhosis, autosomal recessive 1A (cirhin) 2.82 2.74 -1.18 -1.05 
BRCA2 breast cancer 2, early onset 3.31 2.92 1.05 1.1 
SH3GL2 SH3-domain GRB2-like 2 2.75 3.52 1.33 1.28 
LYAR Ly1 antibody reactive 5.21 5.02 -1.47 -1.44 
SLC1A5 solute carrier family 1 (neutral amino acid 
transporter), member 5 
3.17 2.79 1.91 1.91 
FAM161A family with sequence similarity 161, member A 2.4 2.49 1.21 1.41 
E2F3 E2F transcription factor 3 4.34 4.33 1.51 1.43 
SLC10A4 solute carrier family 10, member 4 2.48 2.26 1.02 1.01 
EXOSC8 exosome component 8 3.09 2.9 -1.78 -1.57 
GAP43 growth associated protein 43 6.38 6.3 1.29 1.21 
PPP1R17 protein phosphatase 1, regulatory subunit 17 4.2 5.06 1.62 1.47 
KIF26A kinesin family member 26A 4.74 4.95 2.45 1.88 
ANP32E acidic (leucine-rich) nuclear phosphoprotein 32 
family, member E 
3.75 3.71 -1.31 -1.49 
DNAAF2 dynein, axonemal, assembly factor 2 3.5 3.42 -1.33 -1.46 
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ZNF649 zinc finger protein 649 2.09 2.36 1.1 1.05 
ME2 malic enzyme 2, NAD(+)-dependent, mitochondrial 2.14 1.88 1.15 1.32 
MPP6 membrane protein, palmitoylated 6 (MAGUK p55 
subfamily member 6) 
4.32 4.23 -1.32 -1.23 
BCL2L12 BCL2-like 12 (proline rich) 2.47 2.52 -1.15 -1.08 
TTC9 tetratricopeptide repeat domain 9 4.74 4.64 1.71 1.37 
DDX11 DEAD/H (Asp-Glu-Ala-Asp/His) box helicase 11 2.37 2.44 1.45 1.62 
ZNF544 zinc finger protein 544 3.31 3.59 -1.51 -1.79 
RAD1 RAD1 homolog (S. pombe) 2.7 2.82 1.6 1.5 
SAP130 Sin3A-associated protein, 130kDa 3.28 3.38 1.97 1.75 
GNA12 guanine nucleotide binding protein (G protein) 
alpha 12 
2.75 2.7 1.97 1.68 
POP1 processing of precursor 1, ribonuclease P/MRP 
subunit (S. cerevisiae) 
2.7 2.95 1.57 1.4 
INTS2 integrator complex subunit 2 2.07 2.27 1.21 1.14 
ERCC6L excision repair cross-complementing rodent repair 
deficiency, complementation group 6-like 
5.99 6.79 1.24 1.21 
PRMT3 protein arginine methyltransferase 3 6.05 6.36 1.26 1.23 
C11orf73 chromosome 11 open reading frame 73 3.89 3.8 2.4 2.18 
ST6GAL2 ST6 beta-galactosamide alpha-2,6-sialyltranferase 2 3.91 4.48 1.28 1.32 
ARHGAP19 Rho GTPase activating protein 19 4.28 4.23 1.12 -1.06 
ZBTB9 zinc finger and BTB domain containing 9 3.71 3.83 2.3 2.12 
WDR77 WD repeat domain 77 3.64 3.33 1.3 1.26 
FBXO45 F-box protein 45 2.09 2.1 -1.03 -1.21 
ZNF35 zinc finger protein 35 3.26 3.48 1.1 1.14 
PGD phosphogluconate dehydrogenase 3.92 3.34 -1.06 -1.03 
TAF1A TATA box binding protein (TBP)-associated factor, 
RNA polymerase I, A, 48kDa 
4.31 4.29 -1.01 1.02 
CPSF6 cleavage and polyadenylation specific factor 6, 
68kDa 
4.4 4.43 1.72 1.89 
TMEM108 transmembrane protein 108 2.35 2.51 1.57 1.65 
ALYREF Aly/REF export factor 5.77 5.36 1.15 1.07 
RIF1 RAP1 interacting factor homolog (yeast) 2.39 2.43 -1.28 -1.09 
SHISA9 shisa family member 9 6.2 5.95 1.44 1.44 
SMARCC1 SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily c, 
member 1 
5.45 5.45 1.8 1.41 
CCDC138 coiled-coil domain containing 138 5.85 5.85 1.12 1.44 
HNRNPU heterogeneous nuclear ribonucleoprotein U 
(scaffold attachment factor A) 
1.91 1.97 -1.05 -1.18 
PPM1G protein phosphatase, Mg2+/Mn2+ dependent, 1G 2.74 2.65 -1.17 -1.07 
VWDE von Willebrand factor D and EGF domains 2.15 2.22 1.15 1.21 
HNRNPA3 heterogeneous nuclear ribonucleoprotein A3 2.46 2.43 1.07 1.08 
PALD1 phosphatase domain containing, paladin 1 5.19 5.63 1.21 1.17 
METTL16 methyltransferase like 16 2.41 2.28 1.07 -1.08 
ACTL6A actin-like 6A 5.68 6 1.57 1.27 
STK38L serine/threonine kinase 38 like 2.42 2.62 1.25 1.16 
RNF34 ring finger protein 34, E3 ubiquitin protein ligase 3.1 2.88 1.21 1.23 
YWHAB tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, beta polypeptide 
3.42 3.33 1.17 -1.21 
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ZBTB8A zinc finger and BTB domain containing 8A 1.95 1.81 1.55 1.39 
FEZ1 fasciculation and elongation protein zeta 1 (zygin I) 2.81 2.95 2.18 2.12 
TACC3 transforming, acidic coiled-coil containing protein 3 4.64 4.34 1.13 -1.03 
HES6 hes family bHLH transcription factor 6 7.18 6.9 1.14 1.16 
STK33 serine/threonine kinase 33 4.28 4.41 1.84 2.09 
TRIB2 tribbles pseudokinase 2 3.07 2.87 1.96 1.47 
PA2G4 proliferation-associated 2G4, 38kDa 3.22 3 -1.28 -1.44 
PAK1IP1 PAK1 interacting protein 1 4.21 4.36 -1.96 -1.8 
ESPL1 extra spindle pole bodies homolog 1 (S. cerevisiae) 3.34 3.35 1.28 1.22 
FAM98B family with sequence similarity 98, member B 5.86 5.57 1.45 1.09 
POLR3F polymerase (RNA) III (DNA directed) polypeptide 
F, 39 kDa 
2.96 3.12 1.63 1.58 
CCDC181 coiled-coil domain containing 181 2.21 2.51 1.06 1.19 
MCM7 minichromosome maintenance complex component 
7 
6.37 6.54 -1.06 -1.16 
CCDC86 coiled-coil domain containing 86 6.61 6.51 2.02 1.92 
FGF13-AS1 FGF13 antisense RNA 1 4.81 4.5 1.44 1.39 
CAPRIN1 cell cycle associated protein 1 3.28 3.36 1.8 1.64 
IPO4 importin 4 4.92 4.69 -1.33 -1.52 
KCNS3 potassium voltage-gated channel, delayed-rectifier, 
subfamily S, member 3 
2.24 2.56 -1.25 -1.19 
RIT2 Ras-like without CAAX 2 7.53 6.13 1.26 1.27 
ZNF594 zinc finger protein 594 2.38 2.8 1.01 -1.06 
SLC25A21 solute carrier family 25 (mitochondrial oxoadipate 
carrier), member 21 
2.04 2.41 -1.06 -1.03 
PRPF40A PRP40 pre-mRNA processing factor 40 homolog A 
(S. cerevisiae) 
2.68 2.38 1.13 1.45 
SALL3 spalt-like transcription factor 3 8.49 8.69 1.5 1.43 
BRD7 bromodomain containing 7 2.8 2.7 1.43 1.32 
METTL8 methyltransferase like 8 2.17 2.06 -1.31 -1.35 
RBMX RNA binding motif protein, X-linked 5.34 5.51 1.66 1.76 
PRKDC protein kinase, DNA-activated, catalytic 
polypeptide 
3.92 4.15 1.18 1.02 
ITGB3BP integrin beta 3 binding protein (beta3-endonexin) 2.92 2.78 1.22 1.3 
CIAPIN1 cytokine induced apoptosis inhibitor 1 3.66 3.68 1.8 1.7 
CEBPZ CCAAT/enhancer binding protein (C/EBP), zeta 2.97 3.05 -2 -1.39 
NMRK2 nicotinamide riboside kinase 2 4.91 4.4 -1.23 -1.1 
B3GNT7 UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 7 
4.57 4.12 1.38 1.3 
PTBP2 polypyrimidine tract binding protein 2 3.43 3.29 -1.33 -1.28 
TTC27 tetratricopeptide repeat domain 27 2.48 2.73 -1.03 1.05 
HPDL 4-hydroxyphenylpyruvate dioxygenase-like 1.62 1.72 -1.01 1.03 
PCNA proliferating cell nuclear antigen 6.42 6.79 1.01 -1.25 
NUDCD1 NudC domain containing 1 3.64 3.34 2.03 2.22 
ZNF480 zinc finger protein 480 3.23 2.06 1.92 1.98 
NOVA1 neuro-oncological ventral antigen 1 4.47 5.32 1.71 1.58 
ANK2 ankyrin 2, neuronal 5.4 5.19 1.88 1.92 
SUV39H2 suppressor of variegation 3-9 homolog 2 
(Drosophila) 
5.71 5.72 1.16 1.16 
MPHOSPH6 M-phase phosphoprotein 6 3.25 3.11 1.6 1.57 
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ADSL adenylosuccinate lyase 5.62 5.88 1.83 1.95 
PPM1E protein phosphatase, Mg2+/Mn2+ dependent, 1E 1.61 2.01 -1.09 -1.15 
FBXL7 F-box and leucine-rich repeat protein 7 4.03 3.78 2.61 1.99 
KNOP1 lysine-rich nucleolar protein 1 5.55 5.79 1.5 1.56 
ZNF215 zinc finger protein 215 4.54 5.02 2.07 2.06 
SRSF9 serine/arginine-rich splicing factor 9 3.26 3.18 1.77 1.57 
SRSF2 serine/arginine-rich splicing factor 2 4.18 4.21 -1.43 -1.42 
EMG1 EMG1 N1-specific pseudouridine methyltransferase 3.18 3.06 -1.22 -1.17 
CEP78 centrosomal protein 78kDa 5.53 5.59 1.47 1.59 
DNA2 DNA replication helicase/nuclease 2 4.7 5.01 -2.01 -1.82 
MEGF10 multiple EGF-like-domains 10 2.29 3.12 -1.08 -1.03 
CEP135 centrosomal protein 135kDa 4.54 3.98 -1.16 -1.07 
OLFM1 olfactomedin 1 7.23 6.76 1.17 1.14 
MAGEE1 melanoma antigen family E, 1 2.78 2.82 2.3 2.25 
RRS1 RRS1 ribosome biogenesis regulator homolog (S. 
cerevisiae) 
5.89 6.03 -1.6 -2.19 
VPS72 vacuolar protein sorting 72 homolog (S. cerevisiae) 2.46 2.48 1.53 1.39 
C2orf69 chromosome 2 open reading frame 69 2.52 2.75 -1.27 -1.35 
NASP nuclear autoantigenic sperm protein (histone-
binding) 
4.08 4.3 -1.95 -1.8 
DESI2 desumoylating isopeptidase 2 3.74 3.49 2.15 1.92 
FBXO30 F-box protein 30 4.28 4.62 1.79 1.51 
YARS tyrosyl-tRNA synthetase 3.9 3.5 1.67 1.55 
TIGD1 tigger transposable element derived 1 2.21 2.68 1.4 1.81 
CBX3 chromobox homolog 3 4.48 4.6 1.94 2.07 
H2AFX H2A histone family, member X 3.77 3.78 1.47 1.34 
MCM4 minichromosome maintenance complex component 
4 
6.96 6.86 1.37 1.31 
S100PBP S100P binding protein 2.42 2.34 1.27 1.19 
PARG poly (ADP-ribose) glycohydrolase 2.85 2.71 1.68 1.4 
GTF2E1 general transcription factor IIE, polypeptide 1, 
alpha 56kDa 
5.75 5.6 1.63 1.28 
PRKCQ-AS1 PRKCQ antisense RNA 1 3.39 3.88 1.1 1.16 
NTM neurotrimin 4.51 4.79 2.2 1.9 
CCDC88A coiled-coil domain containing 88A 2.26 2.32 -1.29 -1.01 
WDR35 WD repeat domain 35 2.83 3.25 -1.14 -1.1 
RTKN2 rhotekin 2 5.73 5.34 -1.05 1.01 
SNHG4 small nucleolar RNA host gene 4 (non-protein 
coding) 
3.31 3.54 2.42 2.47 
MASTL microtubule associated serine/threonine kinase-like 6.65 7.12 1.1 -1.07 
SPATC1L spermatogenesis and centriole associated 1-like 2.83 2.65 1.59 1.59 
RASSF3 Ras association (RalGDS/AF-6) domain family 
member 3 
2.91 2.64 1.83 1.55 
FAM111B family with sequence similarity 111, member B 7.48 5.18 1.54 1.5 
SNRPA small nuclear ribonucleoprotein polypeptide A 5.07 4.99 1.39 1.38 
LOC100506098 uncharacterized LOC100506098 1.98 2.37 1.7 1.94 
U2AF1 U2 small nuclear RNA auxiliary factor 1 4.3 4.08 1.47 1.53 
ACBD6 acyl-CoA binding domain containing 6 2.58 2.68 1.63 1.74 
ASF1A anti-silencing function 1A histone chaperone 3.57 3.39 -1.24 -1.33 
RFC3 replication factor C (activator 1) 3, 38kDa 5.78 6 1.59 1.48 
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HAUS3 HAUS augmin-like complex, subunit 3 3.14 3.01 1.15 1.43 
POLQ polymerase (DNA directed), theta 4.12 4.48 2.37 2.29 
CCL26 chemokine (C-C motif) ligand 26 2.91 3.01 1.32 1.4 
EPHX3 epoxide hydrolase 3 3.8 3.96 1.29 1.38 
ANKRD32 ankyrin repeat domain 32 5.32 4.79 -1.09 -1.14 
MYO5A myosin VA (heavy chain 12, myoxin) 2.03 2 1.33 1.17 
ZNF814 zinc finger protein 814 5.16 6.04 -1.38 -1.45 
KARS lysyl-tRNA synthetase 2.77 2.74 1.6 1.66 
CSE1L CSE1 chromosome segregation 1-like (yeast) 7.12 7.13 1.09 1.2 
EIF3M eukaryotic translation initiation factor 3, subunit M 3.36 3.4 2.01 2.11 
HAS3 hyaluronan synthase 3 4.36 5.15 1.17 1.06 
RRP15 ribosomal RNA processing 15 homolog (S. 
cerevisiae) 
2.91 3.07 -1.7 -1.51 
MRPL50 mitochondrial ribosomal protein L50 3.24 3.23 1.01 -1 
ZNF660 zinc finger protein 660 3.2 2.29 1.6 1.54 
TIPIN TIMELESS interacting protein 4.47 4.61 -2.27 -2.26 
ZBED5 zinc finger, BED-type containing 5 3.5 3.43 2.02 1.87 
ZNF138 zinc finger protein 138 2.24 1.79 -1.64 -1.25 
CRMP1 collapsin response mediator protein 1 8.2 7.93 1.96 1.96 
CABYR calcium binding tyrosine-(Y)-phosphorylation 
regulated 
2.67 3.08 1.72 1.98 
YWHAH tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, eta polypeptide 
4.57 4.3 1.45 1.23 
SNHG3 small nucleolar RNA host gene 3 (non-protein 
coding) 
4.7 4.56 1.49 1.74 
SPRED1 sprouty-related, EVH1 domain containing 1 2.97 2.76 1.48 1.26 
ERH enhancer of rudimentary homolog (Drosophila) 2.93 2.94 1.44 1.51 
SAPCD2 suppressor APC domain containing 2 3.71 3.52 1.75 1.67 
FAM216A family with sequence similarity 216, member A 4.1 4.68 1.82 1.77 
SSB Sjogren syndrome antigen B (autoantigen La) 5.22 4.98 1.3 1.88 
EID2B EP300 interacting inhibitor of differentiation 2B 1.74 1.76 1.25 1.26 
FAM117B family with sequence similarity 117, member B 5.25 5.71 2.55 2.21 
FAM49B family with sequence similarity 49, member B 4.36 4.5 1.64 1.44 
ZNF304 zinc finger protein 304 1.81 2.08 1.44 1.12 
SKIL SKI-like oncogene 2.71 2.82 1.43 1.12 
TMEM132D transmembrane protein 132D 5.84 5.88 1.84 1.84 
KIFC1 kinesin family member C1 3.68 3.49 1.73 1.59 
FAM126A family with sequence similarity 126, member A 3.67 3.53 1.72 1.87 
ZNF607 zinc finger protein 607 2.76 2.69 1.97 1.91 
---   1.74 1.94 -1.3 -1.55 
FANCB Fanconi anemia, complementation group B 2.05 1.83 1.05 1.05 
AUNIP aurora kinase A and ninein interacting protein 5.99 6.03 1.87 1.84 
AIF1L allograft inflammatory factor 1-like 7.2 7.76 2.27 2.07 
MSH6 mutS homolog 6 4.7 4.49 2.15 2.14 
EXOC2 exocyst complex component 2 1.75 1.8 1.18 1.1 
TM6SF1 transmembrane 6 superfamily member 1 2.05 2.07 2.02 2.15 
ZNF669 zinc finger protein 669 3.27 2.7 1.92 1.58 
LRRCC1 leucine rich repeat and coiled-coil centrosomal 
protein 1 
2.57 2.07 -1.5 -1.18 
IQCB1 IQ motif containing B1 1.93 2.1 1.73 1.83 
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GDAP1 ganglioside induced differentiation associated 
protein 1 
4.19 4.76 -1.01 -1 
CIB2 calcium and integrin binding family member 2 2.79 2.9 2.08 2.58 
SNHG15 small nucleolar RNA host gene 15 (non-protein 
coding) 
2.77 2.84 1.63 2 
UTP20 UTP20, small subunit (SSU) processome 
component, homolog (yeast) 
5.36 5.24 -1.64 -1.61 
TRIM24 tripartite motif containing 24 2.68 2.7 2.3 2.47 
CCDC34 coiled-coil domain containing 34 2.39 2.51 1.14 1.37 
GLI2 GLI family zinc finger 2 2.61 2.66 1.43 1.31 
SMC2 structural maintenance of chromosomes 2 5.6 5.19 -1.13 1.02 
PGAP1 post-GPI attachment to proteins 1 1.67 1.82 1.34 1.25 
ZIK1 zinc finger protein interacting with K protein 1 6.09 6.69 1.93 2.06 
SUSD5 sushi domain containing 5 5.4 5.36 3.52 2.44 
AGO2 argonaute RISC catalytic component 2 2.57 2.46 -1.14 -1.51 
RFX5 regulatory factor X, 5 (influences HLA class II 
expression) 
2.28 2.35 1.41 1.54 
RAP1GAP2 RAP1 GTPase activating protein 2 3.68 3.7 1.85 1.86 
CDT1 chromatin licensing and DNA replication factor 1 5.61 5.94 1.49 1.6 
UBE2N ubiquitin-conjugating enzyme E2N 3.34 3.48 1.69 1.59 
ZNF207 zinc finger protein 207 4.19 4.06 1.84 1.83 
NUFIP1 nuclear fragile X mental retardation protein 
interacting protein 1 
2.31 2.45 -1.07 -1.03 
PSMD1 proteasome (prosome, macropain) 26S subunit, 
non-ATPase, 1 
3.14 2.98 1.28 1.4 
DIAPH3 diaphanous-related formin 3 4.06 3.7 2.46 2.39 
---   2.03 1.72 1.25 1.31 
ARL6IP6 ADP-ribosylation-like factor 6 interacting protein 6 3.19 3.17 2.16 2.02 
RNFT2 ring finger protein, transmembrane 2 3.33 3.71 2.12 2.11 
GMNN geminin, DNA replication inhibitor 6.53 6.7 1.05 1.21 
HS3ST3A1 heparan sulfate (glucosamine) 3-O-sulfotransferase 
3A1 
5.5 4.41 1.47 1.41 
HESX1 HESX homeobox 1 2.92 3.02 -1.05 -1.01 
---   5.46 6.63 -2.03 -1.83 
LINC00698 long intergenic non-protein coding RNA 698 3.03 3.07 1.58 1.69 
MYB v-myb avian myeloblastosis viral oncogene 
homolog 
1.86 2.21 1.42 1.45 
TMEM47 transmembrane protein 47 2.22 2.59 1.26 1.2 
SKA2 spindle and kinetochore associated complex subunit 
2 
2.39 2.61 1.15 1.01 
OTUD6B OTU domain containing 6B 9.61 9.81 -1.14 -1.32 
VSIG10 V-set and immunoglobulin domain containing 10 3.74 4.16 -2.1 -1.93 
ARNT2 aryl-hydrocarbon receptor nuclear translocator 2 2.34 2.71 1.41 1.28 
CTSC cathepsin C 6.85 6.13 1.42 1.38 
DHX9 DEAH (Asp-Glu-Ala-His) box helicase 9 4.46 3.21 1.02 -1.3 
TRERF1 transcriptional regulating factor 1 2.3 2.55 1.94 1.87 
CNOT7 CCR4-NOT transcription complex, subunit 7 3.37 3.18 1.24 1.22 
ATP1A2 ATPase, Na+/K+ transporting, alpha 2 polypeptide 1.78 2.35 1.19 1.24 
LOC286467 family with sequence similarity 195, member A 
pseudogene 
2.58 2.63 2.05 2.17 
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CRLF1 cytokine receptor-like factor 1 2.6 3.05 1.74 1.53 
RBP1 retinol binding protein 1, cellular 4.38 3.59 1.99 1.38 
ZFP37 ZFP37 zinc finger protein 2.43 2.51 1.66 1.89 
ZSCAN10 zinc finger and SCAN domain containing 10 3.79 3.82 1.5 1.57 
KCND2 potassium voltage-gated channel, Shal-related 
subfamily, member 2 
6.44 6.41 1.65 1.36 
PUS7 pseudouridylate synthase 7 homolog (S. cerevisiae) 5.24 5.26 -2.24 -2.12 
BEND3 BEN domain containing 3 8.36 8.68 1.34 1.35 
GPR63 G protein-coupled receptor 63 2.32 2.34 1.27 1.17 
RIMS3 regulating synaptic membrane exocytosis 3 2.5 2.54 1.62 1.52 
SYT14 synaptotagmin XIV 2.31 2.55 1.13 1.26 
SLC4A7 solute carrier family 4, sodium bicarbonate 
cotransporter, member 7 
2.63 2.51 1.72 1.67 
EIF4A3 eukaryotic translation initiation factor 4A3 2.77 2.76 1.07 1.07 
LINGO1 leucine rich repeat and Ig domain containing 1 5.1 7.88 1.18 1.3 
DHX36 DEAH (Asp-Glu-Ala-His) box polypeptide 36 2.34 2.25 -1.09 -1.02 
FANCF Fanconi anemia, complementation group F 2.31 2.2 1.12 -1.01 
SMC4 structural maintenance of chromosomes 4 4.81 4.57 1.76 2.22 
ZNF101 zinc finger protein 101 2.38 2.31 1.14 1.19 
DDIT4L DNA-damage-inducible transcript 4-like 3.12 3.22 2.17 1.97 
ARID2 AT rich interactive domain 2 (ARID, RFX-like) 2.21 2.38 1.48 1.47 
ETF1 eukaryotic translation termination factor 1 3.06 3.03 1.45 1.35 
ADNP activity-dependent neuroprotector homeobox 3.08 3.13 2.14 1.57 
KHDRBS1 KH domain containing, RNA binding, signal 
transduction associated 1 
4.28 4.35 2.03 1.79 
LOXL1-AS1 LOXL1 antisense RNA 1 1.83 2.02 1.96 1.64 
GART phosphoribosylglycinamide formyltransferase, 
phosphoribosylglycinamide synthetase, 
phosphoribosylaminoimidazole synthetase 
2.74 2.71 -1.34 -1.37 
LINC00545 long intergenic non-protein coding RNA 545 5.03 7.81 1.52 1.5 
SEPW1 selenoprotein W, 1 2.98 2.86 2.61 2.68 
PCDHB16 protocadherin beta 16 2.37 4.03 1.76 1.71 
NUDT10 nudix (nucleoside diphosphate linked moiety X)-
type motif 10 
4.2 3.61 1.59 1.66 
MEX3B mex-3 RNA binding family member B 2.33 2.01 1.22 1.12 
FDFT1 farnesyl-diphosphate farnesyltransferase 1 7.41 7.1 1.44 1.63 
CPT1C carnitine palmitoyltransferase 1C 1.24 1.62 1.07 1.11 
POPDC3 popeye domain containing 3 4.62 5.02 2.59 3.16 
AMD1 adenosylmethionine decarboxylase 1 4.27 4.55 1.36 1.53 
ZNF74 zinc finger protein 74 2.81 2.72 1.47 1.48 
NAT10 N-acetyltransferase 10 (GCN5-related) 2.99 3.18 -1.09 1.01 
BBS9 Bardet-Biedl syndrome 9 2.65 3.33 1.34 1.19 
CA14 carbonic anhydrase XIV 4.22 4.66 1.91 2.02 
ZNF107 zinc finger protein 107 2.37 1.63 1.07 -1.02 
TRMT6 tRNA methyltransferase 6 homolog (S. cerevisiae) 2.42 2.49 -1.31 -1.25 
CDC25C cell division cycle 25C 4.81 4.6 1.75 1.65 
G3BP2 GTPase activating protein (SH3 domain) binding 
protein 2 
3.92 3.89 1.39 1.24 
CDCA8 cell division cycle associated 8 7.09 7.1 2.13 1.62 
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NOP2 NOP2 nucleolar protein 3.36 3.34 1.15 1.28 
JAKMIP2-AS1 JAKMIP2 antisense RNA 1 2.72 4.12 1.09 1.23 
PRKCQ protein kinase C, theta 5.41 5.98 2.35 2.53 
SSBP1 single-stranded DNA binding protein 1, 
mitochondrial 
2.65 2.57 -1.5 -1.6 
MITD1 MIT, microtubule interacting and transport, domain 
containing 1 
2.13 2.12 1.08 1.07 
ZFP69B ZFP69 zinc finger protein B 6.08 5.6 1.07 1.03 
PARP8 poly (ADP-ribose) polymerase family, member 8 2.24 2.25 1.84 2.06 
ZNF331 zinc finger protein 331 1.71 1.73 1.58 1.74 
CHST6 carbohydrate (N-acetylglucosamine 6-O) 
sulfotransferase 6 
2.7 2.71 1.29 1.32 
C2orf40 chromosome 2 open reading frame 40 2.44 2.85 2.57 3.13 
IPO7 importin 7 2.21 2.16 1.14 1.22 
KDM1A lysine (K)-specific demethylase 1A 4.93 5.26 2.06 2.39 
CLDN11 claudin 11 7.5 5.81 2.38 1.22 
KDELC1 KDEL (Lys-Asp-Glu-Leu) containing 1 2.71 2.75 2.11 2.04 
NPM1 nucleophosmin (nucleolar phosphoprotein B23, 
numatrin) 
4.55 4.64 1.53 1.58 
PRIM1 primase, DNA, polypeptide 1 (49kDa) 3.37 4.55 -1.71 -1.49 
FAM124A family with sequence similarity 124A 2.99 3.26 1.34 1.32 
FLT1 fms-related tyrosine kinase 1 4.96 4.95 2.75 2.39 
LSM5 LSM5 homolog, U6 small nuclear RNA associated 
(S. cerevisiae) 
2.79 2.98 -1.1 -1.2 
MED27 mediator complex subunit 27 4.04 4.12 2.12 2.24 
METAP1 methionyl aminopeptidase 1 2.38 2.45 1.3 1.27 
POLE2 polymerase (DNA directed), epsilon 2, accessory 
subunit 
3.95 4.14 -1.47 -1.43 
ZNF354A zinc finger protein 354A 2.46 2.27 2.1 2.39 
CSNK2A1 casein kinase 2, alpha 1 polypeptide 3.15 2.95 1.7 1.53 
LCK lymphocyte-specific protein tyrosine kinase 3.64 4.46 1.25 1.3 
UCK2 uridine-cytidine kinase 2 2.69 2.59 1.19 1.13 
THUMPD1 THUMP domain containing 1 2.88 2.75 1.12 -1.01 
DNMT1 DNA (cytosine-5-)-methyltransferase 1 6.6 6.88 1.93 1.7 
ZNF347 zinc finger protein 347 2.28 2.22 1.75 1.48 
FAM200A family with sequence similarity 200, member A 2.07 2.09 1.62 1.34 
DCAF13 DDB1 and CUL4 associated factor 13 4.7 5.01 1.57 1.87 
IRAK1BP1 interleukin-1 receptor-associated kinase 1 binding 
protein 1 
2.64 3.42 1.58 1.56 
CSTF2 cleavage stimulation factor, 3' pre-RNA, subunit 2, 
64kDa 
4.88 4.9 1.63 1.62 
DCK deoxycytidine kinase 3.3 3.27 1.77 1.41 
SP4 Sp4 transcription factor 2.54 2.64 -1 1.02 
MKI67 marker of proliferation Ki-67 5.63 4.81 1.81 1.65 
NPFFR2 neuropeptide FF receptor 2 8.8 6.58 2.33 1.68 
SCML2 sex comb on midleg-like 2 (Drosophila) 4.21 4.03 1.32 1.53 
TRIML2 tripartite motif family-like 2 2.04 2.07 1.02 1.03 
PACRGL PARK2 co-regulated-like 2.84 2.76 1.89 1.55 
ZNF280C zinc finger protein 280C 3.02 2.81 -1.05 -1.17 
CDK2AP1 cyclin-dependent kinase 2 associated protein 1 5.53 5.84 1.59 1.36 
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GEMIN5 gem (nuclear organelle) associated protein 5 2.94 2.99 -1.19 -1.2 
UTP15 UTP15, U3 small nucleolar ribonucleoprotein, 
homolog (S. cerevisiae) 
2.96 3.15 -1.65 -1.57 
SNHG12 small nucleolar RNA host gene 12 (non-protein 
coding) 
2.5 2.19 -1.05 2.01 
PPP4R1 protein phosphatase 4, regulatory subunit 1 3.27 3.14 1.25 1.12 
ZRANB2 zinc finger, RAN-binding domain containing 2 2.75 2.7 1.8 2.15 
SLITRK5 SLIT and NTRK-like family, member 5 2.94 2.88 1.48 1.5 
HEATR2 HEAT repeat containing 2 2.72 2.45 -1.06 -1.25 
KNTC1 kinetochore associated 1 4.25 4.37 1.82 2.02 
SRSF7 serine/arginine-rich splicing factor 7 2.29 2.74 -1.03 -1.33 
SNORA64 small nucleolar RNA, H/ACA box 64 4.03 3.77 1.75 1.75 
PVT1 Pvt1 oncogene (non-protein coding) 3.26 3.58 2.26 2.56 
FOXH1 forkhead box H1 9.86 8.56 -1.05 -1.05 
TTLL12 tubulin tyrosine ligase-like family, member 12 3.16 3.08 1.08 1.07 
EXOSC2 exosome component 2 2.39 2.35 -1.29 -1.31 
MRE11A MRE11 meiotic recombination 11 homolog A (S. 
cerevisiae) 
1.92 1.68 -1.17 -1.18 
NUP160 nucleoporin 160kDa 2.63 2.71 1.07 -1.03 
C21orf59 chromosome 21 open reading frame 59 2.24 2.23 -1.39 -1.37 
TRDMT1 tRNA aspartic acid methyltransferase 1 4.76 5.63 1.37 1.41 
GNAS-AS1 GNAS antisense RNA 1 1.65 1.91 -1.23 -1.18 
TBCB tubulin folding cofactor B 2.44 2.16 1.09 1.04 
MRAP2 melanocortin 2 receptor accessory protein 2 3.15 4.11 3.94 3.31 
RAB39B RAB39B, member RAS oncogene family 4.96 4.71 1.19 1.12 
P2RY1 purinergic receptor P2Y, G-protein coupled, 1 3.9 2.92 1.12 1.18 
IVNS1ABP influenza virus NS1A binding protein 2.21 2.37 2.63 2.06 
DIAPH2 diaphanous-related formin 2 8.42 9.08 -1.8 -1.61 
MCM5 minichromosome maintenance complex component 
5 
6.56 6.9 -2.34 -2.38 
CECR1 cat eye syndrome chromosome region, candidate 1 2.01 2.16 1.91 1.67 
SNX16 sorting nexin 16 2.81 2.31 1.51 1.47 
NUAK1 NUAK family, SNF1-like kinase, 1 4.19 3.71 2.12 1.22 
FBN3 fibrillin 3 2.73 2.88 1.7 1.75 
ZNF134 zinc finger protein 134 2.78 3.11 1.27 1.04 
ZNF253 zinc finger protein 253 3.03 3.15 1.57 1.96 
DDX25 DEAD (Asp-Glu-Ala-Asp) box helicase 25 2.34 2.94 -1.05 -1 
C10orf2 chromosome 10 open reading frame 2 2.64 2.89 -1.3 -1.39 
DANCR differentiation antagonizing non-protein coding 
RNA 
7.79 7.9 -1.11 -1.25 
RBM12B RNA binding motif protein 12B 2.37 2.68 2.29 1.73 
SNAPC1 small nuclear RNA activating complex, polypeptide 
1, 43kDa 
1.63 1.56 -1 -1.07 
KIF20B kinesin family member 20B 7.38 6.85 1.46 1.75 
CHAMP1 chromosome alignment maintaining phosphoprotein 
1 
2.99 3.23 1.15 -1.17 
IDO1 indoleamine 2,3-dioxygenase 1 3.23 4.69 2.09 2.28 
GPATCH4 G patch domain containing 4 5.13 4.47 -2.09 -2.06 
PCYT1B phosphate cytidylyltransferase 1, choline, beta 3.63 3.9 1.26 1.25 
ZNF135 zinc finger protein 135 2.69 2.94 1.49 1.42 
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PRIMA1 proline rich membrane anchor 1 3.14 2.85 2.53 2.44 
GINS3 GINS complex subunit 3 (Psf3 homolog) 8.34 8.75 1.12 1.03 
TMX1 thioredoxin-related transmembrane protein 1 2.03 1.98 -1.01 -1.1 
TMEFF2 transmembrane protein with EGF-like and two 
follistatin-like domains 2 
2.23 2.22 1.28 1 
C17orf104 chromosome 17 open reading frame 104 1.45 1.55 1.07 1.09 
ZNF300 zinc finger protein 300 1.45 1.56 1.08 1.12 
FARSB phenylalanyl-tRNA synthetase, beta subunit 2.69 2.75 1.36 1.52 
ADAMTS19 ADAM metallopeptidase with thrombospondin type 
1 motif, 19 
6.87 7.11 3.17 2.24 
STIP1 stress-induced-phosphoprotein 1 2.04 1.57 -1.39 -1.45 
TTL tubulin tyrosine ligase 2.56 2.32 -1.31 -1.35 
TPR translocated promoter region, nuclear basket protein 1.83 1.61 1.04 1.44 
PPAT phosphoribosyl pyrophosphate amidotransferase 8.16 8.31 1.77 1.78 
TIMP4 TIMP metallopeptidase inhibitor 4 6.95 6.29 2.21 2.25 
TRBC2 T cell receptor beta constant 2 2.76 3.4 1.97 1.88 
CDC25A cell division cycle 25A 7.93 8.91 1.2 1.16 
PFAS phosphoribosylformylglycinamidine synthase 7.64 8.61 -1.59 -1.98 
SKA3 spindle and kinetochore associated complex subunit 
3 
7.34 8.77 2.31 2.25 
RPRM reprimo, TP53 dependent G2 arrest mediator 
candidate 
8.21 5.08 1.74 1.58 
SLITRK4 SLIT and NTRK-like family, member 4 2.1 1.95 1.63 1.93 
LRAT lecithin retinol acyltransferase 
(phosphatidylcholine--retinol O-acyltransferase) 
2.21 2.44 1.02 1.04 
CIT citron (rho-interacting, serine/threonine kinase 21) 2.97 3.13 2.06 1.82 
NAP1L2 nucleosome assembly protein 1-like 2 6.8 7.41 1.02 -1.14 
PMS1 PMS1 postmeiotic segregation increased 1 (S. 
cerevisiae) 
2.02 1.93 -1.57 -1.05 
ZNF587B zinc finger protein 587B 2.62 2.93 -2.42 -2.62 
GTSE1 G-2 and S-phase expressed 1 7.27 6.16 1.66 1.32 
POU5F1P4 POU class 5 homeobox 1 pseudogene 4 11.4 10.37 -1.85 -1.68 
POLA1 polymerase (DNA directed), alpha 1, catalytic 
subunit 
7.69 8.1 1.4 1.41 
ACD adrenocortical dysplasia homolog (mouse) 2.32 2.33 1.42 1.4 
RRP36 ribosomal RNA processing 36 homolog (S. 
cerevisiae) 
4.67 4.54 1.31 1.5 
METTL3 methyltransferase like 3 1.78 1.61 -1.17 -1.11 
TRIM45 tripartite motif containing 45 2.47 2.83 2.99 2.95 
ADD2 adducin 2 (beta) 4.99 5.43 1.16 1.2 
CPXM1 carboxypeptidase X (M14 family), member 1 4.82 4.41 3.01 3.2 
RGS5 regulator of G-protein signaling 5 6.11 5.64 3.8 3.32 
THY1 Thy-1 cell surface antigen 7.55 7.97 3.07 2.56 
DAZL deleted in azoospermia-like 1.68 1.98 1.43 1.42 
C16orf59 chromosome 16 open reading frame 59 3.09 2.92 1.44 1.44 
CCDC160 coiled-coil domain containing 160 3.49 2.51 1.08 1.13 
ITGB5 integrin, beta 5 5.23 4.8 1.38 1.14 
MIAT myocardial infarction associated transcript (non-
protein coding) 
1.26 1.48 1.16 1.22 
PTPRG protein tyrosine phosphatase, receptor type, G 3.67 3.75 -2.14 -3.15 
 134 
 
TCERG1L transcription elongation regulator 1-like 3.88 3.65 1.75 1.67 
STOX2 storkhead box 2 11.38 12.57 -1.47 -1.6 
MGC57346 uncharacterized LOC401884 3.32 3.51 3.19 3.11 
LOC100506392 uncharacterized LOC100506392 1.44 1.46 1.1 1.13 
NPTX2 neuronal pentraxin II 3.3 5.24 1.27 1.43 
FGD1 FYVE, RhoGEF and PH domain containing 1 2.99 3.27 3.1 2.67 
JPH3 junctophilin 3 2.76 2.63 2.54 2.27 
TLCD1 TLC domain containing 1 4.68 4.35 1.39 1.63 
GTF2F2 general transcription factor IIF, polypeptide 2, 
30kDa 
2.52 2.44 1.15 1.16 
INSM1 insulinoma-associated 1 1.66 2.12 1.43 1.43 
PRMT6 protein arginine methyltransferase 6 3.35 3.19 -2.1 -3.11 
GAS2L3 growth arrest-specific 2 like 3 2.62 2.24 1.67 1.42 
NTPCR nucleoside-triphosphatase, cancer-related 2.36 2.43 1.53 1.54 
TEX9 testis expressed 9 4.24 3.8 -1.09 -1.1 
KIAA1244 KIAA1244 1.5 1.59 -1.18 -1.16 
FAM189A2 family with sequence similarity 189, member A2 5.05 4.34 1.69 1.63 
PRPS1 phosphoribosyl pyrophosphate synthetase 1 2.96 2.73 1.09 -1 
ZNF426 zinc finger protein 426 2.07 2.16 1.58 1.27 
DYRK2 dual-specificity tyrosine-(Y)-phosphorylation 
regulated kinase 2 
3.08 3.23 1.39 1.04 
PIF1 PIF1 5'-to-3' DNA helicase 5.15 4.8 1.37 1.35 
LRRC34 leucine rich repeat containing 34 1.07 1.08 -1.25 -1.2 
VRTN vertebrae development associated 3.41 3.56 -1.93 -1.81 
FHOD3 formin homology 2 domain containing 3 1.64 1.93 2.4 2.1 
PLA2G3 phospholipase A2, group III 7.95 8.55 1.01 1.04 
TMEM132B transmembrane protein 132B 3.34 4.14 2.05 1.35 
DLAT dihydrolipoamide S-acetyltransferase 3.6 3.31 1.41 1.48 
TMEM69 transmembrane protein 69 2.72 2.88 1.84 1.67 
SFR1 SWI5-dependent recombination repair 1 1.99 1.97 1.39 1.39 
COL9A3 collagen, type IX, alpha 3 4.02 3.91 2.58 2.43 
CNIH3 cornichon family AMPA receptor auxiliary protein 
3 
3.54 3.45 1.41 1.13 
THBS2 thrombospondin 2 11.74 13.82 2.23 1.28 
NUDT15 nudix (nucleoside diphosphate linked moiety X)-
type motif 15 
12.65 11.67 -1.06 -1.31 
RABGAP1L RAB GTPase activating protein 1-like 2.04 2.32 -1.59 -1.49 
---   2.1 1.95 -1.32 -1.51 
CHODL chondrolectin 4.44 3.79 1.8 1.78 
LOC100505946 uncharacterized LOC100505946 2.83 3.19 2.3 2.16 
CHRDL1 chordin-like 1 4.76 6.24 1.28 1.34 
PIM2 pim-2 oncogene 3.04 3.32 -1.45 -1.57 
TDRP testis development related protein 2.42 2.77 1.9 1.76 
GNPTAB N-acetylglucosamine-1-phosphate transferase, alpha 
and beta subunits 
1.72 1.88 1.01 -1.12 
PDCL phosducin-like 2.78 2.85 1.84 1.72 
G6PC3 glucose 6 phosphatase, catalytic, 3 3.47 3.66 2.22 2.14 
ACTA1 actin, alpha 1, skeletal muscle 16.68 13.95 1.65 1.28 
LDB2 LIM domain binding 2 8.63 8.32 1.36 1.07 
HNRNPL heterogeneous nuclear ribonucleoprotein L 3.86 3.86 1.3 1.16 
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CXCL6 chemokine (C-X-C motif) ligand 6 1.3 1.67 -1.51 -1.46 
CCNA1 cyclin A1 1.85 2.08 1.32 1.42 
CDKN2AIPNL CDKN2A interacting protein N-terminal like 3.95 3.49 1.56 1.34 
OGFOD1 2-oxoglutarate and iron-dependent oxygenase 
domain containing 1 
2.55 2.69 1.26 1.25 
ZCCHC3 zinc finger, CCHC domain containing 3 4.14 4.09 2.42 1.87 
UST uronyl-2-sulfotransferase 7.16 6.39 2.76 2.48 
PCDHB15 protocadherin beta 15 1.7 1.94 1.68 1.92 
LOC100506691 uncharacterized LOC100506691 1.42 1.65 1.71 1.64 
NLGN1 neuroligin 1 4.42 4.12 1.27 1.35 
CCDC14 coiled-coil domain containing 14 1.96 1.85 1.36 1.58 
SNORA61 small nucleolar RNA, H/ACA box 61 2.29 1.79 -1.46 1.37 
NEFH neurofilament, heavy polypeptide 1.74 2.19 1.1 1.13 
CDH13 cadherin 13 1.61 1.77 2.43 1.45 
PIGW phosphatidylinositol glycan anchor biosynthesis, 
class W 
5.69 5.98 -2.88 -3.37 
CYB5R2 cytochrome b5 reductase 2 2.05 2.25 3.67 3.61 
UNC5A unc-5 homolog A (C. elegans) 2.82 3.34 2.18 2.24 
GLT8D2 glycosyltransferase 8 domain containing 2 1.53 1.96 3.54 3.71 
DYX1C1 dyslexia susceptibility 1 candidate 1 1.44 1.4 1.06 1.11 
MAGOH mago-nashi homolog, proliferation-associated 
(Drosophila) 
2.95 2.82 1.21 1.25 
RFXAP regulatory factor X-associated protein 1.67 1.6 1.16 1.1 
RBBP7 retinoblastoma binding protein 7 2.55 3.06 2.29 2.26 
FAM162B family with sequence similarity 162, member B 1.34 1.75 2.07 2.09 
GPR19 G protein-coupled receptor 19 6.5 8.25 1.47 1.58 
MNS1 meiosis-specific nuclear structural 1 2.28 2.11 -1.13 -1.06 
IFITM1 interferon induced transmembrane protein 1 9.81 8.13 3.69 4.23 
NRK Nik related kinase 1.58 1.85 1.95 1.9 
CTTNBP2 cortactin binding protein 2 1.28 1.57 3.92 3.66 
LOXL3 lysyl oxidase-like 3 3.26 3.48 2.15 2.28 
LOC100996301 homeotic protein female sterile-like 6.83 6.17 -2.75 -2.77 
HIP1 huntingtin interacting protein 1 2.31 2.29 2.04 1.52 
WIF1 WNT inhibitory factor 1 1.67 2.25 -1.11 -1.13 
MGC24103 uncharacterized MGC24103 1.21 1.29 2.75 3.62 
CHD7 chromodomain helicase DNA binding protein 7 3.19 3.07 1.21 1.19 
FGFR2 fibroblast growth factor receptor 2 1.95 2.17 3.71 2.86 
LINC00664 long intergenic non-protein coding RNA 664 1.51 1.39 1.21 1.24 
ST6GALNAC5 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-
galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-
sialyltransferase 5 
3.91 3.25 1.72 1.66 
IRX1 iroquois homeobox 1 1.02 1.02 1.24 1.05 
RGMA RGM domain family, member A 3.41 3.75 2.18 2.32 
GLB1L3 galactosidase, beta 1-like 3 8.42 9.89 -1.11 -1.08 
CALCB calcitonin-related polypeptide beta 3.38 4.07 1.3 1.3 
NODAL nodal growth differentiation factor 15.52 14.81 1.5 1.49 
GDF3 growth differentiation factor 3 31.41 22.98 1.58 1.73 
ABHD12B abhydrolase domain containing 12B 4.09 4.15 -1.17 -1.15 
FKBP1B FK506 binding protein 1B, 12.6 kDa 3.59 3.69 2.68 2.6 
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HNRNPA1 heterogeneous nuclear ribonucleoprotein A1 4.18 4.27 3.22 2.99 
ARMC9 armadillo repeat containing 9 3.47 3.78 2.82 2.32 
RPL4 ribosomal protein L4 3.67 3.57 3.15 3.07 
CDYL chromodomain protein, Y-like 4.17 3.99 3.01 2.69 
BZW2 basic leucine zipper and W2 domains 2 4.45 4.54 3.22 3.33 
PAQR3 progestin and adipoQ receptor family member III 4.76 4.73 2.23 2.23 
LCMT1 leucine carboxyl methyltransferase 1 3.36 3.58 2.63 2.95 
Sep-02 septin 2 4.44 4.21 3.45 3.27 
MEX3C mex-3 RNA binding family member C 4.02 4.04 3.51 2.56 
CCDC43 coiled-coil domain containing 43 3.91 3.81 2.16 2.13 
PPP1CC protein phosphatase 1, catalytic subunit, gamma 
isozyme 
4.65 4.78 2.35 2.2 
PTPN14 protein tyrosine phosphatase, non-receptor type 14 4.24 4.55 3.53 2.87 
SLC25A6 "solute carrier family 25 (mitochondrial carrier; 
adenine nucleotide translocator), member 6" 
4.2 3.89 3.6 3.22 
---   4 4.34 4.08 3.35 
LINC00094 long intergenic non-protein coding RNA 94 3.29 3.45 3.42 3.32 
FNBP1L formin binding protein 1-like 5.09 5.05 3.45 3.18 
GTPBP4 GTP binding protein 4 4.9 5.08 2.25 2.1 
NUPL1 nucleoporin like 1 3.55 3.54 3 2.31 
IFT52 intraflagellar transport 52 homolog 
(Chlamydomonas) 
3.07 3.27 3.28 3.47 
DCP2 decapping mRNA 2 4.37 4.33 2.68 2.45 
CAMSAP2 calmodulin regulated spectrin-associated protein 
family, member 2 
3.24 3.25 3.82 3.39 
CELF2 CUGBP, Elav-like family member 2 5.1 4.6 3.76 3.62 
NEDD1 neural precursor cell expressed, developmentally 
down-regulated 1 
4.03 3.65 2.35 2.35 
ZNF827 zinc finger protein 827 4.41 5 2.99 2.71 
COPG2 coatomer protein complex, subunit gamma 2 3.83 3.37 3.8 3.45 
SLC7A1 solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 1 
5.16 4.92 3.17 2.47 
PHACTR2 phosphatase and actin regulator 2 4.27 3.23 3.36 2.76 
NAA40 N(alpha)-acetyltransferase 40, NatD catalytic 
subunit 
4.65 4.48 2.85 2.79 
TMEM206 transmembrane protein 206 4.38 4.59 2.23 2.2 
YEATS2 YEATS domain containing 2 2.7 2.68 2.67 2.09 
GNPDA1 glucosamine-6-phosphate deaminase 1 4.53 4.55 3.05 3.46 
TPGS2 tubulin polyglutamylase complex subunit 2 4.54 4.23 3.02 2.46 
PTPN12 protein tyrosine phosphatase, non-receptor type 12 4.05 3.31 2.28 2.06 
KIAA1324L KIAA1324-like 5.25 5.37 4.3 3.94 
LDOC1L leucine zipper, down-regulated in cancer 1-like 4.06 4.12 3.2 2.5 
ZBED4 zinc finger, BED-type containing 4 6.33 5.74 3.38 2.4 
RNF145 ring finger protein 145 4.44 4.01 2.94 2.63 
CCT4 chaperonin containing TCP1, subunit 4 (delta) 4.92 4.92 2.7 2.62 
KPNB1 karyopherin (importin) beta 1 6.09 6.04 2.3 2.16 
ZNF14 zinc finger protein 14 2.54 2.49 2.69 2.7 
DPY19L3 dpy-19-like 3 (C. elegans) 3.48 3.35 2.23 2.04 
ADO 2-aminoethanethiol (cysteamine) dioxygenase 4.22 4.25 2.54 1.97 
TRO trophinin 3.15 3.01 3.08 3.67 
 137 
 
MYL6B myosin, light chain 6B, alkali, smooth muscle and 
non-muscle 
3.41 3.62 2.8 2.94 
CNIH4 cornichon family AMPA receptor auxiliary protein 
4 
3.11 3.29 2.51 2.73 
TUBG1 tubulin, gamma 1 3.68 3.44 1.98 2.13 
RAVER2 ribonucleoprotein, PTB-binding 2 3.62 3.69 3.51 3.1 
UBE2D1 ubiquitin-conjugating enzyme E2D 1 5.65 5.01 2.37 1.95 
HMGN4 high mobility group nucleosomal binding domain 4 2.9 2.87 3.44 3.17 
SUPT3H suppressor of Ty 3 homolog (S. cerevisiae) 4.2 4.06 3.97 4.17 
AP3M2 adaptor-related protein complex 3, mu 2 subunit 3.88 4.01 3.2 3 
TWSG1 twisted gastrulation BMP signaling modulator 1 3.46 3.2 4.26 3.86 
RAP2A RAP2A, member of RAS oncogene family 7.12 5.62 2.9 2.48 
KRAS Kirsten rat sarcoma viral oncogene homolog 3.4 3.11 2.3 1.86 
RALA v-ral simian leukemia viral oncogene homolog A 
(ras related) 
3.78 3.75 1.97 1.94 
LUZP1 leucine zipper protein 1 5.4 5.53 3.27 2.82 
SMURF2 SMAD specific E3 ubiquitin protein ligase 2 5.42 5.27 3.45 2.57 
UBAP2 ubiquitin associated protein 2 4.71 4.67 2.39 2.36 
TMEM165 transmembrane protein 165 3.05 2.81 3.21 2.88 
ANKRD27 ankyrin repeat domain 27 (VPS9 domain) 2.99 3.03 2.02 1.81 
MYH10 myosin, heavy chain 10, non-muscle 5.01 5.3 4.59 4.05 
RBM12 RNA binding motif protein 12 5.27 6.07 2.87 2.61 
FLNA filamin A, alpha 3.18 2.84 2.14 1.93 
GYG1 glycogenin 1 3.19 3.11 3.3 3.29 
EPRS glutamyl-prolyl-tRNA synthetase 3.24 3.03 2.41 2.23 
ENOPH1 enolase-phosphatase 1 4.98 5.22 1.97 2.02 
TCEAL8 transcription elongation factor A (SII)-like 8 6.08 5.87 3.62 3.46 
HSDL1 hydroxysteroid dehydrogenase like 1 3.41 3.6 2.03 1.83 
MAPRE1 microtubule-associated protein, RP/EB family, 
member 1 
3.25 2.79 1.8 1.76 
KCNMB4 potassium large conductance calcium-activated 
channel, subfamily M, beta member 4 
5.67 5.47 4.3 3.81 
ZNF280B zinc finger protein 280B 6.44 6.43 2.89 2.73 
KIF3C kinesin family member 3C 5.62 5.65 3.13 2.96 
ABCC1 ATP-binding cassette, sub-family C (CFTR/MRP), 
member 1 
4.36 4.6 3.88 3.7 
EFCAB11 EF-hand calcium binding domain 11 3.49 3.29 2.05 1.84 
CKAP5 cytoskeleton associated protein 5 3.82 3.51 2.15 2.11 
SLC7A6OS solute carrier family 7, member 6 opposite strand 3.34 3.41 2.51 2.47 
SAE1 SUMO1 activating enzyme subunit 1 5.59 5.3 2.46 2.38 
ZBTB34 zinc finger and BTB domain containing 34 2.79 2.99 4.28 3.57 
GCA grancalcin, EF-hand calcium binding protein 2.68 2.82 4.85 4.31 
YWHAZ tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta polypeptide 
4.94 4.2 3.6 3.21 
HNRNPLL heterogeneous nuclear ribonucleoprotein L-like 3.85 3.83 2.72 2.32 
SNRPB small nuclear ribonucleoprotein polypeptides B and 
B1 
4.08 3.74 1.6 1.78 
BLVRA biliverdin reductase A 4.35 4.26 4.43 5.46 
ZNF85 zinc finger protein 85 5.59 5.8 2.8 3.35 
GPRC5B G protein-coupled receptor, family C, group 5, 5.39 5.91 2.45 2.38 
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member B 
UNC119B unc-119 homolog B (C. elegans) 4.22 4.65 3.63 3.33 
RNF2 ring finger protein 2 3.58 3.73 2.52 2.22 
RBPJ recombination signal binding protein for 
immunoglobulin kappa J region 
3.99 4.25 2.12 2.23 
GNG4 guanine nucleotide binding protein (G protein), 
gamma 4 
5.7 6.08 3.69 3.34 
PDE7A phosphodiesterase 7A 4.68 4.67 4.07 3.85 
CCT6A chaperonin containing TCP1, subunit 6A (zeta 1) 5.62 5.66 1.69 1.76 
CCT8 chaperonin containing TCP1, subunit 8 (theta) 3.85 3.79 2.01 2.13 
RAB23 RAB23, member RAS oncogene family 3.42 3.35 4.88 4.75 
SMARCA4 SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily a, 
member 4 
5.48 5.53 2.26 1.71 
MARS methionyl-tRNA synthetase 4.04 3.72 1.58 1.66 
TMEM216 transmembrane protein 216 5.2 5.39 3.45 3.73 
KIAA1549 KIAA1549 2.65 2.64 2.28 2.18 
LRP12 low density lipoprotein receptor-related protein 12 3.62 3.65 5.2 3.7 
PRKCI protein kinase C, iota 5.2 5.07 3.34 3.18 
HDDC2 HD domain containing 2 3.68 3.49 2.47 2.63 
UBE2I ubiquitin-conjugating enzyme E2I 3.48 3.41 2.33 2.21 
ZNF267 zinc finger protein 267 5.38 5.08 1.65 2.69 
TKT transketolase 6.44 6.33 2.88 2.74 
CCDC8 coiled-coil domain containing 8 3.5 3.08 3.44 2.81 
BOD1 biorientation of chromosomes in cell division 1 3.42 3.58 2.6 2.76 
NCKAP1 NCK-associated protein 1 4.77 5.1 4.26 3.63 
AKIRIN1 akirin 1 3.92 3.98 2.07 1.77 
RAD21 RAD21 homolog (S. pombe) 3.56 3.13 2.78 2.4 
CTTNBP2NL CTTNBP2 N-terminal like 3.74 3.92 3.98 3.21 
FAM169A family with sequence similarity 169, member A 6.49 5.66 2.17 2.09 
RPS3 ribosomal protein S3 2.71 2.46 2.3 2.5 
TPM2 tropomyosin 2 (beta) 4.43 4.32 4.07 2.95 
DSE dermatan sulfate epimerase 5.23 5.74 3.93 3.34 
CNOT6 CCR4-NOT transcription complex, subunit 6 3.05 3.16 1.86 1.52 
INPP5F inositol polyphosphate-5-phosphatase F 4.12 4.21 3.61 3.41 
USP22 ubiquitin specific peptidase 22 5.87 5.21 2.44 1.8 
PHF19 PHD finger protein 19 2.64 2.77 2.44 2.34 
MYO10 myosin X 3.38 3.58 3.44 2.32 
AGPAT4 1-acylglycerol-3-phosphate O-acyltransferase 4 3.85 3.71 5.54 4.41 
DNM1L dynamin 1-like 2.96 2.77 1.56 1.61 
TUBB4B tubulin, beta 4B class IVb 3.49 3.12 1.97 1.68 
IMPDH2 IMP (inosine 5'-monophosphate) dehydrogenase 2 4.55 4.53 4.65 5.09 
STAM signal transducing adaptor molecule (SH3 domain 
and ITAM motif) 1 
3.54 3.79 2.23 2.23 
TCF4 transcription factor 4 5.13 5.5 3.98 3.58 
CWC27 CWC27 spliceosome-associated protein homolog 
(S. cerevisiae) 
6.47 5.58 1.95 2.22 
PPP1R9A protein phosphatase 1, regulatory subunit 9A 3.14 3.17 1.8 1.83 
RNF219 ring finger protein 219 2.61 2.66 2.33 2.19 
LPHN1 latrophilin 1 4.88 5.09 2.39 2.11 
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CENPJ centromere protein J 3.45 2.84 1.71 1.79 
GBAS glioblastoma amplified sequence 2.91 3.1 4.57 4.11 
ZNF765 zinc finger protein 765 3.96 3.81 2.79 2.7 
UBE2E1 ubiquitin-conjugating enzyme E2E 1 2.91 3.09 2.93 2.52 
ANKRD33B ankyrin repeat domain 33B 3.28 3.33 3.83 3.3 
FSCN1 fascin homolog 1, actin-bundling protein 
(Strongylocentrotus purpuratus) 
8.77 6.71 3.9 3.48 
CENPQ centromere protein Q 5.43 5.63 1.6 1.82 
BEND5 BEN domain containing 5 3.57 3.69 4.83 4.07 
ABCC5 ATP-binding cassette, sub-family C (CFTR/MRP), 
member 5 
3.33 3.3 3.3 3.27 
STMN3 stathmin-like 3 4.48 5.01 1.81 1.53 
ENAH enabled homolog (Drosophila) 4.35 5.02 3.42 3.1 
CCNJL cyclin J-like 3.28 3.59 1.92 2 
KIF3A kinesin family member 3A 3.35 3.35 3.76 3.25 
GPSM2 G-protein signaling modulator 2 2.85 2.36 2.36 2 
ALDOA aldolase A, fructose-bisphosphate 4.7 4.3 4.95 4.03 
HACE1 HECT domain and ankyrin repeat containing E3 
ubiquitin protein ligase 1 
3.31 3.54 5.02 4.74 
SPIN1 spindlin 1 3.39 3.13 2.2 1.69 
SLC22A15 solute carrier family 22, member 15 3.07 2.48 2.8 2.94 
WDYHV1 WDYHV motif containing 1 2.92 2.92 2.73 2.98 
TUBB tubulin, beta class I 6.41 5.78 2.46 2.02 
CDK7 cyclin-dependent kinase 7 2.5 2.32 2.41 2.99 
CMTM7 CKLF-like MARVEL transmembrane domain 
containing 7 
6.4 5.79 4.92 5.13 
LARP6 La ribonucleoprotein domain family, member 6 2.88 2.73 2.81 3.27 
BTF3L4 basic transcription factor 3-like 4 3.6 3.83 2.63 2.38 
TMEM125 transmembrane protein 125 2.68 2.98 2.53 2.81 
STXBP1 syntaxin binding protein 1 5.8 6.26 5.47 4.8 
ZNF720 zinc finger protein 720 3.06 3.12 2.68 2.37 
HIF1A hypoxia inducible factor 1, alpha subunit (basic 
helix-loop-helix transcription factor) 
4.14 4.09 4.5 4.38 
BDNF brain-derived neurotrophic factor 2.71 2.61 2.62 1.94 
CHSY1 chondroitin sulfate synthase 1 5.36 5.72 4.02 2.5 
UXS1 UDP-glucuronate decarboxylase 1 2.73 2.78 2.08 1.92 
TMEM184B transmembrane protein 184B 2.68 2.79 4.37 4 
IGF2BP1 insulin-like growth factor 2 mRNA binding protein 
1 
7.57 7.91 3.45 3.2 
GLMN glomulin, FKBP associated protein 6.64 6.7 1.67 1.89 
IARS isoleucyl-tRNA synthetase 6.15 5.93 2.08 2.02 
MTA3 metastasis associated 1 family, member 3 3.62 4.03 2.04 2.02 
C18orf54 chromosome 18 open reading frame 54 4.84 4.63 2.58 2.65 
CLDN6 claudin 6 6.67 6.23 3 2.71 
FHDC1 FH2 domain containing 1 7.04 7.06 2.96 3.08 
ERI1 exoribonuclease 1 2.98 2.95 1.75 1.54 
SFT2D1 SFT2 domain containing 1 3.25 3.23 2.17 1.84 
WASF1 WAS protein family, member 1 4.65 4.38 6.82 4.54 
USP54 ubiquitin specific peptidase 54 3.47 3.37 1.39 1.72 
PTK7 protein tyrosine kinase 7 4.32 3.74 6.66 5.94 
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CLSTN1 calsyntenin 1 3.03 2.93 2.81 2.52 
NUP37 nucleoporin 37kDa 6.68 6.72 3.52 3.25 
GRIP1 glutamate receptor interacting protein 1 3.36 3.44 4.57 4.16 
PCYOX1L prenylcysteine oxidase 1 like 4.38 5.21 5.79 5.73 
SLC3A2 solute carrier family 3 (amino acid transporter 
heavy chain), member 2 
3.94 3.27 2.56 2.49 
AGTPBP1 ATP/GTP binding protein 1 5.11 5.4 2.2 2.82 
CLMP CXADR-like membrane protein 4.9 3.81 5.64 6.2 
RPAP3 RNA polymerase II associated protein 3 3.21 2.5 1.52 2.18 
MORF4L1 mortality factor 4 like 1 3.32 3.64 2.74 2.92 
ABL1 c-abl oncogene 1, non-receptor tyrosine kinase 3.73 3.83 2.16 1.73 
AMMECR1 Alport syndrome, mental retardation, midface 
hypoplasia and elliptocytosis chromosomal region 
gene 1 
4.11 3.82 3.65 3.39 
CBX5 chromobox homolog 5 4.39 4.6 2 1.57 
CFL1 cofilin 1 (non-muscle) 4.49 3.59 2.23 1.82 
UBXN2A UBX domain protein 2A 2.88 2.36 2.63 1.96 
STARD3NL STARD3 N-terminal like 3.29 3.38 3.96 3.98 
EPB41L2 erythrocyte membrane protein band 4.1-like 2 6.31 5.59 1.52 1.75 
MSANTD3 Myb/SANT-like DNA-binding domain containing 3 3.12 3.1 2.96 2.83 
RIMS2 regulating synaptic membrane exocytosis 2 6.97 6.13 5.49 5.01 
ERC2 ELKS/RAB6-interacting/CAST family member 2 2.87 3.24 1.85 1.96 
SYT13 synaptotagmin XIII 2.67 3.02 3.84 4.17 
AFAP1 actin filament associated protein 1 2.94 2.83 3.21 2.07 
RCBTB1 regulator of chromosome condensation (RCC1) and 
BTB (POZ) domain containing protein 1 
2.87 2.96 1.86 1.92 
SLC45A4 solute carrier family 45, member 4 3.64 3.71 1.72 1.71 
SMARCA5 SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily a, 
member 5 
4.36 4.49 1.74 1.61 
ARL2 ADP-ribosylation factor-like 2 4.83 4.51 3.52 3.68 
TUBB3 tubulin, beta 3 class III 7.07 6.09 1.71 1.31 
SP8 Sp8 transcription factor 4.24 3.9 1.7 1.75 
PFN1 profilin 1 5.23 4.17 1.92 1.43 
BTBD10 BTB (POZ) domain containing 10 3.02 2.62 2.18 2 
RNF144A ring finger protein 144A 5.44 6.18 3.19 2.79 
PPIL1 peptidylprolyl isomerase (cyclophilin)-like 1 7.36 7.93 2.03 2.08 
CERS5 ceramide synthase 5 3.05 2.9 3.13 3.06 
GEMIN2 gem (nuclear organelle) associated protein 2 4.09 4.07 1.93 2.15 
KDM5B lysine (K)-specific demethylase 5B 4.56 5.08 5.21 3.75 
PELI2 pellino E3 ubiquitin protein ligase family member 2 3.46 4.03 1.99 2.19 
WARS tryptophanyl-tRNA synthetase 5.61 4.65 1.59 1.57 
SLBP stem-loop binding protein 3.21 3.21 3.45 3.17 
PAFAH1B3 platelet-activating factor acetylhydrolase 1b, 
catalytic subunit 3 (29kDa) 
4.16 3.87 1.57 1.52 
ZCCHC17 zinc finger, CCHC domain containing 17 3.7 3.59 2.32 2.32 
ZNF682 zinc finger protein 682 3.53 3.41 2.25 2.94 
SPINK5 serine peptidase inhibitor, Kazal type 5 5.15 4.53 4.45 5.28 
GNAL guanine nucleotide binding protein (G protein), 
alpha activating activity polypeptide, olfactory type 
6.84 4.96 1.58 1.55 
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TMEM237 transmembrane protein 237 6.64 7.81 3.47 3.19 
ARHGAP28 Rho GTPase activating protein 28 7.9 6.89 6.23 5.64 
BBS7 Bardet-Biedl syndrome 7 2.95 2.8 2.6 2.6 
RAB8B RAB8B, member RAS oncogene family 2.33 2.49 2.52 2.46 
MARVELD1 MARVEL domain containing 1 6.9 6.65 5.82 5.06 
NEK2 NIMA-related kinase 2 3.59 3.07 2.11 1.93 
LOC100507507 uncharacterized LOC100507507 5.29 4.92 2.82 2.73 
GNB4 guanine nucleotide binding protein (G protein), beta 
polypeptide 4 
3.93 3.58 2.91 2.54 
HSP90AB1 heat shock protein 90kDa alpha (cytosolic), class B 
member 1 
7.63 6.76 4.39 4.01 
LOC550643 uncharacterized LOC550643 3.53 3.36 4.37 4.85 
VCL vinculin 5.02 5.5 2.87 2.55 
NAE1 NEDD8 activating enzyme E1 subunit 1 5.12 5.36 1.78 2.05 
DGKZ diacylglycerol kinase, zeta 6.9 6.83 3.78 3.42 
C10orf118 chromosome 10 open reading frame 118 2.13 1.67 2.33 2.49 
CKAP2L cytoskeleton associated protein 2-like 7.66 6.76 2.75 2.93 
HDAC2 histone deacetylase 2 7.53 7.45 2.61 2.48 
SNHG1 small nucleolar RNA host gene 1 (non-protein 
coding) 
6.37 6.77 2.74 3.62 
SMC3 structural maintenance of chromosomes 3 4.09 3.23 1.18 1.7 
OVOL2 ovo-like zinc finger 2 3.08 3.53 3.01 3.44 
SPTLC2 serine palmitoyltransferase, long chain base subunit 
2 
2 2.07 2.93 2.58 
---   2.93 2.47 3.04 2.46 
PJA1 praja ring finger 1, E3 ubiquitin protein ligase 4.32 4.33 7.61 7.26 
MARK1 MAP/microtubule affinity-regulating kinase 1 4.61 4.64 2.97 2.65 
ZNF608 zinc finger protein 608 4.71 4.29 2.29 2.13 
MAGEL2 MAGE-like 2 2.97 3.14 6.04 4.73 
TCTEX1D2 Tctex1 domain containing 2 2.9 3.04 3.52 3.4 
HRASLS HRAS-like suppressor 3.77 4.78 1.97 1.53 
GTF2IRD1 GTF2I repeat domain containing 1 2.78 2.71 3.48 3.56 
SQLE squalene epoxidase 9.37 8.15 2.54 2.61 
ANTXR1 anthrax toxin receptor 1 5.06 4.8 4.19 3.12 
CCDC6 coiled-coil domain containing 6 2.93 3.16 2.11 2.14 
UBTD2 ubiquitin domain containing 2 2.53 2.7 2.46 1.99 
CSRP2 cysteine and glycine-rich protein 2 4.6 4.72 4.46 4 
ASPHD2 aspartate beta-hydroxylase domain containing 2 6.48 6.28 2.52 2.28 
FAM118B family with sequence similarity 118, member B 4.01 4.04 1.33 1.47 
ZFP82 ZFP82 zinc finger protein 6.12 6.13 3.23 3.57 
FAT1 FAT atypical cadherin 1 3.52 3.61 2.07 1.62 
GARS glycyl-tRNA synthetase 7.37 6.74 3.58 3.25 
LTA4H leukotriene A4 hydrolase 2.62 2.84 2.46 2.49 
FAM63B family with sequence similarity 63, member B 1.88 1.66 2.11 1.56 
HMGA2 high mobility group AT-hook 2 7.07 7.6 5.86 5.63 
PLEKHB2 pleckstrin homology domain containing, family B 
(evectins) member 2 
3.32 3.17 2.33 1.86 
RPL27A ribosomal protein L27a 7.79 8.98 3.09 2.85 
ACPL2 acid phosphatase-like 2 2.97 2.23 1.91 1.94 
UBA2 ubiquitin-like modifier activating enzyme 2 4.13 4.31 2.43 2.41 
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SWAP70 SWAP switching B-cell complex 70kDa subunit 6.56 6.56 2.79 2.09 
DNER delta/notch-like EGF repeat containing 2.52 3.24 2.26 1.62 
C6orf132 chromosome 6 open reading frame 132 2.78 3.2 2.01 1.75 
ESCO1 establishment of sister chromatid cohesion N-
acetyltransferase 1 
3.04 2.11 1.26 1.68 
RPGRIP1L RPGRIP1-like 2.16 2.37 2.36 2.83 
B4GALT6 UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase, polypeptide 6 
7.4 7.57 4.25 3.77 
LIN9 lin-9 homolog (C. elegans) 4.58 4.61 2.1 2.21 
CDR2L cerebellar degeneration-related protein 2-like 2.93 2.72 1.86 1.7 
HIATL1 hippocampus abundant transcript-like 1 3.48 3.42 2.09 2.08 
TMEM159 transmembrane protein 159 2.58 2.9 4.35 4.7 
AP2B1 adaptor-related protein complex 2, beta 1 subunit 4 3.8 4.29 3.56 
NCBP2 nuclear cap binding protein subunit 2, 20kDa 2.52 2.53 2.01 2.19 
ADORA2B adenosine A2b receptor 2.67 2.72 7.43 6.95 
GPD2 glycerol-3-phosphate dehydrogenase 2 
(mitochondrial) 
3.42 3.19 1.65 1.45 
CCT2 chaperonin containing TCP1, subunit 2 (beta) 5.85 5.23 1.64 1.58 
RPL22L1 ribosomal protein L22-like 1 6.6 7.3 2.51 2.92 
STMN1 stathmin 1 5.81 5.77 2.32 2.17 
EML1 echinoderm microtubule associated protein like 1 4.69 5.03 4.68 4.32 
MCM3AP-AS1 MCM3AP antisense RNA 1 4.22 4.09 1.74 2.15 
JAG1 jagged 1 2.68 3.03 2.88 2.24 
TUBB2A tubulin, beta 2A class IIa 10.24 9.97 1.84 1.64 
MAP4K5 mitogen-activated protein kinase kinase kinase 
kinase 5 
2.15 2.03 2.48 2.29 
SLC39A6 solute carrier family 39 (zinc transporter), member 
6 
2.08 2.01 5.29 4.85 
SLC27A6 solute carrier family 27 (fatty acid transporter), 
member 6 
1.97 2.02 6.36 5.34 
ARPC2 actin related protein 2/3 complex, subunit 2, 34kDa 3.07 2.9 3.29 3 
FGD6 FYVE, RhoGEF and PH domain containing 6 2.44 2.29 1.81 2.05 
PRKCDBP protein kinase C, delta binding protein 8.87 6.93 3.89 3.43 
FJX1 four jointed box 1 (Drosophila) 5.77 5.31 2.75 2.48 
E2F7 E2F transcription factor 7 7.38 8.18 1.98 1.77 
AP1M2 adaptor-related protein complex 1, mu 2 subunit 2.82 2.85 2.59 2.94 
SUPT20H suppressor of Ty 20 homolog (S. cerevisiae) 2.88 2.68 1.91 1.9 
ZNF610 zinc finger protein 610 2.34 2.28 2.01 2.08 
FAM65B family with sequence similarity 65, member B 1.83 2.25 4.06 4.76 
G2E3 G2/M-phase specific E3 ubiquitin protein ligase 5.55 4.93 2.39 2.56 
PRICKLE1 prickle homolog 1 (Drosophila) 6.72 7.98 3.68 2.83 
GLRX3 glutaredoxin 3 4.67 4.34 1.45 1.45 
FAM19A4 family with sequence similarity 19 (chemokine (C-
C motif)-like), member A4 
2.89 3.76 4 6.57 
RAD54L RAD54-like (S. cerevisiae) 3.84 3.54 1.62 1.75 
---   2.25 2.29 2.14 2.05 
SMYD3 SET and MYND domain containing 3 2.15 2.09 5.75 5.13 
EHD4 EH-domain containing 4 2.79 2.68 3.04 2.75 
---   2.78 2.37 3.11 2.72 
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RHOQ ras homolog family member Q 2.27 2.28 2.12 2.25 
SPAG5 sperm associated antigen 5 4.33 4.12 1.57 1.9 
BMPR1A bone morphogenetic protein receptor, type IA 10.54 9.54 2.78 2.46 
GPR143 G protein-coupled receptor 143 2.25 2.71 1.93 1.91 
DCAF16 DDB1 and CUL4 associated factor 16 4.45 4.64 5.02 4.17 
FAM175A family with sequence similarity 175, member A 2.84 2.66 2.13 2.71 
MICALL1 MICAL-like 1 3.79 3.7 2.47 2.02 
ILF2 interleukin enhancer binding factor 2 6.51 6.16 2.3 2.32 
SET SET nuclear oncogene 7.31 7.36 1.86 1.75 
SPOCK1 sparc/osteonectin, cwcv and kazal-like domains 
proteoglycan (testican) 1 
3.29 3.99 7.19 6.9 
PRMT1 protein arginine methyltransferase 1 8.68 7.77 2.32 2.37 
SKP2 S-phase kinase-associated protein 2, E3 ubiquitin 
protein ligase 
3.62 3.64 5.13 5.02 
KIAA1841 KIAA1841 2.24 1.94 1.24 1.46 
MRS2 MRS2 magnesium transporter 5 5.47 1.62 1.83 
ATL1 atlastin GTPase 1 2.59 3.37 2.46 2.03 
RPL8 ribosomal protein L8 2.63 2.49 2.35 2.26 
EIF2S3 eukaryotic translation initiation factor 2, subunit 3 
gamma, 52kDa 
3.46 3.61 2.75 2.41 
EFS embryonal Fyn-associated substrate 5.5 5.27 6.35 5.61 
TSHZ3 teashirt zinc finger homeobox 3 2.67 3.39 5.14 4.33 
ACTG2 actin, gamma 2, smooth muscle, enteric 3.66 4.41 6.3 3.75 
MAP3K7 mitogen-activated protein kinase kinase kinase 7 2.65 2.49 1.89 2.05 
SPATS2 spermatogenesis associated, serine-rich 2 3.4 3.06 4.2 4.22 
SGCE sarcoglycan, epsilon 2.62 2.56 3.9 3.95 
PIAS3 protein inhibitor of activated STAT, 3 2.41 2.38 3.37 3.34 
MBOAT2 membrane bound O-acyltransferase domain 
containing 2 
5.32 5.4 6.15 5.21 
TMEM55A transmembrane protein 55A 8.39 8.54 3.82 3.37 
TFAP2C transcription factor AP-2 gamma (activating 
enhancer binding protein 2 gamma) 
4.25 4.27 4.98 4.44 
FXYD5 FXYD domain containing ion transport regulator 5 3.31 3.03 2.79 2.9 
CCDC109B coiled-coil domain containing 109B 5.69 6.49 4.12 3.58 
TAF1B TATA box binding protein (TBP)-associated factor, 
RNA polymerase I, B, 63kDa 
3.25 3.06 1.73 1.63 
INTU inturned planar cell polarity protein 2.11 2.08 2.15 2.21 
SNHG16 small nucleolar RNA host gene 16 (non-protein 
coding) 
2.66 2.98 2.51 2.6 
C3orf14 chromosome 3 open reading frame 14 4.43 4.38 1.43 1.15 
FUBP1 far upstream element (FUSE) binding protein 1 5.23 4.89 2.05 1.88 
MFAP2 microfibrillar-associated protein 2 4.46 4.08 4.45 4.06 
HDHD1 haloacid dehalogenase-like hydrolase domain 
containing 1 
2.57 2.54 2.02 1.88 
ZNF670 zinc finger protein 670 5.71 5.83 1.09 1.05 
LDOC1 leucine zipper, down-regulated in cancer 1 5.73 5.64 7.25 7.35 
FAM102B family with sequence similarity 102, member B 2.63 2.56 1.88 1.82 
LOC100506548 uncharacterized LOC100506548 1.71 1.65 5 5.9 
ADRBK2 adrenergic, beta, receptor kinase 2 3.13 3.16 2.36 2.29 
ZNF124 zinc finger protein 124 3.87 3.7 4.53 4.25 
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C5orf54 chromosome 5 open reading frame 54 1.87 2.09 2.62 2.85 
ACLY ATP citrate lyase 9.98 8.97 2.17 2.39 
NAT14 N-acetyltransferase 14 (GCN5-related, putative) 2.46 2.36 2.57 2.35 
CASP3 caspase 3, apoptosis-related cysteine peptidase 7.31 7.55 1.8 1.8 
ASAP1 ArfGAP with SH3 domain, ankyrin repeat and PH 
domain 1 
2.67 2.56 2.97 2.91 
ABRACL ABRA C-terminal like 5.16 5.27 1.35 1.19 
SCG2 secretogranin II 1.86 2.15 3.97 3.43 
STC1 stanniocalcin 1 3.28 3.07 3.77 3.05 
HNRNPA0 heterogeneous nuclear ribonucleoprotein A0 4 3.99 1.99 1.48 
TEAD4 TEA domain family member 4 7.45 6.9 1.9 1.74 
CDCA4 cell division cycle associated 4 4.64 4.43 2.38 2.25 
NT5DC2 5'-nucleotidase domain containing 2 6.1 5.86 7.2 7.39 
PROSER1 proline and serine rich 1 3.97 4.09 1.55 1.47 
SV2A synaptic vesicle glycoprotein 2A 7.99 8.18 3.93 4.41 
GLI3 GLI family zinc finger 3 2.74 3.15 4.14 3.41 
NES nestin 7.52 7.17 1.95 1.65 
TEX10 testis expressed 10 8.1 8.42 2.81 2.9 
AP1S2 adaptor-related protein complex 1, sigma 2 subunit 6.67 6.84 4.21 4.08 
DNAJC18 DnaJ (Hsp40) homolog, subfamily C, member 18 2.76 3.1 2.88 2.8 
LOC100505501 uncharacterized LOC100505501 6.65 8.66 1.37 1.27 
JPH1 junctophilin 1 6.22 6.71 3.55 3.19 
FOCAD focadhesin 4.83 4.93 4.86 4.6 
PPIH peptidylprolyl isomerase H (cyclophilin H) 4.12 4.11 1.88 1.98 
OSBPL10 oxysterol binding protein-like 10 2.61 2.92 2.45 2.32 
TNPO1 transportin 1 3.99 4 2.3 2.09 
C14orf166 chromosome 14 open reading frame 166 3.49 3.53 1.99 2.24 
ZNF195 zinc finger protein 195 5.57 4.95 1.01 1.28 
RUNX1T1 "runt-related transcription factor 1; translocated to, 
1 (cyclin D-related)" 
4.84 4.43 6.08 4.96 
NUP205 nucleoporin 205kDa 7.57 7.6 2.64 2.45 
NEO1 neogenin 1 2.73 2.67 3.47 3.34 
LRRC49 leucine rich repeat containing 49 4.65 5.01 2.13 2.46 
ZNF256 zinc finger protein 256 4.57 5.39 2.12 1.81 
SPA17 sperm autoantigenic protein 17 6.7 6.46 2.28 1.75 
CMTM4 CKLF-like MARVEL transmembrane domain 
containing 4 
2.4 2.39 3.58 3.33 
PRKD1 protein kinase D1 3.09 3.06 4.48 4.23 
SNRPD1 small nuclear ribonucleoprotein D1 polypeptide 
16kDa 
6.08 6.04 1.42 1.59 
CENPL centromere protein L 6.37 7.19 3.27 2.77 
HSPA13 heat shock protein 70kDa family, member 13 1.94 2 2.5 3.32 
GSKIP GSK3B interacting protein 2.73 2.48 1.86 2.18 
TMEM147 transmembrane protein 147 3.01 2.85 2.04 1.83 
INTS9 integrator complex subunit 9 3.07 3.16 1.55 1.46 
ALDH1A3 aldehyde dehydrogenase 1 family, member A3 4.04 3.46 2.91 1.87 
NSG1 neuron specific gene family member 1 2.84 3.83 7.76 7.78 
LHFPL2 lipoma HMGIC fusion partner-like 2 3.5 3.33 3.64 4.03 
PEA15 phosphoprotein enriched in astrocytes 15 4.15 3.72 4.13 3.7 
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SLC35F1 solute carrier family 35, member F1 4.81 5.22 2.55 2.5 
MYL9 myosin, light chain 9, regulatory 5.96 5.26 7.54 6.04 
CCDC113 coiled-coil domain containing 113 1.72 1.96 1.67 1.42 
SNRPD2 small nuclear ribonucleoprotein D2 polypeptide 
16.5kDa 
3.52 3.31 2.5 2.7 
SASS6 spindle assembly 6 homolog (C. elegans) 4.21 4.65 1.03 1.29 
PLK4 polo-like kinase 4 5.89 6.16 1.56 1.58 
PLCB4 phospholipase C, beta 4 4.91 4.87 2.55 2.55 
MID1 midline 1 (Opitz/BBB syndrome) 4.01 4.47 4.39 3.15 
WFDC2 WAP four-disulfide core domain 2 3.26 2.68 3.04 3.07 
USP14 ubiquitin specific peptidase 14 (tRNA-guanine 
transglycosylase) 
3.04 3.09 1.68 1.54 
PPIA peptidylprolyl isomerase A (cyclophilin A) 3.77 4.12 1.71 1.66 
ZNF708 zinc finger protein 708 3.67 4.1 -1.06 1.26 
CRABP2 cellular retinoic acid binding protein 2 2.37 2.51 7.17 6.68 
KCNG1 potassium voltage-gated channel, subfamily G, 
member 1 
7.57 5.82 4.24 3.84 
ATP8B2 ATPase, aminophospholipid transporter, class I, 
type 8B, member 2 
2.64 2.72 2.11 2.02 
ZNF100 zinc finger protein 100 4.27 4.62 1.13 1.48 
OSBPL3 oxysterol binding protein-like 3 3.54 3.12 2.99 3.3 
EEF1E1 eukaryotic translation elongation factor 1 epsilon 1 5.52 5.6 1.32 1.63 
SNHG6 small nucleolar RNA host gene 6 (non-protein 
coding) 
2.4 2.39 1.97 2.26 
TC2N tandem C2 domains, nuclear 1.79 1.95 1.44 1.77 
EGLN3 egl-9 family hypoxia-inducible factor 3 3.48 3.48 4.78 3.11 
EPHA4 EPH receptor A4 6.17 4.75 2.58 2.37 
ANXA5 annexin A5 2.8 2.86 3.8 3.91 
BIK BCL2-interacting killer (apoptosis-inducing) 2.16 2.54 3.78 3.48 
NHS Nance-Horan syndrome (congenital cataracts and 
dental anomalies) 
2.78 2.75 1.36 1.44 
PLEKHH1 pleckstrin homology domain containing, family H 
(with MyTH4 domain) member 1 
2.15 2.22 3.69 3.54 
RAB11FIP4 RAB11 family interacting protein 4 (class II) 1.76 1.8 2.31 1.97 
FLVCR1-AS1 FLVCR1 antisense RNA 1 (head to head) 5.54 5.76 2.97 3.52 
NGFRAP1 nerve growth factor receptor (TNFRSF16) 
associated protein 1 
3.76 3.77 2.39 2.34 
WWC3 WWC family member 3 4.86 4.54 4.76 3.56 
PABPC3 poly(A) binding protein, cytoplasmic 3 5.29 5.51 4.36 3.58 
FBLN1 fibulin 1 3.67 3.38 9.39 8.72 
RPL39L ribosomal protein L39-like 6.88 7.16 2.99 3.29 
RASGEF1A RasGEF domain family, member 1A 6.03 7.13 2.71 3.2 
SPG20 spastic paraplegia 20 (Troyer syndrome) 3.38 3.09 4.08 4.29 
FUNDC1 FUN14 domain containing 1 2.14 2.1 1.67 1.6 
ISYNA1 inositol-3-phosphate synthase 1 2.6 2.75 4.03 3.92 
BLMH bleomycin hydrolase 3.44 3.28 2.04 2.09 
FGFR1 fibroblast growth factor receptor 1 7.12 7.28 2.77 2.75 
RGS17 regulator of G-protein signaling 17 4.43 4.59 1.64 1.76 
NEIL3 nei endonuclease VIII-like 3 (E. coli) 7.15 7.03 2.5 2.51 
CENPM centromere protein M 8.63 7.76 1.99 1.7 
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MZT1 mitotic spindle organizing protein 1 7.66 6.75 2.51 2.52 
LOC646903 uncharacterized LOC646903 2.66 2.86 2.43 2.31 
FRAS1 Fraser syndrome 1 6.76 6.98 6.64 5.83 
ZNF165 zinc finger protein 165 4.75 4.74 1.19 1.3 
ZNF185 zinc finger protein 185 (LIM domain) 2.19 2.12 6.91 6.28 
TYRO3 TYRO3 protein tyrosine kinase 2.27 2.22 2.85 2.65 
RNF24 ring finger protein 24 3.63 3.62 2.94 2.89 
RASGRF2 Ras protein-specific guanine nucleotide-releasing 
factor 2 
4.57 5.23 2.22 1.75 
MIF macrophage migration inhibitory factor 
(glycosylation-inhibiting factor) 
2.91 2.72 3.26 3.11 
ZNF93 zinc finger protein 93 10.9 10.31 4.03 4.7 
---   2.88 2.57 2.81 2.54 
MTFR2 mitochondrial fission regulator 2 5.31 6.54 1.48 1.39 
ABHD17C abhydrolase domain containing 17C 2.86 2.92 2.04 1.91 
GMFB glia maturation factor, beta 3.53 3.47 1.46 1.54 
C7orf49 chromosome 7 open reading frame 49 2.88 2.71 2.47 2.5 
NMNAT2 nicotinamide nucleotide adenylyltransferase 2 2.53 2.79 3.21 2.73 
SYNGR3 synaptogyrin 3 2.6 2.98 1.81 1.93 
SRI sorcin 2 2.35 1.8 1.74 
ZNF137P zinc finger protein 137, pseudogene 1.82 1.66 1.63 1.75 
ADAMTS3 ADAM metallopeptidase with thrombospondin type 
1 motif, 3 
2.32 2.14 2.84 2.79 
CAV1 caveolin 1, caveolae protein, 22kDa 16.14 12.89 4.33 2.84 
FERMT1 fermitin family member 1 4.42 6.24 7.18 5.32 
LOC728392 uncharacterized LOC728392 3.12 3.61 7.73 6.55 
SERPINB9 serpin peptidase inhibitor, clade B (ovalbumin), 
member 9 
6.71 3.95 6.45 4.89 
C1orf198 chromosome 1 open reading frame 198 4.1 4.12 7.25 5.8 
TLDC1 TBC/LysM-associated domain containing 1 1.97 2.05 3.63 3.32 
RNF150 ring finger protein 150 3.06 3.7 4.07 3.75 
RECQL RecQ protein-like (DNA helicase Q1-like) 2.62 2.47 1.68 1.85 
ENO2 enolase 2 (gamma, neuronal) 2.89 3.19 2.77 2.23 
ZC2HC1A zinc finger, C2HC-type containing 1A 6.12 6.21 6.88 7.09 
RPS6KA6 ribosomal protein S6 kinase, 90kDa, polypeptide 6 2.82 2.65 1.61 1.73 
KIF2A kinesin heavy chain member 2A 8.08 7.75 2.59 2.7 
TYMS thymidylate synthetase 7.54 7.15 3.27 2.56 
CTGF connective tissue growth factor 4.27 5.63 5.45 1.38 
RUSC1 RUN and SH3 domain containing 1 2.95 2.84 1.76 1.98 
PCDH18 protocadherin 18 6.53 8.33 7.1 5.8 
GUCA1A guanylate cyclase activator 1A (retina) 2.58 3.49 6.99 6.47 
NPM3 nucleophosmin/nucleoplasmin 3 14.9 14.38 2.77 2.69 
STRAP serine/threonine kinase receptor associated protein 3.59 3.7 2.49 2.56 
ADAM17 ADAM metallopeptidase domain 17 2.31 2.22 3.52 3.1 
LOC100288637 OTU domain containing 7A pseudogene 4.36 4.62 2.16 1.81 
BNC2 basonuclin 2 2.05 2.65 5.76 5.17 
EOGT EGF domain-specific O-linked N-
acetylglucosamine (GlcNAc) transferase 
17.02 15.39 1.28 1.19 
ACYP1 acylphosphatase 1, erythrocyte (common) type 2.03 1.69 1.18 1.15 
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HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase 10.11 9.74 1.38 1.7 
CACNA2D3 calcium channel, voltage-dependent, alpha 2/delta 
subunit 3 
2.01 2.14 2.71 2.83 
CTPS2 CTP synthase 2 2.9 3.3 2.21 2.18 
TMA16 translation machinery associated 16 homolog (S. 
cerevisiae) 
11.49 11.19 3.15 2.87 
PTBP3 polypyrimidine tract binding protein 3 2.14 1.95 1.87 1.57 
DNAJB6 DnaJ (Hsp40) homolog, subfamily B, member 6 10.36 10.06 1.52 1.12 
DOK5 docking protein 5 5.18 4.47 4.42 3.86 
RCAN2 regulator of calcineurin 2 7.86 6.17 2.17 1.48 
CETN3 centrin, EF-hand protein, 3 1.99 2.09 2.35 2.08 
DNAJC10 DnaJ (Hsp40) homolog, subfamily C, member 10 3.11 2.98 1.25 1.37 
FREM2 FRAS1 related extracellular matrix protein 2 1.71 1.93 11.76 8.47 
HIST1H4C histone cluster 1, H4c 7.58 7.82 2.57 2.27 
PPP2R3A protein phosphatase 2, regulatory subunit B'', alpha 2.83 2.9 3.89 4.1 
PGM2L1 phosphoglucomutase 2-like 1 3.66 4.26 2.11 2.07 
SH3PXD2B SH3 and PX domains 2B 3.8 3.54 2.96 2.38 
EIF4EBP1 eukaryotic translation initiation factor 4E binding 
protein 1 
2.43 1.85 3.82 4.03 
PAK6 p21 protein (Cdc42/Rac)-activated kinase 6 2.68 2.97 9.71 7.54 
TNNT1 troponin T type 1 (skeletal, slow) 4.46 4.28 5.89 8.23 
ADD3 adducin 3 (gamma) 2.01 1.94 2.55 2.61 
SLC16A9 solute carrier family 16, member 9 3.69 5.51 2.56 2.24 
MACC1 metastasis associated in colon cancer 1 1.69 1.86 1.71 1.88 
NOX4 NADPH oxidase 4 2.28 3.23 13.34 10.25 
SYCP2L synaptonemal complex protein 2-like 2.04 2.13 2.39 2.83 
ZFAS1 ZNFX1 antisense RNA 1 2.37 2.33 5.15 6.25 
PDE9A phosphodiesterase 9A 3.58 3.15 2.07 2.25 
SOX8 SRY (sex determining region Y)-box 8 3.33 3.72 2.83 2.74 
ALPK3 alpha-kinase 3 2.95 2.92 2.44 2.56 
B3GALNT1 beta-1,3-N-acetylgalactosaminyltransferase 1 
(globoside blood group) 
5.16 4.54 4.22 3.87 
WDR54 WD repeat domain 54 5.51 5.98 6.6 5.36 
STON1 stonin 1 1.98 2.07 9.11 7.78 
ZNF239 zinc finger protein 239 8.7 9.3 2.24 2.33 
KISS1R KISS1 receptor 1.43 1.74 1.94 1.65 
PMEPA1 prostate transmembrane protein, androgen induced 
1 
9.7 8.84 2.33 2.13 
PIFO primary cilia formation 2.94 2.95 5.85 6.6 
SEL1L3 sel-1 suppressor of lin-12-like 3 (C. elegans) 2.42 2.64 1.06 -1.18 
PSMD10 proteasome (prosome, macropain) 26S subunit, 
non-ATPase, 10 
1.85 1.93 1.93 1.91 
NFE2L3 nuclear factor, erythroid 2-like 3 5.33 5.64 1.5 1.9 
RNF175 ring finger protein 175 4.98 6.01 1.35 1.38 
LMO3 LIM domain only 3 (rhombotin-like 2) 2 2.32 4.99 4.49 
SH2D3A SH2 domain containing 3A 2.64 2.89 1.52 1.52 
TP53I3 tumor protein p53 inducible protein 3 4.09 3.83 2.34 1.78 
NPEPPS aminopeptidase puromycin sensitive 2.31 2.16 3.35 2.94 
PCDH10 protocadherin 10 11.37 8.48 6.02 4.34 
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RGS10 regulator of G-protein signaling 10 1.67 2.16 7.65 7.01 
CLDN10 claudin 10 3.33 4.5 7.39 8.29 
BAX BCL2-associated X protein 2.92 2.42 1.01 -1.1 
ZNF57 zinc finger protein 57 1.81 2 1.38 1.29 
DOCK11 dedicator of cytokinesis 11 1.11 1.23 2.22 2.3 
SH3GL3 SH3-domain GRB2-like 3 8.15 8.59 9.4 8.92 
CAPG capping protein (actin filament), gelsolin-like 1.84 1.73 3.29 3.54 
TMTC2 transmembrane and tetratricopeptide repeat 
containing 2 
2.59 1.97 7.35 4.98 
ZNF114 zinc finger protein 114 5.16 6.23 1.29 1.3 
ODC1 ornithine decarboxylase 1 4.58 4.16 3.91 6.52 
SLIT2 slit homolog 2 (Drosophila) 7.4 6.28 10.74 7.64 
MMP2 matrix metallopeptidase 2 (gelatinase A, 72kDa 
gelatinase, 72kDa type IV collagenase) 
11.56 10.14 16.58 14.37 
CLGN calmegin 2.4 2.41 3.11 5.73 
IFT80 intraflagellar transport 80 homolog 
(Chlamydomonas) 
1.65 1.68 2.62 3.31 
IGDCC3 immunoglobulin superfamily, DCC subclass, 
member 3 
7.73 7.73 11.95 9.88 
TAC1 tachykinin, precursor 1 15.09 12.96 1.05 -1.01 
FAM150B family with sequence similarity 150, member B 2.33 2.29 14.47 15.75 
GPR64 G protein-coupled receptor 64 12.82 8.58 1.24 1.37 
FZD2 frizzled family receptor 2 5.65 5.65 8.8 8.04 
MEST mesoderm specific transcript 1.49 1.7 9.32 7.69 
MIR205HG MIR205 host gene (non-protein coding) 1.18 1.1 6.21 6.93 
HJURP Holliday junction recognition protein 15.43 15.69 3.75 3.13 
C4orf46 chromosome 4 open reading frame 46 13.45 13.82 2.83 1.99 
TRIP13 thyroid hormone receptor interactor 13 21.07 21.92 3.05 2.8 
IPW imprinted in Prader-Willi syndrome (non-protein 
coding) 
13.92 15.04 2.31 2.07 
BLM Bloom syndrome, RecQ helicase-like 18.43 19.19 3.05 3.31 
CHEK1 checkpoint kinase 1 21.88 22.73 2.43 2.15 
CENPW centromere protein W 20.73 20.07 4.02 3.32 
DEPDC1 DEP domain containing 1 16.21 15.08 3.95 3.21 
NUSAP1 nucleolar and spindle associated protein 1 15.88 14.12 3.22 2.44 
BIRC5 baculoviral IAP repeat containing 5 15.65 14.9 3.68 3.06 
STIL SCL/TAL1 interrupting locus 23.52 23.86 2.18 1.78 
RMI2 RecQ mediated genome instability 2 15.76 16.83 2.48 2.29 
ZWILCH zwilch kinetochore protein 11.48 11.48 1.88 1.86 
MSH2 mutS homolog 2 19.88 21.27 2.09 2.25 
KIAA0101 KIAA0101 14.34 15.11 2.4 2.04 
KIF14 kinesin family member 14 15.06 14.71 1.8 1.69 
CENPA centromere protein A 11.97 11.52 4.13 3.04 
PRKX protein kinase, X-linked 13.83 12.48 2.81 1.96 
FANCI Fanconi anemia, complementation group I 10.14 10.58 2.8 2.62 
CEP55 centrosomal protein 55kDa 28.08 21.73 2.85 2.12 
PSRC1 proline/serine-rich coiled-coil 1 15 14.95 4.04 3.54 
BUB1 BUB1 mitotic checkpoint serine/threonine kinase 11.76 11.01 2.36 2.01 
CENPE centromere protein E, 312kDa 19.59 14.62 2.48 3.39 
DBF4 DBF4 homolog (S. cerevisiae) 22.16 22.81 1.79 1.9 
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HOMER1 homer homolog 1 (Drosophila) 19.53 20.24 4.33 3.98 
PARPBP PARP1 binding protein 16.82 16.26 1.35 1.27 
KIF5C kinesin family member 5C 14 13.36 2.07 2.21 
OXCT1 3-oxoacid CoA transferase 1 13.26 14.99 3.58 3.09 
EZH2 enhancer of zeste homolog 2 (Drosophila) 17.54 18.78 1.73 1.73 
FBXO5 F-box protein 5 11.65 11.18 1.97 1.76 
CDC6 cell division cycle 6 25.82 24.27 1.68 1.57 
WDHD1 WD repeat and HMG-box DNA binding protein 1 10.56 11.06 1.78 1.82 
RCC2 regulator of chromosome condensation 2 37.22 37.39 3.67 3.1 
GJC1 gap junction protein, gamma 1, 45kDa 15.96 15.72 4.98 4.05 
MIS18BP1 MIS18 binding protein 1 10.44 8.7 1.4 1.77 
CENPF centromere protein F, 350/400kDa 19.13 19.93 2.7 2.64 
OIP5 Opa interacting protein 5 33.95 33.66 3.44 2.53 
VRK1 vaccinia related kinase 1 10.9 11.2 1.5 1.46 
CCDC112 coiled-coil domain containing 112 9.52 10.68 2.57 2.91 
TPX2 TPX2, microtubule-associated 11.86 10.64 2.96 2.09 
DSCC1 DNA replication and sister chromatid cohesion 1 15.14 15.12 1.62 1.45 
DTL denticleless E3 ubiquitin protein ligase homolog 
(Drosophila) 
29.61 34.56 2.43 2.42 
MCM10 minichromosome maintenance complex component 
10 
16.19 17.43 1.58 1.48 
RASL11B RAS-like, family 11, member B 13.65 14.67 3.2 2.59 
CD200 CD200 molecule 24.1 19.9 5.54 5.44 
TTF2 transcription termination factor, RNA polymerase II 24.02 25.13 3.42 2.7 
MND1 meiotic nuclear divisions 1 homolog (S. cerevisiae) 16.31 15.86 1.31 1.23 
SHCBP1 SHC SH2-domain binding protein 1 11.72 13.72 2.51 1.96 
SPC25 SPC25, NDC80 kinetochore complex component 27.12 26.06 1.68 1.44 
KIF15 kinesin family member 15 14.6 15.36 1.49 1.64 
IRX2 iroquois homeobox 2 16.74 19.55 5.21 3.9 
LRP8 low density lipoprotein receptor-related protein 8, 
apolipoprotein e receptor 
23.98 19.74 1.64 1.7 
ASPM asp (abnormal spindle) homolog, microcephaly 
associated (Drosophila) 
13.92 12.35 1.71 1.53 
SOX2 SRY (sex determining region Y)-box 2 15.59 14.05 1.65 1.48 
ZNF423 zinc finger protein 423 23.57 25.74 4.38 3.7 
JARID2 jumonji, AT rich interactive domain 2 10.74 11.85 2.11 1.62 
VANGL2 VANGL planar cell polarity protein 2 12.02 10.66 4.41 4.16 
SPDL1 spindle apparatus coiled-coil protein 1 16.77 15.93 4.03 4.4 
BORA bora, aurora kinase A activator 9.89 9.49 3.21 2.79 
BCL11A B-cell CLL/lymphoma 11A (zinc finger protein) 18.92 20.7 4.02 4.03 
IL17RD interleukin 17 receptor D 14.33 14.58 1.56 1.52 
HELLS helicase, lymphoid-specific 37.71 37.52 1.76 1.73 
RNF182 ring finger protein 182 8.31 9.62 3.08 2.08 
KIF2C kinesin family member 2C 10.19 9.79 3.07 2.59 
PSIP1 PC4 and SFRS1 interacting protein 1 12.56 12.69 1.55 1.59 
CKAP2 cytoskeleton associated protein 2 17.74 15.57 4.84 4.62 
NDC80 NDC80 kinetochore complex component 28.16 27.01 2.23 1.7 
NELL2 NEL-like 2 (chicken) 14.66 15.71 2.26 1.85 
HMGB2 high mobility group box 2 19.01 18.24 5.82 3.95 
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SUPT16H suppressor of Ty 16 homolog (S. cerevisiae) 10.16 7.88 3.37 2.65 
MLF1 myeloid leukemia factor 1 8.78 10.05 4.94 5.23 
FANCD2 Fanconi anemia, complementation group D2 10.81 11.85 2.51 2.36 
NEFM neurofilament, medium polypeptide 21.41 11.93 1.85 1.57 
NBEA neurobeachin 9.57 8.7 2.74 2.43 
RAD51AP1 RAD51 associated protein 1 33.91 36.23 4.38 3.86 
CYYR1 cysteine/tyrosine-rich 1 21.37 19.71 3.85 2.88 
PTTG3P pituitary tumor-transforming 3, pseudogene 15.38 17.52 4.69 3.51 
NUDT11 nudix (nucleoside diphosphate linked moiety X)-
type motif 11 
21.75 22.61 6.49 6.36 
TERF1 telomeric repeat binding factor (NIMA-interacting) 
1 
14.61 15.86 1.8 1.86 
SEMA6A sema domain, transmembrane domain (TM), and 
cytoplasmic domain, (semaphorin) 6A 
15.31 13.95 2.8 2.59 
LMNB1 lamin B1 61.12 41.09 3 1.94 
ZFP42 ZFP42 zinc finger protein 25.99 26.45 5.9 4.61 
MIS18A MIS18 kinetochore protein homolog A (S. pombe) 11.62 11.46 1.85 1.81 
RIMKLB ribosomal modification protein rimK-like family 
member B 
11.12 10.55 1.87 1.94 
CKS2 CDC28 protein kinase regulatory subunit 2 11.48 11.04 2.55 1.95 
NUF2 NUF2, NDC80 kinetochore complex component 29.06 25.82 4.07 3.51 
PTTG1 pituitary tumor-transforming 1 26.11 27.28 7.53 5.8 
AURKB aurora kinase B 36.75 33.23 3.79 3.03 
NUP93 nucleoporin 93kDa 9.74 9.45 2.57 2.8 
NCAPD2 non-SMC condensin I complex, subunit D2 10.05 9.29 3.38 2.73 
TRIM59 tripartite motif containing 59 28.27 25.23 5.78 4.77 
FOXM1 forkhead box M1 12.11 11.64 2.27 2.18 
AURKA aurora kinase A 23.47 23.32 4.9 3.71 
KIF4A kinesin family member 4A 39.48 37.68 4.94 3.5 
KIF18B kinesin family member 18B 10.93 11.49 2.32 1.94 
VAT1L vesicle amine transport 1-like 27.38 28.63 4.66 3.47 
HMMR hyaluronan-mediated motility receptor (RHAMM) 41.9 41.11 3.23 2.98 
COCH cochlin 12.71 9.38 1.55 1.62 
SYT1 synaptotagmin I 20.13 18.92 4.94 3.87 
MYEF2 myelin expression factor 2 23.91 26.4 5.23 5.08 
CDCA5 cell division cycle associated 5 12.18 12.28 2.31 2.14 
RHNO1 RAD9-HUS1-RAD1 interacting nuclear orphan 1 9.84 9.93 4.11 3.38 
CALB1 calbindin 1, 28kDa 50.39 37.71 1.15 1.19 
UBE2T ubiquitin-conjugating enzyme E2T (putative) 7.32 6.86 1.78 1.71 
OTX2 orthodenticle homeobox 2 64.2 50.05 2.25 1.89 
NETO2 neuropilin (NRP) and tolloid (TLL)-like 2 22.34 19.99 2.84 2.56 
NLGN4X neuroligin 4, X-linked 34.12 32.98 3.99 3.19 
SLC7A3 solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 3 
35.75 38.32 2.82 2.57 
ZWINT ZW10 interacting kinetochore protein 35.35 35.81 3.95 3.01 
TMEM158 transmembrane protein 158 (gene/pseudogene) 22.06 16.02 4.87 3.91 
FAM46B family with sequence similarity 46, member B 11.31 12.84 5.47 5.41 
EXO1 exonuclease 1 10.06 11.6 2.06 2.16 
ZNF788 zinc finger family member 788 8.64 9.52 2.23 1.93 
CDKN3 cyclin-dependent kinase inhibitor 3 43.45 37.24 4.65 3.63 
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SGOL2 shugoshin-like 2 (S. pombe) 24.76 22.28 2.33 2.9 
CDC7 cell division cycle 7 33.01 34.18 4.16 4.32 
ZIC3 Zic family member 3 19.86 18.49 1.54 1.36 
FAM64A family with sequence similarity 64, member A 12.48 13.19 1.13 -1.1 
FAT3 FAT atypical cadherin 3 15.7 15.14 2.31 1.67 
TCEAL2 transcription elongation factor A (SII)-like 2 6.83 11.4 1.4 1.68 
FGF2 fibroblast growth factor 2 (basic) 13.21 15.37 1.59 1.66 
RNASEH2A ribonuclease H2, subunit A 8.37 8.34 2.16 1.98 
FGFBP3 fibroblast growth factor binding protein 3 40.13 40.77 1.12 1.14 
CDCA7L cell division cycle associated 7-like 12.04 15.19 1.07 -1.17 
C11orf82 chromosome 11 open reading frame 82 13.32 12.04 1.41 1.48 
ELAVL2 ELAV like neuron-specific RNA binding protein 2 7.52 10.87 2.28 1.86 
ROR1 receptor tyrosine kinase-like orphan receptor 1 10.71 11.35 4.05 4.58 
MELK maternal embryonic leucine zipper kinase 20.76 19.1 5.15 5.19 
PLP1 proteolipid protein 1 36.9 56.89 1.76 1.59 
LOC100127983 uncharacterized LOC100127983 10.93 11.57 6.27 6.19 
BARD1 BRCA1 associated RING domain 1 7.83 8.47 3.24 3.52 
KAL1 Kallmann syndrome 1 sequence 47.35 42.3 1.75 1.48 
GINS2 GINS complex subunit 2 (Psf2 homolog) 12.26 12.55 1.21 1.15 
ZNF273 zinc finger protein 273 9.15 8.42 1.88 2.5 
SALL2 spalt-like transcription factor 2 45.72 49.71 6.02 5.21 
TRAF5 TNF receptor-associated factor 5 6.41 5.73 3.1 3.26 
MCM3 minichromosome maintenance complex component 
3 
11.37 11.65 1.24 1.17 
BUB1B BUB1 mitotic checkpoint serine/threonine kinase B 48.47 49.37 4.54 3.02 
KIF11 kinesin family member 11 48.78 49.8 5.22 3.88 
SCG3 secretogranin III 30.21 30.22 1.13 1.09 
SALL4 spalt-like transcription factor 4 14.65 13.97 1.82 1.93 
FAM83D family with sequence similarity 83, member D 14.04 14.26 1.52 1.15 
HAUS1 HAUS augmin-like complex, subunit 1 8.25 8.46 3.41 3.76 
RFWD3 ring finger and WD repeat domain 3 9.29 9 1.82 1.44 
MCM2 minichromosome maintenance complex component 
2 
9.62 9.91 1.35 1.31 
TCEAL7 transcription elongation factor A (SII)-like 7 7.13 13.43 4.8 4.7 
PWAR5 Prader Willi/Angelman region RNA 5 5.71 6.31 1.06 1.03 
PRKAR2B protein kinase, cAMP-dependent, regulatory, type 
II, beta 
22.33 30.31 8.54 5.55 
RFC4 replication factor C (activator 1) 4, 37kDa 7.45 7.42 2.27 2.55 
C5orf34 chromosome 5 open reading frame 34 5.23 5.05 2.4 2.75 
MICB MHC class I polypeptide-related sequence B 17.53 16.84 1.11 1.62 
LMNB2 lamin B2 11.62 10.86 3.03 2.53 
GPM6B glycoprotein M6B 31.61 40.77 2.24 2.21 
E2F5 E2F transcription factor 5, p130-binding 18.16 14.96 4.9 4.76 
CTBP2 C-terminal binding protein 2 24.5 25.24 6.94 6.87 
PRTFDC1 phosphoribosyl transferase domain containing 1 12.85 14.99 2.11 2.01 
SHISA2 shisa family member 2 23.41 17.92 15.57 8.37 
CRABP1 cellular retinoic acid binding protein 1 7.57 7.06 1.48 1.59 
CACHD1 cache domain containing 1 19.86 19.47 2.59 2.13 
CENPK centromere protein K 35.28 34.66 4.6 4.17 
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H2AFZ H2A histone family, member Z 12.81 12.82 3.78 3.42 
NMU neuromedin U 19.27 18.06 2.06 1.96 
GPC4 glypican 4 68.23 66.25 7.38 5.76 
KLHL7 kelch-like family member 7 8.22 8.71 1.94 2.31 
MCM6 minichromosome maintenance complex component 
6 
8.98 9.99 1.91 2.06 
SFRP2 secreted frizzled-related protein 2 59.18 63.81 11.62 7.54 
VASH2 vasohibin 2 78.7 80.16 1.59 1.53 
ITM2A integral membrane protein 2A 10.66 14.09 5.12 6 
KIF18A kinesin family member 18A 7.63 6.64 1.43 1.65 
E2F8 E2F transcription factor 8 15.52 15.77 1.7 1.59 
MIR17HG miR-17-92 cluster host gene (non-protein coding) 8.36 7.8 1.38 1.07 
DEPDC1B DEP domain containing 1B 60.79 65.07 3.62 2.62 
DBN1 drebrin 1 11.94 11.53 4.4 4.11 
GABRB3 gamma-aminobutyric acid (GABA) A receptor, beta 
3 
32.65 26.61 -1.23 -1.35 
RBPMS2 RNA binding protein with multiple splicing 2 20.33 20.8 2.26 2.24 
CDCA3 cell division cycle associated 3 10.47 10.1 2.82 2.4 
BEND4 BEN domain containing 4 13.5 19.52 1.09 1.1 
NCAPG non-SMC condensin I complex, subunit G 35.9 30.66 3.02 2.54 
KPNA2 karyopherin alpha 2 (RAG cohort 1, importin alpha 
1) 
16.68 17.33 8 6.47 
CCNA2 cyclin A2 56.5 53.01 7.03 4.82 
C9orf135 chromosome 9 open reading frame 135 58.42 47.8 -1.12 -1.05 
DNMT3B DNA (cytosine-5-)-methyltransferase 3 beta 87.44 100.68 2.73 2.4 
CHN1 chimerin 1 12.19 12.07 12.6 11.79 
SLC38A1 solute carrier family 38, member 1 16.29 14.96 6.73 6.17 
MAMDC2 MAM domain containing 2 5.3 6.65 4.25 1.98 
PPP2R2B protein phosphatase 2, regulatory subunit B, beta 14.88 17.03 3.42 2.34 
USP44 ubiquitin specific peptidase 44 59.3 69.45 1.23 1.13 
LECT1 leukocyte cell derived chemotaxin 1 8.87 13.67 1.14 1.17 
KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral 
oncogene homolog 
9.23 6.76 3.2 2.53 
NEFL neurofilament, light polypeptide 10.62 6.97 1.24 1.17 
CDCA2 cell division cycle associated 2 14.9 12.91 3.08 2.89 
PBX1 pre-B-cell leukemia homeobox 1 8.46 8.93 6.29 5.5 
L1TD1 LINE-1 type transposase domain containing 1 129.02 128.61 2.59 2.9 
KBTBD8 kelch repeat and BTB (POZ) domain containing 8 13.66 14.23 1.53 1.39 
DCLK1 doublecortin-like kinase 1 14.75 12.61 1.11 1.1 
FEN1 flap structure-specific endonuclease 1 10.42 9.76 1.33 1.18 
NCAPG2 non-SMC condensin II complex, subunit G2 7.92 8.53 1.63 1.49 
CENPH centromere protein H 25.81 28.49 5.61 4.32 
GFPT2 glutamine-fructose-6-phosphate transaminase 2 14.31 13.85 7.47 6.71 
SKA1 spindle and kinetochore associated complex subunit 
1 
9.2 7.05 1.31 1.2 
SFRP1 secreted frizzled-related protein 1 22.82 19.47 15.64 10.48 
CNTNAP2 contactin associated protein-like 2 30.05 20.59 1.7 1.63 
POU5F1P3 POU class 5 homeobox 1 pseudogene 3 94.83 89.47 1.46 1.35 
KIF23 kinesin family member 23 65.1 64.96 6.33 3.63 
PRC1 protein regulator of cytokinesis 1 21.63 20.46 7.91 6.07 
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CHML choroideremia-like (Rab escort protein 2) 6.66 7.37 2.82 3.54 
LPAR4 lysophosphatidic acid receptor 4 5.08 7.41 1.13 1.21 
SBK1 SH3 domain binding kinase 1 9.32 9.93 3.13 2.38 
ZNF738 zinc finger protein 738 23.49 26.24 7.19 6.1 
NTS neurotensin 252.33 173.69 1.36 1.39 
ZNF681 zinc finger protein 681 4.8 5.01 1.94 2.62 
CCNJ cyclin J 11.57 11.43 4.37 3.58 
UBE2C ubiquitin-conjugating enzyme E2C 48.61 43.49 9.19 6.67 
ZNF883 zinc finger protein 883 3.21 3.41 1.76 1.89 
TMSB15A thymosin beta 15a 43.97 55.28 4.14 3.16 
DPPA4 developmental pluripotency associated 4 82.17 90.28 5.34 5.38 
LINC00458 long intergenic non-protein coding RNA 458 147.3 89 1.38 1.42 
LPHN3 latrophilin 3 7.85 7.6 2.73 2.22 
FAR2 fatty acyl CoA reductase 2 17.66 13.67 2.86 3.14 
MTMR2 myotubularin related protein 2 9.77 9.66 4.1 3.81 
SPP1 secreted phosphoprotein 1 11.38 12.65 27.89 12.35 
GAL galanin/GMAP prepropeptide 184.47 132.03 4.47 3.12 
SEMA3A sema domain, immunoglobulin domain (Ig), short 
basic domain, secreted, (semaphorin) 3A 
11.44 10.01 3.13 2.49 
SEPHS1 selenophosphate synthetase 1 16.16 17.81 -1.42 -1.7 
DZIP1 DAZ interacting zinc finger protein 1 9.84 8.83 9.99 8.7 
ORC1 origin recognition complex, subunit 1 11.18 12.57 1.18 1.24 
DACT1 dishevelled-binding antagonist of beta-catenin 1 27.74 32.11 14.78 11.89 
AKR1B1 aldo-keto reductase family 1, member B1 (aldose 
reductase) 
23.27 21.9 18.82 20.55 
POLR3G polymerase (RNA) III (DNA directed) polypeptide 
G (32kD) 
16.02 15.4 -1.69 -1.72 
NAP1L1 nucleosome assembly protein 1-like 1 7.18 7.15 4.27 4.02 
MLF1IP MLF1 interacting protein 9.87 10.24 1.06 1.11 
LINC00617 long intergenic non-protein coding RNA 617 13.21 10.68 1.44 1.48 
NCAPH non-SMC condensin I complex, subunit H 9.51 9.8 2.23 2.16 
PRDM14 PR domain containing 14 10.53 10.81 1.94 1.93 
ZNF850 zinc finger protein 850 7.6 9.06 2.49 1.46 
FABP7 fatty acid binding protein 7, brain 12.59 13.49 1.32 1.31 
TAF4B TAF4b RNA polymerase II, TATA box binding 
protein (TBP)-associated factor, 105kDa 
6.88 6.62 1.82 1.76 
KIAA1524 KIAA1524 9.61 8.76 1.42 1.41 
HAS2 hyaluronan synthase 2 79.44 31.32 10.09 6.16 
BRINP1 bone morphogenetic protein/retinoic acid inducible 
neural-specific 1 
13.89 17.31 1.89 1.54 
FAM101B family with sequence similarity 101, member B 5.7 7.24 8.73 7.53 
ESRG embryonic stem cell related (non-protein coding) 287.72 303.39 1.34 1.33 
ERVMER34-1 endogenous retrovirus group MER34, member 1 8.42 9.11 1.54 1.67 
SCGB3A2 secretoglobin, family 3A, member 2 14.73 15.61 3.74 3.75 
LOC100131138 uncharacterized LOC100131138 9.75 9.97 3.96 2.75 
LOC100996702 uncharacterized LOC100996702 23.71 15.39 6.49 5.29 
PKIA protein kinase (cAMP-dependent, catalytic) 
inhibitor alpha 
6.97 7.18 10.09 8.01 
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ST6GALNAC3 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-
galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-
sialyltransferase 3 
5.67 6.84 14.12 11.23 
LEFTY1 left-right determination factor 1 81.51 75.24 1.17 1.25 
LRFN5 leucine rich repeat and fibronectin type III domain 
containing 5 
15.51 11.36 5 4.73 
 
 
Table 12   Cluster group IV: Proliferation process 
Total number of genes: 101 
The list of 101 genes represents a cluster group IV that is responsible proliferation process as 
described in chapter 3.4.4, Fig. 18. Column 1(from left to right) represents the gene symbol 
and column 2 represents the corresponding gene description. Column 3 and 4 contain the fold 
change values of hHEPs vs. hESCs. Column 5 and 6 contain fold change values of hHEPs vs. 
HLCs. HLCs-total: the heterogeneous population of hepatocyte like cells; HLCs-island: 
hepatocyte like islands extracted from the heterogeneous population; hESCs: human 
embryonic stem cells; hHEPs: freshly isolated adult hepatocytes; vs.: versus. 
 
Symbol Description hESC1 hESC2 HLCs-
total 
HLCs-
islands 
CRISPLD1 cysteine-rich secretory protein LCCL domain 
containing 1 
45.31 49.08 22.7 18.38 
LDHB lactate dehydrogenase B 37.39 37.57 19.9 20.66 
RAB34 RAB34, member RAS oncogene family 45.95 47.3 34.95 36.02 
BCAT1 branched chain amino-acid transaminase 1, 
cytosolic 
52.24 50.59 20.82 16.16 
ARMCX2 armadillo repeat containing, X-linked 2 39.14 41.94 30.45 27.19 
ATP1B3 ATPase, Na+/K+ transporting, beta 3 polypeptide 41.87 42.6 20.23 20.16 
SLC39A10 solute carrier family 39 (zinc transporter), member 
10 
42.79 46.17 20.66 18.06 
MLLT11 "myeloid/lymphoid or mixed-lineage leukemia 
(trithorax homolog, Drosophila); translocated to, 
11" 
72.73 66.23 41.66 40.18 
GALNT7 UDP-N-acetyl-alpha-D-galactosamine:polypeptide 
N-acetylgalactosaminyltransferase 7 (GalNAc-T7) 
63.46 62.13 34.75 28.83 
ESRP1 epithelial splicing regulatory protein 1 48.43 54.82 19.9 18.72 
MAP1B microtubule-associated protein 1B 34.3 29.79 17.3 11.53 
SCRN1 secernin 1 28.22 31.15 22.23 21.71 
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GULP1 GULP, engulfment adaptor PTB domain containing 
1 
64.83 63.68 53.1 57.15 
ROBO1 roundabout, axon guidance receptor, homolog 1 
(Drosophila) 
29.88 27.15 21.46 16.03 
ZNF462 zinc finger protein 462 37.69 43.13 12.24 8.31 
ANLN anillin, actin binding protein 57.2 46.26 14.45 12.05 
GPX8 glutathione peroxidase 8 (putative) 34.56 31.12 81.19 70.66 
SLC25A36 solute carrier family 25 (pyrimidine nucleotide 
carrier ), member 36 
18.29 18.52 21.34 23.86 
TPM4 tropomyosin 4 40.61 34.4 42.82 24.32 
TUBA1A tubulin, alpha 1a 130.56 138.57 44.32 27.78 
ARMCX1 armadillo repeat containing, X-linked 1 17.84 18.83 22.43 22 
SLC25A24 "solute carrier family 25 (mitochondrial carrier; 
phosphate carrier), member 24" 
30.27 29.23 26.02 21.61 
OLFML3 olfactomedin-like 3 25.14 24.06 39.52 34.71 
SLC2A3 solute carrier family 2 (facilitated glucose 
transporter), member 3 
49.64 40 82.56 55.25 
TUBB6 tubulin, beta 6 class V 25.5 26.37 18.1 14.18 
ORC6 origin recognition complex, subunit 6 47.07 50.38 12 9.7 
CDK1 cyclin-dependent kinase 1 66.44 61.11 15.31 11.37 
STK39 serine threonine kinase 39 41.18 45.04 48.3 43.8 
GSTP1 glutathione S-transferase pi 1 26.79 24.18 20.27 21.48 
PTPN13 protein tyrosine phosphatase, non-receptor type 13 
(APO-1/CD95 (Fas)-associated phosphatase) 
18.56 18.32 16.75 12.15 
VCAN versican 40.66 47.37 19.36 13.68 
TPBG trophoblast glycoprotein 21.04 21.12 14.25 12.8 
CCNB1 cyclin B1 77.57 80.26 10.72 6.77 
PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 92.76 109.28 8.36 6.42 
BEX2 brain expressed X-linked 2 65.6 74.76 10.06 11.01 
TMEM200A transmembrane protein 200A 33.76 42.8 59.23 63.09 
TOP2A topoisomerase (DNA) II alpha 170kDa 136.26 123.63 27.44 20.4 
IGF2BP3 insulin-like growth factor 2 mRNA binding protein 
3 
93.98 119.63 82.4 84.22 
HDGFRP3 hepatoma-derived growth factor, related protein 3 46.46 43.7 15.26 14.99 
FGF13 fibroblast growth factor 13 127.62 111.4 6.49 5.45 
ASNS asparagine synthetase (glutamine-hydrolyzing) 171.4 141.14 70.22 51.2 
MTHFD2 methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 2, methenyltetrahydrofolate 
cyclohydrolase 
169.24 168.72 74.36 50.11 
FZD7 frizzled family receptor 7 76.61 90.01 13.2 8.53 
LRRN1 leucine rich repeat neuronal 1 132.36 146.27 29.16 16.38 
CCNB2 cyclin B2 62.33 60.73 11.45 7.95 
LIN28B lin-28 homolog B (C. elegans) 210.7 219.75 68.89 69.17 
C12orf75 chromosome 12 open reading frame 75 24.53 27.62 66.44 64.83 
PODXL podocalyxin-like 150.11 162.84 121.81 88.51 
FBN2 fibrillin 2 32.58 25.27 76.09 39.12 
UCHL1 ubiquitin carboxyl-terminal esterase L1 (ubiquitin 
thiolesterase) 
91.54 78.85 9.32 6.48 
BEX1 brain expressed, X-linked 1 30.02 37.37 12.45 14.4 
SPINT2 serine peptidase inhibitor, Kunitz type, 2 17.32 16.62 34.9 34.36 
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MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast) 70.18 68.16 12.48 9.78 
NDN necdin, melanoma antigen (MAGE) family member 16.56 15.73 29.48 28.05 
CDCA7 cell division cycle associated 7 88.2 99.74 14.46 13.02 
PROM1 prominin 1 74.29 84.96 78.17 86.63 
ANXA3 annexin A3 44.54 33.67 86.45 89.08 
DLGAP5 discs, large (Drosophila) homolog-associated 
protein 5 
196.14 186.34 9.79 6.51 
PFKP phosphofructokinase, platelet 10.39 10.9 37.24 35.55 
PNMAL1 paraneoplastic Ma antigen family-like 1 15.96 17.84 13.5 11.56 
KIF20A kinesin family member 20A 65.97 62.32 11.71 6.66 
LAMA1 laminin, alpha 1 11.77 12.36 40.28 37.81 
TUBB2B tubulin, beta 2B class IIb 520.97 480.79 46.91 33.21 
COL1A2 collagen, type I, alpha 2 35.92 37.83 366.26 303.88 
ECT2 epithelial cell transforming sequence 2 oncogene 38.76 36.97 6.11 5.87 
SOX11 SRY (sex determining region Y)-box 11 37.38 38.36 15.14 12.11 
BEX4 brain expressed, X-linked 4 22.2 20.48 16.57 14.03 
TET1 tet methylcytosine dioxygenase 1 33.93 40.1 20.19 21.51 
RRM2 ribonucleotide reductase M2 84.08 83.58 4.62 3.08 
CDC20 cell division cycle 20 86.22 87.08 6.89 4.41 
SERPINE2 serpin peptidase inhibitor, clade E (nexin, 
plasminogen activator inhibitor type 1), member 2 
562.4 455.04 250.58 213.5 
NAP1L3 nucleosome assembly protein 1-like 3 185.73 182.37 59.82 66.29 
TRIM6 tripartite motif containing 6 11.82 13.15 17.4 17.96 
GINS1 GINS complex subunit 1 (Psf1 homolog) 54.1 59.43 5.48 4.89 
HEPH hephaestin 26.59 30.33 117.42 137.47 
MARCKSL1 MARCKS-like 1 44.39 43.1 11.08 8.58 
EPCAM epithelial cell adhesion molecule 212.55 226.35 282.3 295.41 
PTPLA protein tyrosine phosphatase-like (proline instead of 
catalytic arginine), member A 
17.4 15.86 15.92 16.71 
KRT19 keratin 19 60.73 43.74 424.71 405.28 
PTN pleiotrophin 12.24 14.84 186.97 197.5 
LRRC1 leucine rich repeat containing 1 7.6 7.41 61.81 60.09 
GJA1 gap junction protein, alpha 1, 43kDa 769.53 727.24 461.87 401.33 
SPARC secreted protein, acidic, cysteine-rich (osteonectin) 11.47 11.36 125.16 124.77 
TTK TTK protein kinase 68.59 68.37 5.75 5.49 
FAR1 fatty acyl CoA reductase 1 17.63 16.56 8.43 9.56 
LIN28A lin-28 homolog A (C. elegans) 569.99 593.31 14.62 7.94 
CTHRC1 collagen triple helix repeat containing 1 3.44 6.21 36 41.32 
VIM vimentin 18.72 16.02 24.75 22.57 
RACGAP1 Rac GTPase activating protein 1 28.97 26.95 10.3 7.6 
SACS spastic ataxia of Charlevoix-Saguenay (sacsin) 20.85 20.93 5.1 4.25 
DPYSL3 dihydropyrimidinase-like 3 12.86 16.14 10.44 6.74 
LAMB1 laminin, beta 1 9 9.63 105.09 105.77 
PKIB protein kinase (cAMP-dependent, catalytic) 
inhibitor beta 
11.47 11.58 10.65 10.99 
LOC100506013 uncharacterized LOC100506013 57.47 68.39 5.09 6.4 
PTPRZ1 protein tyrosine phosphatase, receptor-type, Z 
polypeptide 1 
149.56 159.77 3.58 4.42 
HK1 hexokinase 1 19.14 17.64 15.08 14.92 
 157 
 
ACTC1 actin, alpha, cardiac muscle 1 39.83 47.6 151.73 125.86 
GPC3 glypican 3 3.39 4.48 44.9 63.52 
PITX2 paired-like homeodomain 2 40.84 36.35 103.41 93.1 
ZIC2 Zic family member 2 300.65 264.28 1.89 1.66 
DLK1 delta-like 1 homolog (Drosophila) 3.11 3.93 684.86 644 
 
 
Table 13  Cluster group V: ECM and Migration 
Total number of genes: 505 
The list of 505 genes represents a cluster group V that is responsible for proliferation process 
as described in chapter 3.4.5, Fig. 18. Column 1(from left to right) represents the gene symbol 
and column 2 represents the corresponding gene description. Column 3 and 4 contain the fold 
change values of hHEPs vs. hESCs. Column 5 and 6 contain fold change values of hHEPs vs. 
HLCs. HLCs-total: the heterogeneous population of hepatocyte like cells; HLCs-island: 
hepatocyte like islands extracted from the heterogeneous population; hESCs: human 
embryonic stem cells; hHEPs: freshly isolated adult hepatocytes; vs.: versus. 
 
Symbol Description hESC1 hESC2 HLCs-
total 
HLCs-
islands 
ELF4 E74-like factor 4 (ets domain transcription factor) 1.37 1.41 6.26 5.78 
PCDH7 protocadherin 7 2.08 1.98 3.81 4.3 
ATP1A1 ATPase, Na+/K+ transporting, alpha 1 polypeptide 1.82 1.78 4.88 4.69 
TMEM87B transmembrane protein 87B 1.22 1.14 3.61 3.55 
TMEM51 transmembrane protein 51 1.89 1.81 5.06 4.91 
SBSPON somatomedin B and thrombospondin, type 1 
domain containing 
1.07 1.14 7.18 6.76 
PLCE1 phospholipase C, epsilon 1 1.2 -1.02 3.66 3.75 
SUSD1 sushi domain containing 1 1.49 1.45 2.8 2.87 
CLDN4 claudin 4 -1.1 -1.16 5.17 5.13 
TSPAN13 tetraspanin 13 1.14 1.18 3.22 3.57 
ENDOD1 endonuclease domain containing 1 1.27 1.35 3.85 3.38 
ITGAV integrin, alpha V 2.62 2.36 7.43 5.86 
ADAM9 ADAM metallopeptidase domain 9 1 -1.07 7.87 8.11 
DFNA5 deafness, autosomal dominant 5 -1.35 -1.16 5.76 5.05 
KLF5 Kruppel-like factor 5 (intestinal) 1.81 1.4 5.32 3.37 
PRICKLE2 prickle homolog 2 (Drosophila) 1.2 1.3 7.12 5.78 
UPK3A uroplakin 3A -1.08 -1.14 4.01 6.5 
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ADAMTS9 ADAM metallopeptidase with thrombospondin type 
1 motif, 9 
1.17 1.06 9.21 7.53 
CCNG2 cyclin G2 1.71 1.58 6.25 5.69 
TMC4 transmembrane channel-like 4 1.45 1.66 3.89 4.62 
IGFBP6 insulin-like growth factor binding protein 6 2.24 2.2 8.23 7.58 
---   1.19 1.14 3.7 4.92 
S100A6 S100 calcium binding protein A6 -1.18 -1.14 5.49 7.79 
NEU1 sialidase 1 (lysosomal sialidase) 1.55 1.25 2.31 3.01 
GABRB1 gamma-aminobutyric acid (GABA) A receptor, beta 
1 
1.17 1.23 4.79 4.82 
C1orf116 chromosome 1 open reading frame 116 1.62 1.75 2.68 2.79 
CLDN7 claudin 7 1.96 1.93 2.96 3.06 
HSPA12A heat shock 70kDa protein 12A 1.89 1.96 3.19 2.95 
WIPF1 WAS/WASL interacting protein family, member 1 -1.01 -1.09 11.02 8.91 
CDX2 caudal type homeobox 2 1.2 1.17 2.53 2.42 
ITGB6 integrin, beta 6 1.43 1.51 10.28 9.05 
SLC2A5 solute carrier family 2 (facilitated glucose/fructose 
transporter), member 5 
1.74 1.78 5.83 9.12 
NDNF neuron-derived neurotrophic factor 2.19 2.31 6.63 6.56 
SLCO2A1 solute carrier organic anion transporter family, 
member 2A1 
1.99 1.57 5.57 5.04 
DPEP1 dipeptidase 1 (renal) -1.09 -1.05 6.85 9.92 
GABRA2 gamma-aminobutyric acid (GABA) A receptor, 
alpha 2 
-1.08 -1.02 3.41 2.64 
PAPPA pregnancy-associated plasma protein A, pappalysin 
1 
1.25 1.23 13.73 8.29 
LIFR leukemia inhibitory factor receptor alpha 1.27 -1.09 15.31 14.77 
CPE carboxypeptidase E 1.38 1.05 6.28 4.64 
SH3YL1 SH3 and SYLF domain containing 1 -1.49 -1.45 3.9 4.34 
DAB2 Dab, mitogen-responsive phosphoprotein, homolog 
2 (Drosophila) 
1.14 1.02 5.06 4.34 
SLC1A3 solute carrier family 1 (glial high affinity glutamate 
transporter), member 3 
1.6 1.46 3.82 4.27 
ME1 malic enzyme 1, NADP(+)-dependent, cytosolic 2.81 2.37 2.77 2.33 
TNFSF4 tumor necrosis factor (ligand) superfamily, member 
4 
1.47 1.43 4.34 3.99 
SFXN3 sideroflexin 3 -1.14 -1.14 3.28 3.58 
TMEM255A transmembrane protein 255A 1.77 1.26 10.12 8.81 
BAMBI BMP and activin membrane-bound inhibitor 2.09 1.49 7.61 6.54 
SLC7A6 solute carrier family 7 (amino acid transporter light 
chain, y+L system), member 6 
2.27 2.05 2.52 2.67 
OLR1 oxidized low density lipoprotein (lectin-like) 
receptor 1 
1.24 1.27 4.65 2.6 
USH1C Usher syndrome 1C (autosomal recessive, severe) 1.81 1.84 2.63 3.41 
SESN3 sestrin 3 1.79 2.04 6.74 4.56 
LYPD1 LY6/PLAUR domain containing 1 2.43 2.54 3.02 3.18 
HEG1 heart development protein with EGF-like domains 1 2.06 1.75 4.57 2.7 
LIMA1 LIM domain and actin binding 1 1.88 2.01 3.81 3.61 
TACSTD2 tumor-associated calcium signal transducer 2 -1.34 -1.19 3.28 3.03 
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MFI2 antigen p97 (melanoma associated) identified by 
monoclonal antibodies 133.2 and 96.5 
1.52 1.56 3.29 3.5 
PNLIPRP2 pancreatic lipase-related protein 2 1.13 1.15 2.43 4.57 
LOC100129550 uncharacterized LOC100129550 1.05 -1.02 2.25 2.04 
CD3D CD3d molecule, delta (CD3-TCR complex) -1.24 -1.27 3.15 5.25 
KCNJ16 potassium inwardly-rectifying channel, subfamily J, 
member 16 
1.18 1.24 1.87 2.08 
LMCD1 LIM and cysteine-rich domains 1 1.05 1.09 11.62 11.72 
UBASH3B ubiquitin associated and SH3 domain containing B 1.55 1.4 8.62 6.94 
TMEM144 transmembrane protein 144 1.29 1.32 2.15 1.88 
STX3 syntaxin 3 2.26 2.09 3.38 3.81 
IGSF1 immunoglobulin superfamily, member 1 1.49 1.52 3.26 4.92 
TSPAN3 tetraspanin 3 2.02 2.18 3.21 3.66 
ABCC4 ATP-binding cassette, sub-family C (CFTR/MRP), 
member 4 
2.14 2.09 2.88 2.7 
REEP1 receptor accessory protein 1 1.2 1.34 5.52 11.55 
PRSS8 protease, serine, 8 2.27 2.05 3.46 3.82 
RAB11FIP1 RAB11 family interacting protein 1 (class I) 2.2 2.3 6.51 4.96 
XKRX XK, Kell blood group complex subunit-related, X-
linked 
2 2.1 2.14 2.34 
TIMP2 TIMP metallopeptidase inhibitor 2 2.28 2.39 5.92 5.26 
WNT5A wingless-type MMTV integration site family, 
member 5A 
-1.32 -1.27 10.77 8.97 
FXYD3 FXYD domain containing ion transport regulator 3 1.74 1.84 2.43 2.52 
MSX2 msh homeobox 2 2.88 1.69 14 11.3 
OSR2 odd-skipped related transciption factor 2 1.09 1.04 2.42 1.83 
FMO1 flavin containing monooxygenase 1 1.13 1.24 9.33 11.2 
TFF1 trefoil factor 1 1.18 1.27 4.56 8.38 
COL12A1 collagen, type XII, alpha 1 1.55 1.54 6.5 6.1 
FAM3B family with sequence similarity 3, member B 1.41 1.42 3.25 3.56 
S100A10 S100 calcium binding protein A10 1.85 2.02 9.53 9.38 
PLP2 proteolipid protein 2 (colonic epithelium-enriched) 1.53 1.68 4.14 4.54 
MSX1 msh homeobox 1 2.02 1.34 16.98 12.78 
THBD thrombomodulin -1.17 -1.24 10.81 8.42 
GATA3 GATA binding protein 3 1.86 1.43 24.77 18.79 
FBLN5 fibulin 5 1.56 1.65 15.93 15.47 
GALNT10 UDP-N-acetyl-alpha-D-galactosamine:polypeptide 
N-acetylgalactosaminyltransferase 10 (GalNAc-
T10) 
2.77 2.44 11.5 10.07 
MAP7D2 MAP7 domain containing 2 1.09 1.23 1.58 1.89 
PRR15L proline rich 15-like -1.2 -1.09 3.48 4.1 
EGF epidermal growth factor 2.98 2.4 3.59 4.87 
PALLD palladin, cytoskeletal associated protein 1.36 1.42 11.58 9.66 
FLNC filamin C, gamma 3.01 2.74 9.16 8.51 
NPPB natriuretic peptide B 2.21 1.93 9.3 5.84 
SEMA3C sema domain, immunoglobulin domain (Ig), short 
basic domain, secreted, (semaphorin) 3C 
1.68 1.84 13.18 9.6 
EPS8L3 EPS8-like 3 1.5 1.56 2.37 3.14 
GCNT3 glucosaminyl (N-acetyl) transferase 3, mucin type 1.05 1.11 2.16 2.64 
GPR87 G protein-coupled receptor 87 1.25 1.32 20.4 18.85 
 160 
 
DUSP9 dual specificity phosphatase 9 -1.76 -1.67 2.12 2.65 
LRP2 low density lipoprotein receptor-related protein 2 1.11 1.16 13.64 13.92 
GXYLT2 glucoside xylosyltransferase 2 2.23 2.02 10.61 10.95 
GPRC5A G protein-coupled receptor, family C, group 5, 
member A 
1.3 1.34 7.17 5.21 
RRAS related RAS viral (r-ras) oncogene homolog -1.17 -1.1 4.32 4.74 
KLHL13 kelch-like family member 13 -1.59 -1.22 3.25 3.95 
C7orf60 chromosome 7 open reading frame 60 -1.01 1.13 5.9 5.23 
TNNC1 troponin C type 1 (slow) 1.3 1.12 2.69 3.34 
ANXA2P2 annexin A2 pseudogene 2 2.44 2.46 8.07 7.01 
BMP2 bone morphogenetic protein 2 5.9 2.31 7.74 7.75 
P4HA2 prolyl 4-hydroxylase, alpha polypeptide II -2.73 -3.03 12.15 10.77 
ISX intestine-specific homeobox 1.44 1.46 1.98 2.37 
MFSD6 major facilitator superfamily domain containing 6 1.52 1.69 2.6 2.21 
GALNT6 UDP-N-acetyl-alpha-D-galactosamine:polypeptide 
N-acetylgalactosaminyltransferase 6 (GalNAc-T6) 
1.47 1.5 4.69 4.67 
KRT7 keratin 7 -1.03 -1.02 10.65 8.5 
CNTN4 contactin 4 1.4 1.35 8.2 8.55 
SLC16A3 solute carrier family 16 (monocarboxylate 
transporter), member 3 
1.07 -1.01 33.72 28.34 
PLA2G10 phospholipase A2, group X 1.73 1.88 4.49 5.52 
TMEM65 transmembrane protein 65 1.62 1.65 2.72 2.21 
ERMP1 endoplasmic reticulum metallopeptidase 1 1 1.02 3.17 2.68 
CSGALNACT1 chondroitin sulfate N-
acetylgalactosaminyltransferase 1 
-1.04 -1.02 4.1 4.28 
CD44 CD44 molecule (Indian blood group) 1.48 1.55 4.14 3.44 
CYBA cytochrome b-245, alpha polypeptide 1.72 1.59 3.49 3.43 
TDP2 tyrosyl-DNA phosphodiesterase 2 1.42 1.32 1.91 2.31 
TIMP1 TIMP metallopeptidase inhibitor 1 -1.79 -1.94 7.71 7.15 
GLS glutaminase 4.11 3.26 5.42 4.63 
PMP22 peripheral myelin protein 22 2.06 1.76 28.66 25.04 
FILIP1L filamin A interacting protein 1-like 1.19 1.21 3.63 3.49 
APPL2 adaptor protein, phosphotyrosine interaction, PH 
domain and leucine zipper containing 2 
1.27 1.02 2.4 2.01 
F2RL1 coagulation factor II (thrombin) receptor-like 1 1.92 2.06 5.18 5.59 
TUFT1 tuftelin 1 1.6 1.73 2.74 2.43 
CD109 CD109 molecule 1.82 2.01 2.69 2.9 
LGALS2 lectin, galactoside-binding, soluble, 2 -1.96 -2.13 1.87 3.08 
GATA5 GATA binding protein 5 -1.01 1.07 3.9 3.76 
FHL2 four and a half LIM domains 2 2.36 3.23 4.31 3.01 
GUCY2C guanylate cyclase 2C (heat stable enterotoxin 
receptor) 
1.25 1.18 5.36 9.01 
GNRH2 gonadotropin-releasing hormone 2 -1.16 -1.1 25.36 32.29 
TYRP1 tyrosinase-related protein 1 1.36 1.47 25.63 12.91 
TMEM164 transmembrane protein 164 2.68 2.59 2.95 2.9 
SLC51B solute carrier family 51, beta subunit 1.41 1.47 5.18 4.67 
FMOD fibromodulin -1.06 1.01 25.34 24.2 
SLC44A3 solute carrier family 44, member 3 -2.56 -2.3 3.37 3.98 
LAYN layilin 1.83 2.08 11.16 10.21 
MXRA7 matrix-remodelling associated 7 -1.36 -1.32 3.79 3.26 
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MPZL1 myelin protein zero-like 1 2.45 2.38 4.16 4.31 
MFGE8 milk fat globule-EGF factor 8 protein 1.64 1.97 5.83 6.41 
DUOX2 dual oxidase 2 1.02 1.03 10.67 15.22 
GOLGA8A golgin A8 family, member A -1.11 -1.3 2.26 3.7 
CIDEC cell death-inducing DFFA-like effector c 1.67 1.75 3.23 4.85 
FZD6 frizzled family receptor 6 1.45 1.44 9.64 9.65 
BBS12 Bardet-Biedl syndrome 12 1.75 1.59 5.37 8.06 
DCDC2 doublecortin domain containing 2 -1.33 -1.27 1.21 1.72 
SRPX2 sushi-repeat containing protein, X-linked 2 1.44 1.51 2.49 2.15 
DSC2 desmocollin 2 3.65 3.03 6.15 4.37 
OGFRL1 opioid growth factor receptor-like 1 2.14 2.13 11.22 12.56 
CA8 carbonic anhydrase VIII 1.12 1.15 7.19 5.76 
CDH6 cadherin 6, type 2, K-cadherin (fetal kidney) 1.57 1.75 1.76 1.64 
PHGR1 proline/histidine/glycine-rich 1 1.44 1.56 3.12 4.17 
XPR1 xenotropic and polytropic retrovirus receptor 1 1.76 1.82 2.76 2.58 
EPHX4 epoxide hydrolase 4 1.5 1.63 1.41 1.62 
LOC400043 uncharacterized LOC400043 1.54 1.57 50.89 50.16 
SLC10A2 solute carrier family 10 (sodium/bile acid 
cotransporter), member 2 
1.31 1.33 1.58 1.59 
ANKS1A ankyrin repeat and sterile alpha motif domain 
containing 1A 
2.08 2.19 10.67 8.81 
ALDH18A1 aldehyde dehydrogenase 18 family, member A1 2.19 2.28 3.46 4.05 
GNPDA2 glucosamine-6-phosphate deaminase 2 1.43 1.48 2.82 2.84 
QSOX1 quiescin Q6 sulfhydryl oxidase 1 1.67 1.6 4.02 4.08 
LPAR1 lysophosphatidic acid receptor 1 1.75 1.64 3.54 3.52 
RECK reversion-inducing-cysteine-rich protein with kazal 
motifs 
1.67 1.34 5.7 4.27 
ITGA3 integrin, alpha 3 (antigen CD49C, alpha 3 subunit 
of VLA-3 receptor) 
1.52 1.47 2 2.01 
TTC39A tetratricopeptide repeat domain 39A 1.9 1.94 1.98 2.33 
LCT lactase 1.48 1.57 8.98 9.6 
ASAP2 ArfGAP with SH3 domain, ankyrin repeat and PH 
domain 2 
-1.07 1.72 6.74 6.56 
AGR2 anterior gradient 2 1.67 1.76 4.81 7.39 
MXRA5 matrix-remodelling associated 5 3.18 2.72 12.65 9.32 
RBP2 retinol binding protein 2, cellular 1.04 1.04 12.37 18.33 
NOG noggin 1.59 1.59 10.18 6.46 
MOSPD1 motile sperm domain containing 1 2.47 2.13 3.22 3.39 
LOX lysyl oxidase 1.1 1.25 59.72 39.8 
WLS wntless Wnt ligand secretion mediator 2.17 1.51 5.93 4.71 
LGALS3 lectin, galactoside-binding, soluble, 3 -1.93 -1.66 16.68 19.64 
ARHGEF3 Rho guanine nucleotide exchange factor (GEF) 3 1.89 1.99 25.17 20.18 
PLAC8 placenta-specific 8 -2.22 -2.09 5.92 6 
ARL14 ADP-ribosylation factor-like 14 -1.05 -1.08 1.25 1.69 
FBN1 fibrillin 1 2.57 2.64 17.9 11.19 
TGFB1I1 transforming growth factor beta 1 induced transcript 
1 
2.91 3.7 10.49 9.98 
ZNF518B zinc finger protein 518B 3.37 2.89 3.46 2.63 
PLIN3 perilipin 3 2.59 2.61 4.04 3.71 
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CAPN2 calpain 2, (m/II) large subunit -1.27 -1.24 4.52 4.44 
FOXQ1 forkhead box Q1 4.41 2.91 2.18 1.71 
MYZAP myocardial zonula adherens protein 1.35 1.36 1.95 1.95 
KDELR3 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum 
protein retention receptor 3 
-1.36 -1.32 5.19 5.91 
MUM1L1 melanoma associated antigen (mutated) 1-like 1 -1.5 -1.54 24.33 35.81 
LAMC1 laminin, gamma 1 (formerly LAMB2) 2.82 2.74 7.87 6.97 
PGF placental growth factor 1.05 1.14 3.5 4.2 
AMOTL2 angiomotin like 2 4.6 4.18 5.04 3.11 
UGCG UDP-glucose ceramide glucosyltransferase 1.19 1.08 3.07 2.87 
LAMA5 laminin, alpha 5 1.19 1.18 3.41 3.05 
CASK calcium/calmodulin-dependent serine protein kinase 
(MAGUK family) 
1.74 1.54 2.33 2 
ST6GALNAC2 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-
galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-
sialyltransferase 2 
1.15 1.03 3.61 3.52 
IKBIP IKBKB interacting protein 2.07 2.02 5.33 6.22 
S100A14 S100 calcium binding protein A14 -2.51 -2.48 14.3 17.37 
RSPO3 R-spondin 3 1.64 1.82 14.66 8.89 
SYTL2 synaptotagmin-like 2 2.08 2.4 2.54 2.83 
SCGN secretagogin, EF-hand calcium binding protein -1.11 -1.09 6.86 8.89 
NEDD4L neural precursor cell expressed, developmentally 
down-regulated 4-like, E3 ubiquitin protein ligase 
1.83 2.01 3.37 3.62 
LYPD6B LY6/PLAUR domain containing 6B 2.36 2.48 6.94 6.61 
RHOBTB1 Rho-related BTB domain containing 1 1.49 1.8 4.78 3.63 
TANC2 tetratricopeptide repeat, ankyrin repeat and coiled-
coil containing 2 
2.42 2.31 10.67 8.01 
AGR3 anterior gradient 3 1.1 1.08 1.27 1.3 
FBXL2 F-box and leucine-rich repeat protein 2 2.77 2.98 6.61 6.13 
SLC7A7 solute carrier family 7 (amino acid transporter light 
chain, y+L system), member 7 
-1.06 -1.1 22.85 25.26 
CRYAB crystallin, alpha B 2.39 2.65 4.28 4.31 
CKAP4 cytoskeleton-associated protein 4 2.23 2.15 4.59 4.13 
FKBP10 FK506 binding protein 10, 65 kDa 1.87 1.86 5.42 5.12 
CACNB3 calcium channel, voltage-dependent, beta 3 subunit 2.3 2.15 4.86 5.14 
MYLIP myosin regulatory light chain interacting protein 1.55 1.7 9.78 8.93 
LAMB3 laminin, beta 3 -2.12 -2.06 1.87 3.71 
TWIST1 twist family bHLH transcription factor 1 2.21 1.77 5.39 4.19 
RHOC ras homolog family member C -1.26 -1.59 2.73 3 
SMAD7 SMAD family member 7 3.08 2.79 3.39 2.39 
TMCO3 transmembrane and coiled-coil domains 3 2.18 2.2 6.45 6.24 
KRT6A keratin 6A 1.07 1.07 2.87 2.53 
MCOLN3 mucolipin 3 1.9 2.19 3.63 4.27 
PIGZ phosphatidylinositol glycan anchor biosynthesis, 
class Z 
-1.06 -1.01 1.93 2.48 
MYOF myoferlin 2.15 1.87 37.45 30.45 
PRDM1 PR domain containing 1, with ZNF domain 3.43 2.22 2.21 2.37 
MMD monocyte to macrophage differentiation-associated 1.43 1.54 4.08 4.32 
ITGA2 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-
2 receptor) 
1.83 1.88 6.52 5.74 
 163 
 
PLAGL1 pleiomorphic adenoma gene-like 1 1.26 1.2 32.43 24.05 
B3GNT5 UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 5 
3.34 2.8 4.48 4.6 
METRNL meteorin, glial cell differentiation regulator-like 1.11 1.19 4.54 3.9 
LIPH lipase, member H -1.15 -1.15 1.79 2.31 
GPR124 G protein-coupled receptor 124 1.36 1.41 13.62 8.45 
ARL4C ADP-ribosylation factor-like 4C 2.06 2.13 5.3 3.35 
HILPDA hypoxia inducible lipid droplet-associated 1.55 1.68 4.68 3.24 
AMOT angiomotin 1.2 1.4 11.52 11.14 
ST6GALNAC1 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-
galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-
sialyltransferase 1 
-1.15 -1.19 1.84 2.83 
FKBP14 FK506 binding protein 14, 22 kDa 1.76 1.7 5.25 4.52 
LOXL1 lysyl oxidase-like 1 2.06 2.19 27.21 19.02 
CMTM3 CKLF-like MARVEL transmembrane domain 
containing 3 
3.2 2.98 4.71 4.11 
ERP27 endoplasmic reticulum protein 27 1.88 1.99 19.5 20.04 
FKBP11 FK506 binding protein 11, 19 kDa -1.23 -1.15 4.41 5.42 
HOXC6 homeobox C6 1.76 1.89 25.24 22.72 
NPNT nephronectin -1.22 -1.1 82 70.71 
HSD3B1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and 
steroid delta-isomerase 1 
1.33 1.27 10.13 7.94 
STXBP6 syntaxin binding protein 6 (amisyn) -1.26 -1.05 3.23 3 
LAMP3 lysosomal-associated membrane protein 3 1.74 1.74 2.18 2.28 
CYP1B1 cytochrome P450, family 1, subfamily B, 
polypeptide 1 
-1.09 -1.1 4.11 2.27 
SLN sarcolipin 1.7 1.73 47.49 57.27 
SH3BGRL3 SH3 domain binding glutamic acid-rich protein like 
3 
1.64 1.4 2.24 1.85 
MMP1 matrix metallopeptidase 1 (interstitial collagenase) 2.16 5.16 13.57 8.49 
C19orf69 chromosome 19 open reading frame 69 1.26 1.32 2.28 2.65 
PRSS23 protease, serine, 23 1.78 2.03 25.11 18.51 
PLD5 phospholipase D family, member 5 1.85 1.98 3.2 2.87 
EGFL6 EGF-like-domain, multiple 6 1.07 1.25 38.34 29.34 
FLRT2 fibronectin leucine rich transmembrane protein 2 5.28 3.49 8.23 5.51 
PLA2G4A phospholipase A2, group IVA (cytosolic, calcium-
dependent) 
-1.31 -1.26 7.53 5.92 
S100A4 S100 calcium binding protein A4 -1.29 -1.08 8.34 9.14 
SLC26A3 solute carrier family 26 (anion exchanger), member 
3 
-1.31 -1.3 8.54 9.81 
TFAP2A transcription factor AP-2 alpha (activating enhancer 
binding protein 2 alpha) 
1.36 1.4 8.97 8.16 
PTPRM protein tyrosine phosphatase, receptor type, M -1.68 -2.64 2.68 2.4 
COL4A5 collagen, type IV, alpha 5 1.98 1.88 3.6 3.11 
C19orf33 chromosome 19 open reading frame 33 1.39 1.41 2.34 2.52 
LOC100132735 uncharacterized LOC100132735 1.07 1.13 16.45 20.97 
MUC13 mucin 13, cell surface associated -1.17 -1.17 1.29 1.33 
LOC100506718 uncharacterized LOC100506718 3.24 2.47 13.26 11.41 
GEM GTP binding protein overexpressed in skeletal 
muscle 
2 2.1 2.36 2.33 
COL5A1 collagen, type V, alpha 1 4.61 3.46 75.47 48.97 
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DCN decorin 1.01 1.05 34.38 38.09 
CDH17 cadherin 17, LI cadherin (liver-intestine) 1.65 1.76 15.9 16.55 
MAGED2 melanoma antigen family D, 2 2.57 2.29 4.72 5.06 
ISL1 ISL LIM homeobox 1 2.94 2.26 16.82 14.98 
BNC1 basonuclin 1 -1.1 -1.07 66.82 61.54 
MECOM MDS1 and EVI1 complex locus 1.36 1.39 2.18 2.4 
CGA glycoprotein hormones, alpha polypeptide 1.52 1.63 13.72 36.81 
KRT6C keratin 6C 1.36 1.44 1.42 1.45 
CCDC80 coiled-coil domain containing 80 1.07 1.18 9.31 5.98 
HEY1 hes-related family bHLH transcription factor with 
YRPW motif 1 
2.14 2.77 21.98 15.19 
RASGRP1 RAS guanyl releasing protein 1 (calcium and DAG-
regulated) 
1.09 -1.01 1.48 1.3 
C15orf48 chromosome 15 open reading frame 48 -1.85 -1.72 1.66 2.26 
TSPAN2 tetraspanin 2 2.09 2.3 3.37 3.02 
FOXF1 forkhead box F1 1.52 1.65 9.7 6.49 
TMEM98 transmembrane protein 98 2.44 2.35 11.16 10.21 
SFN stratifin 3.59 3.61 5.04 3.83 
IGFBP3 insulin-like growth factor binding protein 3 -2.38 -2.08 43.85 31.24 
CEACAM6 carcinoembryonic antigen-related cell adhesion 
molecule 6 (non-specific cross reacting antigen) 
1.22 1.23 1.24 1.28 
H2AFY H2A histone family, member Y 2.58 2.27 2.39 2.44 
CA4 carbonic anhydrase IV 1.1 1.22 4.08 4.19 
COL15A1 collagen, type XV, alpha 1 1.21 1.22 93.05 57.56 
OXTR oxytocin receptor 2.13 1.93 2.27 2.18 
INPP4B inositol polyphosphate-4-phosphatase, type II, 
105kDa 
-1.05 1.03 1.12 1.2 
ACTA2 actin, alpha 2, smooth muscle, aorta -1.91 -1.87 10.71 4.63 
MEP1A meprin A, alpha (PABA peptide hydrolase) 1.28 1.31 29.65 45.18 
CRISPLD2 cysteine-rich secretory protein LCCL domain 
containing 2 
2.04 2.19 82.66 68.64 
PDCD4 programmed cell death 4 (neoplastic transformation 
inhibitor) 
-3.31 -3.71 6.12 5.15 
SHISA6 shisa family member 6 2.95 2.52 2.93 1.95 
RAB31 RAB31, member RAS oncogene family 6.4 6.33 12.54 11.53 
WBP5 WW domain binding protein 5 6.84 6.94 12.37 13.2 
TMSB10 thymosin beta 10 7.75 6.63 6.9 6.68 
NCK2 NCK adaptor protein 2 7.14 7.12 6.82 6.3 
ARID3A AT rich interactive domain 3A (BRIGHT-like) 7.02 6.37 14.37 10.92 
MAP9 microtubule-associated protein 9 5.99 5.12 4.94 6.56 
RAB38 RAB38, member RAS oncogene family 10.38 8.92 8.36 7.9 
IGF1R insulin-like growth factor 1 receptor 7.9 8.47 6.95 5.23 
PAPSS1 3'-phosphoadenosine 5'-phosphosulfate synthase 1 7.9 7.96 13.43 11.4 
IQGAP1 IQ motif containing GTPase activating protein 1 7.96 6.91 13.58 12.15 
ZNF816 zinc finger protein 816 7.07 6.59 6.22 7.2 
LRP4 low density lipoprotein receptor-related protein 4 6.86 8.05 6.47 5.42 
ZNF415 zinc finger protein 415 4.69 4.42 6.62 7.85 
PLAG1 pleiomorphic adenoma gene 1 5.67 5.84 9.62 8.78 
S100A11 S100 calcium binding protein A11 6.3 5.01 14.08 10.16 
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TRPC1 transient receptor potential cation channel, 
subfamily C, member 1 
5.23 5.26 12.75 11.57 
GLIS2 GLIS family zinc finger 2 4.46 5.13 8.75 6.82 
VGLL3 vestigial like 3 (Drosophila) 5.77 5.71 10.89 9.51 
LINC00960 long intergenic non-protein coding RNA 960 6.18 5.7 10.15 11.52 
ZNF430 zinc finger protein 430 7.35 7.65 6.4 8.8 
FSTL1 follistatin-like 1 10.29 10.45 18.47 15.65 
MARCKS myristoylated alanine-rich protein kinase C 
substrate 
11.29 11.18 10.07 7.92 
ZDHHC13 zinc finger, DHHC-type containing 13 7.62 7.25 5.34 5.37 
ANK3 ankyrin 3, node of Ranvier (ankyrin G) 4.63 4.71 6.12 5.86 
DSG2 desmoglein 2 4.72 4.52 7.73 6.86 
SGK223 homolog of rat pragma of Rnd2 9.75 9.71 8.66 6.36 
HK2 hexokinase 2 7.63 8.06 6.54 4.99 
PDZRN3 PDZ domain containing ring finger 3 4.92 5.02 20.43 15.21 
UBE2Q2 ubiquitin-conjugating enzyme E2Q family member 
2 
4.61 5.21 10.2 12.42 
SSBP2 single-stranded DNA binding protein 2 3.71 3.48 12.17 11.58 
EZR ezrin 6.57 5.91 11.31 9.38 
C3orf52 chromosome 3 open reading frame 52 8.44 9.3 9.63 8.16 
TPM1 tropomyosin 1 (alpha) 5.85 5.8 15 13.45 
TUSC3 tumor suppressor candidate 3 9.72 9.74 13 10.75 
TNFAIP8 tumor necrosis factor, alpha-induced protein 8 3.32 3.18 10.11 9.11 
PEG10 paternally expressed 10 5.69 5.5 6.41 4.14 
FAM217B family with sequence similarity 217, member B 10.65 10.06 4.8 4.06 
SPINT1 serine peptidase inhibitor, Kunitz type 1 4.4 4.31 7.41 6.99 
NEXN nexilin (F actin binding protein) 6.76 6.29 6.54 6.68 
CRIM1 cysteine rich transmembrane BMP regulator 1 
(chordin-like) 
4.94 4.46 11.43 5.93 
STC2 stanniocalcin 2 5.43 4.35 7.52 4.75 
ID3 inhibitor of DNA binding 3, dominant negative 
helix-loop-helix protein 
13.96 11.71 8.65 6.16 
FAM57A family with sequence similarity 57, member A 4.81 5.13 6.89 7.06 
TAGLN transgelin 15.46 11.42 12.65 6.79 
ZNF711 zinc finger protein 711 6.36 6.24 5.6 5.58 
DDX26B DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 
26B 
5.7 5.18 6.52 6.44 
CORO2A coronin, actin binding protein, 2A 6.32 6.18 5.36 4.78 
FUT8 fucosyltransferase 8 (alpha (1,6) fucosyltransferase) 5.59 4.76 16.78 14.46 
LPCAT1 lysophosphatidylcholine acyltransferase 1 11.23 11.06 8.87 7.42 
TES testis derived transcript (3 LIM domains) 8.01 7.06 7.3 5.47 
ID4 inhibitor of DNA binding 4, dominant negative 
helix-loop-helix protein 
5.92 4.93 13.85 12.26 
ZNF83 zinc finger protein 83 2.73 2.32 12.62 18.7 
ZNF468 zinc finger protein 468 13.62 13.1 19.75 16.11 
DKK3 dickkopf WNT signaling pathway inhibitor 3 9.74 8.41 19.05 14.99 
IGF2BP2 insulin-like growth factor 2 mRNA binding protein 
2 
8.88 9.44 9.11 7.07 
LXN latexin 3.62 3.89 4.66 4.45 
PHLDA2 pleckstrin homology-like domain, family A, 6.66 6.61 4.33 4.35 
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member 2 
GALNT12 UDP-N-acetyl-alpha-D-galactosamine:polypeptide 
N-acetylgalactosaminyltransferase 12 (GalNAc-
T12) 
4.65 4.95 6.14 7.23 
CDS1 CDP-diacylglycerol synthase (phosphatidate 
cytidylyltransferase) 1 
5.39 6.51 11.29 11.23 
GOLM1 golgi membrane protein 1 3.52 3.98 4.78 4.8 
DLG5 discs, large homolog 5 (Drosophila) 7.85 7.49 4.45 3.96 
TNFRSF21 tumor necrosis factor receptor superfamily, member 
21 
10.08 8.37 19.95 14.03 
METTL9 methyltransferase like 9 4.37 4.82 7.94 7.76 
PFKM phosphofructokinase, muscle 7.7 8.33 9.98 9.39 
PRSS16 protease, serine, 16 (thymus) 4.09 3.86 5.47 5.04 
COL4A1 collagen, type IV, alpha 1 6.83 6.37 35.58 25.43 
C5orf30 chromosome 5 open reading frame 30 6.84 7.07 36.89 31.41 
PXDN peroxidasin homolog (Drosophila) 11.72 11.54 10.53 7.95 
SUCO SUN domain containing ossification factor 3.69 3.69 10.25 11.26 
RAB25 RAB25, member RAS oncogene family 3.95 4.54 13.77 15.12 
SLC7A11 solute carrier family 7 (anionic amino acid 
transporter light chain, xc- system), member 11 
14.84 12.25 8.73 9.46 
TRNP1 TMF1-regulated nuclear protein 1 8.06 8.22 15.68 16.6 
COL4A2 collagen, type IV, alpha 2 3.1 3.02 22.61 14.52 
ITM2C integral membrane protein 2C 6.74 6.17 7.01 6.62 
TSPAN5 tetraspanin 5 3.8 3.86 14.54 11.66 
EFNB2 ephrin-B2 7.34 7.86 26.67 17.68 
LHFP lipoma HMGIC fusion partner 2.65 4.13 28.09 17.07 
CRNDE colorectal neoplasia differentially expressed (non-
protein coding) 
6.95 5.51 4.43 3.43 
ASRGL1 asparaginase like 1 3.54 3.41 3.64 4.68 
F2R coagulation factor II (thrombin) receptor 6.07 6.37 7.54 5.25 
SERPINH1 serpin peptidase inhibitor, clade H (heat shock 
protein 47), member 1, (collagen binding protein 1) 
5.75 4.85 11.48 10.36 
APOBEC3B apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like 3B 
4.65 4.82 5.09 4.87 
TMED3 transmembrane emp24 protein transport domain 
containing 3 
3.75 4.12 11.79 14.36 
PFN2 profilin 2 6.47 6.97 8.06 6.91 
CDC42EP3 CDC42 effector protein (Rho GTPase binding) 3 5.53 5.51 9.22 4.85 
EFEMP1 EGF containing fibulin-like extracellular matrix 
protein 1 
2.85 3.22 9.8 6.92 
SLC35F2 solute carrier family 35, member F2 9.24 8.76 36.26 32.88 
RAB3B RAB3B, member RAS oncogene family 5.58 5.57 3.57 4.3 
DPP10-AS1 DPP10 antisense RNA 1 11.05 10.15 4.48 4.31 
PIP5K1B phosphatidylinositol-4-phosphate 5-kinase, type I, 
beta 
3.4 2.85 4.73 4.57 
TMEM243 transmembrane protein 243, mitochondrial 2.88 2.93 5.1 6.37 
EPB41L3 erythrocyte membrane protein band 4.1-like 3 8.12 4.73 10.9 8.92 
SLC6A8 solute carrier family 6 (neurotransmitter 
transporter), member 8 
4.98 6.57 3.16 3.01 
NXN nucleoredoxin 15.94 13.98 11.19 8.85 
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UGT8 UDP glycosyltransferase 8 3.79 3.66 2.89 3.59 
LEPREL4 leprecan-like 4 3.85 3.58 10.09 8.93 
MST4 serine/threonine protein kinase MST4 8.7 8.32 12.57 10.98 
AMIGO2 adhesion molecule with Ig-like domain 2 10.85 9.08 27.45 19.82 
COTL1 coactosin-like 1 (Dictyostelium) 7.71 8.36 6.48 5.34 
CCNE1 cyclin E1 8.81 8.86 6.75 7.32 
TUBA1C tubulin, alpha 1c 11.76 10.65 5.22 4.55 
C12orf5 chromosome 12 open reading frame 5 6.68 6.45 3.58 2.62 
MB21D2 Mab-21 domain containing 2 10.67 10.45 4.41 3.93 
PKM pyruvate kinase, muscle 7.85 7.05 5.52 3.77 
CLIC1 chloride intracellular channel 1 7.38 6.79 5.81 5.8 
KIAA1211 KIAA1211 8.29 8.61 11.23 9.01 
EPPK1 epiplakin 1 4.31 5.41 6.94 5.16 
CTSV cathepsin V 9.4 8.85 9.57 9.23 
CKB creatine kinase, brain 3.39 3.26 14.97 17.43 
AKAP12 A kinase (PRKA) anchor protein 12 5.12 6.81 7.37 5.36 
IGDCC4 immunoglobulin superfamily, DCC subclass, 
member 4 
9.82 9.46 24.92 20.44 
LAPTM4B lysosomal protein transmembrane 4 beta 15.36 12.55 9.84 7.74 
SMIM3 small integral membrane protein 3 14.39 16.96 24.19 22.51 
VLDLR very low density lipoprotein receptor 15.83 13.12 27.61 18.94 
ZNF320 zinc finger protein 320 15.22 15.22 7.82 6.25 
SOGA2 SOGA family member 2 16.33 14.59 5.89 4.03 
DPYSL2 dihydropyrimidinase-like 2 8.61 10.63 6.6 4.69 
FAM129A family with sequence similarity 129, member A 3.98 3.74 4.8 4.62 
ELOVL7 ELOVL fatty acid elongase 7 2.27 2.63 2.83 3.16 
DMKN dermokine 14.38 12.37 5.7 6.6 
PCSK5 proprotein convertase subtilisin/kexin type 5 2.24 2.75 22.3 21.76 
COL4A6 collagen, type IV, alpha 6 4.57 4.03 7.36 5.43 
LOC100288911 uncharacterized LOC100288911 4.95 4.95 4.69 4.22 
TFPI2 tissue factor pathway inhibitor 2 4.36 4.51 22.43 10.05 
PNMA1 paraneoplastic Ma antigen 1 14.06 14.44 6.25 4.63 
DPP10 dipeptidyl-peptidase 10 (non-functional) 5.43 5.04 3.06 2.33 
DUSP4 dual specificity phosphatase 4 8.4 5.78 4.81 3.01 
PABPC4L poly(A) binding protein, cytoplasmic 4-like 2.87 2.54 13.35 9.94 
PAM peptidylglycine alpha-amidating monooxygenase 5.17 6.15 23.65 20.21 
COL5A2 collagen, type V, alpha 2 8.99 5.18 37.78 27.96 
ENPP5 ectonucleotide pyrophosphatase/phosphodiesterase 
5 (putative) 
2.72 2.71 3.63 3.81 
ZNF614 zinc finger protein 614 5.5 5.75 3.84 4.36 
SOX4 SRY (sex determining region Y)-box 4 16.58 15.89 7.95 5.96 
PRSS35 protease, serine, 35 2.45 2.16 38.35 26.26 
ZNF43 zinc finger protein 43 8.05 6.01 2.78 3.86 
LRCH2 leucine-rich repeats and calponin homology (CH) 
domain containing 2 
4.16 4.6 27.14 22.99 
STMN2 stathmin-like 2 3.31 2.77 34.35 20.26 
COLEC12 collectin sub-family member 12 7.95 3.64 44.89 30.97 
YBX3 Y box binding protein 3 13.06 12.72 8.91 7.56 
FMNL2 formin-like 2 6.65 5.94 2.85 2.7 
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COL21A1 collagen, type XXI, alpha 1 3.53 4.28 32.61 25.26 
MATN3 matrilin 3 19.36 12.68 12.5 10.29 
HS6ST2 heparan sulfate 6-O-sulfotransferase 2 4.8 5.06 29.91 25.33 
ANXA1 annexin A1 3.37 3.25 34.41 29.07 
SLC7A5 solute carrier family 7 (amino acid transporter light 
chain, L system), member 5 
32.63 28 9.98 6.1 
COL1A1 collagen, type I, alpha 1 6.98 8.52 85.17 68.58 
PAQR8 progestin and adipoQ receptor family member VIII 2.27 2.53 8.86 8.18 
CCND2 cyclin D2 16.6 15.8 25.94 18.36 
GPX7 glutathione peroxidase 7 2.2 2.05 6.85 7.4 
NQO1 NAD(P)H dehydrogenase, quinone 1 19.85 17.68 11.32 11.84 
ZNF204P zinc finger protein 204, pseudogene 10.11 6.61 3.8 6.83 
SPIN4 spindlin family, member 4 12.76 15.55 25.89 22.13 
GPR160 G protein-coupled receptor 160 6.63 7.72 4.84 5.61 
PDGFA platelet-derived growth factor alpha polypeptide 18.8 17.54 14.29 12.51 
GRHL2 grainyhead-like 2 (Drosophila) 5.85 6.95 10.03 8.29 
COL11A1 collagen, type XI, alpha 1 4.72 4.29 42.48 25.22 
SRPX sushi-repeat containing protein, X-linked 1.66 2.18 20.99 24.04 
ANXA2 annexin A2 3.95 3.5 10.54 9.82 
NANOS1 nanos homolog 1 (Drosophila) 14.46 14.01 10.52 7.65 
EDNRB endothelin receptor type B 5.14 4.41 10.41 9.49 
DDR1 discoidin domain receptor tyrosine kinase 1 4.67 4.74 6.32 5.69 
CDH11 cadherin 11, type 2, OB-cadherin (osteoblast) 5.91 6.08 25.53 20.22 
ARG2 arginase 2 3.77 4.07 10.43 10.33 
HSPB8 heat shock 22kDa protein 8 3.79 2.72 18.56 17.34 
SELM selenoprotein M 1.53 1.71 27.48 31.59 
USP46 ubiquitin specific peptidase 46 7.18 7.11 3.8 3.68 
BASP1 brain abundant, membrane attached signal protein 1 18.23 18.79 15.5 15.07 
MTHFD1L methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 1-like 
12.3 11.94 5.41 4.85 
SLC26A2 solute carrier family 26 (anion exchanger), member 
2 
4.01 3.72 10.84 11 
RCN2 reticulocalbin 2, EF-hand calcium binding domain 11.64 13.68 6.12 7.08 
C4orf48 chromosome 4 open reading frame 48 3.35 3.15 9.38 8.62 
FLVCR1 feline leukemia virus subgroup C cellular receptor 1 13.08 14.2 3.94 3.62 
PBK PDZ binding kinase 9.39 9.3 7.8 5.56 
GALNT3 UDP-N-acetyl-alpha-D-galactosamine:polypeptide 
N-acetylgalactosaminyltransferase 3 (GalNAc-T3) 
4.96 5.5 3.5 3.29 
IMPDH1 IMP (inosine 5'-monophosphate) dehydrogenase 1 6.65 6.69 5.15 4.92 
AACS acetoacetyl-CoA synthetase 8.92 10.32 3.02 3.19 
PSPH phosphoserine phosphatase 4.28 3.83 2.27 1.79 
CDH3 cadherin 3, type 1, P-cadherin (placental) 13.13 13.79 30.49 28.28 
ARHGEF10 Rho guanine nucleotide exchange factor (GEF) 10 7.24 7.09 6.13 6.19 
BTBD3 BTB (POZ) domain containing 3 6.84 6.16 7.72 6.69 
HN1 hematological and neurological expressed 1 14.01 15.2 3.7 3.36 
PKDCC protein kinase domain containing, cytoplasmic 1.98 1.77 7.34 6.31 
TUBA1B tubulin, alpha 1b 8.63 8.75 4.81 4.31 
ELOVL4 ELOVL fatty acid elongase 4 4.21 5.03 3.84 4.8 
LBH limb bud and heart development 12.32 10.22 48.77 38.69 
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F3 coagulation factor III (thromboplastin, tissue factor) 3.6 2.99 61.05 57.05 
PCDHB2 protocadherin beta 2 23.16 25.23 14.57 9.8 
MOB3B MOB kinase activator 3B 2.97 3.39 4.8 5.18 
FZD3 frizzled family receptor 3 6.74 6.91 4.68 4.64 
PRR15 proline rich 15 3.53 3.57 19.59 17.78 
ITGA6 integrin, alpha 6 2.92 3.38 2.6 1.9 
NSUN7 NOP2/Sun domain family, member 7 2.12 2.46 2.71 3.51 
CDKN1C cyclin-dependent kinase inhibitor 1C (p57, Kip2) 2.04 1.68 41.98 43.81 
PARM1 prostate androgen-regulated mucin-like protein 1 1.93 2.12 29.63 30.34 
MN1 meningioma (disrupted in balanced translocation) 1 3.75 3.31 6.37 4.66 
PDP1 pyruvate dehyrogenase phosphatase catalytic 
subunit 1 
3.1 3.05 2.7 2.22 
TMSB15B thymosin beta 15B 6.32 6.86 3.83 3.63 
BTG3 BTG family, member 3 2.47 2.43 10.58 10.48 
GCNT1 glucosaminyl (N-acetyl) transferase 1, core 2 4.52 3.57 5.64 5.8 
SLC2A1 solute carrier family 2 (facilitated glucose 
transporter), member 1 
4.12 4.64 16.63 12.79 
PDPN podoplanin 6.19 6.63 47.83 43.22 
PLXDC2 plexin domain containing 2 7.61 6.85 15.89 18.53 
NAALAD2 N-acetylated alpha-linked acidic dipeptidase 2 1.21 1.4 16.12 15.54 
PRTG protogenin 2.75 2.94 26.69 24.12 
NLRP2 NLR family, pyrin domain containing 2 36.58 41.46 12.51 13.75 
DKK1 dickkopf WNT signaling pathway inhibitor 1 43.01 19.91 10.07 6.92 
PTX3 pentraxin 3, long 1.75 1.96 8.7 8.53 
NID2 nidogen 2 (osteonidogen) 1.59 2.01 230.76 174.9 
GREM1 gremlin 1, DAN family BMP antagonist 8.94 8.73 5.7 1.61 
CXCL5 chemokine (C-X-C motif) ligand 5 2.85 3.2 1.31 2.27 
COL6A3 collagen, type VI, alpha 3 7.45 9.96 232.63 149.56 
ANKRD1 ankyrin repeat domain 1 (cardiac muscle) 2.62 2.16 31.63 21.14 
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